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Discovery of phosphodiesterase-10 (PDE10) inhibitors for the treatment of 
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Fuerst5; Lisa Gold6; Nicole Hill5; Pete H Hutson6; Sarah Huszar7; Monika Kandebo6; 
Amanda Kemmerer3; Somang H Kim4; Raghu Krishnan3; Wei Lemaire3; Bennett Ma4; 
Georgia McGaughey8; Sanjeev Munshi9; Shannon Nguyen7; Sophie Parmentier-
Batteur6; John D Schreier1; Sujata Sharma9; William D Shipe2; Sean Smith6; Jason 
Uslaner7; Youwei Yan9; Christopher D Cox1. (1) Program Team Chemistry, Merck & 
Co., Inc., West Point PA 19486, United States (2) Automated Synthesis and 
Purification, Merck & Co., Inc., West Point PA 19486, United States (3) In Vitro 
Sciences, Merck & Co., Inc., West Point PA 19486, United States (4) Drug Metabolism, 
Merck & Co., Inc., West Point PA 19486, United States (5) Basic Pharmaceutical 
Sciences, Merck & Co., Inc., West Point PA 19486, United States (6) 
Neurosymptomatics, Merck & Co., Inc., West Point PA 19486, United States (7) In Vivo 
Pharmacology, Merck & Co., Inc., West Point PA 19486, United States (8) Chemistry 
Modeling and Informatics, Merck & Co., Inc., West Point PA 19486, United States (9) 
Structural Chemistry, Merck & Co., Inc., West Point PA 19486, United States  
Schizophrenia is a chronic and debilitating neurological disease with onset typically 
occurring during early adulthood. The disease is characterized by a combination of 
positive (hallucinations), negative (anhedonia, social withdrawal), and cognitive 
symptoms, and is estimated to affect 1% of the global population. While currently 
marketed "typical" and "atypical" therapeutics exist, they are prone to an array of 
adverse events (AEs), often resulting in discontinuation due to poor efficacy and/or 
tolerability. As such, alternative pharmacological approaches toward treating 
schizophrenia represent an unmet medical need.   The phosphodiestereases (PDEs) 
are a superfamily of 11 enzymes responsible for the hydrolytic degradation of the 
second messengers cAMP and cGMP. Specifically, PDE10 is highly expressed and 
localized in the mammalian striatum, and is implicated in the regulation of cyclic 
nucleotide signalling cascades that intersect both the glutamatergic and dopaminergic 
pathways regulating behavioral control. As such, inhibition of PDE10 is hypothesized to 
represent a mechanistically novel approach toward the treatment of schizophrenia, and 
recent preclinical results support this hypothesis.   We describe the discovery and 
development of potent and orally bioavailable tetrahydropyridopyrimidine inhibitors of 
PDE10 obtained by systematic optimization of a proprietary Merck HTS lead. Leading 
compounds exhibit sub-nanomolar potencies, excellent pharmacokinetic (PK) 
properties, and clean off-target profiles. These inhibitors display in vivo target 
engagement as measured by both an ex vivo occupancy assay and increased striatal 
cGMP levels upon oral dosing. They also display dose-dependent efficacy in key 
pharmacodynamic (PD) assays predictive of anti-psychotic activity, including the 
psychostimulant-induced rat hyperlocomotion assay and the conditioned avoidance 
response assay. 
MEDI 3 
Discovery of JNJ-42601572, a γ-secretase modulator with potent, central activity 
in mouse and dog 
Francois Bischoff, fbischof@its.jnj.com; Harrie Gijsen, hgijsen@its.jnj.com; Didier 
Berthelot; Michel De Cleyn; Gregor Macdonald; Daniel Oehlrich; Michel Surkyn; Andres 
Trabanco; Gary Tresadern; Sven Van Brandt; Adriana I Velter; Herman Borghys; 
Chantal Masungi; Marc Mercken. Department of Neuroscience, Janssen Research & 
Development, Beerse B-2340, Belgium  
Accumulation of neurotoxic amyloid-beta 42 peptides (Ab42) in the brain is a hallmark of 
Alzheimer's disease (AD). Gamma-secretase, an intramembrane-cleaving protease 
responsible for the production of amyloid-beta peptides, has emerged as an important 
target for the development of novel therapeutics for AD. γ-Secretase modulation rather 
than plain inhibition has been postulated to be an alternative strategy to intervene 
pharmacologically within the amyloid cascade. It causes a product shift at the expense 
of Ab42 to the shorter, more soluble and less amyloidogenic Ab38 without inhibiting 
NOTCH proteolytic processing. The design and the synthesis of several chemical sub-
classes of in vitro and in vivo potent γ-secretase modulators (GSM) will be presented as 
well as their drug-like properties. This study has led to the identification of our lead 
compound, JNJ-42601572 which, in a non-transgenic mouse brain, upon oral dosing 
(30 mg/kg, 4 h) induces a 63% lowering of Ab42 levels and a 91% increase of Ab38 
levels with unchanged total levels of amyloid peptides. Moreover, JNJ-42601572 elicits 
very potent in vivo activity across species as it induces upon oral dosing (20 mg/kg, 8 h) 
a 60% lowering of Ab42 levels and a 60% increase of Ab38 levels in dog cerebrospinal 
fluid. 
MEDI 4 
Discovery of a series of brain-penetrant kynurenine aminotransferase II inhibitors 
for the treatment of schizophrenia 
Amy B. Dounay, amy.dounay@pfizer.com. Neuroscience Medicinal Chemistry, Pfizer 
Worldwide Research and Development, Groton CT 06340, United States  
Kynurenine aminotransferase (KAT) II has been identified as a potential new target for 
treatment of cognitive impairment associated with schizophrenia. Following a high 
throughput screen, cyclic hydroxamic acid PF-04859989 emerged as a lead compound 
for the program. PF-04859989 represents the first reported brain penetrant tool 
compound for KATII. Additionally, our studies revealed that PF-04859989 inhibits KATII 
irreversibly by forming a covalent adduct with co-factor pyridoxal phosphate (PLP) in the 
enzyme active site. Key challenges for the medicinal chemistry team included 
developing a clear understanding of the structural features affecting the irreversibility of 
inhibition and design of compounds with potency at both rat and human KATII 
isozymes. X-ray crystallography, homology modeling, and biophysical studies to probe 
irreversibility have been critical components of the team's design strategy. Additionally, 
protein NMR experiments with 13C-labeled PF-04859989 have provided deeper insight 
into the mechanism of irreversible inhibition. Highlights of these studies and their impact 
on the team's lead optimization efforts will be described. 
MEDI 5 
Design and synthesis of Benzimidazole based inhibitors of Raf kinase: A med. 
Chem approach towards the discovery of Phase II clinical candidate RAF265 
Savithri Ramurthy1, savithri.ramurthy@novartis.com; Payman Amiri2; Abran Costales1; 
Johanna M Jansen1; Barry Levine3; Sylvia Ma2; Christopher M McBride3; Teresa Pick4; 
Daniel J. Poon1; Cynthia M. Shafer1; Darrin Stuart2; Leonard Sung3; Ahmad Hashash5; 
Paul Renhowe1; Eleni Venetsanakos2; Jeremy Murray3; Brent Appleton1; Mina Aikawa2; 
Joelle Verhagen3; Kimberly Aarderlin2. (1) Global Discovery chemistry / Oncology and 
Exploratory Chemistry, Novartis Institutes for Biomedical Research, Emeryville CA 
94608, United States (2) Oncolgy, Novartis Institutes for Biomedical Research, 
Emeryville CA 94608, United States (3) NA, United States (4) Lawrence Livermore 
Laboratories, United States (5) Gilead Sciences, United States  
The Ras/Raf/MEK/ERK pathway plays a central role in mediating proliferation and 
survival signals from the cell membrane to the nucleus and cytoplasm. Activation of this 
pathway often occurs in cancer cells, the importance of which is underscored by the 
observation that activating mutations in Ras and B-Raf frequently occur in human 
cancer. Thus a potent Raf inhibitor could have a significant impact in treating cancers 
that are dependent on activated Ras or Raf for survival and proliferation signaling. 
Malignant melanoma represents a promising indication for a Raf inhibitor given the high 
percentage of B-Raf (60-70%) mutations and the huge unmet medical need.   Here, we 
describe the medicinal chemistry approaches which led to the discovery of Raf265, a 
novel, orally bioavailable small molecule inhibitor of c-Raf, B-Raf and mutant B-Raf 
(V600E) that also inhibits VEGFR-2. This target profile provides two potential 
mechanisms for inhibiting tumor growth: direct anti-proliferative/pro-apoptotic effects on 
tumor cells through inhibition of Raf, and anti-angiogenic activity through inhibition of 
VEGFR-2. Design strategy, synthesis and the in vitro, in vivo activities of the early 
Benzimidazole analogs and Raf 265 will also be discussed. 
MEDI 6 
Inhibitors of ketohexokinase: Discovery of pyrimidinopyrimidines with specific 
substitution that complements the adenosine 5'-triphosphate (ATP) binding site 
Bruce E. Maryanoff, bmaryano@scripps.edu; John O’Neill; David McComsey; Stephen 
Yabut; Diane Luci; Alfonzo Jordan; John Masucci; William Jones; Marta Abad; Alan 
Gibbs; Ioanna Petrounia. Johnson & Johnson Pharmaceutical Research & 
Development, Spring House PA 19477-0776, United States  
Ketohexokinase (KHK; fructokinase) phosphorylates fructose on position C1 with the 
agency of ATP to yield fructose-1-phosphate, which enters normal metabolic pathways. 
Attenuation of fructose metabolism by the inhibition of KHK should reduce body weight, 
free fatty acids, and triglycerides, thereby offering a novel approach to treat diabetes 
and obesity in response to modern diets. We have identified potent, selective inhibitors 
of human hepatic KHK within a series of pyrimidino[5,4-d]pyrimidines. Several 
compounds exhibited KHK IC50 values in the range of 5-20 nM and showed potent 
cellular KHK inhibition (IC50 < 500 nM), which relates to their intrinsic potency vs KHK 
and their ability to penetrate cells. X-ray co-crystal structures of ligand•KHK complexes 
revealed the important interactions within the enzyme's ATP-binding pocket (e.g., see 
Figure). The structure-activity relationship (SAR) for this pharmacophore will be 
discussed in the context of our X-ray results.  
  
MEDI 7 
Discovery of BMS-626531, a potent and selective inhibitor of p38α MAP kinase as 
a clinical candidate for the treatment of inflammatory diseases 
Alaric J. Dyckman, alaric.dyckman@bms.com; Tianle Li; John Hynes; Hong Wu; 
Stephen T. Wrobleski; Shuqun Lin; Chunjian Liu; James Lin; John Wityak; Jagabandhu 
Das; Robert V. Moquin; Kathleen M. Gillooly; Sidney Pitt; Ding Ren Shen; Rosemary F. 
Zhang; Kim W. McIntyre; David J. Shuster; Hongjian Zhang; Punit H. Marathe; Arthur M. 
Doweyko; John S. Sack; Jingsong Wang; Murray McKinnon; John H. Dodd; Joel C. 
Barrish; Gary L. Schieven; Katerina Leftheris. Research and Development, Bristol-
Myers Squibb, Princeton NJ 08543-4000, United States  
The mitogen-activated protein kinase p38α has been shown to be on the critical path to 
pro-inflammatory cytokine production (notably TNF-α and IL-1β). In recent years, 
biotherapeutic treatments have provided clinical validation for anti-cytokine approaches 
to treating rheumatoid arthritis, Crohn's disease and psoriasis. Small molecule-based 
inhibition of p38α as an alternative approach to block production of these cytokines 
offers the potential benefits of reduced cost and ease of administration. These aspects, 
along with the ability to simultaneously affect multiple cytokines and inflammatory 
mediators, have stimulated continued efforts to develop safe, potent and orally active 
p38α inhibitors. This presentation will describe the structure-based design, synthesis, 
and structure-activity relationship of a novel series of p38α inhibitors. A survey of the 
pharmacokinetic properties of these molecules and their in vivo efficacy in various 
models of acute and chronic inflammation will be highlighted. The discovery and profile 
of the clinical development candidate BMS-626531 will be discussed for the first time. 
MEDI 8 
Identification of novel and selective ITK inhibitors through a template hopping 
strategy 
Aoife C Maxwell, aoife.c.maxwell@gsk.com; Catherine Alder; Amanda Campbell; 
Aurelie Champigny; Martin Ambler; John Harling; Callum Scullion; Ian Smith; Don 
Somers; Chris Tame; Caroline Wilson; James Woolven. Respiratory CEDD, 
GlaxoSmithKline, Stevenage Hertfordshire SG1 2NY, United Kingdom  
Interleukin-2 inducible Tyrosine kinase (ITK) is a non-receptor protein tyrosine kinase 
which is expressed in T cells, mast cells and NK cells. ITK plays a role in signalling, 
downstream of the T cell receptor. Inhibition of ITK potentially constitutes a novel, non-
steroidal treatment for asthma and other T-cell mediated diseases. In-house kinase 
cross-screening resulted in the identification of an aminopyrazole-based series of ITK 
inhibitors. Initial work on this series highlighted selectivity issues with several other 
kinases including LCK, AurA and AurB. These issues could not be readily resolved via 
simple modifications. A template hopping strategy was therefore initiated in order to 
identify an inherently more selective hinge binder which would still be capable of 
capitalising on the SAR already developed in the aminopyrazole series. Herein we 
describe the strategy we used to identify a selective hinge binder, how this resulted in 
the identification of a novel and selective series of ITK inhibitors and modelling and 
crystallographic rationale for the observed selectivity. 
MEDI 9 
Discovery and optimization of a series of benzothiazole PI3K / mTOR dual 
inhibitors 
Noel D D'Angelo1, dangelo@amgen.com; Tae-Seong Kim1; Kristin Andrews2; Shon K 
Booker1; Sean Caenepeel3; Kui Chen4; Derin D'Amico1; Dan Freeman3; Jian Jiang5; 
Longbin Liu1; John D McCarter4; Tisha San Miguel4; Erin L Mullady6; Michael Schrag5; 
Raju Subramanian5; Jin Tang7; Robert C Wahl4; Ling Wang3; Douglas A Whittington7; 
Tian Wu8; Ning Xi1; Yang Xu5; Peter Yakowec7; Kevin Yang1; Leeanne P Zalameda4; 
Nancy Zhang3; Paul Hughes3; Mark H Norman1. (1) Department of Medicinal Chemistry, 
Amgen, Inc., Thousand Oaks CA 91320, United States (2) Department of Molecular 
Structure, Amgen, Inc., Thousand Oaks CA 91320, United States (3) Department of 
Oncology Research, Amgen, Inc., Thousand Oaks CA 91320, United States (4) 
Department of High-Throughput Screening and Molecular Pharmacology, Amgen, Inc., 
Thousand Oaks CA 91320, United States (5) Department of Pharmacokinetics and 
Drug Metabolism, Amgen, Inc., Thousand Oaks CA 91320, United States (6) 
Department of High-Throughput Screening and Molecular Pharmacology, Amgen, Inc., 
Cambridge MA 02142, United States (7) Department of Molecular Structure, Amgen, 
Inc., Cambridge MA 02142, United States (8) Department of Pharmaceutics, Amgen, 
Inc., Thousand Oaks CA 91320, United States  
Phosphoinositide 3-kinases (PI3K's) are a family of lipid kinases that play key regulatory 
roles in cell proliferation, survival, and cell translation. The mutation or amplification of 
PI3K-alpha in humans has been implicated in the growth of multiple tumor types. 
Consequently, the PI3K's in general and PI3K-alpha in particular have become targets 
of intense research for drug discovery. Our studies began with the identification of 
benzothiazole compound 1 from a high throughput screen. Extensive SAR studies led to 
the discovery of sulfonamides 38 and 45 as early leads, based on their in vitro cellular 
potencies. Subsequent modifications of the central pyrimidine ring dramatically 
improved enzyme and cellular potency and led to the identification of chloropyridine 70. 
Further aryl sulfonamide SAR studies optimized in vitro clearance and led to the 
identification of 82 as a potent dual inhibitor of PI3K and mTOR. This molecule exhibited 
potent enzyme and cell activity, low clearance, and high oral bioavailability. In addition, 
compound 82 demonstrated tumor growth inhibition in U-87 MG, A549, and HCT116 
tumor xenograft models. 
MEDI 10 
Discovery of potent and highly selective PI3-Kinase Delta inhibitors: Taming time-
dependent inhibition 
Brian S Safina, bsafina@gene.com. Discovery Chemistry, Genentech Inc., South San 
Francisco CA 94080, United States  
PI3K-δ is a lipid kinase and a member of a larger family of enzymes, PI3K Class IA(α, β, 
δ) and IB (γ) that catalyze the phosphorylation of PIP2 to PIP3. PI3Kδ is mainly 
expressed in leukocytes, where it plays a critical, non-redundant role in B cell receptor 
mediated signals and thus, provides an attractive opportunity to treat rheumatoid 
arthritis. We report the discovery of novel, potent and selective PI3Kδ inhibitors and 
describe our hypothesis for isoform (α, β, γ) selectivity gained from interactions in the 
affinity pocket. The critical component of our initial pharmacophore was implicated in 
causing CYP3A4 time-dependant inhibition (TDI) and strategies, such as diverting 
metabolism, MetID and key SAR will be presented in detail. Ultimately, a structure-
based design approach was employed to identify a suitable drug-like replacement for 
further optimization. The results of those efforts will be disclosed in the subsequent talk. 
MEDI 11 
Designer lipids for cytoplasmic delivery of nucleic acids 
Francis C. Szoka, PhD., szoka@cgl.ucsf.edu. Departments of Bioengineering, 
Therapeutic Sciences &Pharmaceutical Chemistry, University of California, San 
Francisco CA 94143-0912, United States  
We have synthesized a family of zwitterlipids that are pH and/or enzyme responsive that 
form liposomes at pH 7.4 and efficiently encapsulate nucleic acids. The liposomes were 
used to explore the lipid chemical-attributes that control cytoplasmic delivery of the 
liposomal contents. Both classes of lipids, pH and enzymatically triggered, become 
positively charged upon triggering. The pKa of the zwitterlipid and lipid acyl chain 
composition are critical to obtain significant levels of siRNA transfer using an in vivo 
factor VII knockdown assay in mice. Adverse effects such as the induction of 
inflammatory mediators was minimal for most lipids studied. Supported by NIH 
EB03008 & Pfizer, Inc. 
MEDI 12 
pH-Responsive polymeric carriers for siRNA drug delivery 
Patrick Stayton, stayton@uw.edu. Seattle, University of Washington, Seattle WA 
98195, United States  
RNA drugs have significant therapeutic potential, but effectively formulating and 
delivering them remains a widely recognized challenge. We have been developing 
synthetic polymeric carriers that mimic the highly efficient intracellular delivery systems 
found in pathogenic viruses and organisms. Their most important property ties together 
the sensing of pH changes to membrane destabilizing activity, and the carriers thus 
possess a hidden functionality that is expressed in the endosomal compartment to 
increase cytosolic delivery of macromolecules. Another important aspect of these 
polymeric carriers is the development of controlled polymerization techniques to 
streamline bioconjugation of targeting agents, as well as to generate controlled carrier 
architectures.  Optimization of architecture and delivery activity has led to carriers with 
excellent efficacy and pharmaco-kinetic properties. 
MEDI 13 
siRNA delivery using PRINT particles 
Joseph M. DeSimone, desimone@unc.edu. Departments of Chemistry and 
Pharmacology, University of North Carolina - Chapel Hill, Chapel Hill NC 27599, United 
States and Department of Chemical and Biomolecular Engineering, North Carolina 
State University, Chapel Hill NC 27599, United States  
The PRINT platform enables unprecedented control over particle size, shape, 
composition, deformability, surface chemistry and cargo loading. Two different matrices 
are being explored for siRNA delivery: PLGA and PEG hydrogels. The PLGA matrix 
utilizes a non-polyplex forming method to deliver siRNA while a cleavable siRNA 
'prodrug' approach is being developed for the PEG hydrogel system. Targeting is being 
achieved by coating the particles with different ligands that can physisorb to the particle 
surface. Various disease models are being investigated for the application of the siRNA-
containing PRINT particles. 
MEDI 14 
Liposome and polymer conjugate delivery of siRNA 
Steven L. Colletti, steve_colletti@merck.com. Department of Medicinal Chemistry, 
Merck & Co., Inc., West Point PA 19486, United States  
The recent field of RNA interference (RNAi) continues to grow and evolve at a rapid 
pace toward the realization of therapeutics. An important key to the discovery of RNAi 
therapeutics, is the safe and effective delivery of short interfering RNA (siRNA). Merck 
and Co. entered the field with the acquisition of Sirna Therapeutics, and has since 
developed multiple platforms for siRNA delivery. Medicinal chemistry design has been 
at the core of these delivery strategies. This presentation will highlight some of the 
advances in lipid nanoparticle and polymer conjugate delivery of siRNA. The application 
of medicinal chemistry principles, such as structure activity relationships (SAR), will be 
featured, as well as issues of absorption, distribution, metabolism, excretion, and 
toxicity (ADMET). 
MEDI 15 
Potent and highly selective benzimidazole inhibitors of PI3-Kinase delta 
Zachary K Sweeney, sweeney.zachary@gene.com. Small Molecule Drug Discovery, 
Genentech, Inc., South San Francisco California 94080, United States  
Inhibition of PI3Kδ is considered to be an attractive mechanism for the treatment of 
inflammatory diseases and leukocyte malignancies. Using a structure-based design 
approach, we have identified a series of potent and selective benzimidazole-based 
inhibitors of PI3Kδ. These inhibitors do not occupy the selectivity pocket between 
Trp760 and Met752 that is induced by other families of PI3Kδ inhibitors. The 
pharmacokinetic properties of these compounds and the ability of representative 
inhibitors to modulate the function of B-cells in vivo will be described. 
MEDI 16 
Discovery and development of pyrrolidinoiminopyrimidinones as potent and 
selective BACE1 inhibitors 
Johnny Zhu1, johnnyzzhu@msn.com; Xiaoxiang Liu1; Mihirbaran Mandal1; Robert 
Mazzola1; James Durkins1; John Caldwell1; Johannes Voigt2; Corey Strickland3; Mathew 
Kennedy4; Xia Chen4; Reshma Kuvelkar4; Prescott Leach4; Michael Grzelak4; Lynn 
Hyde4; Qi Zhang4; Giuseppe Terracina4; Lili Zhang4; Leonard Favreau5; Eric Parker4; 
Brian McKittrick1; Andrew Stamford1; Michael Czarniecki1; William Greenlee1; John 
Hunter4. (1) Medicinal Chemistry, Merck Research Laboratories, Kenilworth NJ 07033, 
United States (2) CM&I, Merck Research Laboratories, United States (3) Structural 
Chemistry, Merck Research Laboratories, United States (4) Neurobiology, Merck 
Research Laboratory, United States (5) DMPK, SPRI, United States  
Alzheimer's disease is caused by widespread neuronal dysfunction and cell death that 
is believed to be initiated by synaptic deposition of Ab42 oligomers related to their 
overproduction, decreased clearance or enhanced aggregation. Ab42 is generated from 
the membrane bound Amyloid Precursor protein (APP) via sequential cleavages first by 
b-secretase-1 (BACE1) followed by g-secretase. BACE inhibition has been viewed as 
an attractive path for potential treatment of Alzheimer's disease through reduction of 
Ab42 production    A unique structural class of cyclic acylguanidine BACE inhibitors has 
been designed and validated as highly potent and selective and CNS penetrant BACE 
inhibitors, starting from a fragment based protein NMR screening lead with extensive 
use of X-ray crystallography and CADD technologies. Here we will briefly discuss the in 
vivo rat efficacy guided SAR work evolving from iminopyrimidinone 3 to 7 through 
rational design based on conformational analysis.      
  
MEDI 17 
Novel kappa opioid peptides with drug-like properties 
Jane V. Aldrich1, jaldrich@ku.edu; Santosh S. Kulkarni1; Sanjeewa N. Senadheera1; 
Nicolette C. Ross2; Kate J. Reilley2; Shainnel O. Eans2; Michelle L. Ganno2; Jay P. 
McLaughlin2. (1) Department of Medicinal Chemistry, The University of Kansas, 
Lawrence KS 66045, United States (2) Torrey Pines Institute for Molecular Studies, Port 
St. Lucie FL 34990, United States  
Ligands for kappa opioid receptors (KOR) have potential therapeutic application in a 
number of areas, including in the treatment of pain and drug abuse. A major challenge 
in developing peptides for these receptors and other targets as potential therapeutic 
agents has been their metabolic stability and distribution following systemic 
administration. The novel cyclic tetrapeptide CJ-15,208 was reported to be a KOR 
antagonist in vitro (Saito et al., J. Antibiot. 2002, 55, 847). Because of its cyclic structure 
this peptide was expected to be resistant to proteolytic degradation and potentially 
systemically active. Therefore we synthesized this peptide (Ross et al., Tetrahedron 
Lett. 2010, 51, 5020) along with a number of analogs and evaluated selected peptides 
in vivo. Unexpectedly the lead peptide exhibited analgesic activity in the 55oC warm 
water tail withdrawal assay in mice following systemic (intraperitoneal) administration 
(ED50 (and 95% confidence interval) = 4.5 (1.2-20.3) mg/kg). Characterization in 
additional in vivo assays indicated that this peptide is a mixed agonist/antagonist and 
suggests that it could be a potentially clinically useful analgesic with decreased liabilities 
compared to current narcotic analgesics (e.g. morphine). Analogs of the lead peptide 
exhibited different pharmacological profiles in vivo in terms of agonist activity and the 
opioid receptors involved. An analog that exhibits primarily KOR antagonist activity in 
vivo is also systemically active and blocks stress-induced reinstatement of cocaine 
seeking behavior. These cyclic peptides represent significant advances in the 
development of potential peptide therapeutics for KOR. Research supported by NIDA 
grants R01 DA018832 and DA023924. 
MEDI 18 
Discovery of novel small molecule Mer kinase inhibitors for the treatment of 
pediatric acute lymphoblastic leukemia 
Xiaodong Wang1, xiaodonw@unc.edu; Jing Liu1; Chao Yang1; Catherine Simpson1; 
Amy Deusen1; Jacqueline Norris-Drouin1; William Janzen1; Dmitri Kireev1; Stephen 
Frye1; Deborah DeRychere2; Doug Graham2; Debra Hunter3; H Shelton Earp3. (1) 
Division of Medicinal Chemistry and Natural Products, University of North Carolina, 
Chapel Hill NC 27599, United States (2) Department of Pediatrics, University of 
Colorado at Denver, Aurora CO 80045, United States (3) Department of Medicine and 
Pharmacology, University of North Carolina, Chapel Hill NC 27599, United States  
Ectopic Mer expression in T-cell acute lymphoblastic leukemia (ALL) is suspected to be 
responsible for drug resistance in children and Mer kinase inhibitors may act as 
chemosensitizers to increase efficacy and reduce toxicities of current regimens in this 
disease. Based on the known X-ray crystal structure of Mer with Compound 52, a 
rational structure-based design approach was applied to discover novel small molecule 
Mer inhibitors. A strong structure-activity relationship (SAR) has been built up within the 
Tyro-3, Axl, and Mer family of receptor tyrosine kinases for the pyrazolopyrimidine 
scaffold. In the process, Sub-nanomolar Mer inhibitors have been discovered. The lead 
compound has been evaluated for selectivity against other kinase families with 
promising results. Optimization of this scaffold toward a clinical candidate is underway. 
MEDI 19 
Selective small molecule probes for inhibition of breast cancer stem cells 
Andrew R Germain1, agermain21@yahoo.com; Leigh C Carmody1; Barbara J 
Morgan1; Etienne Donckele1; Cristina Fernandez1; Erin Forbeck1; Timothy A Lewis1; 
Partha P Nag1; Byung-Chul Suh1; Amal Ting1; Lynn Verplank1; Willmen Youngsaye1; 
Yuxiong Feng2; Piyush Gupta2; Sivaraman Dandapani1; Benito Munoz1; Michelle 
Palmer1; Eric Lander1; Stuart L Schreiber1. (1) Probe Development Center, The Broad 
Institute, Cambridge MA 02142, United States (2) The Whitehead Institute, Cambridge 
MA 02142, United States  
Cancer stem cells (CSCs), which drive tumor growth, are known to be resistant to 
standard chemotherapy and radiation treatment. [i] This raises a very significant unmet 
need to find therapies that can target CSCs within tumors because these cells are 
responsible for recurrence, the primary cause of patient mortality. However, CSCs are 
not stable outside the tumor environment and are not easy to grow in culture media. 
Hence, stable sibling cell lines that were induced into epithelial-to-mesenchymal 
transdifferentiation (EMT) to stably propagate CSC-enriched populations[ii] were used 
to screen a library of about 300,000 compounds from the Molecular Libraries Small 
Molecule Repository (MLSMR). Several classes of selective inhibitors of CSCs were 
identified. The use of isogenic control cell lines for the secondary validation assays 
minimized the probability of false hits advancing along the critical path to probe 
development. Medicinal chemistry efforts on the identified hits resulted in chemical 
probes with increased potency and selectivity. In addition to advancing the basic 
research in the biology of CSCs, these small molecule probes are attractive starting 
points for developing anticancer drugs.        [i] Bao S, Wu Q, McLendon RE, Hao Y, Shi 
Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote 
radioresistance by preferential activation of the DNA damage response. Nature 2006 
Dec 7;444(7120):756-60. PubMed PMID: 17051156      [ii] Gupta PB, Onder TT, Jiang 
G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors 
of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-59. 
PubMed PMID: 19682730 
MEDI 20 
Lipid conjugated prodrugs for enzyme-triggered liposomal drug delivery to 
tumors 
Mads H. Clausen, mhc@kemi.dtu.dk. Department of Chemistry, Technical University of 
Denmarkl, Kgs. Lyngby 2800, Denmark  
For some time we have been developing novel enzyme-triggered prodrugs for drug 
delivery targeting cancer. The liposomal prodrugs take advantage of the EPR effect to 
localize to tumors and of the local over-expression of secretory phospholipase A2 in 
tumors. Compared to conventional liposomal drug delivery systems, our prodrug-lipid 
conjugates have two main advantages: 1) the drugs are covalently linked to the lipids 
and thus leakage is circumvented and 2) the lipophilic bilayer of the formulated 
liposomes effectively shields the drugs from the aqueous environment in vivo. 
Consequently, the strategy accommodates therapeutic agents with otherwise 
unfavorable pharmacokinetic properties.  We have designed and synthesized different 
prodrugs, including published examples using capsaicin, chlorambucil and all-trans 
retinoic acid as the cytotoxic agents. Currently, we are investigating more potent agents 
targeting nuclear receptors and structural proteins. The presentation will highlight 
various strategies and recent progress towards improved systems, including chemical 
synthesis, enzyme activity and cytotoxicity. 
MEDI 21 
Small-molecule and peptide inhibitors of the toll-like receptors 
Hang (Hubert) Yin, hubert.yin@colorado.edu. Department of Chemistry and 
Biochemistry, University of Colorado at Boulder, Boulder CO 80309-0215, United States  
The protein-protein and protein−RNA interfaces have been regarded as “undruggable” 
despite their importance in many biological processes. The toll-like receptors provide 
exciting targets for a number of infectious diseases, pain management, and cancers. 
Our previous work showed that a rationally designed peptide can disrupt the TLR4–
MD2 association, thereby blocking TLR4 signaling. Aiming to identify more drug-like, 
small molecule inhibitors of these TLRs, we developed a novel in silico screening 
methodology incorporating Molecular Mechanics (MM)/implicit solvent methods to 
evaluate binding free energies and applied this technology to the identification of 
inhibitors of the TLR4/MD-2 interaction. In silico and cellular assay results demonstrated 
that the identified compounds selectively block TLR4 activation in live cells. Animal 
model tests showed that these compounds could potentiate morphine-induced 
analgesia in vivo, presumably by attenuating the opioid-induced TLR4 activation. To 
demonstrate the general applicability of this methodology, we further developed a series 
of small-molecule probes that were shown to be competitive inhibitors of dsRNA binding 
to TLR3 with high affinity and specificity. In a multitude of assays, the optimized small 
molecule inhibitor was profiled as a potent antagonist to TLR3 signaling and also 
repressed the expression of downstream signaling pathways mediated by the 
TLR3/dsRNA complex, including TNF-α and IL-1β.  
MEDI 22 
Discovery of small molecule inhibitors of the vitamin D receptor-coregulator 
interactions as transcriptional regulators for the 24-hydroxylase gene CYP24A1 
Alexander (Leggy) Arnold, arnold2@uwm.edu; Premchendar Nandhikonda; Wen Z 
Lynt; Megan M McCallum; Athena Baranowski; Tahniyath Ara. Department of Chemistry 
and Biochemistry, University of Wisconsin Milwaukee, Milwaukee Wisconsin 53211, 
United States  
The development of new anti-cancer therapies based on vitamin D analogs have been 
complicated by the fact that these compounds have a high risk of causing 
hypercalcemia and hypercalciurea. Vitamin D analogs, such as the endogenous vitamin 
D analog, 1,25-dihydroxy vitamin D3 (1,25-(OH)2D3), bind to the vitamin D receptor 
(VDR), which in turn regulates genes responsible for cell differentiation, proliferation, 
and calcium homeostasis. One of the most important genes regulated by VDR is the 24-
hydroxylase gene (CYP24A1), which is over-expressed in many cancers and regulates 
1,25-(OH)2D3 levels through catabolism. Herein, we describe the identification of novel 
transcriptional inhibitors of CYP24A1 using high throughput screening. These molecules 
disrupt the interactions between VDR and coregulator proteins, which are essential for 
the VDR-mediated expression of CYP24A1. Our hypotheses is that down-regulation of 
CYP24A1 in the presence of these compounds will locally elevate 1,25-(OH)2D3 levels 
inducing anti-proliferation and differentiation of cancer cells. 
MEDI 23 
Modular synthesis and biological evaluation of novel estrogen receptor ligands 
based on a 7-thia-bicyclo[2.2.1]hept-2-ene-7-oxide or 7-oxabicyclo[2.2.1]hept-5-
ene skeleton 
Haibing Zhou1, zhouhb@whu.edu.cn; Yangfan Zheng1; Pengcheng Wang1; John A. 
Katzenellenbogen2; Kendall W. Nettles3. (1) School of Pharmaceutical Sciences, Wuhan 
University, Wuhan Hubei 430071, China (2) Department of Chemistry, University of 
Illinois, 600 South Mathews Avenue, Urbana IL 61801, United States (3) Department of 
Cancer Biology, The Scripps Research Institute, 5353 Parkside Dr./Jupiter FL 33458, 
United States  
The estrogen receptors (ERs), members of the family of nuclear receptors, have 
emerged as attractive pharmaceutical targets for therapeutic intervention in a wide 
variety of diseases, including osteoporosis and breast cancer. Our particular interest is 
to synthesize a series of SERMs possessing a more three-dimensional topology central 
hydrophobic core. This design strategy was based on structural studies of the ligand 
binding pockets of both ERα and ERβ that reveal substantial unoccupied space above 
and below the mean plane of the endogenous ligand, estradiol (E2). By incorporating a 
hydrophobic bicyclic unit as the core structure of new ligands, we hoped to exploit this 
unfilled space in the ER binding pocket and thereby, potentially, to enhance the potency 
(e.g., the binding affinity, selectivity etc). We describe our effects on the development of 
novel ER ligands based on an inherently three-dimensional 7-thia-bicyclo[2.2.1]hept-2-
ene-7-oxide or 7-oxabicyclo[2.2.1]hept-5-ene core structure. Most of these compounds 
were conveniently synthesized by a Diels-Alder reaction of various 3,4-diarylthiophene 
or furans with a variety of dienophiles under mild conditions. Some of these ligands 
have unexpected biological selectivities that could be medically important. 
MEDI 24 
Small molecule allosteric regulators of coagulation 
Umesh R Desai, urdesai@vcu.edu. Medicinal Chemistry, Virginia Commonwealth 
University, Richmond VA 23219, United States  
A central paradigm of regulating clotting has revolved around targeting the active site of 
one or more enzymes of the coagulation cascade. Thousands of molecules have been 
studied as active site inhibitors and a couple have reached the clinic. Yet, antithrombotic 
therapy continues to suffer from high risk for bleeding and adverse reactions. We 
propose a novel strategy for new line of coagulation regulation that promises to offer 
higher selectivity and regulation capability. Our strategy revolves around synthetic, 
small molecule-based allosteric regulation of thrombin, factor Xa and factor XIa. A small 
library of approximately 30 molecules was designed based on our macromolecular 
leads called sulfated low molecular weight lignins. The small molecules were 
synthesized in less than 10 steps were found to potently inhibit thrombin, factor Xa and 
factor XIa. The inhibition arises primarily from an allosteric disruption of enzymatic 
catalytic apparatus. Competitive inhibition studies show that the designed small 
molecules interact with exosite II-like domain of these enzymes. Studies using A549 
lung and HepG2 liver cell lines show no toxicity at concentrations as high as 50 mg/L of 
the most active molecules. The novel molecular mechanism of action and the novel 
structural scaffold of these anticoagulants suggest a strong possibility for discovering 
radically new anticoagulants. 
MEDI 25 
Computational design development of prolyl oligopeptidase inhibitors 
Nicolas Moitessier, nicolas.moitessier@mcgill.ca. Department of chemistry, McGill 
University, Montreal Quebec H3A2K6, Canada  
Prolyl oligopeptidase (POP) is an enzyme implicated in a number of neurodegenerative 
diseases and neurological disorders. More specifically, it has been identified as a 
potential therapeutic target in the treatment of Alzheimer's disease. Through the use of 
our recently developed computational tools for drug discovery (Forecaster platform), 
covalent and non covalent POP inhibitors were identified and/or designed. Following 
this design stage, synthesis, and biological evaluation were carried out and were 
compared to our predictions. Some of the computational tools will first be presented in 
the context of POP inhibition followed by development of polycyclic chiral inhibitors 
which required the development of synthetic methodologies and strategies. 
MEDI 26 
Discovery of a dual CCR2 / CCR5 antagonist with a superior cardiovascular 
profile for the treatment of autoimmune diseases 
Robert O Hughes1, robert.o.hughes@pfizer.com; D Joseph Rogier1; Rajesh Devraj1; 
Chu-Biao Xue2; Ganfeng Cao2; Steven R Turner1; Philip A Morton1; Kelly Keys1; 
Maryanne Covington2; Brian R Bond1; Ying Yu1; Holly Meade1; William F Hood1; Steve 
Roeberds1; Robert Newton2; Brian Metcalf2. (1) Pfizer Research and Development, 
Cambridge MA 02451, United States (2) Incyte Corporation, Willmington MA 19880, 
United States  
Chemokines are chemotactic cytokines which are critical for the regulation of cellular 
trafficking.  The chemoattractive activity of the chemokines is mediated through binding 
to G-protein coupled receptors. Chemokine-receptor binding initiates a cascade of 
intracellular signalling events mediated by receptor-associated heterotrimeric G 
proteins, culminating in alterations in the cytoskeleton associated with directed cell 
migration. Leukocyte trafficking and survival contributes importantly to chronic 
inflammatory states such as Rheumatoid Arthritis (RA), atherosclerosis, multiple 
sclerosis (MS) and diabetic nephropathy. The C-C class of chemokine receptors 
expressed on a subset of leukocytes responsible for both innate and adaptive immunity, 
particularly CCR1, CCR2, and CCR5, are promising and tractable targets for 
development of new pharmacological inhibitors of inflammation and autoimmunity. As 
these chemokine receptors are expressed on a subset of cells responsible for both 
innate and adaptive immunity, we and others have attempted to develop small molecule 
antagonists of these members of the C-C chemokine receptor family. Attractive as these 
targets are, the development of small molecule antagonists has been hampered by the 
challenging physical property space required to achieve potency and cardiovascular 
(CV) safety concerns. In this presentation we will disclose some of our findings towards 
the development of novel orally bioavailable, potent and safe dual inhibitors of CCR2 
and CCR5. We describe key preclinical data that led to optimal compound selection. 
Three generations of clinical candidates will be described. 
MEDI 27 
PF-4958242: A novel AMPA positive allosteric modulator (PAM) for the treatment 
of cognitive deficits associated with schizophrenia 
Christopher J O'Donnell, christopher.j.odonnell@pfizer.com. Neurosciences Medicinal 
Chemistry, Pfizer Inc, Groton CT 06340, United States  
The amino acid neurotransmitter glutamate (Glu) mediates virtually all excitatory 
neurotransmissions in the mammalian brain and AMPA (a-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid) receptors mediate the majority of these 
neurotransmissions and are essential in a broad range of physiological processes. 
Glutamate dysregulation/NMDA hypofunction are hypothesized to be key pathologies of 
schizophrenia and potentiating or modulating AMPA receptors can enhance Glu 
signaling, improve performance in preclinical models of cognition and improve long term 
potentiation. The medicinal chemistry strategy along with the preclinical pharmacology, 
pharmacokinetics and safety date that led to the discovery of PF-4958242, a novel 
AMPA positive allosteric modulator will be described. PF-4958242 is currently in Ph 1 
clinical trials and the single dose escalation human PK data will be disclosed. Taken 
together, this compound provides an exciting opportunity to treat the cognitive deficits 
associated with schizophrenia. 
MEDI 28 
Discovery of TAK-960: An orally available small molecule inhibitor of Polo-Like 
Kinase 1 (PLK1) 
Zhe Nie1, zhe.nie@takedasd.com; Victoria Feher1, 2; Srinivasa R Natala1; Christopher 
McBride1; Andre Kiryanov1; Benjamin Jones1; Betty Lam1; Yan Liu1, 3; Stephen Kaldor1, 
4; Jeffrey Stafford1, 5; Kouki Hikami6; Noriko Uchiyama6; Tomohiro Kawamoto6; Yuichi 
Hikichi6; Lilly Zhang1; David Hosfield1, 7; Robert Skene1; Hua Zou1; Sheldon Cao1, 8; 
Takashi Ichikawa1, 6. (1) Takeda San Diego, United States (2) UC Irvine, United States 
(3) University of Florida, United States (4) Kaldor Consulting, United States (5) 
Quanticell Pharma Inc., United States (6) Takeda Pharmaceutical Company, Ltd., 
Japan (7) Affinity Pharmaceuticals, United States (8) Cerep Ltd., United States  
This oral presentation will focus on the discovery of TAK-960, an orally available, potent 
and selective PLK1 inhibitor currently in a Phase I clinical trial in patients with advanced 
non-hematologic malignances. PLK1 inhibition is an attractive approach for the 
treatment of proliferative diseases, for PLK1 plays a key role in the regulation of mitotic 
progression and the over-expression of PLK1 is associated with poor prognosis and 
survival rates in a number of human cancers. Using structure based drug design we 
identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting 
in the selection of development candidate TAK-960. The discovery of TAK-960 provides 
an interesting example of how the addition of fluorine atoms during optimization 
significantly alters the attributes of the leads series. We will show the beneficial 
influence of adding fluorine atoms on dissociation kinetics of the ligands upon binding to 
PLK1, MDR1 transporter affinity and oral bioavailability. 
MEDI 29 
Discovery of GS-9256: A novel phosphinate HCV NS3 protease inhibitor 
Christopher Sheng1, csheng@gilead.com; Mike Clarke1; Mingzhe Ji1; Hyungjung 
Pyun1; Qiaoyin Wu1; Ruby Cai1; Kleem Chaudhary1; Jianying Wang1; Chin Tay2; Xiaowu 
Chen3; Todd Appleby3; Roshy Pakdaman4; Chris Yang4; Huiling Yang5; Margaret 
Robinson5; Ruth Wang5; Edward Doerffler1; Xiaohong Liu5; Ona Barauskas5; Brian 
Schultz5; Bill Delaney5; Choung Kim1. (1) Dept. of medicinal chemistry, Gilead Sciences 
Inc, Foster City CA 94404, United States (2) Dept of toxicology, Gilead Sciences Inc, 
United States (3) Dept of structural chemistry, Gilead Sciences Inc, United States (4) 
DMPK, Gilead Sciences Inc, United States (5) Dept of biology, Gilead Sciences Inc, 
United States  
GS-9256 is a specific inhibitor of HCV NS3 protease and is currently in phase 2 
development for the treatment of genotype 1 (GT1) HCV infection. GS-9256 
demonstrated potent and selective inhibition of NS3 protease in biochemical assays (Ki 
= 90 pM for GT1 NS3 with >10,000-fold selectivity over all tested mammalian 
proteases). In multiple GT1a and 1b replicon cell lines, GS-9256 had median EC50 
values of 30 nM and 99 nM, respectively. CC50 values ranged between 19,000 – 45,000 
nM. This presentation will describe detailed SAR and pharmacokinetic optimizations 
leading to the discovery of GS-9256. 
MEDI 30 
Discovery of a potent and selective γ-secretase inhibitor for the treatment of 
Alzheimer's disease 
Wen-Lian Wu1, wen-lian.wu@merck.com; Theodros Asberom1; Thomas Bara1; Chad 
Bennett1; Duane Burnett1; Mary Ann Caplen1; John Clader1; David Cole1; Michael 
Czarniecki1; Martin Domalski1; William J Greenlee1; Hubert Josien1; Chad Knutson1; 
Hongmei Li1; Mark McBriar1; Troy McCracken1; Brian McKittrick1; Dmitri Pissarnitski1; Li 
Qiang1; Murali Rajagopalan1; Thavalakulamgar K Sasikumar1; Jing Su1; Haiqun Tang1; 
Monica Vicarel1; Ruo Xu1; Zhiqiang Zhao1; Mary Cohen-Williams2; Robert Del Vecchio2; 
Lynn Hyde2; Prescott Leach2; Julie Lee2; Eric Parker2; Lixin Song2; Giuseppe 
Terracina2; Lili Zhang2; Qi Zhang2; Shiying Chen3; Inhou Chu3; Xiaoming Cui3; James 
Jean3; Amin A Nomeir3; Tony Soares3; Ann Thomas3; Greg Tucker3; Xiaoying Xu3; Qiao 
Zhou3. (1) Department of Medicinal Chemistry, Merck Research Laboratory, Kenilworth 
NJ 07033, United States (2) Department of In Vitro and in Vivo Biology, Merck 
Research Laboratory, Kenilworth NJ 07033, United States (3) Department of Drug 
Metabolism & Pharmacokinetics, Merck Research Laboratory, Kenilworth NJ 07033, 
United States  
Alzheimer's disease (AD) is a neurodegenerative disorder manifested by cognitive 
impairment, behavioral disturbances, speech difficulties, and deterioration of many other 
activities of daily life. Two major pathological hallmarks of AD are intracellular 
neurofibrillary tangles and extracellular amyloid plaques. The latter is mainly comprised 
of aggregated forms of the 40-42 residue amyloid β-peptides (Aβ), which are produced 
by sequential cleavage of the amyloid precursor protein (APP) by BACE and γ-
secretase. Reduction of Aβ by inhibition of γ-secretase represents an attractive strategy 
to combat Alzheimer's disease. In addition to APP, γ-secretase has many other 
substrates, notably Notch. Inhibition of Notch processing is responsible for many of the 
mechanism-based side effects associated with γ-secretase inhibition. It is imperative to 
balance the therapeutic efficacy and the risk of mechanism-based toxicity. Starting from 
a known sulfone-based γ-secretase inhibitor (GSI), conformational restriction led to a 
novel series of tricyclic analogs. Further optimization of the tricyclic core and the side 
chain culminated in the discovery of a clinical candidate, which demonstrated excellent 
in vitro and in vivo efficacy in several animal models with a high therapeutic window. 
MEDI 31 
Design and synthesis of novel macrocyclic structures as potent Hsp90 inhibitors 
Christoph W Zapf1, chzapf@gmail.com; Jonathan D Bloom2; Russell G Dushin1; 
Jennifer M Golas1; Hao Liu2; Judy Lucas1; Frank Boschelli1; Erik Vogan2; Jeremy I 
Levin2; Thomas Nittoli2. (1) Pfizer, Cambridge Massachusetts 02140, United States (2) 
Wyeth, Pearl River NY 10965, United States  
We wish to disclose a series of macrocyclic lactones and lactams some of which have 
been found to be highly potent at inhibiting Hsp90 in an enzyme and cell-based assays. 
The lactones and lactams were accessed by novel synthetic methods which allowed 
their preparation in good yields. Based on potency and physical properties we selected 
analogs for X-ray crystallography as well as in vivo tumor exposure and biomarker 
studies. 
MEDI 32 
Synthesis and evaluation of pyrazole analogs as antimitotic agents 
Yuuki Hirata1, yuuki.hirata@kyowa-kirin.co.jp; Tomoyuki Nakazato1; Yusuke Yamada1; 
Toshikazu Saitoh1; Kazuhiko Kato1; Junichiro Yamamoto1; Kimihisa Ueno1; Yoshisuke 
Nakasato1; Asae Igarashi2; Ryuichiro Nakai2; Tetsuo Yoshida3; Shinji Nara1. (1) 
Department of Medicinal Chemistry Research Laboratories, Kyowa Hakko Kirin 
Co.,Ltd., 1188 Shimotogari, Nagaizumi-cho Sunto-gun, Shizuoka 411-8731, Japan (2) 
Department of Drug Discovery Research Laboratories, Kyowa Hakko Kirin Co.,Ltd., 
Japan (3) Department of Innovative Drug Research Laboratories, Kyowa Hakko Kirin 
Co.,Ltd, Japan  
Compound 1 was found as an antimitotic agent. Compound 1 induced mitotic arrest and 
cell growth inhibition in tumor cells, suggesting that compound 1 could be a potential 
candidate as an anticancer agent. The derivative analogues of the compound 1 were 
synthesized using SNAr-type or copper-catalyzed reaction between pyrazoles 2 and 2-
halothiazoles 3. Several analogues exhibited significant improvement in the 
antiproliferative activity against HeLa cells. Synthetic studies and SAR of pyrazoles and 
quinolones will be presented.  
  
MEDI 33 
N-alkylated diaryl pyrazoles: Selective Aurora kinase inhibitors 
Jeffrey M. Ralph, Jeffrey.m.ralph@gsk.com; Yanhong Feng; Thomas H Faitg; 
Domingos J Silva; Jerry L Adams; Mary Ann Hardwicke; Jamin Wang; Catherine 
Oleykowski; Melody Diamond; David Sutton; Leo Faucette; Ramona Plant. Oncology 
R&D, Protein Dynamics DPU, GlaxoSmithKline, 1250 S. Collegeville Rd, Collegeville 
PA 19426, United States  
This image cannot currently be displayed.
A series of N-alkylated diaryl pyrazoles has been prepared as inhibitors of Aurora B. 
Originally pursued as ErbB+ kinase inhibitors, pyrazolopyridines such as compound 1 
were identified as early leads for the Aurora effort. These compounds displayed good 
activity against Aurora B in enzymatic and cellular assays. However, the series suffered 
from poor developability, which we attributed to high molecular weight and clogP. In an 
effort to identify more developable Aurora inhibitors, we have investigated the 
corresponding pyrazoles, derived from the pyrazolopyridines by removal of the central 
phenyl ring. The pyrazoles proved to be excellent Aurora inhibitors, with potent 
enzymatic and cellular activities, good kinase selectivity and improved developability 
properties. 
   
MEDI 34 
Evaluation of N-acyl sulfonamide prodrug inhibitors of MEK kinase 
Jeffrey m Ralph, jeffrey.m.ralph@gsk.com; Jerry L Adams; Domingos J Silva; Yanhong 
Feng; Peter J Martin; Swarupa G Kulkarni; Katherine G Moss; Cynthia Rominger; 
Maureen R Bleam; Sylvie G Laquerre. Oncology R&D, Protein Dynamics DPU, 
GlaxoSmithKline, Collegeville PA 19426, United States  
A series of novel N-acylsulfonamide prodrugs were evaluated and profiled as inhibitors 
of MEK kinase. Our pursuit of MEK inhibitors led us to compound 1, which displayed 
highly potent and selective inhibition of MEK enzymatic and cellular activities. However, 
compound 1 had poor solubility and no oral exposure in rats. Using a prodrug approach, 
solubility and pharmacokinetic parameters of a series of MEK inhibitors were improved, 
culminating in the discovery of the propionyl sulphonamide 7. Optimization led to the 
discovery of compound 7, which showed improved solubility and PK. This poster 
describes the SAR leading to compound 7 and the multi-species in vitro and in vivo PK 
to support compound 7 as a potential candidate.   
  
MEDI 35 
Exploitation of multitarget prostate cancer clinical candidate VN/124-1 (TOK-001) 
to develop a novel class of androgen receptor down regulating agents for 
prostate cancer therapy 
Purushottamachar P Puranik1, purupuranik@gmail.com; Abhijit M Godbole2; Vincent 
C. O. Njar1; Zeynep Ates-Alagoz3; Lalji K Gediya1. (1) Department of Pharamaceutical 
Sciences, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia 
Pennsylvania 19107, United States (2) Department of Pharmacology & Experimental 
Therapeutics, School of medicine, University of Maryland Baltimore, Baltimore Maryland 
21201, United States (3) Department of Pharmaceutical Sciences, Philadelphia College 
of Pharmacy, University of the Sciences, Philadelphia Pennsylvania 19104, United 
States  
The androgen receptor (AR) is a critical mediator of prostate cancer (PC) proliferation at 
virtually all stages of PC, including the dreaded castration-resistant stage. Selective AR 
down-regulators (SARDs) reduce AR protein levels as well as block AR activity and 
therefore are promising agents for the treatment of PC. Our clinical candidate novel 
VN/124-1 (TOK-001) is a potent CYP17 inhibitor/antiandrogen with modest AR down-
regulating activity (EC50 ~ 10 µM). In the present study we used VN/124-1 to conduct 
lead optimization to develop a novel class of AR down-regulating agents. A series of 
new compounds were designed, synthesized and evaluated for their abilities to 
suppress AR expression in LNCaP cells and inhibition of LNCaP cell viability by 
Western blot analysis and MTT assay, respectively. Our design strategy involved 
systematic modification of rings A, B or D; and modifications at C-3, C-16 and C-17 of 
our lead VN/124-1, resulted in novel potent anti-PC agents. 
MEDI 36 
Library of chimera of novoniocin and silybin manifest antiproliferative activity 
through Hsp90 inhibition 
Huiping Zhao, hpzhao@ku.edu; Brian S. J. Blagg. Medicinal Chemistry Department, 
The University of Kansas, Lawrence KS 66045, United States  
Hsp90 is a promising therapeutic target for cancer and neurodegenerative diseases. 
The potential therapeutic benefits associated with Hsp90 modulation highlight the 
importance of identifying novel Hsp90 modulators. Novobiocin and silybin were 
identified as Hsp90 inhibitors and SAR studies revealed essential structural features for 
their Hsp90 modulation. A library of chimerical compounds incorporated these structural 
features were designed and synthesized, their biological activities were evaluated in 
multiple cancer cell lines. 
MEDI 37 
Potent and selective cyclic sulfones as mTOR selective inhibitors 
Kevin K.-C. Liu, kevin.k.liu@pfizer.com; Simon Bailey; Chunze Li; Dac Dinh; Aihua 
Zou; John Li; Xiao-Hong Yu; Peter A Wells. Department of Chemistry, Pfizer Inc, San 
Diego CA 92121, United States  
mTOR is a protein kinase and member of the phosphoinositide-3-kinase-related kinase 
(PIKK) family. Genomic aberrations in PI3K pathway are the 2nd most frequent in 
human cancers. The catalytic domain of mTOR comprises at least two functional 
complexes, mTORC1 (raptor) and mTORC2 (rictor), which play critical roles in cellular 
signaling, growth and survival, metabolism, and protein synthesis. Rapamycin and its 
analogs (Raplogs) target mTORC1 only and they are known to only give modest clinical 
efficacy. We are hoping that mTOR kinase inhibitors which not only inhibit mTORC1 but 
also mTORC2 as well may yield a more efficious anti-cancer agent. A series of 
mTORC1 and 2 selective inhibitors with a cyclic sulfone scaffold are described showing 
excellent biochemical potencies, selectivties over PI3Ka and other broad-panel kinases. 
The SAR of this series compounds will be discussed   
MEDI 38 
Discovery of TAK-960 part II: Development and in vivo characterization of 7,7-
difluoro-pyrimidodiazepinone derivatives as potent inhibitors of Polo-like Kinase 
1 (PLK1) 
Christopher McBride1, chris.mcbride@takedasd.com; Zhe Nie1; Victoria Feher1, 2; 
Srinivasa Natala1; Andre Kiryanov1; Benjamin Jones1; Betty Lam1; Yan Liu1, 3; Stephen 
Kaldor1, 4; Jeffrey Stafford1, 5; Kouki Hikami6; Noriko Uchiyama6; Tomohiro Kawamoto6; 
Yuichi Hikichi6; Lilly Zhang1; David Hosfield1, 7; Robert Skene1; Hua Zou1; Sheldon Cao1, 
8; Takashi Ichikawa1, 6. (1) Takeda San Diego, United States (2) UC Irvine, United 
States (3) University of Florida, United States (4) Kaldor Consulting, United States (5) 
Quanticell Pharma, Inc, United States (6) Takeda Pharmaceutical Company, Ltd., 
Japan (7) Affinity Pharmaceuticals, United States (8) Cerep Ltd., United States  
This poster describes the identification of the clinical candidate TAK-960, an orally 
available and highly selective small molecule Polo-like Kinase 1 (PLK1) inhibitor 
currently in a Phase I study in patients with advanced non-hematologic malignancies. 
PLK1 inhibition is an attractive approach for the treatment of proliferative diseases 
based on its key role in the regulation of mitotic progression. The over-expression of 
PLK1 is associated with poor prognosis and survival rates in a number of human 
cancers. In Part I of this presentation, we discussed the structure based design of a 7,7-
difluoro-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one lead scaffold which 
binds PLK1 in an ATP competitive manner and exhibits slow dissociation kinetics. This 
part of the presentation will describe amendments to the C2, N5, and N9 positions of the 
core and the resulting in vitro properties (enzymatic binding, cellular activity, DMPK). 
Herein, we also share some results from the pharmacokinetic, pharmacodynamic and 
efficacy studies which led to the identification of TAK-960. This work provides a 
noteworthy example of how the addition of fluorine atoms during optimization 
significantly alters the attributes of the lead series. TAK-960 is active against a broad 
spectrum of cancer cell lines including MDR1 expressing cell lines. 
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Discovery of TAK-960 Part I: Design and synthesis of 7,7-difluoro-
pyrimidodiazepinone derivatives as potent inhibitors of Polo-like Kinase 1 (PLK1) 
Srinivasa Reddy Natala1, snatala@takedasd.com; Zhe Nie1; Victoria Feher1, 2; 
Christopher McBride1; Andre Kiryanov1; Benjamin Jones1; Betty Lam1; Yan Liu1, 3; 
Stephen Kaldor1, 4; Jeffrey Stafford1, 5; Kouki Hikami6; Noriko Uchiyama6; Tomohiro 
Kawamoto6; Yuichi Hikichi6; Lilly Zhang1; David Hosfield1, 7; Robert Skene1; Hua Zou1; 
Sheldon Cao1, 8; Takashi Ichikawa1, 6. (1) Takeda San Diego, United States (2) Current: 
UC Irvine, United States (3) Current: Moffitt Cancer Center, United States (4) Current: 
Kaldor Consulting, United States (5) Current: Quanticell Pharma, Inc, United States (6) 
Takeda Pharmaceutical Company, Ltd., Japan (7) Current: Affinity Pharmaceuticals, 
United States (8) Current: Cerep Ltd, United States  
Polo-like Kinase 1 (PLK1) has recently emerged as an attractive drug target for treating 
proliferative disorders such as cancer. PLK1 is overexpressed in variety of human 
cancers and is associated with poor prognosis and survival rates. PLK1 plays a critical 
role in the cell cycle, controlling entry into and progression through mitosis at multiple 
stages. Inhibition of PLK1 function causes G2/M cell cycle arrest and tumor cell 
apoptosis resulting in tumor growth suppression, which has been observed in both 
animal models and clinical evidence from humans. In comparison to marketed 
antimicrotubule drugs (i.e. Taxanes and Vincas), inhibitors of PLK1 are expected to be 
more selective for mitosis and mitigate side effects such as neuropathy.     In this 
presentation, we will discuss the structure based design of an 8,9-dihydro-5H-
pyrimido[4,5-b][1,4]diazepin-6(7H)-one core and the structure activity relationship 
studies of its C7-position. This investigation led us to the identification of novel and 
potent 7,7-difluoro-pyrimidodiazepinone derivatives as PLK1 inhibitors. Analysis of co-
crystal structures of this series demonstrates that appropriate C7 substitutions interact 
favorably with “roof pocket” and adjacent water molecules which were believed to 
contribute to their improved enzyme potency, efficacy and slow dissociation kinetics. 
Further lead optimization of this series (Part II), led to the identification of a novel orally 
available small molecule PLK1 inhibitor TAK-960, which is currently in Phase-I clinical 
trial. 
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Design and synthesis of novel HER2/EGFR dual inhibitors: Discovery of TAK-285 
bearing a pyrrolo[3,2-d]pyrimidine scaffold 
Tomoyasu Ishikawa1, Ishikawa_Tomoyasu@takeda.co.jp; Masaki Seto1; Hiroshi 
Banno1; Youichi Kawakita1; Mami Oorui1; Takahiko Taniguchi1; Yoshikazu Ohta1; 
Toshiya Tamura1; Akiko Nakayama1; Hiroshi Miki1; Hidenori Kamiguchi1; Toshimasa 
Tanaka1; Noriyuki Habuka1; Satoshi Sogabe1; Jason Yano2; Kathleen Aertgeerts2; Keiji 
Kamiyama1. (1) Pharmaceutical Research Division, Takeda Pharmaceutical Company 
Limited, Tsukuba Ibaraki 300-4293, Japan (2) Structural Biology, Takeda San Diego 
Inc., San Diego California CA92121, United States  
Pyrrolo[3,2-d]pyrimidine derivatives capable of fitting into the ATP binding site of the 
HER2/EGFR protein were designed and synthesized. The clinical candidate, TAK-285, 
potently inhibited HER2 and EGFR with IC50 values of 17 and 23 nM, respectively, 
indicating selective inhibition of the HER family kinases. TAK-285 also inhibited the 
growth of the HER2-overexpressing human breast cancer cell line BT474 (GI50 17 nM). 
Furthermore, reflecting its good oral bioavailability, TAK-285 exhibited potent, dose-
dependent efficacy in rats and inhibited the growth of HER2-overexpressing 4-1ST 
tumors with T/C of 38% and 14% at 6.25 and 12.5 mg/kg and, notably, tumor regression 
with T/C of -12% and -16% at 25 and 50 mg/kg.  The first X-ray co-crystal structures of 
TAK-285 with HER2 and EGFR demonstrated TAK-285 interaction with the expected 
residues in their respective ATP pockets. Therefore, TAK-285 appears to be a 
promising candidate for clinical development as a novel HER2/EGFR dual kinase 
inhibitor. 
MEDI 41 
Molecular dynamics simulation studies of recognition of anticancer drug-induced 
DNA damage by repair proteins 
Robert M Elder, robert.elder@colorado.edu; Arthi Jayaraman. Department of Chemical 
& Biological Engineering, University of Colorado-Boulder, Boulder CO 80303, United 
States  
Platinum-based chemotherapeutic drugs, such as cisplatin, work by covalently binding 
to DNA, inducing severe local structural changes. Numerous proteins, including DNA 
repair and tumor-suppressor proteins, recognize these structural changes induced by 
the drug-DNA adducts. Some of these protein-DNA interactions lead to arrest of the cell 
cycle and apoptosis of the cancer cells, which leads to high cure rates for certain 
cancers. However, some protein-DNA interactions lead to repair of the drug-DNA 
adduct and resistance to the drug. In order to circumvent and develop better drug, one 
needs to understand the molecular-mechanism underlying differential recognition of the 
various drug-DNA adducts. We use atomistic molecular dynamics simulations to probe 
the thermodynamic and structural differences in protein-drug-DNA complexes with the 
goal of engineering new drugs with desirable protein interactions. 
MEDI 42 
DNA methyltransferase inhibitors: Homology modeling, docking, and structure-
based pharmacophore 
José L Medina-Franco, jmedina@tpims.org; Jakyung Yoo. Torrey Pines Institute for 
Molecular Studies, Port St Lucie Florida 34987, United States  
DNA methylation is a covalent chemical modification of DNA catalyzed by DNA 
methyltransferases (DNMTs) and plays a crucial role in epigenetic modifications. 
Inhibition of DNMT is a promising strategy for the treatment of cancer and other 
diseases. To understand the interaction of known inhibitors with DNMT1, we performed 
docking studies of DNMT1 inhibitors with a homology model of the catalytic domain of 
human DNMT1. The docking models allowed the identification of key molecular 
interactions between the inhibitors and the binding pocket. We also report a structure-
based pharmacophore model that was derived from the optimized docked 
conformations of the inhibitors [1]. The common pharmacophore features are in 
agreement with the hypothetical binding profile proposed by docking studies. The 
results of this work will be valuable for the structure-based design and virtual screening 
for novel inhibitors targeting DNMT1 [2]. [1] Yoo, J.; Medina-Franco, J. L. J. Comp.-
Aided Mol. Des., submitted. [2] Medina-Franco, J. L.; Caulfield, T. Drug Discovery 
Today, (2011) in press. PMID: 21315180. 
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Identification of novel and potent ALK inhibitor CH5424802 
Kohsuke Asoh, asokus@chugai-pharm.co.jp; Nobuhiro Oikawa; Kazutomo Kinoshita; 
Noriyuki Furuichi; Toshiya Itoh; Hatsuo Kawada; Sousuke Hara; Takuho Miyagi; Jun 
Ohwada; Saori Taniguchi; Kazuo Hattori; Takuo Tsukuda; Takamitsu Kobayashi; 
Takaaki A Fukami; Kenji Takanashi; Hiroshi Sakamoto; Toshiyuki Tsukaguchi; Sayuri 
Hiroshima; Tatsushi Kodama; Nobuya Ishii; Yuko Aoki; Nobuo Shimma. Chugai 
Pharmaceutical Co., Ltd., Japan  
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in 
some cancers, due to gene alterations such as chromosomal translocation, 
amplification, or point mutation. We discovered a compound with a unique tetracyclic 
structure showing inhibitory activity against ALK from our corporate library. Our 
chemical modification of the scaffold enabled us to select CH5424802 as a clinical 
candidate. CH5424802 has a preferable PK profile and good oral bioavailability in rats 
and monkeys, and showed preferential antitumor activity against cancers with gene 
alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-
ALK fusion both in vitro and in vivo. CH5424802 also inhibited ALK L1196M, which 
corresponds to the gatekeeper mutation conferring common resistance to kinase 
inhibitors. CH5424802 is currently being investigated in Phase I/II clinical trials for 
patients with ALK-positive NSCLC. Our poster presentation will also show the synthesis 
of the tetracyclic derivatives and the modification strategy to improve kinase selectivity 
and metabolic stability as well as ALK inhibition potency. 
MEDI 44 
Design and synthesis of novel linkable proteasome inhibitors and their folate 
conjugates 
Longwu Qi1, lqi@endocyte.com; Iontcho R. Vlahov1; Fei You1; Yu Wang1; Spencer J. 
Hahn1; Paul J. Kleindl1; Christopher P. Leamon2. (1) Department of Discovery 
Chemistry, Endocyte Inc., West Lafayette IN 47906, United States (2) Department of 
Discovery Biology, Endocyte Inc., West Lafayette IN 47906, United States  
In this poster we present our results related to the design and synthesis of novel 
proteasome inhibitors and their conjugates with folic acid (FA). In vivo FA will serve as a 
high affinity ligand for the folate receptor – a protein, highly expressed on the outer layer 
of cellular membranes in a variety of cancer types. Consequently, such approach might 
prove to be useful for targeted treatment of solid tumors thus minimizing side effects, 
associated with the therapeutic applications of non-targeted cytotoxic agents. In the 
molecular drug design we focused our attention on boronic-acid-based proteasome 
inhibitors. In their chemical structures we placed several linkable functional groups 
serving as regioselective site of conjugation. All conjugates were synthesized using a 
proprietary protocol and involving incorporation of two additional molecular modules in 
the construct: a carbohydrate-based, negatively charged spacer unit, and a bio-
releasable disulfide-based linker system. 
MEDI 45 
Folate receptor binding conjugates of antifolate 
Fei You, Fei_You@Endocyte.com; Iontcho R. Vlahov; Christopher P. Leamon. 
Endocyte, Inc., West Lafayette IN 47906, United States  
Antifolates are used in cancer chemotherapy by interfering DNA and RNA synthesis of 
cancer cells. Some antifolates have high binding affinity to folate receptor (FR). FR is 
frequently over-expressed in some of the most prevalent tumors. FR-binding antifolates 
can be used as ligands for FR-targeted delivery of therapeutic agents. To demonstrate 
the dual roles of antifolates as ligands and therapeutic agents, we reported here an 
improved synthesis of antifolate CB3717 and its conjugates of cytotoxic molecules. A 
hydrophilic spacer unit and two biologically releasable disulfide-based linker systems 
were used to construct the conjugates. These conjugates showed high relative affinity 
for FR and excellent anti-tumor activities.  
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Efficient total synthesis of Tubulysin B 
Iontcho R Vlahov, ivlahov@endocyte.com; Michael Groaning; Hari Krishna R 
Santhapuram; Paul J Kleindl; Fei You; Yu Wang; Lecun Xu; Katheryn Stanford; Allen 
Ritter; Christopher P Leamon. Endocyte, Inc., West Lafayette IN 47906, United States  
Tubulysins are natural products isolated from myxobacterial species. As cytoskeleton 
interacting agents, tubulysins are mitotic poisons and are extremely potent cytotoxins, 
thus exceeding the cell growth inhibition of any clinicaly relevant traditional 
chemotherapeutic. Structurally, tubulysins are closely related linear tetrapeptides 
comprised of unusual and/or hydrophobic amino acid segments. The isolation of a 
single natural tubulysin from culture extracts requires multistep chromatography and 
provides only limited quantities. Several total syntheses of natural tubulysins and some 
structurally simplified analogues have been reported, but their application is limited to 
small lab scale. Among the multiple challenging synthetic and stereochemical issues, 
most striking is the generation of the labile N,O-diacyl N,O-acetal. In this poster we 
present an efficient jet simplified synthesis of tubulysin B. The optimized synthetic 
protocol relies on chemical as well as enzymatic steps and is readily scalable to 
meaningful quantities. 
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Property guided design of a brain penetrant PI3K inhibitor 
Jennafer Dotson1, jenna@gene.com; Timothy Heffron1; Jodie Pang2; Laurent 
Salphati2. (1) Discovery Chemistry, Genentech, South San Francisco Ca 94080, United 
States (2) Drug Met & Pharm, Genentech, South San Francisco Ca 94002, United 
States  
The well documented deregulation of the PI3K/AKT/mTOR pathway in numerous tumor 
types has established a significant desire for PI3K inhibitors with drug-like properties. 
Furthermore, activation of the PI3K pathway is observed in the majority of all 
glioblastomas. This highlights the need for brain penetrant PI3K inhibitors. This poster 
will discuss how we used property-guided design to achieve significant brain penetration 
with PI3K inhibitors. 
MEDI 48 
Design, synthesis and biological evaluation of novel, conformationally restricted, 
water soluble, substituted pyrrolo[3,2-d]pyrimidines as antitubulin antitumor 
agents 
Roheeth K Pavana1, kp.roheeth@gmail.com; Aleem Gangjee1; Ernest Hamel2; Susan 
L Mooberry3. (1) Division of Medicinal Chemistry, Graduate School of Pharmaceutical 
Sciences, Duquesne University, Pittsburgh PA 15282, United States (2) Screening 
Technologies Branch, Developmental Therapeutics Program, Division of Cancer 
Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of 
Health, Frederick Maryland 21702, United States (3) Department of Pharmacology, 
University of Texas Health Science Center at San Antonio, San Antonio Texas 78229, 
United States  
Despite the unprecedented success of microtubule disrupting agents in cancer 
chemotherapy, multidrug resistance (MDR) is a major limitation of cancer 
chemotherapy, and MDR tumors are usually resistant to tubulin-binding drugs. Our 
efforts in the design of multiple RTK-inhibitors to elucidate the plausible binding modes 
of our compounds led to the discovery of highly potent antimitotic antitumor agents that 
bind to the colchicine-binding site of tubulin and also overcome clinically relevant 
mechanisms of drug resistance: P-glycoprotein and βIII-Tubulin mediated resistance. 
Conformationally restricted pyrrolo[3,2-d]pyrimidine analogs of the lead compounds 
were designed and synthesized. These compounds inhibited microtubule polymerization 
and had GI50's which were two-digit nanomolar against tumor cells in the NCI 60 human 
tumor cell line anticancer drug screen. The design, synthesis and biological activities of 
these analogs will be presented. 
MEDI 49 
Synthesis and biological evaluation of some 16b-azolyl-3b-amino-5a-androstane 
derivatives as potential anticancer agents 
Xianming Hu, xmhu@whu.edu.cn; Hao Guo. State Key Laboratory of Virology, Ministry 
of Education Key Laboratory of Combinatorial Biosynthesis and Drug 
Discovery,Department of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, 
China  
Nitrogen containing steroids have the ability to regulate a variety of biological processes 
and thus are potential drug candidates for the treatment of a large number of diseases. 
An increasing numbers of publications had recently reported the anticancer activities of 
a wide range of natural, semisynthetic and synthetic aminosteroidal compounds. 
However, to the best of our knowledge, little attention has been given to 16-azolyl-3-
amino-androstanes.  On the basis of the above details, we synthesized a series of 
androstane-based aminosteroids to screen their anticancer activity against different 
cancer cell lines in vitro in order to get more potent anticancer agents. The routes 
utilized for the synthesis of our target compounds 16a-g,18a-g,18a-g,19a-g are outlined 
in Figure1 
    
The new compounds were screened for their anticancer activity against the human 
cancer cell lines SW480,A549,HepG2, HeLa and SiHa in vitro using the MTT assay. 
The results of the in vitro study showed that a number of compounds have shown IC50 
values lower than 20μM against the five cancer cell lines. 
MEDI 50 
Indenoisoquinolines: A new class of rexinoids with promising chemopreventive 
potential 
Martin M. Conda-Sheridan1, martinconda@hotmail.com; P.V. Narasimha Reddy1; Lian 
Chen2; Eun-Jung Park3; Tamara P. Kondratyuk3; John M. Pezzuto3; Richard B. van 
Breemen2; Mark Cushman1. (1) College of Pharmacy and the Purdue Center for Cancer 
Research, Purdue University, West Lafayette In 47906, United States (2) College of 
Pharmacy, University of Illinois, Chicago Illinois 60612, United States (3) College of 
Pharmacy, University of Hawaii at Hilo, Hilo Hawaii 96720, United States  
The retinoid X receptor (RXR) plays an important role in cell differentiation, proliferation, 
and apoptosis. Activation of the RXR transcriptional activity by synthetic ligands termed 
rexinoids is a promising chemopreventive strategy. An indenoisoquinoline synthesized 
in our laboratory, AM-6-36, was found to induce the transcriptional activity of this 
receptor response-element in a dose-dependent manner, as determined in a luciferase 
assay, and upregulated the cyclin-dependent kinase inhibitor p21WAF1/CIP1. This report 
will detail the synthesis and biological evaluation of the metabolic products of the RXR 
ligand AM-6-36. In addition, the synthesis and biological evaluation of a series of 
analogs will be reported. AM-6-36 and some of its analogs had in vitro potencies greater 
than the clinically used drug bexarotene. These results provide a foundation for the 
development of a new class of promising RXR activating ligands. 
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Synthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET 
cancer imaging agents for VEGFR 
Mingzhang Gao1, migao@iupui.edu; Christian M. Lola1; Min Wang1; Kathy D. Miller2; 
Qi-Huang Zheng1. (1) Department of Radiology and Imaging Sciences, Indiana 
University School of Medicine, Indianapolis IN 46202, United States (2) Department of 
Medicine, Indiana University School of Medicine, Indianapolis IN 46202, United States  
Vandetanib [N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-
yl)methoxy)quinazolin-4-amine], also known as ZD6474, is an antagonist of the vascular 
endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor 
(EGFR), and it is tyrosine kinase inhibitor, developed by AstraZeneca as a cancer 
therapeutic agent. VEGF is the most common and direct acting angiogenic factor in 
cancer. Vandetanib and its chloro-analog [chloro-Vandetanib, N-(4-chloro-2-
fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine] 
displayed relatively low nanomolar IC50 values for VEGF compared to EGF. Carbon-11-
labeled Vandetanib and chloro-Vandetanib may serve as new probes for the biomedical 
imaging technique positron emission tomography (PET), and enable non-invasive 
monitoring of VEGFR in cancer. Here we report the synthesis of [11C]Vandetanib and 
[11C]chloro-Vandetanib as new PET cancer imaging agents for VEGFR. Vandetanib and 
chloro-Vandetanib, and their corresponding N- and O-desmethylated precursors for 
radiolabeling were synthesized from 7-(benzyloxy)-4-chloro-6-methoxyquinazoline in 5, 
4 and 6 steps with 39% and 41%, 46% and 49%, 7% and 7% overall chemical yields, 
respectively. The N- or O-desmethylated precursors were labeled with [11C]CH3OTf 
under basic conditions through either N- or O-[11C]methylation to provide the target 
tracers [11C]Vandetanib {N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-
[11C]methylpiperidin-4-yl)methoxy)quinazolin-4-amine or N-(4-bromo-2-fluorophenyl)-6-
[11C]methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine} and [11C]chloro-
Vandetanib {N-(4-chloro-2-fluorophenyl)-6-methoxy-7-((1-[11C]methylpiperidin-4-
yl)methoxy)quinazolin-4-amine or N-(4-chloro-2-fluorophenyl)-6-[11C]methoxy-7-((1-
methylpiperidin-4-yl)methoxy)quinazolin-4-amine} in 40-50% decay corrected 
radiochemical yields based on [11C]CO2, and 370-555 GBq/μmol specific activity at end 
of bombardment (EOB). The radiolabeling reaction was performed in a home-built 
automated 11C-radiosynthesis module, and the target tracer was purified by HPLC. In 
summary, a synthetic route to labeling N- and O-desmethylated precursors and 
Vandetanib and chloro-Vandetanib has been described, and a radiosynthesis approach 
to [11C]Vandetanib and [11C]chloro-Vandetanib via either N- or O-[11C]methylation has 
been developed. 
MEDI 52 
Synthesis and biological evaluation of N4-(substitutedphenyl)-N4-
methyl/desmethyl-9H-pyrimido[4,5-b]indole-2,4-diamines as antimitotic agents 
Nilesh Zaware1, nileshpharm@yahoo.com; Aleem Gangjee1; Susan L Mooberry2; 
Ernest Hamel3. (1) Graduate School of Pharmaceutical Sciences, Duquesne University, 
Pittsburgh PA 15217, United States (2) Department of Pharmacology, University of 
Texas Health Science Center at San Antonio, San Antonio Texas 78229, United States 
(3) Screening Technologies Branch, National Institutes of Health, Frederick Maryland 
21702, United States  
Paclitaxel and vinblastine are established antimitotic agents used for the treatment of 
cancer. However their efficacy is limited by multidrug resistance (MDR). In 2010, we 
reported N-(4-methoxyphenyl)-N-2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-
amine as a potent cytotoxic agent with microtubule depolymerizing activities. This 
compound inhibits tubulin polymerization and the binding of [3H]colchicine to tubulin. 
This agent also circumvents clinically relevant mechanisms of drug resistance. Further 
analogue design afforded a series of nine N4-(substituted phenyl)-N4-methyl/desmethyl-
9H-pyrimido[4,5-b]indole-2,4-diamines. The synthesis involved a Fisher indole 
cyclization of 2-amino-6-hydrazinylpyrimidin-4(3H)-one with cyclohexanone, followed by 
oxidation, chlorination and aniline displacement. One of these compounds displayed low 
nanomolar inhibition of MDA-MB-435 tumor cells. This agent demonstrated nanomolar 
GI50 values against 57 of the NCI 60 panel cell lines in the NCI 60 panel and was 
therefore selected for advancement to hollow fiber assay in vivo screen. The synthesis, 
and preliminary biological activity of this series will be presented. 
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Synthesis and biological evaluation of 5-chloro-N4-substituted-N4-methyl-9H-
pyrimido[4,5-b]indole-2,4-diamines as antimitotic agents 
Ravi Kumar Vyas Devambatla1, drk_vyas@yahoo.co.in; Aleem Gangjee1; Nilesh 
Zaware1; Susan L Mooberry2; Ernest Hamel3. (1) Division of Medicinal Chemistry, 
Duquesne University, Pittsburgh Pennsylvania 15282, United States (2) Department of 
Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio 
Texas 78229, United States (3) Division of Cancer Treatment and Diagnosis, National 
Cancer Institute at Frederick, Frederick Maryland 21702, United States  
Agents that interfere with microtubules including the vinca alkaloids and the taxanes are 
important antitumor agents. Despite the unprecedented success of these agents in 
cancer chemotherapy, multidrug resistance is a major limitation. We recently reported 
N-(4-methoxyphenyl)-N-2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine (1) 
as a potent antimitotic tubulin-binding agent. This compound inhibits tubulin 
polymerization, the binding of [3H]colchicine to tubulin, and circumvents clinically 
relevant mechanisms of drug resistance. Further analog design from lead compound 1 
yielded 5-chloro-N4-(4-methoxyphenyl)-N4-methyl-9H-pyrimido[4,5-b]indole-2,4-diamine 
(2). The synthesis of 2 was accomplished by simultaneous displacement of the 4-chloro 
group of known N-(4,5-dichloro-9H-pyrimido[4,5-b]indol-2-yl)pivalamide with 4-methoxy-
N-methylaniline and deprotection. Compound 2 is a potent inhibitor of MDA-MB-435 
tumor cells in culture and was selected for in vivo screen in the hollow fiber assay of the 
NCI Developmental Therapeutics Program. This prompted the design of five novel 
analogues with variations in the aniline substitution. The synthesis, and preliminary 
biological activity of 2 and its analogs will be presented. 
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Syntheses and antitumor activities on NCI-60 human tumor cell line protocol of N-
hydroxyethyl-4-aza-didehyropodophyllotoxin derivatives 
Ajay Kumar1, drajay_ipu@yahoo.co.in; Vineet Kumar2; Antonio E Alegria1; Sanjay V 
Malhotra2. (1) Department of Chemistry, University of Puerto Rico Humacao, Humacao 
Puerto Rico 00791, United States (2) Laboratory of Synthetic Chemistry, SAIC-
Frederick Inc., National Cancer Institute at Frederick, Frederick MD 21702, United 
States  
Podophyllotoxin has been known to possess anti-tumor activity and is still considered 
an important lead for research and development of antineoplastic agents. Derivatives of 
podophyllotoxin, namely etoposide, etopophos and teniposide have been developed 
and are currently used in clinic for the treatment of a variety of malignancies. The 
structural complexity of podophyllotoxin, arising from the presence of four stereogenic 
carbons in ring C has restricted most of the structural activity relationship (SAR) studied 
by derivatization of the parent natural product rather than by de novo multi-step 
chemical synthesis. A library of N-hydroxy aza-podophyllotoxin derivatives were 
screened for their antitumor activity using the National Cancer Institute's 60 human 
tumor cell lines protocol to study their structure activity relationships. This was followed 
by a screen of in vivo activity using a panel of tumor hollow-grafts implanted in mice 
consisting of breast (MDA-MB-231), non-small lung (NCI-H23 and NCI-H522), colon 
(SW-620 and COLO 205), melanoma (UACC-62, MDA-MB-435 and LOXIMVI), ovarian 
(OVCAR-5 and OVCAR-3) and CNS (U251 and SF-295) cell lines. This is the first report 
of aza-podophyllotoxins anticancer activity evaluation on such a broad panel of cancer 
cell lines. The toxicity of all the active compounds was low, while their antiproliferative 
activity was high, providing a wide therapeutic window for their potential application as 
anticancer drugs. 
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Design and synthesis of novel taxol analogs and thier folate conjugates 
Hari Krishna R Santhapuram1, hkrishna@endocyte.com; Iontcho R Vlahov1; Longwu 
Qi1; Christopher P Leamon2; Yu Wang1; Spencer J Han1; Jeremy F Vaughn1. (1) 
Department of Discovery Chemistry, Endocyte, Inc., West Lafayette IN 47906, United 
States (2) Department of Discovery Biology, Endocyte, Inc., West Lafayette IN 47906, 
United States  
The taxanes are diterpene natural products isolated from the bark of Taxus brevifolia 
and the pacific yew. Taxanes stabilize microtubules, thereby inhibiting the process of 
cell division. Taxanes are recognized as one of the most important drugs available for 
treatment of solid tumors. However, there are severe side effects associated with 
administering any non-targeted drugs. Receptor targeted, releasable, drug conjugates 
selectively deliver toxic agents into pathologic cells, minimizing toxicity to normal cells. 
In this poster we report the design and synthesis of novel 3'-amino functionalized semi-
synthetic taxanes. Further, these compounds are conjugated via proprietary modular 
approach, comprised of: the ligand folic acid (FA), a highly charged water-soluble 
carbohydrate-based spacer unit, a self-immolative linker system containing a reducible 
disulfide bond, and the taxane. 
   
MEDI 56 
Synthesis of a releasable folate conjugate of gliotoxin 
Paul J. Kleindl, pkleindl@endocyte.com; Iontcho R. Vlahov; Hari K. Santhapuram; 
Christopher P. Leamon. Endocyte Inc., W. Lafayette Indiana 47906, United States  
Gliotoxin, a member of the epipolythiodioxypiperazine (ETP) class of natural 
mycotoxins, has shown the ability to induce apoptosis (programmed cell death) in a 
number of cell lines and has also shown anti-inflammatory activity. Unfortunately, 
systemic toxicities have prevented the advancement of gliotoxin as a therapeutic agent. 
Synthesis of a releasable, folate conjugate of gliotoxin has the potential to reduce side-
effects by targeting only cancer cells and activated macrophages which overexpress the 
folate receptor (FR). The primary –OH on gliotoxin was regioselectively modified to form 
an azido-ethyldisulfanylethyl carbonate adduct. Reaction of this adduct with a 
propargylglycine containing, water soluble, peptidic, folate spacer following a Huisgen 
cycloaddition protocol resulted in the desired folate-gliotoxin conjugate.   
  
MEDI 57 
Design and synthesis of folate-valinomycin conjugate 
Yu Wang, kwang@endocyte.com; Iontcho R. Vlahov; Spencer J. Hahn; Hari K. 
Santhapuram; Christopher P. Leamon. Endocyte, Inc., West Lafayette Indiana 47906, 
United States  
Valinomycin is a dodecadepsipeptide antibiotic that selectively transports potassium ion 
across biological membranes, causing damage to bacteria cells. It has been reported to 
display antitumor activities, but its use has been limited due to high toxicity. Selective 
targeting receptors overexpressed on pathologic cells with ligand-drug conjugates 
provide an opportunity to reduce toxicity to normal cells. In this poster we present the 
design of valinomycin conjugates targeting folate receptor (FR) positive pathologic cells. 
Furthermore we report the total synthesis of a novel valinomycin derivative exploiting 
solid-support-based macrolactamization as a key reaction step. A phenol group, 
introduced in the macrocyclic backbone of valinomycin, serves as a tether for 
attachment of carbohydrate-based hydrophilic spacers via a disulfide-based release 
system. 
MEDI 58 
2-Methyl-6-substituted pyrrolo[2,3-d]pyrimidine classical antifolates as selective 
folate receptor substrates, glycinamide ribonucleotide formyltransferase 
inhibitors and antitumor agents 
Sai Zhao1, zhaos2390@duq.edu; Aleem Gangjee1; Lei Wang1; Larry H. Matherly2, 3, 4; 
Roy L. Kisliuk5. (1) Department of Medicinal Chemistry, Duquesne University, Pittsburgh 
PA 15282, United States (2) Developmental Therapeutics Program, Barbara Ann 
Karmanos Cancer Institute, Detroit MI 48201, United States (3) Graduate Program in 
Cancer Biology, Wayne State University School of Medicine, Detroit MI 48201, United 
States (4) Department of Pharmacology, Wayne State University School of Medicine, 
Detroit MI 48201, United States (5) Department of Biochemistry, Tufts University School 
of Medicine, Boston MA 02111, United States  
The important role of reduced folates in one-carbon transfer reactions has made folate 
metabolism an attractive target in cancer chemotherapy for decades. Clinically used 
antifolates enter cells via folate uptake systems, such as reduced folate carrier (RFC), 
folate receptors (FRs), and proton-coupled folate transporter (PCFT). Toxicity of 
clinically used antifolates is due to their lack of selectivity for tumor cells, since these 
antifolates are transported by RFC which occurs in normal as well as tumor cells. FR is 
usually not expressed in normal cells. However, FR is expressed in some tumor cells, 
such as ovarian, breast etc. Thus specific FR targeted agents that also possess 
cytotoxic activity without transport by RFC circumvent the major toxicities of currently 
used antifolates that all use RFC for transport. 2-Methyl-6-substituted pyrrolo[2,3-
d]pyrimidine antifolates were designed to evaluate the importance of the 2-amino group 
for transport by RFC, FR, and /or PCFT as well as for inhibition of folate metabolizing 
enzymes. This report will present the design, synthesis and evaluation of the title 
compounds. 
MEDI 59 
Mechanistic studies to determine how using cell-delivered nanoparticles to cause 
local hyperthermia increases survival in a murine metastatic pancreatic cancer 
model 
Matthew T. Basel1, mbasel@vet.ksu.edu; Sivasai Balivada1; Atsushi Kawabata1; 
Hongwang Wang2; Tej B Shrestha1; Gwi-Moon Seo1; Marla Pyle1; Gayani Ayabaweera2; 
Raj Dani2; Olga B Koper2, 3; Viktor Chikan2; Masaaki Tamura1; Stefan H. Bossmann2; 
Deryl L. Troyer1. (1) Department of Anatomy and Physiology, Kansas State University, 
Manhattan KS 66506, United States (2) Department of Chemistry, Kansas State 
University, Manhattan KS 66506, United States (3) Nanoscale Corporation, Manhattan 
KS 66506, United States  
We have previously demonstrated that cell-delivered-nanoparticle-generated (CDNG) 
hyperthermia can increase survival in a murine metastatic pancreatic cancer model. 
This system uses tumor homing monocyte/macrophage-like cells (Mo/Ma) to deliver 
magnetic nanoparticles specifically to tumor tissues. Treating with AMF induces 
hyperthermia. Here we explore the mechanisms of how CDNG hyperthermia works. A 
murine model of metastatic pancreatic cancer was created by injecting Pan02 cells 
intraperitoneally into C57BL/6 mice. Mice were treated on days 5, 9, and 13 with 
nanoparticle loaded Mo/Ma (or appropriate controls). On days 8, 12, and 16, mice were 
treated with 30 minutes of alternating magnetic fields to induce hyperthermia. Mice were 
then euthanatized and tissues were collected and fixed. Sections were made and were 
examined using immunohistochemistry, western blots, and/or RT-PCR for a variety of 
hyperthermia markers, immune cell markers and apoptosis markers. These data were 
then examined to determine what mechanism(s) might be operative in CDNG 
hyperthermia attenuation of metastatic pancreatic cancer. 
MEDI 60 
SN38-prodrug and nanoparticle-generated hyperthermia show antagonistic 
effects when co-delivered to a murine model of pancreatic cancer 
Matthew T. Basel1, mbasel@vet.ksu.edu; Sivasai Balivada1; Tej B Shrestha1; Gwi-
Moon Seo1; Hongwang Wang2; Marla Pyle1; Gayani Ayabaweera2; Raj Dani2; Viktor 
Chikan2; Masaaki Tamura1; Stefan H. Bossmann2; Deryl L. Troyer1. (1) Department of 
Anatomy and Physiology, Kansas State University, Manhattan KS 66506, United States 
(2) Department of Chemistry, Kansas State University, Manhattan KS 66506, United 
States  
Several chemotherapeutic drugs have shown synergistic effects with hyperthermia in 
treating various cancers. Irinotecan has been shown to be one of these 
thermochemotherapuetic prodrugs. Carboxylesterase cleaves irinotecan to SN38, which 
is the active metabolite of irinotecan. Previously we have demonstrated a cell-delivered-
nanoparticle-generated (CDNG) hyperthermia system that substantially increases 
survival in a murine metastatic pancreatic cancer model that uses tumor homing 
monocyte/macrophage-like cells (Mo/Ma) to deliver magnetic nanoparticles directly and 
specifically to tumor sites for alternating magnetic field induced hyperthermia. We have 
also previously demonstrated a self-contained enzyme/prodrug therapy that uses the 
same tumor homing monocyte/macrophage-like cells to deliver an SN38-Dextran 
prodrug and an inducible carboxylesterase gene that also increases survival in the 
same model. Therefore, both systems were combined and co-loaded into Mo/Ma and 
co-delivered to a murine metastatic cancer model. Surprisingly, the SN38 treatment and 
the nanoparticle treatment showed strong antagonism with nearly complete suppression 
of treatment effect. 
MEDI 61 
Design and synthesis of chromones as novel antimelanoma agents 
Shivaputra A Patil1, spatil3@uthsc.edu; Xiaochen S Li1; William L Seibel2; Wei Li1; 
Duane D Miller1. (1) Department of Pharmaceutical Sciences, College of Pharmacy, The 
University of Tennessee Health Science Center, Memphis TN 38163, United States (2) 
Compound Library and Cheminformatics, Drug Discovery Center, University of 
Cincinnati, Cincinnati OH 45237, United States  
Late-stage malignant melanoma is difficult to treat by present chemotherapies; 
therefore, there is a dire need to find new chemotherapies for melanoma. Our laboratory 
is focused on the discovery of novel anticancer agents for melanoma (Li et al 2007, 
Chen et al 2008, Lu et al 2008, and Zhao et al 2009). In an effort to find out new small 
molecules as anti-melanoma agents, we screened a library of compounds from the 
University of Cincinnti and identified two compounds, 7-(4-Bromocarbonyl-piperazin-1-
yl)-1-cyclopropyl-6-fluoro-4-oxo-1,2,3,4-tetrahydro-quinoline-3-carboxylic acid and 2-
Amino-4-(5-bromo-2-methoxy- phenyl)-7-hydroxy-4H-chromene-3-carbonitrile as initial 
hits. 7-(4-Bromocarbonyl-piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,2,3,4-tetrahydro-
quinoline-3-carboxylic acid being an alkylating agent, we are highly interested in the 
chromenes and the chomene scaffold have been well represented within potent anti-
cancer agents (Kemnitzer et al 2008, 2004). This synthetically feasible scaffold will 
serve as a starting point in our program to find highly potent new anti-melanoma agents 
by synthesizing a new library of chromenes and evaluating them for activity against 
melanoma. 
MEDI 62 
Novel inhibitors of Mer kinase as potential anticancer agents in the treatment of 
acute lymphoblastic leukemia (ALL) 
Weihe Zhang1, zhangwh@email.unc.edu; Jing Liu1; Chao Yang1; Stephen V Frye1; 
Xiaodong Wang1; Catherine Catherine Simpson1; Amy Van Deusen1; Jacqueline Norris-
Drouin1; William P Janzen1; Dmitri B Kireev1; Deborah DeRyckere2; Douglas K 
Graham2; Debra Hunter3; H Shelton Earp, III3; Chatura Jayakody1; Victoria Korboukh1. 
(1) Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Center 
for Integrative Chemical Biology and Drug Discovery (CICBDD), Division of Medicinal 
Chemistry and Natural Products, Chapel Hill NC 27599, United States (2) School of 
Medicine, University of Colorado at Denver, Department of Pediatrics, Aurora CO 
80045, United States (3) Department of Medicine and Pharmacology, University of 
North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill 
NC 27599, United States  
Acute lymphoblastic leukemia (ALL) is the most common cancer in children, 
representing 23 percent of cancer diagnoses among children younger than 15 years of 
age. Ectopic Mer expression in T-cell ALL is suspected to be responsible for drug 
resistance in children and Mer kinase inhibitors may act as chemosensitizers to 
increase efficacy and reduce toxicities of current regimens in this disease. We took the 
advantage of known X-ray crystal structure of Mer by using structure based design built 
our compound library. The small compounds with a pyrazolopyrimidine core structure 
from this library exhibited selective inhibitory activity on Mer among the Tyro3/Axl/Mer 
(TAM) family of receptor tyrosine kinases. Sub-nanomolar specific Mer inhibitors have 
been discovered through the Hit-to-Lead modification process. Optimization of the 
physical properties towards clinical candidates is under investigation. 
MEDI 63 
Bioluminescent blue light for photodynamic therapy for different types of cancer 
Tej B Shrestha1, tbs3@ksu.edu; Matthew T Basel1; Hongwang Wang2; Sivasai 
Balivada1; Gwi M Seo1; Marla Pyle1; Stefan H Bossmann2; Deryl L Troyer1. (1) 
Department ofAnatomy and Physiology, Kansas State University, Manhattan Kansas 
66506, United States (2) Department of Chemistry, Kansas State University, Manhattan 
Kansas 66506, United States  
The biggest obstacle for photodynamic therapy for deeply-seated tumors is poor light 
penetration through the human body. In situ generation of blue light by employing 
tumor-homing stem cells may be able to overcome this obstacle. 5-Aminolevulenicacid 
is used by cells for the biosynthesis of protoporphyrine IX, which can be effectively used 
as photosensitizer. We have demonstrated that neural stem cells(NSC) and rat 
umbilical cord matrix-derived stem cells(RUCMSC) home to B16F10 and 4T1 tumors. 
We have transiently transfected tumor-homing mouse NSC and RUCMSC with Gaussia 
luciferase(gluc), and injected these cells intravenously into C57BL/6 mice bearing 
B16F10 tumors. These stem cells have accumulated in the tumor tissue and expressed 
gluc in vivo. Upon intravenously administering coelenterazine, the gluc's substrate, 
intense bioluminescence(λmax=480nm) occurs which is absorbed by protoporphyrine IX. 
Both in vitro and in vivo data show that this novel approach for photodynamic therapy 
can be applied for the treatment of deep-seated tumors. 
MEDI 64 
Fragment based approach to targeting the Rad51:BRCA2 protein-protein 
interaction 
Anthony G Coyne, agc40@cam.ac.uk. Chemistry, University of Cambridge, 
Cambridge Cambridgeshire CB2 1EW, United Kingdom  
Anthony G. Coyne, agc40@cam.ac.uk, Department of Chemistry, University of 
Cambridge, CB2 1EW, United Kingdom; Duncan E. Scott,(1) Chris Abell, (1) May Marsh, 
(2) Marko Hyvonen, (2) Tom L. Blundell, (2) Ashok Venkitaraman. (3) (1) Department of 
Chemistry, University of Cambridge, CB2 1EW, UK. (2) Department of Biochemistry, 
University of Cambridge, Tennis Court Road, Cambridge, UK CB2 1GA, United 
Kingdom. (3) Cambridge Molecular Therapeutics Programme, Hutchison/MRC 
Research Centre, University of Cambridge, Hills Road, Cambridge, CB2 0XZ, United 
Kingdom   The druggability of protein-protein interaction sites has been of enormous 
interest to medicinal chemists in recent years. However there has been only moderate 
success in discovering small molecules that can disrupt such interactions. One of the 
approaches that has proven successful is using fragment based drug discovery. We are 
interested in targeting the Rad51:BRCA2 protein-protein interaction using fragment 
based approaches. The Rad51:BRCA2 interaction is clinically important as it is 
essential for DNA repair by homologous recombination which is a key cellular pathway 
involved in the resistance of cancer cells to ionizing radiation. Inhibition of this 
interaction will render cells unable to repair DNA damage and in conjunction with other 
drugs enable a method to target cancer cells. We will report the results of our fragment 
screening work against this protein-protein interaction and our attempts to develop small 
molecules to target this interaction. We will show that a combination of synthetic 
chemistry, structural biology and biophysical techniques, as part of the fragment based 
approach, can be used to disrupt these challenging targets. 
MEDI 65 
Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK) 
Tommy Rennison1, tommy.rennison@ncl.ac.uk; Sonsoles Rodriguez-Aristegui1; Julia 
Bardos2; Nicola J Curtin1; M Dennis3; Ray Finlay3; Bernard T Golding1; Ian R 
Hardcastle1; David R Newell1; Gail L Wrigley3; Celine Cano1; Roger J Griffin1. (1) 
Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle Upon 
Tyne NE2 7RU, United Kingdom (2) KuDOS Pharmaceuticals Ltd, Cambridge CB4 
0PE, United Kingdom (3) Department of Oncology Innovative Medicines, AstraZeneca 
SK10 4TG, United Kingdom  
The serine/threonine kinase DNA-dependent protein kinase (DNA-PK) is a member of 
the phosphatidylinositol 3-kinase related kinase (PIKK) family of enzymes, and plays an 
important role in DNA double-strand break (DSB) repair.1 ATP-competitive DNA-PK 
inhibitors may, therefore, be useful as agents to improve the activity of radio- and 
chemo-therapy by preventing the repair of DNA damage in cancer cells.2    
    
Structure activity studies based on the non-selective PIKK inhibitor LY294002 lead to 
identification of the lead inhibitor NU7441 (IC50 DNA-PK = 30 nM)3. This confirmed 
promising activity in a range of human tumour cell lines.4 Further biological studies with 
NU7441 were hampered by sub-optimal pharmaceutical properties.   Homology model-
directed synthesis lead to KU0060648 which was more potent against DNA-PK (IC50 = 5 
nM) but also against PI3-Kinase (IC50 = 7 nM). In an attempt to gain selectivity, novel 
analogues were synthesised bearing a variety of groups at the 7-, 8- and 9-positions of 
the dibenzothiophene as well as the 5' and 6' positions on the chromenone.       1. S. P. 
Jackson, J. Bartek, Nature, 2009, 461, 1071.  2 S. Boulton et al., Carcinogenesis, 1997, 
17, 2285.  3 I. R. Hardcastle et al, J. Med. Chem., 2005, 48, 7829.  4 Y. Zhao et al, 
Cancer Res., 2006, 66, 5354. 
MEDI 66 
Novel hydroxyethyl-, and methylpyrazoline derivatives of acetyl-combretastatin 
A4: Synthesis, structural analysis, and biological evaluation 
Moses Lee1, lee@hope.edu; Megan Lee1; Armaan Dandavati1; Olivia Brockway1; 
Robert Sjoholm1; Samuel Tzou1; Sameer Chavda1; Cara Westbrook2; Gregory Fraley1; 
Matthias Zeller3; Susan Mooberry2; Balaji Babu1. (1) Hope College, United States (2) 
University of Texas Health Science Center, United States (3) Youngstown State 
University, United States  
Combretastatin A4 (CA-4) is a stilbene naturally occurring anticancer product isolated 
from Combretum caffrum. It exhibits a wide range of biological functions including the 
inhibition of tubulin polymerization. CA-4 is, however, impaired by its poor solubility in 
water and cell culture media. As a result, there is an intense effort underway in the 
design, synthesis, and testing of novel CA-4 analogs that exhibit comparable activity to 
CA-4 itself but exhibit enhanced water solubility. Efforts in our laboratory are focused on 
developing a novel class of CA-4 analogs with enhanced water solubility. The target 
compounds in this study contain a polar group, such as hydroxyethyl or 
methylpyrazoline, and are derived from a previously unknown acetyl-CA-4. The 
rationale, synthesis, structural analysis, and the ability of the target compounds to inhibit 
the growth of murine lymphoma (L1210), melanoma (B16), and human melanoma 
MDA-MB-435 cells will be described, along with their ability to cause microtubule 
depolymerization in cells. 
MEDI 67 
Non-ATP competitive CDK2 cyclin groove inhibitors through REPLACE mediated 
fragment assembly 
Joshua K Bolger, bolgerj@sccp.sc.edu; Padmavathy N Premnath; Shu Liu; Campbell 
McInnes. Pharmaceutical and Biomedical Sciences, University of South Carolina, 
Columbia SC 29208, United States  
A strategy for fragment based design of protein-protein interaction inhibitors which 
provides advantages over conventional methods was recently proposed and validated. 
REPLACE (Replacement with Partial Ligand Alternatives through Computational 
Enrichment) is an iterative approach for generating fragment alternatives to known 
peptide determinants. We further exemplify this approach through the optimization of 
individual partial ligand alternatives and generate more pharmaceutically relevant and 
non-ATP competitive inhibitors of the CDK2/cyclin A substrate recruitment binding site 
by combining these fragments. A diverse set of substituted aryl heterocycles replacing a 
critical charge-charge interaction were synthesized and provided insights into the H-
bonding requirements of the cyclin groove. In addition the structure-activity relationship 
of a bisarylether system replacing a phenylalanine determinant has been developed 
while allowing increased complementarity with the hydrophobic pocket. This work 
further validates REPLACE as an effective strategy for converting peptidic compounds 
to more drug-like and non peptide compounds for inhibition of protein-protein 
interactions. 
MEDI 68 
Investigations of various heterocycles to improve metabolic stability within a 
series of PI3K/mTOR dual inhibitors 
Markian M. Stec1, mstec@amgen.com; Kristin L. Andrews2; Shon K. Booker1; Sean 
Caenepeel3; Daniel J. Freeman3; Jian Jiang4; Lillian Liao1; John McCarter5; Erin 
Mullady5; Tisha San Miguel5; Raju Subramanian4; Nuria Tamayo1; Ling Wang3; Kevin 
Yang1; Leeanne P. Zalameda5; Nancy Zhang3; Paul E. Hughes3; Mark H. Norman1. (1) 
Department of Medicinal Chemistry, Amgen Inc., United States (2) Molecular Structure, 
Amgen Inc., United States (3) Oncology, Amgen Inc., United States (4) 
Pharmacokinetics and Drug Metabolism, Amgen Inc., United States (5) High-
Throughput Screening/Molecular Pharmcology, Amgen Inc., United States  
Many human cancers have activated phosphoinositide 3-kinase (PI3K) signaling, often 
as a result of gain-of-function mutations in PI3Ka or loss-of-function mutations in PTEN 
(a phosphatase that performs the reverse phosphorylation event performed by Class I 
PI3Ks). These genetic alterations strongly link constitutive PI3K signaling to 
tumorigenesis and have stimulated an interest in targeting PI3Ka, and other kinases in 
the PI3K/Akt pathway, for the treatment of cancer.  We have recently reported on N-(6-
(6-chloro-5-(4-fluorophenylsulfonamido)pyridin-3-yl)benzo[d]thiazol-2-yl)acetamide 
which is a potent and efficacious inhibitor of PI3Ka and mTOR in vitro and in vivo. 
However, in hepatocyte and in vivo metabolism studies, this compound was found to 
undergo deacetylation on the 2-amino substituent of the benzothiazole core. As an 
approach to reduce or eliminate this metabolic deacetylation, a variety of analogs were 
examined as an alternative to the benzothiazole ring. In vitro studies of these analogs 
will be presented as well as in vivo data on advanced compounds.    Keywords: 
Phosphoinositide 3-kinase, PI3K, mTOR, Akt, hepatocyte 
MEDI 69 
Identification of non-amidine inhibitors of acid-sensing ion channel-3 (ASIC3) 
Scott D Kuduk1, scott_d_kuduk@merck.com; Ronald K Chang1; Christina N Di Marco1; 
Robert M DiPardo1; Sean P Cook2; Matthew J Cato2; Aneta Jovanovska2; Mark O 
Urban2; Michael Leitl2; Robert H Spencer2; Stefanie A Kane2; George D Hartman1; Mark 
T Bilodeau1. (1) Department of Medicinal Chemistry, Merck & Co., West Point PA 
19438, United States (2) Department of Pain Research, Merck & Co., West Point PA 
19438, United States  
The search for novel treatments for chronic pain and inflammation continues to be an 
area of medical need. Under conditions of acidosis, tissue damage often results leading 
to acute or chronic pain. Numerous receptors and ion channels expressed in neurons 
have been shown to be modulated by protons. Among them, the acid-sensing ion 
channel-3 (ASIC3) is representative of a proton-gated subgroup of degenerin/epithelial 
Na+ cation channel family. There is substantial evidence that ASIC3 serves as a pH 
sensor playing an important role in conveying the pain sensation resulting from tissue 
acidosis. Accordingly, small molecule inhibitors of the ASIC3 channels are of 
considerable interest to study the physiological role of ASIC3. This paper describes 
efforts to identify non-amidine chemotypes from existing leads in an effort to identify 
potent blockers to advance the therapeutic evaluation of ASIC3 inhibition. 
MEDI 70 
Structural modification of neuroprotective small molecules for target 
identification studies: Toward possible amyotrophic lateral sclerosis therapeutics 
Paul C Trippier1, p-tripper@northwestern.edu; Tian Chen1; Radhia Benmohammed2; 
Donald R Kirsch2; Robert J Ferrante3, 4; Richard I Morimoto5; Richard B Silverman1. (1) 
Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life 
Processes Institute, Center for Molecular Innovation and Drug Discovery, Northwestern 
University, Evanston IL 60208-3113, United States (2) Cambria Pharmaceuticals, 
Cambridge MA 02142, United States (3) Department of Neurology , Laboratory 
Medicine and Pathology and Psychiatry, Boston University, Boston MA 02118, United 
States (4) Geriatric Research Education and Clinical Center, Bedford Veterans 
Administration Medical Center, Boston MA 02118, United States (5) Department of 
Molecular Biosciences, Rice Institute for Biomedical Research, Northwestern University, 
Evanston IL 60208-3500, United States  
Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease is a neurodegenerative 
disorder affecting an estimated 87,000 people worldwide. ALS is characterized by rapid 
and progressive loss of motor function, leading to paralysis and resulting in death, on 
average within 3-5 years. Riluzole is currently the only approved treatment for ALS and 
extends survival, on average by only 2-3 months. The need for the development of 
further therapeutic options for this disease is apparent.    Our laboratories have 
developed lead compounds with demonstrable activity in G93A-SOD1 mice models of 
ALS. We present herein, ongoing efforts to both investigate further the pharmacophore 
with structure activity relationship studies and the modification of these leads to be 
amenable to target identification studies by a range of chemical and molecular biological 
techniques. 
MEDI 71 
Octahydropyrano[3, 4-c]pyrrole NK1 receptor antagonists 
Jianming Bao1, bao_jainming@merck.com; Jonathan Young1; Huagang Lu1; Ronsar 
Eid1; Andrew Kassick1; Emma J. Carlson2; Alan Wheeldon2; Richard Tschirret-Guth3; 
Marc M. Kurtz4; Gary G. Chicchi4; Kwei-Lan Tsao4; Song Zheng3; Tong Xinchun3; 
Sander G Mills1; Robert J DeVita1. (1) Medicinal Chemistry, Merck Research 
Laboratories, Rahway NJ 07065, United States (2) In Vivo neuroscience, Merck 
Research Laboratories, Rahway NJ 07065, United States (3) Drug Metabolism, Merck 
Research Laboratories, Rahway NJ 07065, United States (4) Immunology and 
Rheumatology, Merck Research Laboratories, Rahway NJ 07065, United States  
The substance-P-preferring neurokinin receptor (NK1) is present in high concentration 
in areas of the brain that mediate many important biological functions. In an efforts to 
discover highly potent and selective NK1 antagonists for chemotherapy-induced nausea 
and vomiting (CINV), we had identified a new class of NK1 receptor antagonists with an 
octahydropyrano[3, 4-c]pyrrole core. This series of NK1 antagonists, for which SAR 
around R1 and R2 will be presented, had many attractive properties including potent 
NK1 inhibition in the presence of human serum, excellent functional activity, and good 
pharmacokinetic properties. In addition, many compounds in this series displayed high 
NK1 receptor occupancy for 24 hours as assessed by the gerbil foot tapping model.  
  
MEDI 72 
WY-50295: Improved synthesis of a starting point for Alzheimer's disease drug 
discovery 
Victor P. Ghidu1, vghidu@temple.edu; Jin Chu2; Wayne Childers1; Domenico Pratico2; 
Magid Abou-Gharbia1. (1) School of Pharmacy, Temple University, Philadelphia PA 
19140, United States (2) Department of Pharmacology, Temple University School of 
Medicine, Philadelphia PA 19140, United States  
Recent data show that genetic or pharmacological inhibition of the enzyme 5-
lipoxygenase (5-LO) reduces levels of neurotoxic beta-amyloid peptides and plaque 
deposition in Tg2576 mice, a transgenic model of Alzheimer's-like amyloidosis. This 
occurs through a novel mechanism that involves decreased expression of gamma 
secretase, one of the enzymes responsible for the improper metabolism of amyloid 
precursor protein thought to underlie Alzheimer's pathology. This reduction in gamma 
secretase is not accompanied by a reduction in Notch-1 processing, a liability seen with 
known gamma secretase inhibitors. An alternate route to achieve this result that has not 
been explored is to inhibit 5-lipoxygenase activating protein (FLAP), a cofactor required 
for 5-LO activity.  FLAP inhibitors are known but do not penetrate the CNS because of 
their high molecular weight and high polar surface area. We recently developed an 
improved synthesis of WY-50295, a suspected FLAP inhibitor.  Here we present that 
improved synthesis as well as our plans to enhance the CNS penetration of WY-50295 
through a prodrug approach in order to develop tool molecules that can be used to 
assess the potential CNS therapeutic utility of FLAP inhibitors. 
MEDI 73 
Small molecule discovery: Phenylalkylamine-benzenesulfonamides as 5-HT6 
receptor ligands 
Donald Sikazwe1, 2, sikazwe@uiwtx.edu; Malgorzata Dukat1; Brian Roth3; Richard 
Glennon1. (1) Department of Medicinal Chemistry, Virginia Commonwealth University, 
School of Pharmacy, Richmond VA 23298, United States (2) Department of 
Pharmaceutical Sciences, University of the Incarnate Word, Feik School of Pharmacy, 
Richmond VA 23298, United States (3) Department of Pharmacology, University of 
North Carolina, Chapel Hill NC 27599, United States  
To investigate the binding conformation of phenylalkylamine-benzenesulfonamides 
relative to ergolines. The hypothesis tested was that: since sulfonamide-arylalkylamines 
bind to 5-HT6 in an extended ergoline type of conformation,phenylethylamines, 
phenylpiperazines and pyrroloethylamines bearing the appropriate substituents should 
also bind. Rationale: 5-HT6 is a GPCR (g-protein coupled receptor) found almost 
exclusively in the brain, whose biological role is still unclear. In order to probe this 
receptor's role in CNS disorders (Alzheimer's, schizophrenia, anxiety, convulsive, 
satiety, etc.) small molecules with selective activity (agonist or antagonist) at this 
receptor are desired. Because of the privileged location of 5-HT6, drugs targeting this 
receptor would lack peripheral side effects. Methodology: Several compounds were 
rationally designed using structural information from reported ligands (Ro 04-6790, SB-
271046, and MS-245), synthesized, characterized elementally and by NMR studies, and 
evaluated for activity at 5-HT6 using in vitro binding affinity assays. 
Findings/conclusions:  1) We identified phenylethylamines, phenylpiperazines and 
pyrroloethylamines as novel 5-HT6 ligands. These simpler structures can serve as 
templates for generating even more ligands for this receptor. 2) These novel 
structuctures bind to 5-HT6 receptors with reasonably high affinities. 3) Since 
arylethylamines bind in the ergoline extended conformation, these compounds also bind 
with the same conformation. 
MEDI 74 
Discovery of imidazoles as potent calcitonin gene-related peptide (CGRP) 
antagonists 
George Tora, george.tora@bms.com; Andrew P Degnan; Ling Chen; Charles M 
Conway; Guanglin Luo; Cen Xu; John E Macor; Gene M Dubowchik. Research and 
Development, Bristol-Myers Squibb, Princeton NJ 08543, United States  
Calcitonin gene-related peptide (CGRP), a 37-amino acid peptide belonging to a family 
of structurally-related peptides which includes adrenomedullin and amylin, has been 
implicated in the pathogenesis of migraine. In an earlier paper, we disclosed our 
intranasal (IN) development candidate BMS-694153. Although potent, compounds from 
this series lacked the bilayer permeability required to support oral dosing. In an effort to 
decrease solvation by water, a core amide was replaced with a number of novel 
heterocyclic replacements. A promising imidazole-containing series was identified. 
Several analogues were identified which maintained excellent potency and improved 
cell permeability. 
MEDI 75 
Glutamate isosteres showing selectivity toward the vesicular glutamate 
transporter vs. the obligate exchange transporter, system xc- 
Syed Kaleem Ahmed, syed.ahmed@mso.umt.edu; Sarjubhai A Patel; Richard J 
Bridges; Charles M Thompson. Department of Biomedical and Pharmaceutical 
Sciences, The University of Montana, Missoula Montana 59812, United States  
The vesicular glutamate transporter (VGLUT) regulates uptake of glutamate (l-Glu) 
between cytosolic and luminal compartments. System xc- (Sxc-), a chloride-dependent, 
sodium-independent obligate exchanger, couples the export of intracellular l-Glu with 
the import of extracellular l-cystine. We previously acquired evidence that VGLUT but 
not other glutamate transporters (e.g., EAATs) were inhibited by structures containing a 
weakly basic α-amino group. To test this hypothesis, we prepared a series of glutamate 
analogs in which weak amide and amide-containing isosteres were used in place of the 
α-amino acid group and analyzed as inhibitors of VGLUT and system xc-. Of numerous 
analogs prepared, two were found to be relatively strong inhibitors of VGLUT reducing 
uptake to less than 6% of control at 5 mM but few analogs inhibited system xc- greater 
than 50% of control. In sum, amide-containing isosteres of glutamate adds the requisite 
chemical properties needed to produce selective inhibitors of VGLUT. 
MEDI 76 
Synthesis and biological evaluation of novel arylpiperazine-containing imidazole 
4-carboxamide derivatives: Targeting serotonin 5-HT2A/2C and the serotonin 
transpoter as a potential antidepressant 
Hee Jeong Seo1, shj07@greencross.com; Eun-Jung Park1; Min Ju Kim1; Suk Youn 
Kang1; Suk Ho Lee1; Hyun Jung Kim1; Ki Nam Lee1; Myung Eun Jung1; Woo-Kyu Park2; 
Jeongmin Kim1; Jinhwa Lee1. (1) Department of Research Center, Green Cross 
Corporation, Yongin 446-770, Republic of Korea (2) Department of Pharmacology 
Research Center, Korea Research Institute of Chemical Technology, Daejeon 305-343, 
Republic of Korea  
Serotonin antagonist / reuptake inhibitor (SARI) drugs that block both the serotonin 5-
HT2 receptors and the serotonin transporters have been developed. The human 5-HT2A 
or 5-HT2C receptor has been implicated in several neurological conditions, and potent 
and selective 5-HT2A/2C ligands may have therapeutic potential for treatment of CNS 
diseases, such as depression. Therefore, the 5-HT2A/2C receptors have been considered 
as reasonable targets for the improved treatment of depression. On the other hand, an 
imidazole moiety usually provides good pharmacokinetic properties as a drug 
substance. And the most frequently studied of arylpiperazine analogues have been 
found as serotonin receptor ligands, especially 5-HT1A and 5-HT2A ones. Accordingly, 
we synthesized and evaluated arylpiperazine-containing imidazole 4-carboxamide 
derivatives against serotonin receptor (5-HT2A/2C) antagonists and serotonin reuptake 
inhibition. Some of the compounds show excellent IC50 values and antidepressant-like 
effect in in vivo forced swimming test (FST). Based on these results, further lead 
optimization studies resulted in identifying promising compounds for potentially 
therapeutic use.  
    
MEDI 77 
Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 
receptor antagonists with a carbonyl-based hydrogen bonding acceptor 
Kazuyoshi Aso, Aso_Kazuyoshi@takeda.co.jp; Katsumi Kobayashi; Michiyo 
Mochizuki; Naoyuki Kanzaki; Yuu Sako; Takahiko Yano. Pharmaceutical Research 
Division, Takeda Pharmaceutical Company Ltd., Osaka 5328686, Japan  
A new class of pyrrolo[2,3-d]pyrimidin-4-one corticotrophin-releasing factor 1 (CRF1) 
receptor antagonists has been designed and synthesized. In general, reported CRF1 
receptor antagonists possess a sp2-nitrogen atom as hydrogen bonding acceptor (HBA) 
on their core scaffolds. We proposed to use a carbonyl group of pyrrolo[2,3-d]pyrimidin-
4-one derivatives as a replacement for the sp2-nitrogen atom as HBA in classical CRF1 
receptor antagonists. As a result, several pyrrolo[2,3-d]pyrimidin-4-one derivatives 
showed CRF1 receptor binding affinity with IC50 values in the submicromolar range. Ex 
vivo 125I-sauvagine binding studies showed that 2-(dipropylamino)-3,7-dimethyl-5-(2,4,6-
trimethylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (30 mg/kg, po) was able 
to penetrate into the brain and inhibit radioligand binding to CRF1 receptors (frontal 
cortex, olfactory bulb, and pituitary) in mice. We identified pyrrolo[2,3-d]pyrimidin-4-one 
derivatives as the first CRF1 antagonists with a carbonyl-based HBA. 
MEDI 78 
Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain 
Shifeng Liu1, sliu@xenon-pharma.com; Sultan Chowdhury1; Mikhail Mikhail Chafeev1; 
Jianyu Sun1; Vandna Vandna Raina1; Ray Chui2; Wendy Wendy Young2; Jianmin 
Jianmin Fu1; Jay A. Jay A. Cadieux1. (1) Department of Medicinal Chemistry, Xenon 
Pharmaceuticals Inc, Burnaby BC V5G 4W8, Canada (2) Department of Biological 
Sciences, Xenon Pharmaceuticals Inc, Burnaby BC V5G 4W8, Canada  
Starting from the oxindole 2a identified through a high-throughput screening campaign, 
a series of NaV1.7 blockers were developed. Following the elimination of undesirable 
structural features, preliminary optimization of the oxindole C-3 and N-1 substituents 
afforded the simplified analogue 9b, which demonstrated a 10-fold increase in target 
potency vs. the original HTS hit. A scaffold rigidification strategy then led to the 
discovery of XEN907, a novel spirooxindole NaV1.7 blocker. This lead compound, which 
in turn showed a further 10-fold increase in potency, represents a promising structure 
for further optimization efforts. 
MEDI 79 
Novel amides as potent and selective histamine H3 receptor antagonists 
Ramakrishna Nirogi, nvsrk@suven.com; Anil Shinde; Ramasastri Kambhampati; Amol 
Deshpande; Adireddy Dwarampudi; Narsimhareddy Gangadasari; Atreya Cheppala; 
Namala Rambabu; Vishwottam Kandikere; Pradeep Jayarajan; Nageswararao 
Muddana; Ishtiyaque Ahmad. Discovery Research, Suven Life Sciences Ltd, Hyderabad 
Andhra Pradesh 500034, India  
H3 receptors are widely expressed in the mammalian brain, particularly in areas 
involved in cognitive processes and arousal. They regulate histamine in the brain and 
also affect the release of other neurotransmitters including dopamine, nor-adrenaline, 
serotonin and acetylcholine, suggesting their potential utility for the treatment of a 
variety of cognitive and sleep disorders. Most of the earlier reported dibasic compounds 
suffer from sub-optimal pharmacokinetic properties like exceptionally long half-life in 
both rat and dog.   We report our initial findings towards identification of novel aryl/ 
heteroaryl amide compounds as potent and selective H3 receptor antagonists. The 
series has favorable pharmacokinetic properties (half life ~ 1 hr with adequate oral 
exposure), no CYP liability and excellent brain penetration. The lead compound showed 
dose dependent receptor occupancy and elevate monoamines in microdialysis assay 
and is active in preclinical rodent models of cognition. It also blocks R-α-methyl 
histamine induced water intake. The design, synthesis, SAR and pharmacological 
profile of these new analogs as potential treatments for cognitive dysfunction will be 
presented. 
MEDI 80 
Novel Trolox-C-terminal motifs of Aß42 as neuroprotective agents for the 
treatment of Alzheimer's diseases 
Kiyoshi Fukuhara, fukuhara@nihs.go.jp; Akiko Ohno; Takuya Arai; Haruhiro Okuda. 
Division of Organic Chemistry, National Institute of Health Sciences, Setagaya Tokyo 
158-8501, Japan  
The aggregation pathway of ß-amyloid (Aß) is a key target to prevent or delay the onset 
of Alzheimer's diseases. Because the aggregation of the 40-mer and 42-mer peptides 
(Aß40, Aß42) has been suggested to contribute to oxidative stress that is responsible 
for neurotoxicity. Interestingly, the aggregative ability and neurotoxicity of Aß42 are 
considerably greater than those of Aß40, probably due to its high lipophilic C-terminal 
domain. In this work, novel multifunctional antioxidants were designed by combining 
Trolox, the aromatic portion of vitamin E responsible for radical capture, and the C-
terminal motifs that would be expected for high affinity to Aß42. They effectively 
protected SH-SY5Y neuroblastoma cells against Aß42-induced damage. They also 
showed antioxidative properties as well as vitamin E, and surprisingly strong inhibitory 
activities on Aß42 aggregation, emerging as promising molecules for neuroprotection by 
suppressing the mechanism of free radical generation via aggregation of Aß. 
MEDI 81 
Substituted cyclic ether arylsulfonamides as potent inhibitors of γ-secretase 
Kapil Karki, Kapil.Karki@pfizer.com; Antonia F Stepan; Stacey Becker; Steven 
Capetta; Kenneth DiRico; Christopher O’Donnell; Peter Dorff; Jason K Dutra; Ivan 
Efremov; Michael Green; Gregory Kauffman; Bethany L Kormos; W. Scott McDonald; 
Charles Nolan; Scott Obach; Leslie Pustilnik; David Riddell; Evelyn Sibley; Blossom 
Sneed; Chakrapani Subramanyam; Hao Sun; Theresa O’Sullivan; Annie Won; Liming 
Zhang. Departments of Medicinal Chemistry, Discovery Biology, Drug Metabolism and 
Pharmaceutical Sciences, Pfizer Global Research and Development, Groton CT 06340, 
United States  
Alzheimer's Disease (AD) is the most common form of senile dementia affecting 24 
million people worldwide. It is hypothesized that the Aβ peptide is the primary factor 
causing AD. This peptide is formed through the proteolytic cleavage of the amyloid-β-
precursor protein (APP) by β-secretase (BACE1) and γ-secretase. Reduction of Aβ 
production through the substitution of γ-secretase is therefore one strategy explored 
since the mid 90s to slow progression of Alzheimer's disease. We herein disclose our 
SAR studies into a novel series of sulfonamide containing γ-secretase inhibitors. This 
series of compounds contains range of substituted cyclic ethers in the left hand portion 
of the molecule.  
   . 
MEDI 82 
γ-Secretase modulators: Alternatives for the imidazole moiety 
Francois Bischoff, fbischof@its.jnj.com; Harrie Gijsen, hgijsen@its.jnj.com; Adriana I 
Velter; Gregor Macdonald; Tongfei Wu; Sven Van Brandt; Michel Surkyn; Serge Pieters; 
Didier Berthelot; Michel De Cleyn; Daniel Oehlrich; Chantal Masungi; Marc Mercken. 
Department of Neuroscience, Janssen Research & Development, Beerse B-2340, 
Belgium  
Gamma-secretase modulation has been proposed as a potential disease modifying anti-
Alzheimer's approach. In contrast to γ-secretase inhibitors, modulators cause a product 
shift from the longer amyloid isoforms to shorter, more soluble and less amyloidogenic 
isoforms, without inhibiting NOTCH proteolytic processing. Two main classes of γ-
secretase modulators (GSM) have been described: NSAID derived carboxylic acids and 
non-carboxylic acid compounds.1 Most compounds from the latter class have an N-
(hetero)aryl-imidazole moiety in common, which seems to be crucial for optimal 
potency. Since many of these compounds display undesired properties, such as 
CYP450 and hERG channel inhibition, replacement of the imidazole ring with other 
heterocycles was investigated. The SAR which has emerged from this research will be 
presented. This has resulted into non-imidazole, non-carboxylic acid containing GSM 
compounds with high in vitro and in vivo potency.   1) Oehlrich, D.; Berthelot, D. J.-C. 
Gijsen, H.J.M. J. Med. Chem. 2011, 54, 669-698 
MEDI 83 
Synthesis and preliminary evaluation of substituted N-aryl-piperazine based 
compounds as muscarinic ligands 
Rong Gao, tua63937@temple.edu; Daniel J Canney. Department of Pharmaceutical 
Sciences, Temple University, Philadelphia PA 19140, United States  
The various subtypes of muscarinic receptors (M1-M5) have a wide range of 
physiological effects that includes controlling smooth muscle tone to neurotransmitter 
release in the CNS. Hence these receptor subtypes have been investigated as potential 
therapeutic targets for agents capable of treating Alzheimer's Disease, Parkinson's 
Disease, peptic ulcer disease, COPD, urinary incontinence, and muscle spasms. 
Molecular modification of lead 5-substituted 4,5-dihydro-3,3-diethyl-2(3H)-furanones has 
been undertaken providing a series of lactone-based muscarinic ligands which feature 
N-aryl piperazines as key fragments. Microwave-assisted synthesis of various sterically 
hindered N-aryl piperazines has been developed allowing quick access to structurally 
diverse muscarinic ligands. The novel synthetic methods to the target ligands, the 
results of preliminary binding studies, and the structure activity relationship for the 
series are discussed. 
MEDI 84 
Synthesis of carbon-11-labeled arylpiperazinylalkylthiobenzoxazole derivatives as 
new potent and selective 5-HT1A serotonin receptor PET radioligands 
Mingzhang Gao, migao@iupui.edu; Min Wang; Qi-Huang Zheng. Department of 
Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis IN 
46202, United States  
Serotonin (5-HT) is an important neurotransmitter. 5-HT family contains 14 serotonin 
receptor (5-HTR) subtypes. Among 5-HTRs, 5-HT1A is one of the most studied subtypes 
and is involved in anxiety and depression. Recent reports indicate that 5-HT1AR 
agonists have neuroprotective properties, and 5-HT1AR antagonists could be useful in 
the treatment of Alzheimer's disease. A new series of 
arylpiperazinylalkylthiobenzoxazole derivatives has been recently developed by 
Siracusa et al. as potent and selective 5-HT1A serotonin receptor ligands, these 
compounds showed excellent binding affinity with nanomolar Ki values and selectivity 
for 5-HT1AR over both α1 and D2 receptors. New carbon-11-labeled 
arylpiperazinylalkylthiobenzoxazole derivatives were first designed and synthesized as 
radioligands for biomedical imaging technique positron emission tomography (PET) to 
image 5-HT1AR. Unlabeled arylpiperazinylalkylthiobenzoxazole derivatives (precursors 
and standards) were synthesized from benzo[d]oxazole-2-thiol, 5,7-dimethyl 
benzo[d]oxazole-2-thiol; 1-bromo-4-chlorobutane, 1-bromo-6-chlorohexane; and 1-(2-
methoxyphenyl)piperazine, 2-(piperazin-1-yl)phenol in 2 steps with moderate yields. 
The target tracers, 2-((4-(4-(2-[11C]methoxyphenyl)piperazin-1-
yl)butyl)thio)benzo[d]oxazole, 2-((4-(4-(2-[11C]methoxyphenyl)piperazin-1-yl)butyl)thio)-
5,7-dimethylbenzo[d]oxazole, 2-((6-(4-(2-[11C]methoxyphenyl)piperazin-1-
yl)hexyl)thio)benzo[d]oxazole, and 2-((6-(4-(2-[11C]methoxyphenyl)piperazin-1-
yl)hexyl)thio)-5,7-dimethylbenzo[d]oxazole, were prepared from their corresponding 
precursors, 2-(4-(4-(benzo[d]oxazol-2-ylthio)butyl)piperazin-1-yl)phenol, 2-(4-(4-((5,7-
dimethylbenzo[d]oxazol-2-yl)thio)butyl)piperazin-1-yl)phenol, 2-(4-(6-(benzo[d]oxazol-2-
ylthio)hexyl)piperazin-1-yl)phenol, and 2-(4-(6-((5,7-dimethylbenzo[d]oxazol-2-
yl)thio)hexyl)piperazin-1-yl)phenol, with [11C]CH3OTf through O-[11C]methylation and 
isolated by a simplified solid-phase extraction (SPE) method using a Sep-Pak® Plus 
C18 cartridge in 50-60% radiochemical yields decay corrected to end of bombardment 
(EOB) based on [11C]CO2, with 185-370 GBq/μmol specific activity at end of synthesis 
(EOS). 
MEDI 85 
Synthesis of novel benzothiophene selective estrogen receptor modulators (BT-
SERMs) that provide neuroprotection by a novel GPR30-dependent mechanism 
Vladislav A. Litosh, valitosh@uic.edu; Bradley T. Michalsen; Ronak P. Gandhi; Ramy 
Abdelhamid; Jia Luo; Lawren VandeVrede; Indraneel Kundu; Isaac T. Schiefer; 
Teshome Gherezghiher; Ping Yao; Zhihui Qin; Gregory R. J. Thatcher. Department of 
Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago IL 
60612-7231, United States  
A family of novel benzothiophene selective estrogen receptor modulators (BT-SERMs) 
was synthesized. Their structure-activity relationships for neuroprotection displayed a 
spectrum of ERα and ERβ binding affinity and agonist/antagonist activity, thus leading 
to discovery of a neuroprotective pharmacophore that is present in the clinically relevant 
SERMs, raloxifene, and desmethylarzoxifene (DMA). The 2-(4'-hydroxyphenyl)-
benzo[b]thiophen-6-ol core (BTC) is readily oxidized to a diquinone methide that acts as 
a Michael acceptor toward cysteine, while the derivatives lacking 4'-hydroxyl group in 
the 2-phenyl substituent cannot undergo bioactivation to diquinone methides, which 
indicates that the receptor mediating neuroprotective activity of BT-SERMs could 
potentially be activated by Michael addition or, alternatively, by simple noncovalent 
binding. Collective evidence suggests that the activity of neuroprotective BT-SERMs is 
GPR30-dependent and ER-independent, and not mediated by antioxidant effects. 
Comparison of novel BT-SERM derivatives and analogues identified a neuroprotective 
pharmacophore applicable for design of novel neuroprotective agents with a spectrum 
of ER activity. 
MEDI 86 
Synthesis and biological evaluation of selective Tau binders as PET imaging 
agents for the detection of Alzheimer disease 
Eric Y. Wang, eric.y.wang@siemens.com; Gang Chen; Umesh Gangadharmath; Felipe 
Gomez; Dhanalakshmi Kasi; Qianwa Liang; Changhui Liu; Vani Mocharla; Fanrong Mu; 
Anjana Sinha; A. Katrin Szardenings; Joseph C. Walsh; Chunfang Xia; Chul Yu; Wei 
Zhang; Tieming Zhao; Hartmuth C. Kolb. Discovery, Siemens Molecular Imaging, 
Culver City CA 90230, United States  
Alzheimer's disease (AD) is the leading cause of dementia and the sixth leading cause 
of death in the US. Postmortem examinations of dementia patient's brains confirm the 
presence of AD through the detection of extracellular β-amyloid deposits and 
intracellular neurofibrillary tangles (NFT) that are derived from filaments of abnormal 
hyperphosphorylated microtubule associated Tau proteins. The presence and severity 
of NFTs appear to correlate with the severity of dementia and cognitive impairment. In 
order to develop a non-invasive positron emission tomography (PET) molecular imaging 
agent that can identify NFT's associated with AD, we have synthesized a series of 
compounds that bind to Tau but not to β-amyloid. Selected candidates were labeled 
with [F18] and tested on human AD brain sections. Discussion of SAR, in vitro biological 
data and in vivo PET imaging results will be presented. 
MEDI 87 
Discovery of a substrate-based 18F-labeled apoptosis biomarker for PET imaging 
Gang Chen, gang.gc.chen@siemens.com; Kai Chen; Umesh Gangadharmath; Felipe 
Gomez; Qianwa Liang; Changhui Liu; Vani Mocharla; Fanrong Mu; Helen Su; A. Katrin 
Szardenings; Joseph C. Walsh; Chunfang Xia; Chul Yu; Tieming Zhao; Hartmuth C. 
Kolb. Biomarker Research, Siemens Molecular Imaging, Culver City CA 90230, United 
States  
Apoptosis or programmed cell death plays a crucial role in many diseases and their 
treatments. It is mediated and regulated by a complex signaling cascade involving a 
number of proteases, most importantly members of the caspase family. An 18F-labeled 
biomarker (18F-CP18) for in vivo positron emission tomography (PET) imaging of 
apoptosis was designed based on the natural substrate (DEVD) of caspase-3, an 
enzyme that plays a key role in the apoptotic process. Additional changes to the 
substrate were made to improve cell permeability, biodistribution, and clearance.  
   
The comparison between PET imaging of various xenograft tumors in mice with immuno 
staining showed a good correlation (R2=0.82) of 18F-CP18 uptake in apoptotic areas. 
Further evaluation of this tracer indicates good in vivo stability, distribution, and 
clearance, which makes CP18 a favorable candidate for in vivo apoptosis imaging. 
MEDI 88 
Discovery of diazepinone-based 5-HT3 receptor partial agonists for the potential 
treatment of irritable bowel syndrome 
Kristen N. Ryan1, kristen.ryan@amriglobal.com; Zhenjun Zhang1; Jennifer 
Naginskaya1; Sok Hui Choo1; Liaqat Masih1; Kevin Fitzpatrick1; Jonathan D. 
Wierschke1; Cheng Guo1; Nicholas M. Barnes2; Peter R. Guzzo1; David D. Manning1. 
(1) Discovery R&D, AMRI, Albany NY 12212-5098, United States (2) Celentyx Ltd., 
Edgbaston, Birmingham B15 2SQ, United Kingdom  
Based on the principle that a weak partial agonist can attenuate the action of 
endogenous agonist without fully blocking receptor function, we have discovered novel 
5-HT3 receptor partial agonists bearing diazepinone cores that are predicted to show 
improved therapeutic benefit in the treatment of irritable bowel syndrome over the 
established 5-HT3 receptor antagonists. Examples within this chemical series exhibit 
nanomolar binding affinity for the h5-HT3A receptor and a range of agonist responses in 
HEK293 cells expressing the h5-HT3A receptor.  
  
MEDI 89 
Development of inhalable antibiotics for the treatment of TB 
J'aime R. Manion1, jaime.manion@colorado.edu; Stephen P. Cape2; Nisha K. Shah1; 
Pankaj Pathak3; Sarah C. Evans3; Robert E. Sievers1, 2, 3. (1) Department of Chemistry 
and Biochemistry, University of Colorado, Boulder CO 80309-0215, United States (2) 
Cooperative Institute for Research in Environmental Sciences, University of Colorado, 
Boulder CO 80309-0216, United States (3) Aktiv-Dry LLC, Boulder CO 80301, United 
States  
The goal of this project is the development of unit-dose, inhalable, antibiotic 
microparticles and nanoparticles for use in primary and combined therapy approaches 
to treating tuberculosis (TB) and highly drug-resistant strains of Mycobacterium 
tuberculosis (Mtb) that result in multi drug-resistant (MDR-TB) and extensively drug-
resistant TB. Targeted to the alveolar space by merit of high fine particle fractions (FPF) 
in the <3.3 µm range, these antibiotic microparticles and nanoparticles utilize the same 
inhalation pathway as Mtb, to deliver antibiotic to protected TB lesions. This study 
explores strategies of combining microparticles and nanoparticles with polymer and 
excipients to improve the fine particle fraction and deliver a larger fraction of antibiotic to 
the deep lung. Using inhalable antibiotics in combination with more traditional treatment 
may also provide a strategy for reducing treatment times by potentially increasing the 
targeted dose to mucosal surfaces and tissue of the airways while reducing systemic 
side effects. 
MEDI 90 
Molecules containing reactive peroxide or nitric oxide species for the treatment of 
malaria 
Bryan T. Mott1, 2, mottb@mail.nih.gov; Xinzhuan Su3; Jing Yuan3; Chin-Chien Chang2; 
David J. Maloney2; Ganesha Rai2; Ajit Jadhav2; Anton Simeonov2; David L. Williams4; 
Craig J. Thomas2; Gary H. Posner1. (1) Department of Chemistry, Johns Hopkins 
University, Baltimore MD 21218, United States (2) NIH Chemical Genomics Center, 
National Human Genome Research Institute, Baltimore MD 21218, United States (3) 
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious 
Diseases, Bethesda MD 20810, United States (4) Department of Immunology-
Microbiology, Rush University Medical School, Chicago IL 60612, United States  
Malaria continues to be an epidemic in developing countries, and parasite resistance to 
existing treatments remains a constant threat. It is therefore imperative that new 
treatments are continually sought, ideally those that can target a number of different 
pathways exclusive to the parasite. Proliferation of malaria parasites is known to involve 
several redox pathways, affording the opportunity for redox-active molecules to interfere 
with such proliferation. To that end, molecules based on the natural product artemisinin 
(1, Figure 1), which contains a reactive peroxide linkage, have been developed that 
enhance the innate activity of the structure as demonstrated by improved (over existing 
dosing regimens) curative results in mice. More recently, molecules that generate nitric 
oxide have shown activity against a variety of parasitic diseases, including malaria. A 
nitric oxide-generating furoxan ring (2, Figure 1) has been hybridized with known 
antimalarial compounds such as chloroquine and amodiaquine in an attempt to target 
multiple redox pathways while also blocking resistance against similar quinoline-like 
molecules. Several mechanisms of action for both artemisinin and nitric oxide have 
been proposed, though each is thought to target separate pathways. The biological 
results show that artemisinin continues to be an important chemotype from which new 
antimalarials should be developed, and that nitric oxide donor hybrids represent a 
potential new class of drugs.    
   
MEDI 91 
Virulence-attenuating inhibitors of streptokinase (SK) expression in Group A 
streptococcus (GAS): Activity optimization and target identification 
Bryan Yestrepsky1, byestrep@umich.edu; Colin Kretz2; Yuanxi Xu3; Scott Larsen1; 
Hongmin Sun3; David Ginsburg2. (1) Department of Medicinal Chemistry, University of 
Michigan, Ann Arbor MI 48104, United States (2) Life Sciences Institute, University of 
Michigan, Ann Arbor MI 48104, United States (3) Department of Internal Medicine, 
University of Missouri - Columbia, Columbia MO 65211, United States  
Traditional antibiotics rely on killing bacteria or interrupting bacterial reproduction, 
thereby inducing a direct selective pressure for the evolution of antibiotic resistance. If 
bacterial mechanisms of virulence are inhibited instead, the host could in principle be 
protected long enough for clearance by the immune system, eliminating the selective 
pressure for resistance. SK has been identified as a critical virulence factor in GAS; it 
allows the bacteria to activate human plasmin and dissolve fibrin-rich clots the host 
creates around sites of invasion. High-throughput screening (HTS) identified a 
compound able to interfere with the transcription of the SK gene by GAS. Our group has 
undertaken an effort to optimize the activity and pharmacokinetic competence of this 
lead, as well as the synthesis of a variety of affinity probes probes designed to identify 
the macromolecular target of this scaffold. 
MEDI 92 
Synthesis of analogs with phenanthroline functionality targeting biosynthesis of 
lipid A in various gram-negative bacteria 
Jonathan P Urbanczyk, urbanczyk.jonathan@students.mcm.edu; Hyunshun Shin. 
Department of Chemistry and Biochemistry, McMurry University, Abilene Texas 79606, 
United States  
Pseudomonas aeruginosa (P. aeruginosa) and many other Gram-negative opportunistic 
pathogens continue to plague hospitals causing nosocomial infections. Due to the 
continual resistance towards commercially available antibiotics, there is a great need for 
a new generation of antibiotics. One promising target is the zinc-dependent 
metalloamidase, UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase 
(LpxC), which is the first committed step of Lipid A biosynthesis in Gram-negative 
bacteria. LpxC is an essential enzyme that is coded by a single copy gene that is 
conserved in almost all Gram-negative bacteria.   We here report the synthesis of small 
molecules including 3-(1H-imidazo[4,5-f][1,10]phenanthrolin-2-yl)phenol (HIPP), 2-(4-
(hexyloxy)phenyl)-1H-imidazo[4,5-f][1,10]phenanthroline (HPHIP), and 2-(3-
(heptyloxy)phenyl)-1H-imidazo[4,5-f][1,10]phenanthroline (HPIP) which easily 
coordinate with metals including zinc. In addition, we report our modeling experiments 
have shown an enhanced binding affinity of these compounds with the active site of P. 
aeruginosa LpxC. 
MEDI 93 
Synthesis, SAR, and optimization of DMPK properties of 2-substituted adenosine 
derivatives as bacterial NAD+-dependent DNA ligase inhibitors 
Madhusudhan Gowravaram, madhu.gowravaram@astrazeneca.com; Suzanne S 
Stokes; Hoan Huynh; Min Lu; Robert Albert; Brendan Chen; George Mullen; Marta 
Cavero-Tomas; James Loch; Shannon Zhao; Tom O’Shea; Joseph V Newman; Scott D 
Mills. Infection Innovative Medicines Unit, AstraZeneca R & D Boston, Waltham 
Massachusetts 02451, United States  
DNA ligases are essential enzymes for DNA replication, repair and recombination in all 
organisms. Eubacterial DNA ligase (LigA) requires NAD+ for activity, while eukaryotic 
and most viral DNA ligases require ATP. Because of their essential nature, unique 
structures and widespread existence, bacterial DNA ligases represent a valuable target 
for identifying novel and selective antibacterial agents. High throughput screening of the 
AstraZeneca compound collection identified a class of adenosine analogs as inhibitors 
of bacterial NAD+-dependent DNA ligase. Modifications at the 2-position of the scaffold 
led to the identification of compounds with low nanomolar enzyme potency and good 
microbiological activity. The detailed SAR results and our efforts in improving the DMPK 
properties of these compounds will be presented.   
  
MEDI 94 
Evaluation of antimicrobial activity of Fagara zanthoxyloides extracts 
Alfred K Addo-Mensah, alfred.addo-mensah@tamiu.edu; Cesar Cardenas; Ruby 
Ynalvez. Depart of Biology & Chemistry, Texas A&M International University, laredo 
Texas 78041, United States  
The alcohol extracts of the root bark of the plant Fagara zanthoxyloides (Lam) were 
investigated for their antimicrobial activities. Fagara zanthoxyloides is part of the 
Rutaceae family. It is an indigenous plant that is widely used as chewing stick for tooth 
cleaning in West Africa. This plant has exhibited inhibitory effects on Plasmodium 
falciparum, one of the species that causes malaria. It also has therapeutic effect on 
sickle cell anemia, and has anticancer abilities. The paper disc diffusion method using 
Muller-Hinton agar plates has been used to investigate the antimicrobial activities of the 
root bark extracts. The inhibitory effect of F. zanthozyloides against the bacterial growth 
of Escherichia coli, Methicillin-Susceptible Staphylococcus aureus, Methicillin-Resistant 
Staphylococcus aureus, and Enterococcus faecium were investigated in this study. 
These bacteria present a diverse study group which will allow testing the broad range of 
activity that the extracts from F. zanthoxyloides will have. 
MEDI 95 
Imidazole diamides as inhibitors of bacterial NAD+-dependent DNA ligases 
Hajnalka E. Davis, hajnalka.davis@astrazeneca.com; Marshall Morningstar; Charles J 
Eyerman; Oluyinka Green; Adam Shapiro; Paul R Fleming. Infection Innovative 
Medicines Unit, AstraZeneca R&D Boston, Waltham MA 02451, United States  
DNA ligases are enzymes that play a critical role in DNA replication, recombination and 
repair in living organisms. Bacterial DNA ligase (LigA) shares little sequence homology 
with eukaryotic DNA ligases, therefore it has been evaluated as an antibacterial target. 
High throughput screening identified imidazole diamides as selective inhibitors of LigA, 
showing no inhibitory activity toward human DNA ligase. Co-crystal structures confirmed 
that imidazole diamides bind in the AMP-binding pocket of the LigA adenylation domain. 
Parallel synthesis was employed to evaluate the series. Structure-activity relationships 
were developed around both amides. The compounds prepared had IC50 values ranging 
from 200μM to 0.4μM.    
MEDI 96 
HIV attachment inhibitors with measurable aqueous solubility, significant 
bioavailability, and high potency 
Barry L. Johnson, barry.johnson@bms.com; David J. Carini; Alicia Regueiro-Ren; 
Sandhya Rahematpura; Lawrence G. Hamann; John F. Kadow; Ming Zheng; Dawn D. 
Parker; Beata D. Nowicka-Sans; Sharon Zhang; Pin-fang Lin; Nicholas A. Meanwell. 
Bristol-Myers Squibb, Wallingford CT 06492, United States  
The first step in HIV infection is the attachment of the viral envelope gp120 glycoprotein 
to CD4 on the surface of the human target cell. Inhibitors of this process provide 
another potential avenue for viral suppression. Early program lead inhibitors were very 
potent but suffered from poor oral exposure. It was postulated that low aqueous 
solubility contributed to the observed low bioavailability. One approach explored for 
increasing the aqueous solubility of this class of inhibitors was to reduce the number of 
aromatic rings. Toward this objective, a benzamide moiety was replaced with non-
aromatic cyclic urea moieties. The targeted aqueous solubility was obtained without 
sacrificing a significant level of potency. Subsequent pharmacokinetic studies 
demonstrated improved oral exposure when dosed in rats. 
MEDI 97 
Design, synthesis and SAR study of bridged tricyclic pyrimidinone as HIV 
integrase inhibitors 
Manoj Patel1, manoj.patel@bms.com; B. Narasimhulu Naidu1; Ira Dicker2; Helen 
Hingley2; Zeyu Lin2; Brian Terry2; Tricia Protack2; Nicholas A. Meanwell1; Mark Krystal2; 
Michael A. Walker1. (1) Virology Chemistry, Bristol-Myers Squibb Research and 
Development, Wallingford CT 06492, United States (2) Virology, Bristol-Myers Squibb 
Research and Development, Wallingford CT 06492, United States  
Raltegravir is an important addition to the clinical armamentarium of anti-retroviral 
agents, but resistance to this agent is an emerging issue. One of our objectives for a 
second generation integrase program is to develop a compound that would be 
efficacious against viruses resistant to this first generation integrase inhibitor. To that 
end, we investigated a series of bridged tricyclic pyrimidinones as potential HIV-1 
integrase inhibitors. After surveying several bridged tricyclic pyrimidinones as inhibitors 
of viruses with raltegravir resistant genotypes, the [3.2.2] template was selected for 
further evaluation and optimization. In this presentation, we disclose the synthesis and 
antiviral activity of a series of bridged [3.2.2] tricyclic pyrimidinones as novel HIV-1 
integrase inhibitors that demonstrate potent activity toward viruses resistant to 
raltegravir. 
MEDI 98 
Preclinical drug metabolism and pharmacokinetic evaluation of novel HMDCK 
prodrugs as potent anti-HIV NNRTIs 
Keduo Qian1, kdqian@unc.edu; Kuo-Hsiung Lee1, 2; Lan Xie3. (1) Eshelman School of 
Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill NC 27599, United 
States (2) Chinese Medicine Research and Development Center, China Medical 
University and Hospital, Chapel Hill NC 27599, United States (3) Beijing Institute of 
Pharmacology and Toxicology, Beijing 1000850, China  
The drug metabolism and pharmacokinetic profiles of ester prodrugs (2-9) of HMDCK 
(1) were evaluated. HMDCK is a novel anti-HIV NNRTI functioning by inhibiting the 
production of HIV-1 dsDNA from ssDNA intermediates. However, the insufficient 
metabolic stability of HMDCK limits its further clinical development. In the present study, 
the in vitro metabolic stability of prodrugs 2-9 were investigated using Sprague-Dawley 
rat liver microsomes under oxidative conditions. The L-analine ester prodrug 7 was the 
best compound, with an apparent in vitro t1/2 of 86.63 min and intrinsic clearance (CLint) 
of 0.080 mL/min/mg. The in vivo PK evaluation in male SD rats indicated that 7 
exhibited a higher oral bioavailability (F: 25.7%), lower systemic clearance (CL: 0.016 
L/min/kg), and moderate MRT (1.793 h). Prodrug 7 also had a better water solubility (18 
mg/L) than HMDCK (8.4 mg/L). Overall, these preclinical results supported the further 
development of 7 as a novel NNRTI. 
MEDI 99 
SAR study of CD4 mimics targeting the HIV entry mechanism and their hybrid 
molecules with a CXCR4 antagonist 
Tetsuo Narumi1, tenarumi.mr@tmd.ac.jp; Hiroshi Arai1; Chihiro Ochiai1; Kazuhisa 
Yoshimura2; Shigeyoshi Harada2; Wataru Nomura1; Shuzo Matsushita2; Hirokazu 
Tamamura1. (1) Department of Medicinal Chemistry, Institute of Biomaterials and 
Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku Tokyo 101-0062, 
Japan (2) Center for AIDS Research, Kumamoto University, Japan  
Small-molecule CD4 mimics were previously reported as a novel class of HIV-1 entry 
inhibitors that block the gp120-CD4 interaction and induce a conformational change in 
gp120, exposing its co-receptor-binding site. In this study, the structure-activity 
relationship (SAR) study of a series of CD4 mimic analogs was conducted to investigate 
the contribution from the aromatic and piperidine moieties of CD4 mimic to anti-HIV 
activity, cytotoxicity, and CD4 mimicry effects on conformational changes of gp120. The 
results indicate that i) a certain size and electron-withdrawing ability of the para-position 
of the aromatic ring are indispensable for potent anti-HIV activity; ii) the presence of 
piperidine moiety is important for the CD4 mimicry; and iii) N-substituents of the 
piperidine moiety contribute significantly to anti-HIV activity and cytotoxicity. In addition, 
several hybrid molecules based on conjugation of a CD4 mimic analog with a selective 
CXCR4 antagonist were also synthesized and their utility evaluated. 
MEDI 100 
Novel HCV NS5B polymerase inhibitors: Discovery of indole C2- acyl 
sulfonamides 
Gopinadhan N Anilkumar, gopinadhan.anilkumar@merck.com; Oleg Selyutin; Stuart B 
Rosenblum; Qingbei Zeng; Yueheng Jiang; Luis Torres; Tin-Yau Chan; Haiyan Pu; 
Henry Vaccaro; Li Wang; Frank Bennet; Kevin X Chen; Stephen Gavalas; Yuhua 
Huang; Patrick Pinto; Mousumi Sannigrahi; Francisco Velazquez; Srikanth 
Venkatraman; Bancha Vibulbhan; Charles Lesburg; Jose Duca; Charles McNemar; 
Sony Agrawal; Eric Ferrari; Chuan-kui Jiang; H.-C. Huang; Neng-Yang Shih; George 
Njoroge; Joseph A Kozlowski. Merck Research Laboratories, Kenilworth New Jersey 
07033, United States  
Previous work described a series of novel indole based NS5B palm site polymerase 
inhibitors exemplified by structure I. Further structure – HCV NS5B binding activity 
relationship at the indole C2 position revealed a distinct subseries with biosiosteric C2 
acyl sulfonamides (II) as replacements of C2 carboxylic acids. The optimization 
campaign resulted in the discovery of extended C2 acyl sufonamide derivatives (III) with 
nanomolar enzyme and replicon activity profile.  
  
MEDI 101 
Novel HCV NS5B polymerase inhibitors: Discovery of indole 2- carboxylic acids 
with C3-heterocycles 
Gopinadhan N. Anilkumar, gopinadhan.anilkumar@spcorp.com; Charles Lesburg; 
Oleg Selyutin; Stuart B Rosenblum; Qingbei Zeng; Yueheng Jiang; Tin-Yau Chan; 
Haiyan Pu; Henry Vaccaro; Li Wang; Frank Bennet; Kevin X Chen; Jose Duca; Stephen 
Gavalas; Yuhua Huang; Patrick Pinto; Mousumi Sannigrahi; Francisco Velazquez; 
Srikanth Venkatraman; Bancha Vibulbhan; Sony Agrawal; Nancy Butkiewicz; Eric 
Ferrari; Boris Feld; Zhiqing He; Chuan-kui Jiang; Robert E Palermo; H.-C. Huang; 
Neng-Yang Shih; George Njoroge; Joseph A Kozlowski. Merck Research Laboratories, 
Kenilworth New Jersey 07033, United States  
SAR development of indole-based palm site inhibitors of HCV NS5B polymerase 
exemplified by initial indole lead I (NS5B IC50 = 0.9 mM, replicon EC50 >100 mM) is 
described. Structure-based drug design led to the incorporation of novel heterocyclic 
moieties at the indole C3-position which formed a bidentate interaction with the protein 
backbone. SAR development resulted in novel NS5B polymerase inhibitors exemplified 
by II (NS5B IC50 = 0.017 mM, replicon EC50 = 0.3 mM) with improved enzyme and 
replicon activity. 
   
MEDI 102 
Structure-based drug design and the evaluation of irreversible HCV-protease 
inhibitors 
Lixin Qiao, lqiao@avilatx.com; Deqiang Niu; Zhendong Zhu; Matt Labenski; Margit 
Hagel; Thia St. Martin; Michael Sheet; Hugues Bernard; Mariana Nacht; Willian Westlin; 
Russell Petter; Juswinder Singh. Avila Therapeutics Inc., Waltham MA 02453, United 
States  
Inhibitors of HCV NS3 protease have proven to have significant therapeutic benefit in 
clinical trials. However, the class as a whole suffers from the rapid emergence of drug 
resistant variants, and the effectiveness of current agents is limited to specific 
HCVgenotypes. Moreover, achieving selectivity over host proteases remains a 
considerable challenge.  Using structure-based drug design, we identified a class of 
small molecules that irreversibly bond to a non-catalytic amino acid residue, cysteine 
159, in NS3 protease. This approach significantly improved inhibitor potency against the 
viral proteases and also achieved exceptional selectivity due to the lack of structural 
homology between viral and host proteases. More importantly, the covalent inhibitor 
showed prolonged duration of action (>24 hours) after brief exposure. In this 
presentation, we will report the SAR of our HCV NS3 irreversible inhibitors, together 
with in silico assessment of selected Michael acceptors. 
MEDI 103 
Synthesis and evaluation of novel biotin conjugated lipid prodrugs of cyclic 
cidofovir 
Mahuya Bagui, bagui.mahuya@gmail.com; Mitan R Gokulgandhi; Ashim K Mitra. 
School of Pharmacy,Division of Pharamaceutical Science, University of Missouri-
Kansas City, Kansas City Missouri 64108, United States  
Cidofovir (HPMPC), an acyclic phosphonate nucleotide analogue of cytosine shows 
potential antiviral activity against herpes-, adeno-, polyoma- and poxviruses. It is 
currently used for treatment of AIDS-related cytomegalovirus retinitis. Cyclic cidofovir 
(cHPMPC) displays less nephrotoxicity compared to HPMPC with higher antiviral 
potency. The major drawback with HPMPC/cHPMPC is their low oral bioavailability and 
poor transport across virus infected cells which limit therapeutic efficacy. With an aim to 
obtain targeted drug delivery and enhance lipid mediated cellular permeability here in 
we have evaluated novel transporter targeted lipid prodrugs of cyclic cidofovir. Targeted 
lipid prodrugs were synthesized by conjugating lipid rafts at one end of the cyclic 
cidofovir and tether the other end of these conjugates with biotin ligand for targeting 
sodium-dependent multivitamin transporter. Bifunctional lipid rafts containing 6 and 12 
carbon chains were selected with two different functional groups (-OH and –NH2) for 
linking one end to cyclic cidofovir and other end to biotin. To delineate the individual 
effects of targeting ligand and lipid raft on the prodrug properties, we have also 
synthesized and performed studies with Biotin- cHPMPC and Lipid (C6 and C12) - 
cHPMPC individually. All synthesized prodrugs were characterized by LC-MS/MS, 1H 
NMR and 13C NMR and were evaluated with respect to their physicochemical properties 
i.e., aqueous stability, solubility, octanol/water partition coefficient and cytotoxicity. 
MEDI 104 
Preparing new betulinic acid derivatives for fighting HIV viruses 
Hua Zhao1, zhaoh@savannahstate.edu; Shaletha Holmes1; Himangshu Bose2; Challa 
Suresh1; Zhiyan Song1. (1) Chemistry Program, Savannah State University, Savannah 
GA 31404, United States (2) School of Medicine, Mercer University, Savannah GA 
31404, United States  
Betulinic acid is a naturally occurring pentacyclic triterpenoid that has several important 
biological activities including the inhibition of HIV viruses. This compound can be found 
in many plants such as birch bark. This compound has low toxicity due to its natural 
origin, but its application has been hampered by its low solubility in water and organic 
solvents. Therefore, many derivatives of betulinic acid have been synthesized to 
improve its biological functions including serving as potent and highly selective inhibitors 
of HIV-1. In this study, we have prepared derivatives of betulinic acid by conjugating it 
with an amino acid, followed by complexing the conjugate with organic cations to form 
ionic salts. We hypothesize the incorporation of an amino acid and the formation of an 
ionic compound will greatly improve the solubility of betulinic acid in water and organic 
solvents, which will then enhance the anti-HIV activity of betulinic acid. After the 
preparation of novel ionic salts of betulinic acid, the derivatives were evaluated for 
inhibiting the activities of HIV-1 protease. HIV-1 protease is a retroviral aspartyl 
protease that is essential to the maturation of HIV viruses, and thus the inhibition of 
protease disrupts the HIV's ability to replicate and infect additional cells. Using the HIV-
1 protease-catalyzed peptide hydrolysis assay as monitored by the HPLC analysis, we 
have achieved some preliminary successes, which suggest that new ionic derivatives of 
betulinic acid are more inhibitory to the HIV-1 protease activity than betulinic acid itself. 
MEDI 105 
Synthesis of enantiopur antimalarial 4-aminoquinolinols 
Sylvain Fardeau1, sylvain.fardeau@u-picardie.fr; Alexia Jonet1; Alexandra Dassonville-
Klimpt1; Nicolas Taudon2; Pascal Sonnet1. (1) Department of THERA, UMR-CNRS 
6219, Amiens Picardie 80037, France (2) Laboratoire de bioanalyse et 
pharmacocinétique, Institut de Médecine Tropicale du Service de Santé des Armées, 
Marseille PACA 13262, France  
Malaria is caused by Plasmodim and is responsible for 800.000 deaths in 2009. 
Research of new antimalarial chemotherapy has become urgent because of parasite 
resistance to classical drugs. Herein, we describe an enantiopure way to prepare 
enantiomeric 4-aminoquinolinols derivates. A regioselective Sn2 ring opening of the 
epoxide, by diverse amines, allows us to obtain the corresponding (R) or (S) 4 
aminoquinolinol with good yields and enantiomeric excesses generally above 89%. The 
(S)-enantiomers showed the best antimalarial activity.   
  
MEDI 106 
Efficient synthesis of amino-protected calix[4]arenes selectively functionalized 
with iron chelator ICL670 designed as platform for iron recognition 
Sylvain Fardeau1, 2, sylvain.fardeau@u-picardie.fr; Pascal Rouge1, 2; Mathieu Becuwe3, 
2; Alexandra Dassonville-Klimpt1, 2; Sophie Da Nascimento1, 2; Jean-François Raimbert1, 
2; Dominique Cailleu4, 2; Emmanuel Baudrin1, 2; Pascal Sonnet1, 2. (1) Department of 
THERA, UMR-CNRS 6219, Amiens Picardie 80037, France (2) Institut de Chimie de 
Picardie FR3085 CNRS, Amiens Picardie 80037, France (3) UMR-CNRS 6007, Amiens 
Picardie 80039, France (4) Plate-forme analytique, Amiens Picardie 80039, France  
Development of new tools to enable the selective detection of specific ions, ideally in 
situ, is a very ambitious challenge. For the specific medicinal applications, the 
developed ion sensors should be ideally integrated in miniaturized systems. For such a 
case, electrochemical detection is one of the simplest and cheapest types of 
measurements, and more specifically the potentiometric detection. Fe3+ is a major 
transition metal for all organisms and is an essential element for the critical steps of the 
cellular metabolism. Very few Fe3+ sensors have been reported so far and thus sensing 
and quantification of Fe3+ is still a challenging task. One promising possibility, to develop 
ion sensors, is to use organically functionalized inorganic particles, for instance silica, 
as sensitive element. Herein, we present the design and synthesis of calix[4]arene-
based platforms modified with ICL670 iron chelator and alkylamino chain(s). The 
formation of hydrid material and the first potentiometric test will be discussed. 
MEDI 107 
Synthesis of 4-thiouracil KPGEPGPK analogs as TIIICBP identification tools 
Sylvain Fardeau, sylvain.fardeau@u-picardie.fr; Viviane Silva Pires; Sophie Da 
Nascimento; Pascal Sonnet. Department of THERA, UMR-CNRS 6219, Amiens 
Picardie 80037, France  
In a previous work, the identification of a new receptor for type III collagen named Type 
III Collagen Binding Protein (TIIICBP) has been reported. This receptor which is not yet 
identified is supposed to interact with the octapeptide sequence KPGEPGPK located in 
the a1-chain of CB4 fragment of the type III collagen. Actually, the TIIICBP structure 
and the mechanisms of its corresponding interactions with KPGEPGPK are so far 
unknown. In this work, we described the synthesis of three octapeptides analogues that 
could be able to bind by a covalent way to the receptor TIIICBP via the use of 4-
thiouracil probe. This probe has been incorporated at the 1 and/or 3 positions in 
KPGEPGPK sequence since it has been demonstrated that those positions could be 
mutated without major anti-thrombotic activity modifications. These analogues could be 
used to identify TIIICBP. 
MEDI 108 
Bacterial iron's uptake: A promising solution against multidrug resistant bacteria 
Sylvain Fardeau1, sylvain.fardeau@u-picardie.fr; Catherine Demailly-Mullie1; Alexandra 
Dassonville-Klimpt1; Nicolas Audic2; Pascal Sonnet1. (1) Department of THERA, UMR-
CNRS 6219, Amiens Picardie 80037, France (2) Pharmamens, Amiens Picardie 80037, 
France  
It has been notified the strengthening of bacterial efflux system and the decreased 
permeability of bacterial membranes toward antibiotics. These phenomena have 
enabled the rise of multi-drug resistant bacteria. Besides micro-organisms need for their 
development iron, so they synthesize molecules called siderophores which bind 
extracellular ferric iron and transport it into themselves. Interestingly some micro-
organisms have developed ingenious bacteriostatic agent: a bioactive molecule is linked 
with a siderophore-like fragment. This “Trojan Horse”'s strategy is based upon the 
specific recognition by the bacteria receptors and the absorption allows to bypass 
bacterial membranes and heightens the antibacterial activity. To develop new 
therapeutic agents against multi-drug resistant bacteria, we decided to work on 
siderophore-linked antibiotics: an iron (III) chelator linked by a cleavable chemical bond 
to a therapeutic agent. We reported here the synthesis and biological results of 
catecholamides functionalized multi-amine backbone linked via a cleavable bond to a 
bioactive agent. 
MEDI 109 
Synthesis and evaluation of dual-action hybrid antimicrobials and prodrugs 
Michael J Kelso1, mkelso@uow.edu.au; John B Bremner1; Naveen K Dolla1; Kim 
Lewis2; Summant Puri2; Frederick M Ausubel3. (1) School of Chemistry, University of 
Wollongong, Wollongong New South Wales 2522, Australia (2) Department of Biology 
and Antimicrobial Discovery Centre, Northeastern University, Boston Massachusetts 
02115, United States (3) Department of Genetics, Harvard Medical School, Boston 
Massachusetts 02114, United States  
Clinical antibiotic resistance is often mediated via bacterial multi-drug resistance (MDR) 
efflux pumps. One strategy being explored for countering such resistance is to 
coadminister antibiotics with one or more MDR inhibitors; a strategy that is known to be 
used by plants to resist pathogens. Conceptually the approach is attractive for use in 
humans but in practice it is difficult to achieve therapeutic concentrations of two 
structurally unrelated compounds at target infection sites. In addition, the road to 
regulatory approval is vastly more complex for combination treatments than for single 
agents making this strategy unattractive from a development perspective. In efforts to 
address these shortcomings we've shown that non-cleavable dual-action hybrid 
compounds, comprising an antibacterial (berberine) linked to an MDR inhibitor (INF55), 
are effective antimicrobials against MDR-overexpressing bacterial cells. The 
presentation will summarise the synthesis and evaluation of several hybrids and 
describe our recent efforts towards antibacterial-MDR inhibitor prodrugs. 
MEDI 110 
Design, synthesis, and biological evaluation of novel Mtb-specific Dxr inhibitors 
as potential antitubercular agents 
Geraldine San Jose1, gsanjose@gwu.edu; Kylene Kehn-Hall2; Helena I Boshoff3; 
Fatah Kashanchi2; Cynthia S Dowd1. (1) Department of Chemistry, George Washington 
University, Washington DC 20052, United States (2) Department of Molecular and 
Microbiology, George Mason University, Manassa VA 20110, United States (3) National 
Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda MD 
20892, United States  
Tuberculosis (TB), a highly contagious disease caused by Mycobacterium tuberculosis 
(Mtb), represents one of the most threatening health problems globally. The emergence 
of drug-resistant strains is a serious threat to TB control and treatment. There is an 
urgent need for the discovery and development of novel anti-tubercular agents.  Mtb 
synthesizes isoprenoids, essential for mycobacterial survival, via the nonmevalonate 
pathway; the second step being mediated by the enzyme Dxr. Inhibitors of Dxr are 
potential anti-TB agents. The nonmevalonate pathway is absent in humans, therefore, 
Dxr can be specifically targeted without interfering with human metabolism.  The goal of 
this project is to design, synthesize and evaluate a unique class of analogues of 
fosmidomycin and FR900098, known inhibitors of Dxr, in order to study their structure-
activity relationships and develop a new series of anti-TB drugs. Computational docking, 
synthetic results and biological evaluation will be presented. 
MEDI 111 
Identification and optimization of (E)-1-((2-(1-methyl-1H-imidazol-5-yl) quinolin-4-
yl) methylene) semithiocarbazones as a novel series of IκB kinase β (IKKβ) 
inhibitors 
Youngsook Shin1, yshin@amgen.com; Timothy D. Cushing1; Vijay Baichwal2; Karen 
Berry3; Roland Billedeau4; Viola Bordunov5; Chris Broka4; Mario Cardozo6; Peng 
Cheng1; David Clark1; Stacie Dalrymple5; Michael DeGraffenreid1; Adrian Gill4; Xiaolin 
Hao1; Ronald C. Hawley4; Xiao He1; Juan Jaen1; Sharada S. Labadie4; Marc Labelle1; 
Csaba Lehel2; Pu-Ping Lu1; Joel McIntosh4; Shichang Miao3; Camran Parast2; Eric 
Sjogren4; Marie-Louise Smith1; Francisco X. Talamas4; George Tonn3; Keith Walker4; 
Nigel P. C. Walker6; Holger Wesche2; Chris Whitehead4; Matt Wright3; Michelle 
Browner5. (1) Department of Chemistry, Amgen Inc., South San Francisco CA 94080, 
United States (2) Department of Molecular Biology, Amgen Inc., South San Francisco 
CA 94080, United States (3) Department of PKDM, Amgen Inc., South San Francisco 
CA 94080, United States (4) Department of Chemistry, Roche, Palo Alto CA 94304, 
United States (5) Department of Biology, Roche, Palo Alto CA 94304, United States (6) 
Department of Structural Biology, Amgen Inc., South San Francisco CA 94080, United 
States  
Nuclear factor κB (NF-κB) plays a role in the regulation of inflammatory and immune 
responses, and control of cell division and apoptosis. IκB kinase β (IKKβ) has been 
identified as a potential target for the treatment of inflammatory and autoimmune 
diseases because of its role in the NF-κB signaling pathway. We have developed a 
novel series of (E)-1-((2-(1-methyl-1H-imidazol-5-yl) quinolin-4-yl) methylene) 
semithiocarbazones as potent inhibitors of IKKβ. In this poster we document our early 
SAR efforts at optimization of the quinoline core, the imidazole moiety, and 
semithiocarbazone. The SAR around these groups was limited and most potency gains 
were obtained by substitution around the 6 and 7-positions of the quinoline ring. 
Replacement of the semithiocarbazone with a semicarbazone decreased the potency 
but increased the solubility leading to some measurable pharmacokinetics parameters. 
MEDI 112 
Novel series of IkB kinase β (IKKβ) inhibitors part II: Description of a potent and 
pharmacologically active series of analogs 
Xiao He1, xhe@amgen.com; Timothy D. Cushing1; Vijay Baichwal2; Karen Berry3; 
Roland Billedeau4; Viola Bordunov5; Chris Broka4; Michelle Browner6; Mario Cardozo7; 
Peng Cheng1; David Clark1; Stacie Dalrymple5; Michael DeGraffenreid1; Adrian Gill4; 
Xiaolin Hao1; Ronald C. Hawley4; Sharada S. Labadie4; Marc Labelle1; Csaba Lehel2; 
Pu-Ping Lu1; Joel McIntosh4; Shichang Miao3; Camran Parast2; Youngsook Shin1; Eric 
Sjogren4; Marie-Louise Smith1; Francisco X. Talamas4; George Tonn3; Keith Walker4; 
Nigel P. C. Walker7; Holger Wesche2; Chris Whitehead4; Matt Wright3; Juan C. Jaen1. 
(1) Department of Chemistry, Amgen Inc., South San Francisco CA 94080, United 
States (2) Department of Molecular Biology, Amgen Inc., South San Francisco, CA 
94080, United States (3) Department of PKDM, Amgen Inc., South San Francisco CA 
94080, United States (4) Department of Chemistry, Roche Palo Alto, Palo Alto CA 
94304, United States (5) Department of Biology, Roche Palo Alto, Palo Alto CA 94304, 
United States (6) Department of Discovery Technologies, Roche Palo Alto, Palo Alto CA 
94304, United States (7) Department of Structural Biology, Amgen Inc., South San 
Francisco CA 94080, United States  
The highly homologous IKKβ and IKKα are members of a small class of protein kinases 
known as IkB kinase (IKKs). IKKβ and IKKα activity are required for the activation of the 
transcription factor Nuclear factor κB (NF-κB). NF-κB controls much of the innate 
immune system and is instrumental in the induction of genes leading to a pro-
inflammatory response. Aberrant activation of the NF-κB pathway has been implicated 
in inflammation, autoimmune diseases and cancer. Drugs targeting these kinases are 
very promising candidates for the treatment of many diseases. A Novel series of (E)-1-
((2-(1-methyl-1H-imidazol-5-yl) quinolin-4-yl) methylene) thiosemicarbazides was 
discovered as potent inhibitors of IKKβ. In this poster we document our efforts at further 
optimization of this series, culminating in compound 2 which exhibited submicromolar 
activity in a HWB assay and efficacy in a CIA mouse model. 
MEDI 113 
Benzothiadiazoles as MAPKAP kinase 2 inhibitors 
Jennifer Thomason, jennifer.thomason@pfizer.com; Kerry Combs; Bruce Follows; 
Steve Kirincich; WeiHeng Wang; Jean-Baptiste Telliez; Julie Liu; Ariamala Gopalsamy; 
Lynn Resnick; Frank Lovering. Department of Inflammation and Immunology, Pfizer, 
Cambridge MA 02140, United States  
MK2 (Mitogen Activated Protein Kinase Activated Protein Kinase 2) is a 
Serine/Threonine kinase regulated by phosphorylation by p38 MAP kinase. Activation 
occurs during the inflammation response where MK2 regulates the biosynthesis of 
TNFα, a cytokine that plays a significant role in a number of inflammatory disease states 
including rheumatoid arthritis.  The link between MK2 and TNFα has been established 
from the MK2 knockout study. The -/- MK2 mice have reduced LPS mediated TNFα 
production, are resistant to LPS/D-Gal induced shock and are otherwise healthy. MK2 
knockout mice are also resistant to collagen induced arthritis.  Compounds that inhibit 
MK2, therefore, could potentially be useful in the treatment of many TNFα mediated 
diseases such as rheumatoid arthritis.  The development of a class of novel MK2 
inhibitors containing a thiadiazole core will be discussed. 
MEDI 114 
Delivery of inhaled corticosteroid (ICS) and long acting beta agonist (LABA) via 
mutual prodrug strategy for the treatment of pulmonary inflammation and 
bronchoconstriction 
Musong Kim, Musong.Kim@gilead.com; Alexander Rudoph; Josh Van Veldhuizen; 
William Baker; Marcin Stasiak; Clifford D Wright. Medicinal Chemistry, Gilead Sciences, 
Inc., Seattle WA 98102, United States  
Combination therapy of ICS and LABA is a frontline treatment for asthma and COPD 
patients. We will present the design and synthesis of a novel linking strategy to deliver 
an ICS and LABA from a single chemical entity that is unmasked to the individual 
components by a metabolic process. Data will be presented illustrating improved PK 
and safety in animal models over the individual components. 
MEDI 115 
Discovery of 4,5-dihydroindazole-based dissociated agonists of glucocorticoid 
receptor 
Zhonghui Lu, zhonghui.lu@bms.com; James J.-W. Duan; Bin Jiang; David S. 
Weinstein; Hua Gong; Arthur M. Doweyko; Christine Burke; Sium Habte; Jinhong Wang; 
Ding Shen; Lorraine Mckay; John E. Somerville; Steven G. Nadler; John Dodd; Joel C. 
Barrish. Discovery Chemistry, Bristol-Myers Sqibb Company, Princeton NJ 08543, 
United States  
Synthetic glucocorticoids (GCs) such as dexamethasone, prednisolone and cortivazol 
are among the most effective agents for the treatment of autoimmune and inflammatory 
diseases. Their long-term administration is often complicated by a number of side-
effects which limit broader indication of this class of drugs. Therefore identification of 
glucocorticoid receptor (GR) ligands which maintain the anti-inflammatory and 
immunosuppressive activity of GCs while minimizing side-effects has attracted 
significant interest in the pharmaceutical industry. 4,5-Dihydoindazoles represent a 
structurally simplified chemical series of GR agonists relative to steroidal ligands. The 
synthesis and SAR of these modulators will be described in detail. 
MEDI 116 
Discovery of 2-aryl-5H-chromeno[2,3-b]pyridines (azaxanthenes) as selective 
glucocorticoid receptor modulators 
Hua Gong, hua.gong@bms.com; David S. Weinstein; Arthur M. Doweyko; Jinhong 
Wang; Mark Cunningham; Deborah Holloway; Sium Habte; Christine Burke; David 
Shuster; Luisa Saltercid; Ling Gao; Julie Carman; John Dodd; John E. Somerville; 
Steven G. Nadler; Joel C. Barrish. Research and Development, Bristol-Myers Squibb 
Company, Princeton NJ 08543, United States  
There has been intense interest in the identification of selective GR modulators 
(SGRMs) which maintain the anti-inflammatory and immunosuppresive efficacy of 
steroidal glucocorticoid ligands with a reduced side effect profile. In this presentation 
structure-activity relationship (SAR) for a series of selective GR ligands based on the 
5H-chromeno[2,3-b]pyridine (azaxanthene) scaffold will be described. It was found that 
para-substituted phenyl on the S-enantiomer of the azaxanthene core provides varying 
levels of GR agonist activity. These azaxanthene ligands are pharmacologically 
characterized as competitive partial agonists/partial antagonists of GR transactivation. A 
structural model for ligand binding is also presented. Antiinflammatory efficacy in rats of 
selective compounds in this series and synthesis of the azaxanthenes will also be 
discussed. 
MEDI 117 
Novel agonists and antagonists for protease activated receptor 2 
Annika M. Yau, a.yau@imb.uq.edu.au; Ligong Liu; Robert C Reid; Grant D Barry; 
Jacky Y Suen; Rink-Jan Lohman; Giang T Le; Adam Cotterell; David P Fairlie. Division 
of Chemistry and Structural Biology, Institute for Molecular Bioscience, Brisbane 
Queensland 4072, Australia  
Protease activated receptor 2 (PAR2) is a class A G protein-coupled receptor that is 
expressed on the surface of many types of cells. The roles of PAR2, as implicated in a 
number of diseases including inflammatory disorders, cancers, cardiovascular diseases 
and asthma, make it a potential new drug target. The mechanism of activation of PAR2 
is unique. Unlike other GRCRs, PAR2 has no known endogenous ligand. Instead the N-
terminus of the receptor is cleaved by serine proteases (e.g. trypsin, tryptase but not 
thrombin) at a specific site, and is self-activated through binding of the newly exposed 
N-terminus (also known as a tethered-ligand, TL) to the receptor. Synthetic peptides 
corresponding to TL can also activate PAR2 and are used to characterize physiological 
roles of PAR2. However these peptides have low potency (e.g. SLIGKV-NH2, SLIGRL-
NH2), uncertain target selectivity and poor bioavailability, which limit their usefulness for 
specifically interrogating PAR2 in vivo.   In our drug discovery program, we successfully 
developed potent, selective, non-peptidic PAR2 agonists and antagonists, evaluated in 
both in vitro and in vivo studies. Some of these compounds and activities will be 
described.  References:  1) Barry, G. D.; Suen, J. Y.; Le, G. T.; Cotterell, A.; Reid, R. C.; 
Fairlie, D. P. J. Med. Chem. 2010, 53, 7428.  2) Adams, M. N.; Ramachandran, R.; Yau, 
M. K.; Suen, J. Y.; Fairlie, D. P.; Hollenberg, M. D.; Hooper, J. D. Pharmacol. Ther. 
2011, in press. DOI: 10.1016/j.pharmthera.2011.01.003. 
MEDI 118 
SAR studies on peptide agonists of proteinase activated receptor-2 (PAR-2) 
Myra Beaudoin Bertrand1, myra.beaudoin.bertrand@bms.com; Richmond A Owusu1; 
Paul Davies2; Rui-Qin Liu2; Andrew Watson2; Stephanie Briceno2; Melissa Yarde3; Mary 
Ellen Cvijic3; Carolyn A Weigelt4; Andrew J Tebben4; Keith L Constantine5; Sarah C 
Traeger6; Cullen L Cavallaro7; Percy H Carter1; Jeffrey A Tredup8; Mark Witmer8. (1) 
Department of Immunology Chemistry, Bristol-Myers Squibb, Princeton NJ 08540, 
United States (2) Department of Immunology, Discovery Biology, Bristol-Myers Squibb, 
Princeton NJ 08540, United States (3) Department of Molecular Sciences & Candidate 
Optimization, Bristol-Myers Squibb, Princeton NJ 08540, United States (4) Department 
of Computer Assisted Drug Design, Bristol-Myers Squibb, Princeton NJ 08534, United 
States (5) Department of Mechanistic Biochemistry, Bristol-Myers Squibb, Princeton NJ 
08540, United States (6) Department of Pharmaceutical Candidate Optimization, Bristol-
Myers Squibb, Princeton NJ 08540, United States (7) Department of Chemical and 
Protein Technologies, Bristol-Myers Squibb, Princeton NJ 08540, United States (8) 
Department of Gene Expression and Protein Biochemistry, Bristol-Myers Squibb, 
Princeton NJ 08540, United States  
PAR-2 is a GPCR that has been implicated in the pathophysiology of diseases such as 
rheumatoid arthritis, inflammatory bowel diseases and multiple sclerosis. Human PAR-2 
is activated by cleavage by a serine protease (e.g. Trypsin), thereby revealing the N-
terminal peptide SLIGKV, which in turn intramolecularly binds and activates the 
juxtamembrane region of the receptor. Structure/activity studies based on a related and 
potent PAR-2 peptide agonist 2-furoyl-LIGRLO-NH2 will be presented. The results of 
those studies, in addition to NMR experiments, CD analysis and modeling techniques, 
were used to determine the presence and identity of the peptide's secondary structure. 
PAR-2 macrocycles that mimic this structure were synthesized and will also be 
reported. 
MEDI 119 
Design, synthesis, and structure-activity relationship studies of novel, potent and 
orally bioavailable CRTH2 antagonists 
Tadashi Terasaka1, tadashi.terasaka@jp.astellas.com; Hisashi Hayashida2; Hiroshi 
Matsuda2; Junji Miyata1; Hiroshi Nagata2; Shinji Ito1; Yuji Takasuna1; Miki Kobayashi1; 
Makoto Takeuchi1; Mitsuaki Ohta1. (1) Drug Discovery Research, Astellas Pharma Inc., 
21, Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan (2) Astellas Research Technologies 
Co., Ltd., 21, Miyukigaoka, Tsukuba Ibaraki 305-8585, Japan  
A recent report from our laboratories described the discovery of novel, potent and orally 
bioavailable CRTH2 antagonist, 2 (IC50 = 13 nM to human CRTH2) based on the initial 
optimization of lead compound 1 (IC50 = 42 nM) discoverd from high throughput 
screening of our chemical library. Although compound 2 was designed by 
transformation of acetic acid of 1 to butanoic acid, no detailed information on structure-
activity relationships (SAR) for the butanoic acid compound was available. Therefore, 
we subsequently attempted to optimize compound 2 in order to obtain SAR and improve 
activity and pharmacokinetic properties. Consequently, we discovered several CRTH2 
antagonists with potent activities and improved pharmacokinetic properties compared to 
that of 2. They also demonstrated in vivo efficacy in a guinea pig model of airway 
hyperresponsiveness. 
   
MEDI 120 
Synthesis and structure-activity relationship of novel 4-substituted pyrazolo[1,5-
a]pyridine analogs as potent MAPKAP-K2 inhibitors 
Gen Unoki, g.unoki@teijin.co.jp; Yoshiyuki Matsumoto; Yohei Matsueda; Motoko 
Hamada; Tomomi Kosugi; Mika Kambe; Tomohiro Shimada; Minoru Imai; Hiroaki 
Makino; Yuko Yamakoshi; Osami Takenouchi; Yasuhiro Oue; Yuri Sakai; Aido Fujino; 
Midori Takimoto-Kamimura; Ken-ichiro Kataoka. Teijin Institute for Bio-medical 
Research, Japan  
MAPKAP-K2 (mitogen activated protein kinase-activated protein kinase 2) is a direct 
substrate of the p38 kinase in MAP kinase pathway and it is believed to be a potentially 
safer target compared to p38 for anti-inflammatory therapy.   We have already reported 
a new class of pyrazolo[1,5-a]pyrimidine analogues as MAPKAP-K2 inhibitors. 
According to the X-ray co-crystal structure analysis of complex of MAPKAP-K2 with 
pyrazolo[1,5-a]pyrimidine derivative, it was found that there was a space to 
accommodate a small substituent around 4-position of the pyrazolo[1,5-a]pyrimidine 
scaffold. To introduce a substituent into this space, 4-substituted pyrazolo[1,5-a]pyridine 
derivatives were designed and synthesized. As a result of the exploration of 
substituents on 4-position of the pyrazolo[1,5-a]pyridine, CN group was found to be the 
most appropriate substituent.   We will present the synthesis, the SAR studies and the 
X-ray co-crystal structure of pyrazolo[1,5-a]pyridine analogues.  
MEDI 121 
Design, synthesis, and testing of Kv1.3 blockers based on diphenoxylate 
William Nguyen1, william.nguyen@monash.edu; Heike Wulff2; Brittany Howard1; Paul 
White1; Philip Thompson1; David Manallack1. (1) Medicinal Chemistry & Drug Action, 
Monashi University, Australia (2) University of California, United States  
Psoriasis is an autoimmune disorder of the skin that affects millions of people 
worldwide. Current treatments have limitations concerning their efficacy, side effect 
profiles and cost. The need for better treatments is clear and our research is aimed at 
developing a novel therapy for psoriasis with an improved profile.   Previous research 
has shown that a drug normally used for diarrhoea (diphenoxylate) was able to treat 
psoriasis; however this important observation was not fully evaluated.  Our preliminary 
work has demonstrated that diphenoxylate blocks a key potassium channel (Kv1.3) 
associated with the immune system. Indeed, Kv1.3 channels have been shown to have 
a role in autoimmune disorders such as psoriasis and may explain the observations that 
diphenoxylate was able to treat psoriasis.   Our initial research has generated novel 
analogues of diphenoxylate to explore the SAR of this molecule at Kv1.3 channels. 
Further synthetic work has built on this initial SAR to generate compounds that are over 
100 times more potent at Kv1.3 channels than our original lead, diphenoxylate. In 
addition these potent Kv1.3 blockers are lower in molecular weight and have reduced 
lipophilicity. These interesting leads will be assayed in functional tests to assess their 
antiproliferative activity. 
     Fig 1. Diphenoxylate 
MEDI 122 
Na,K-ATPase α4 as a target for male contraception 
Kwon H Hong1, hong0207@umn.edu; Nicholas P Labello2; Gustavo Blanco3; Gunda I 
Georg1. (1) Department of Medicinal Chemistry, University of Minnesota, Minneapolis 
MN 55414, United States (2) Minnesota Supercomputing Institute, University of 
Minnesota, Minneapolis MN 55455, United States (3) Department of Molecular 
Integrative Physiology, University of Kansas Medical Center, Kansas City KS 66160, 
United States  
Four isoforms of the Na,K-ATPase catalytic subunit (α1-4), a plasma membrane-bound 
enzyme responsible for maintaining the transmembrane Na+ and K+ gradients, have 
been described in mammals. The α4 isoform is expressed specifically in the male germ 
cells of the testis and is essential for sperm motility. The natural cardenolide ouabain is 
a potent and selective inhibitor of Na,K-ATPase α4 (Ki 7 nM) over the ubiquitous α1 
isoform (Ki 43,000 nM). We built a homology model of human Na,K-ATPase α4 based 
on the co-crystal structure of shark Na,K-ATPase α1 in its ouabain-bound state. To 
identify new structures selective toward Na,K-ATPase α4, we performed a high 
throughput virtual screen of a library containing 230K compounds. A number of 
commercially available drugs were identified as possible inhibitors of the enzyme, 
including antihistamines. Following further docking studies, one compound was selected 
for in vitro analysis and shown to inhibit rat sperm motility. 
MEDI 123 
Characterization of the benzene sulfonic acid salt form of VA111913 as a potential 
clinical development candidate for the treatment of dysmenorrhea 
Michael B. Roe, mir@vantia.com; Andrzej R. Batt; Rachel L. C. Handy; Stephen J. 
Pethen; Martin L. Stockley; Robert M. Haigh. Vantia Ltd, Southampton SO16 7NP, 
United Kingdom  
Dysmenorrhea (painful menstrual cramps) is a common gynecological condition 
occurring in more than 50% of menstruating women. These women have increased 
uterine muscle tone and contractions and decreased blood flow to the uterus. This leads 
to the pain experienced in dysmenorrhea. The hormone vasopressin, via the V1a 
receptor, induces contractions in both uterine smooth muscle and uterine blood vessels. 
A V1a receptor antagonist will potentially inhibit these contractions and in turn reduce 
the pain experienced in dysmenorrhea. VA111913 is such an antagonist whose 
structure and properties have been previously disclosed (239th ACS National Meeting, 
San Francisco, CA, March 21-25 2010).   A benzene sulfonic acid salt of VA111913 has 
been identified that confers significant advantages over the free base. It has enhanced 
solubility in water and shows good exposure after oral administration to rats. Its 
preparation, physico-chemical properties and pharmacokinetics will be presented. This 
salt form is suitable for clinical development. 
MEDI 124 
T3P®: The green reagent of choice for condensation reactions 
James Schwindeman1, james.schwindeman@archimica.com; Richard Wisdom2; 
Juergen Brockmann2. (1) Archimica, Inc., Springfield MO 65807, United States (2) 
Archimica, GmbH, Frankfurt, Germany  
n-Propane Phosphonic Acid Cyclic Anhydride (T3P®) is an exceptional reagent for 
amide/peptide bond formation. Further, recent research has extended the application of 
this reagent to other condensation reactions, such as esterifications, and formation of 
both isonitriles and nitriles. In addition, T3P® has found utility as a mild reagent for 
alcohol oxidations and the Lossen rearrangement. T3P® is very easy to use and 
provides excellent selectivity, low epimerization and high yields with simple product 
isolation by liquid/liquid extraction. Because of its properties, hazardous additives such 
as explosive HOBt, are not required. Additionally, the T3P® reagent is really “green” - 
nontoxic, non-allergenic/non-sensitizing, and the salt by-products are non hazardous 
and completely water soluble, in sharp contrast to most other coupling reagents. These 
salts are readily removed via an aqueous wash at the conclusion of the reaction. 
Numerous examples of the condensation reactions will be presented, wherein the 
inherent advantages of T3P® will be highlighted. 
MEDI 125 
Cleavage of carbon-carbon bonds through the mild release of trifluoroacetate 
towards mono-, and difluorinated compounds 
Eun Hoo Kim1, ehkim@purdue.edu; David A. Colby1, 2. (1) Department of Medicinal 
Chemistry and Molecular Pharmacology, Purdue University, West Lafayette IN 47907, 
United States (2) Department of Chemistry, Purdue University, West Lafayette IN 
47907, United States  
Fluorinated compounds are of great interest in medicinal chemistry due to their 
biological activities, and subsequently, have attracted the attention of many synthetic 
chemists. In order to install fluorinated functional groups on complex molecules. A 
method to generate reactive fluorinated intermediates has been discovered using the 
facile release of trifluoroacetate. The application of this process to substrates bearing 
ketones, phosphonates, and sulfones as stabilizing groups is presented to efficiently 
synthesize mono- and difluorinated products. Also, this synthetic method is effectively 
applied to complex chiral substrates to include fluorine without affecting sensitive 
functional groups or causing alpha-epimerization.   
  
MEDI 126 
WITHDRAWN 
MEDI 127 
Lead generation using a privileged structure-based approach 
Sivakumar Annadurai1, sannadur@temple.edu; Rogelio Martinez1; Paul M Dunman2; 
Daniel J Canney1; Magid Abou-Gharbia1. (1) Pharmaceutical Sciences, Moulder Center 
for Drug Discovery Research, Temple University School of Pharmacy, Philadelphia PA 
19140, United States (2) Department of Microbiology and Immunology, University of 
Rochester, School of Medicine and Dentistry, Rochester NY 14642, United States  
The privileged structure-based approach is considered a reliable route to lead 
generation. Privileged structures are substructures capable of providing high affinity 
ligands for more than one biological target. The present study involves the synthesis of 
a library using 2-aminothiazole as the core structure. Bioactive fragments shown to 
produce hits in a variety of biological targets were incorporated on the 2-aminothiazole 
scaffold. Synthetic routes to the privileged structure-based compounds were developed 
using microwave and thermal conditions. Sulfonamidation afforded sulfonamide based 
compounds while Suzuki coupling of the scaffold with an array of boronic acids resulted 
in Suzuki products which were further elaborated by coupling with beta lactam and 
lactone fragments. The library was tested in a variety of biological assays (antimicrobial, 
and as modulators of muscarinic, serotonin receptors and glutamate transporter [GLT-
1]). Data pertaining to those assays and lead molecules that have been identified will be 
presented and discussed. 
MEDI 128 
TIDEA in-silco screening enhances potency, ligand efficiency, and drug-like 
nature while maintaining chemical diversity 
Darryl Rideout, focussynthesis@gmail.com. Focus Synthesis LLC, San Diego CA 
92121, United States  
TIDEA (Target-Independent Drug Enhancement Algorithm) is software for in-silico 
screening of bioactive low-FW ligands that selects more potent ligands without 
knowledge of the target structure or ligand SAR. TIDEA determines a degree of 
adhesiveness that is independent of the specific ligand/target shape complementarity. 
TIDEA has the advantage over conventional methods (rational design, QSAR) of 
maintaining the molecular shape diversity of the original ligand set, making it ideal as a 
filter to improve potency in universal libraries intended for screening against multiple 
targets. Even when every molecule in the test set has a different target, subsets with 
high TIDEA scores (>9.5) show higher average potencies and enrichment of potent 
(<100nM) ligands with statistical significance (p<0.03). TIDEA also distinguishes drug-
like from non-druglike molecules, with a statistical significance of p<0.0001. A 
modification optimized for fragment-based lead discovery, TIDEA/FBLD, selects for 
small molecules with higher ligand efficiency. 
MEDI 129 
Efficient and practical method for the preparation of branched oligoglycerols 
(BGL) from 1,3-methyleneglycerol for water-solubilization of medicinal 
compounds 
Hatsuhiko Hattori, hhattori@ph.tokushima-u.ac.jp; Kohsuke Yoshitomi; Ayato Katagiri; 
Tsuyoshi Matsushita; Masaki Kamiya; Keisuke Ishizawa; Koichiro Tsuchiya; Hisao 
Nemoto. Institute of Health Bioscience, The University of Tokushima, Tokushima 
Tokushima 770-8505, Japan  
Recent improvements of high throughput screening techniques have ironically brought 
into a number of poorly water-soluble medicinal candidates, which have been often 
dropped out due to the poor water-solubility. Our developed branched oligoglycerols 
(BGL) is a chemically pure single molecule without asymmetric center to be suitable for 
water-solubilizing of such a shelved candidate. In this paper, we report a method for 
practical large-scale preparation of BGL from 1,3-methyleneglycerol.   
  
MEDI 130 
Surface modification procedure of acellular vascular grafts with the cell binding 
peptide 
Atsushi Mahara, mahara@ri.ncvc.go.jp; Naoto Mihashi; Jeong-Hun Kang; Tetsuji 
Yamaoka. Department of Biomedical Engineering, National Celebral and 
Cardiovascular Center Research Institute, Suita Osaka 5658565, Japan  
Decellularized tissue has a potential as ideal scaffold to regenerative medicine, because 
of the structural similarity to the native tissue. We have employed the ultrahigh-
hydrostatic pressure (UHP) (1000MPa) as a decellularization technology. In the 
previous study, good anti-thrombogenic and mechanically stable properties of the 
decellularized porcine aorta were confirmed after the transplantation for up to 1 year. 
Nevertheless, calcification on the decellularized tissue was found in rare case. To 
prevent the calcification on the graft, we have developed the surface modification 
procedure of acellular vascular grafts with cell binding peptide. Synthetic peptides 
containing collagen binding domain and cell binding domain were prepared. Binding 
affinity of endotherial cells on the peptide-modified decellularized tissue was observed 
in peptide sequence specific manner in vitro. Moreover, the peptide-modified accellular 
rat aortas were implanted into rats, and the patency and tissue regeneration were 
evaluated. 
MEDI 131 
Quantification of total ω-6, total ω-3 and ω-6/ω-3 ratio in human serum using 
GC/MS 
Mary M Kimani, muriukimarie@yahoo.com; Gerard Dumancus; Neil Purdie. Chemistry, 
Oklahoma State University, stillwater Oklahoma 74075, United States  
Quantitative determination of polyunsaturated fatty acids (PUFAs) in human serum has 
been of great challenge to researchers today. The work in this study has quantified six 
PUFA methyl esters, three which are the (ω-6) esters of linoleic (LAME), conjugated 
linoleic (CLAME) and arachidonic (AAME) and three others that are the (ω-3) esters of 
linoleic (LNAME), eicosapentaenoic (EPAME), and docosahexaenoic (DHAME)) fatty 
acids using GCMS. Blood serum aliquots taken from the same subjects were analyzed 
on the same day using GC/MS and visible spectrophotometric detections. Data 
obtained from GC/MS were quantified according to protocol. Spectral absorbance data 
from 350-550nm were analyzed using chemometric model, PLS2. Results obtained 
from the two methods were correlated using student t-test and resulted in good 
agreements between total (ω-3) and total (ω-6) PUFA levels and for the (ω-6)/ (ω-3) 
ratios α=0.05, tcal=-0.59, tcri=2.18, P=0.57.The greatest achievement of this study is 
that, the study was able to apply the separation method described to blood serum for 
the quantification of total ω-6, total ω-3 and ω-6 to ω-3 ratios using GC/MS for the first 
time therefore improving the GC separation and detection an aspect that is of great 
importance to chromatographers and medical line. 
MEDI 132 
Synthesis and hydrolytic properties of thymidine P-boranomonophosphate 
Zhihong Xu1, 2, zhixu@methodist.edu; Zinaida A. Sergueeva1; Barbara Ramsay Shaw1. 
(1) Department of Chemistry, Duke University, Durham NC 27708, United States (2) 
Department of Chemistry & Physical Science, Methodist University, Durham NC 27708, 
United States  
Structure modification of nucleoside anologs with the isoelectronic substitution of 
borane (BH3) group for one of the nonbridging oxygens in phosphate esters increases 
the lipophilicity and other properties of the phosphate in nucleotides, DNA and RNA. A 
general synthesis for nucleoside P-boranomonophosphates by H-phosphonates used in 
our group was briefly discussed in the recent review by our group (Li et al, Chem. Rev., 
2007). Here we report the H-phosphonate approach to obtain thymidine 5'-P-
boranomonophosphate in a more convenient and detailed procedure.  The reactions 
were monitored by 31P-NMR and identified by spectral data. Hydrolysis studies of 
thymidine P-boranomonophosphate by LC-MS were carried out in buffers of different pH 
and temperature. As predicted, more acidic conditions considerably increased the 
hydrolysis rate. At 22 ºC and 37 ºC, a seven-fold difference in rates was observed. 
Based on our study, we suggest that nucleoside boranomonophosphates should be 
kept in dry form at low temperature. 
MEDI 133 
Synthesis of pentosidine framework 
Yahua Liu, yahualiu@hotmail.com; Weihan Zhang; Lawrence M Sayre. Department of 
Chemistry, Case Western Reserve University, Cleveland OH 44106, United States  
Pentosidine is a fluorescent advanced glycation endproduct that serves as a biomarker 
of diabetic complications, kidney dysfunction, oxidative stress, as well as aging and 
age-related diseases. Pentosidine framework, 4-butyl-2-propyl-4H-aminoimidazo[4,5-
b]pyridine, was synthesized through a five steps reaction sequence including 
regioselective alkylation of 2-(methylthio)imidazo[4,5-b]pyridine, chlorination of 
methylthio group, and amination of 2-chloro-imidazo[4,5-b]pyridine. This method is of 
material accessibility and operational simplicity and also serves as a general method to 
construct 4-alkylated-2-amino-4H-imidazo[4,5-b]pyridines.   
  
MEDI 134 
Phenylalanine derivatives as GPR142 agonists for treatment of type II diabetes 
Xiaohui Du1, xdu@amgen.com; Yong-Jae Kim1; SuJen Lai1; Mike Lizarzaburu1; Simon 
Turcotte1; Kozo Oda2; Ryo Okuyama2; Angela Fu3; Jeff D. Reagan3; Qingxiang Liu3; 
Ying Zhang3; Alykhan Motani3; Peter Fan4; Yumei Xiong3; Wang Shen1; Leping Li1; 
Jonathan Houze1; Julio C. Medina1; Xi Chen1; Futoshi Nara1; Michiko Murakoshi1. (1) 
Department of Small Molecule Chemistry, Amgen, South San Francisco, South San 
Francisco CA 94080, United States (2) Department of Medicinal Chemistry, Daiichi-
Sankyo, Japan (3) Department of Metabolic Disorders, Amgen, South San Francisco, 
South San Francisco CA 94080, United States (4) Department of Pharmacokinetics & 
Drug Metabolism, Amgen, South San Francisco, United States  
GPR142 is a novel GPCR which is predominantly expressed in pancreatic b-cells. 
GPR142 agonists potentiate glucose-sensitive insulin secretion in a GPR142-dependent 
manner from isolated pancreatic islets and in rodent models. We are interested in 
developing small molecule GPR142 agonists to treat type II diabetes. Optimization of 
the SAR of our lead amrinone-phenylalanine series resulted in compound 20, which 
demonstrated glucose-lowering effect in a mouse model. Further optimization led to the 
thiadiazole B ring series which had improved PK and CYP inhibition profile. 
MEDI 135 
Amino-pyrazole phenylalanine GPR142 agonists for the treatment of type II 
diabetes 
Ming Yu1, yum@amgen.com; Mike Lizarzaburu1; Zice Fu1; Angela Fu2; Xianyuan Jiao1; 
Leping Li1; Jim Liu1; Simon Turcotte1; Jonathan Houze1; Julio C. Medina1; Alykhan 
Motani2; Xiaohui Du1; Jeff Reagan2; Kozo Ioda3; Ryo Okuvama3; SuJen Lai1. (1) 
Department of Chemistry, Amgen Inc., South San Francisco CA 94080, United States 
(2) Department of Biology, Amgen Inc., South San Francisco CA 94080, United States 
(3) Department of Chemistry, Daiichi Sankyo, Inc., Japan  
GPR142 is a GPCR highly expressed in islet beta-cells and is responsible for the 
endogenous ligand-mediated glucose-dependent secretion of insulin. Studies in rodent 
islets and in in-vivo models suggest that a suitable small molecule GPR142 agonist 
could be of benefit in the treatment of type II diabetes. This poster highlights our 
systematic lead optimization of the amrinone-phenylalanine series, which led to the 
identification of a novel pyrazole-based scaffold displaying desirable properties 
including high in-vitro activity, minimal CYP inhibitory activity and moderate to excellent 
systemic stability. Combination of the optimal features provided tool compound 30 and 
its pro-drug, which showed good efficacy in mouse oral glucose tolerance test (OGTT) 
studies. 
MEDI 136 
Design, evolution, and in vivo profile of a novel series of GPBAR 1 agonists for 
the treatment of diabetes and metabolic syndrome 
Ravi Kurukulasuriya1, ravi.kurukulasuriya@merck.com; Shrenik Shah1; James 
Dellureficio1; Selena Fung1; Linagqin Guo1; Jason Szewczyk1; Bowei Wang1; Jonathan 
Wilson1; Bahanu Habulihaz2; Gino Salituro2; Stan Mitelman2; James Hubert3; Andrea 
Nawrocki3; Maria Trujillo3; Maryann Powles3; James Ormes4; Donald Marsh5; William 
Hagmann1; Ravi Nargund1; Allessandro Pocai5; Robert J DeVita1. (1) Department of 
Medicinal Chemistry, Merck Research Laboratories, Rahway New Jersey 07065, United 
States (2) Department of Drug Metabolism and Pharmacokinetics, Merck Research 
Laboratories, Rahway New Jersey 07065, United States (3) Department of In Vivo 
Pharmacology, Merck Research Laboratories, Rahway New Jersey 07065, United 
States (4) Basic Pharmaceutical Sciences, Merck Research Laboratories, Rahway New 
Jersey 07065, United States (5) Diabetes Research, Merck Research Laboratories, 
Rahway New Jersey 07065, United States  
GPBAR1 (TGR5), a G protein coupled bile acid receptor, represents an important 
signaling pathway for regulating energy homeostasis and metabolic control. Activation 
of GPBAR1 stimulates cAMP production in both adipose tissue and enteroendocrine 
cells leading to an increase in mitochondrial function and GLP-1 secretion in the 
respective tissues. Herein, we report our efforts on GPBAR1 receptor agonists that led 
to the discovery of a potent series of heterocyclic linked di-aryl compounds with 
balanced activity on both human and mouse receptor. Lead optimization, SAR, in vitro 
potency and in vivo efficacy will be discussed.  
  
MEDI 137 
Discovery of 7-oxo-pyrrolopyridines as potent and selective inhibitors of DPP4 
Wei Wang1, wei.wang@bms.com; Pratik Devasthale1; Aiying Wang2; Tom Harrity2; Don 
Egan2; Nathan Morgan2; Mike Cap2; Aberra Fura3; Herb E. Klei4; Kevin Kish4; Lucy 
Sun5; Paul Levesque5; Robert Zahler1; Mark S. Kirby2; Lawrence G. Hamann1. (1) 
Metabolic Diseases Chemistry, Bristol-Myers Squibb Research and Development, 
Princeton NJ 08540-5400, United States (2) Metabolic Diseases Biology, Bristol-Myers 
Squibb Research and Development, United States (3) Pharmaceutical Candidate 
Optimization, Bristol-Myers Squibb Research and Development, United States (4) 
Macromolecular Crystallography, Bristol-Myers Squibb Research and Development, 
United States (5) Discovery Toxicology, Bristol-Myers Squibb Research and 
Development, United States  
Inhibitors of dipeptidyl peptidase 4 (DPP4), a member of the serine protease super-
family, have attracted considerable attention as novel therapeutic agents for the 
treatment of diabetes mellitus. Sitagliptin (JanuviaTM) and Saxagliptin (OnglyzaTM) are 
the currently approved DPP4 inhibitors in the United States for the treatment of type 2 
diabetes. This presentation describes the design, synthesis, and SAR of a novel class 
of 7-oxopyrrolopyridine-derived DPP4 inhibitors. The preferred stereochemistry of these 
atropisomeric biaryl analogs has been identified as Sa. A selective amide analog 
derived from this series, with a DPP4 Ki of 0.37 nM, showed a significant improvement 
in insulin response in ob/ob mice. 
MEDI 138 
Design, synthesis, and SAR studies of novel polycyclic acids as potent and 
selective inhibitors of human 11b-hydroxysteroid dehydrogenase type 1 (11b-
HSD1) 
Xiang-Yang Ye1, xiang-yang.ye@bms.com; Stephanie Y Chen1; Shung Wu1; Akbar 
Nayeem2; David Yoon1; Haixia Wang1; Zhenqiu Hong1; Steve O’Connor1; Atsu Apedo3; 
James J Li1; Jun Li1; Rajasree Golla4; Ramakrishna Seethala4; Mengmeng Wang5; 
Timothy Harper5; Bogdan G Sleczka3; David Gordon6; Jeffrey A Robl1; Lawrence 
Kennedy1; Steven Walker1. (1) Metabolic Diseases Chemistry, Bristol-Myers Squibb 
Co., Princeton New Jersey 08543-5400, United States (2) CADD, Bristol-Myers Squibb 
Co., Princeton New Jersey 08543-5400, United States (3) DAS, Bristol-Myers Squibb 
Co., Princeton New Jersey 08543-5400, United States (4) Lead Evaluation, Bristol-
Myers Squibb Co., Princeton New Jersey 08543-5400, United States (5) MAP, Bristol-
Myers Squibb Co., Princeton New Jersey 08543-5400, United States (6) Department of 
Biology, Bristol-Myers Squibb Co., Princeton New Jersey 08543-5400, United States  
Starting from high throughput screening hit 2-adamantyl acetic acid 1, a series of 
polycyclic acids 3 have been designed and synthesized as novel, potent, and selective 
inhibitors of human 11b-HSD1. Structure-activity relationships of two different regions of 
the chemotype (polycyclic ring and substituents on quaternary carbon) are discussed.  
  
MEDI 139 
Synthesis and SAR of 5-methyl-5,6,7,8,9,10-hexahydro-7,10-
iminocyclohept[b]indoles and 5-methyl-6,7,8,9,10,11-hexahydro-7,11-imino-5H-
cyclooct[b]indoles as MCH-1 receptor antagonists 
Mark Hadden1, mark.hadden@amriglobal.com; Peter R Guzzo1; Alan J Henderson1; 
Matthew D Surman1; Emily E Freeman1; Lei Zhu1; Michele Luche1; Yuri Khmelnitsky1; 
Sharon Cheetham2; Steven Vickers2; Jean Viggers2. (1) Discovery R&D, AMRI, Albany 
NY 12212-5098, United States (2) RenaSci Consultancy Ltd, Nottingham NG1 1GF, 
United Kingdom  
A new class of MCH-1 receptor antagonists, exemplified by compound 1, was 
discovered and tested in a MCH-1 receptor binding assay. Selected enantiopure 
compounds were obtained by preparatory chiral HPLC and further evaluated for in vitro 
and in vivo properties, and showed weight loss in a 5-day diet-induced obese mouse 
study.    
MEDI 140 
Synthesis and in vivo evaluation of 6-(4-fluorophenoxy)-3-((1-
[11C]methylpiperidin-3-yl)methyl)-2-o-tolylquinazolin-4(3H)-one, a potential PET 
tracer for Growth Hormone Secretagogue receptor (GHSR) 
Rachel A Potter, rpotter8@jhmi.edu; Andrew G Horti; Daniel Holt; Ursula Scheffel; 
Robert F Dannals; Richard L Wahl. Department of Radiology, Johns Hopkins University, 
School of Medicine, Baltimore Maryland 21205, United States  
Since its initial discovery, ghrelin has been shown to play a fundamentally important role 
in diet induced obesity through its action on the ghrelin receptor (GHS-R) located in the 
hypothalamus. While an enormous amount of data highlights the presence of ghrelin in 
the CNS and its role in appetite stimulation, the exact mechanism of action is still largely 
unknown. Imaging the GHS-R receptor in the brain could offer better insight into the 
actual physiological pathways of how ghrelin regulates food intake and thus aid in 
developing potent and more selective anti-obesity drugs. This study describes the 
synthesis, in vitro and in vivo evaluation of 6-(4-fluorophenoxy)-3-((1-
[11C]methylpiperidin-3-yl)methyl)-2-o-tolylquinazolin-4(3H)-one ([11C]), a potential PET 
radioligand for imaging GHSR. 
MEDI 141 
Synthesis of PET TSPO radioligand [18F]PBR06 using a new tosylated precursor 
Min Wang, wang1@iupui.edu; Mingzhang Gao; Qi-Huang Zheng. Department of 
Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis IN 
46202, United States  
The translocator protein 18 kDa (TSPO), formerly known as peripheral-type 
benzodiazepine receptor (PBR), is an attractive target for molecular imaging of 
neuroinflammation and tumor progression. [18F]PBR06 (N-(2,5-dimethoxybenzyl)-2-
[18F]fluoro-N-(2-phenoxyphenyl)acetamide) is a promising PET brain TSPO radioligand 
originally developed by Briard et al at NIMH. Wishing to study this compound in our 
laboratory, we decided to make our own materials by following the literature methods. 
However, the published production of [18F]PBR06 using the reaction of [18F]fluoride ion 
with the corresponding bromo precursor resulted in low specific activity, radiochemical 
yield and chemical purity of [18F]PBR06 in our hands, due to difficult separation of the F-
18 labeled product from the precursor, and moderate leaving group bromo of the 
precursor. While studying the reported methods for [18F]PBR06 production, we 
discovered a new labeling precursor, the previously undescribed tosylate congener of 
PBR06 with better leaving group tosyl, and investigated a fully automated synthesis of 
[18F]PBR06. PBR06 (N-(2,5-dimethoxybenzyl)-2-fluoro-N-(2-phenoxyphenyl)acetamide) 
and its bromo precursor (2-bromo-N-(2,5-dimethoxybenzyl)-N-(2-
phenoxyphenyl)acetamide) were synthesized from 2,5-dimethoxybenzaldehyde in 3 and 
2 steps with 71% and 78% overall chemical yield, respectively, according to the 
literature methods. New tosylated precursor (2-((2,5-dimethoxybenzyl)(2-
phenoxyphenyl)amino)-2-oxoethyl 4-methylbenzenesulfonate) was designed and 
synthesized from ethyl 2-hydroxyacetate, 4-methylbenzene-1-sulfonyl chloride, and N-
(2,5-dimethoxybenzyl)-2-phenoxyaniline in 4 steps with 50% overall chemical yield. 
[18F]PBR06 was prepared by the nucleophilic substitution of either new tosylated 
precursor or previously described bromo precursor in DMSO at 150 oC with 
K[18F]F/Kryptofix 2.2.2 for 15 min and HPLC combined with SPE purification in 20-60% 
decay corrected radiochemical yield from [18F]fluoride at EOB, >99% radiochemical 
purity, 87-95% chemical purity, and 74-222 GBq/µmol specific activity at EOB, in an 
home-built automated multipurpose 18F-radiosynthesis module. The radiosynthesis of 
[18F]PBR06 using new tosylated precursor gave similar radiochemical purity, and much 
higher specific activity, radiochemical yield and chemical purity in comparison with the 
bromo precursor. 
MEDI 142 
Discovery and optimization of 1,5-diarylpyrazole-4-carboxamides as novel CB-1 
inverse agonists 
Annapurna Pendri1, annapurna.pendri@bms.com; Dharmpal S Dodd2; Zheming 
Ruan2; Jing Chen2; Mary Ellen Cvijic2; Rose A Baska2; Liya Kang2; Neil T Burford1; 
Kenneth E Carlson2; William R Ewing2; Samuel W Gerritz1. (1) Research and 
Development, Bristol-Myers Squibb, Wallingford CT 06492, United States (2) Research 
and Development, Bristol-Myers Squibb, Princeton NJ 08453, United States  
As part of an effort to identify novel G-protein coupled receptor ligands, a 8000 member 
GPCR-targeted library of 1,5-diarylpyrazole-4-carboxamides was synthesized using a 
novel solid-phase synthesis. Screening of the library samples provided hits containing 
5-biphenylpyrazole-4-carboxamide motif with promising activity against the cannabinoid 
receptor subtype 1 (CB-1). This presentation will describe the initial discovery and 
optimization of the hit series (i.e. 1 to 2), resulting in the identification CB-1 antagonists 
with low nanomolar activity in both binding and functional assays  
  
MEDI 143 
Structural and mechanistic models of VKORC1 
David E. Lewis, lewisd@uwec.edu; Bradley P. Klemm. Chemistry, University of 
Wisconsin-Eau Claire, Eau Claire WI 54702-4004, United States  
VKORC1 is located in the ER membrane, and is the only enzyme capable of reducing 
vitamin K 2,3-epoxide, and is thus a critical enzyme in the vitamin K cycle. The enzyme 
is inhibited by warfarin, and the use of warfarin rodenicides for over 50 years has 
resulted in a wide range of mutations leading to warfarin resistance, and several inborn 
coagulation deficiencies are traced to SNPs in the VKORC1 gene. In this paper, we 
propose a model for the VKORC1 enzyme consisting of 4 transmembrane helices and 
one short helix in the ER lumen is proposed, along with a region consisting of β-strands.  
This model permits the effects of all known mutations on the activity of the enzyme and 
the binding of warfarin to be rationalized. The reduction of vitamin K 2,3-epoxide 
involves three cysteine residues. 
MEDI 144 
Discovery of small molecule P2Y1 antagonists part I: Biaryl ureas 
Hannguang J. Chao1, Hannguang.chao@bms.com; Huji Turdi1; Timothy F. Herpin1; 
Jacques Y. Roberge1; Yalei Liu1; Dora Schnur2; Michael A. Poss1; Robert Rehfuss3; Ji 
Hua3; Qimin Wu3; Luara A. Price3; Lynn Abel3; William A. Schumacher3; Jeffrey A. 
Bostwick3; Anne B. Stewart3; Martin L. Ogletree3; Ruth R. Wexler4; Patrick Y. S. Lam4; 
R. Michael Lawrence1. (1) Early Discovery Chemistry, Bristol-Myers Squibb, Princeton 
NJ 08543-5400, United States (2) CADD, Bristol-Myers Squibb, Princeton NJ 8543-
5400, United States (3) CV Biology, Bristol-Myers Squibb, Princeton NJ 8543-5400, 
United States (4) Medicinal Chemistry, Bristol-Myers Squibb, Princeton NJ 8543-5400, 
United States  
Two distinct G protein-coupled purinergic receptors, P2Y1 and P2Y12, mediate ADP 
driven platelet activation. The clinical effectiveness of P2Y12 blockade is well 
established. Recent preclinical data suggests that P2Y1 and P2Y12 inhibition provide 
equivalent antithrombotic efficacy, while targeting P2Y1 has the potential for reduced 
bleeding liability.  In this presentation, we will describe the discovery of a 2-
(phenoxypyridine)-3-(phenyl) urea chemotype that inhibited ADP-mediated platelet 
aggregation in human blood samples via high throughput screening. Further 
optimization of this series led to the identification of the lead compound 1-(2-(2-tert-
butylphenoxy) pyridin-3-yl)-3-(4-(trifluoromethoxy) phenyl) urea which was shown to 
antagonize the P2Y1 receptor, leading to an antithrombotic effect in a rat thrombosis 
model. 
MEDI 145 
Discovery of small molecule P2Y1 antagonists part II: 2-aminothiazole based P2Y1 
antagonists as novel antiplatelet agents 
Zulan Pi, zulan.pi@bms.com; James Sutton; John Lloyd; Robert Rehfuss; Ji Hua; 
Qimin Wu; Laura A. Price; Ruth R. Wexler; Patrick Y. S. Lam. Research and 
Development, Bristol-Myers Squibb Company, Princeton New Jersey 08543-5400, 
United States  
Two distinct G protein-coupled purinergic receptors, P2Y1 and P2Y12, mediate ADP 
driven platelet activation. The clinical effectiveness of P2Y12 blockade is well 
established. Recent preclinical data suggests that P2Y1 and P2Y12 inhibition provide 
equivalent antithrombotic efficacy, while targeting P2Y1 has the potential for reduced 
bleeding liability. BMS previously identified a series of t-butylphenoxylpyridinyl urea 
analogs as small molecule P2Y1 antagonists. This poster presents our efforts to employ 
2-aminothiazole as a urea replacement, which led to the discovery of a series of novel t-
butylphenoxylpyridinyl-2-aminothiazole analogs as potent P2Y1 inhibitors. 
MEDI 146 
Discovery of small molecule P2Y1 antagonists part III: C-N linked indolinyl diaryl 
ureas as novel antiplatelet agents 
Jennifer X Qiao1, jennifer.qiao@bms.com; Tammy C Wang1; Réjean Ruel1; Carl 
Thibeault1; Sheldon Hiebert1; Gilles Bouthillier1; John Lloyd1; Zulan Pi1; Alexander 
Kover1; Ji Hua2; Laura A Price2; Qimin Wu2; Joanna Zheng2; Ming Chang2; Christine 
Huang2; Jeffrey S Bostwick2; Anne B Stewart2; William A Schumacher2; Carol A 
Watson2; Pancras C Wong2; Robert Rehfuss2; Ruth R Wexler1; Patrick Y.S. Lam1. (1) 
Medicinal Chemistry, Bristol Myers Squibb, Pennington NJ 08534, United States (2) 
Bristol Myers Squibb, United States  
Two distinct G protein-coupled purinergic receptors, P2Y1 and P2Y12, mediate ADP 
driven platelet activation. The clinical effectiveness of P2Y12 blockade is well 
established. Recent preclinical data suggests that P2Y1 and P2Y12 inhibition provide 
equivalent antithrombotic efficacy, while targeting P2Y1 has the potential for reduced 
bleeding liability. BMS previously identified a series of t-butylphenoxylpyridinyl urea 
analogs as small molecule P2Y1 antagonists. In this presentation, we will describe our 
SAR efforts focused at identifying t-butylphenoxy replacements, which led to the 
discovery of novel C-N linked indolinyldiaryl urea analogs as potent P2Y1 antagonists. 
The dose-dependent effects of the lead compound in this series were demonstrated in 
rat models of thrombosis and hemostasis. 
MEDI 147 
Diphenylpyridylethanamines (DPPE) as novel cholesterol ester transfer protein 
(CETP) inhibitors 
Lalgudi S Harikrishnan, lalgudi.harikrishnan@bms.com; Muthoni G Kamau; Heather J 
Finlay; Ji Jiang; James Li; Jennifer X Qiao; Tammy C Wang; Christopher B Cooper; 
Michael A Poss; Mark E Salvati; Ruth R Wexler; Leonard P Adam; David S Taylor; Alice 
Ye A Chen; Xiaohong Yin; Doree F Sitkoff; Carolyn A Weigelt; Ramakrishna Seethala; 
Tara L Peterson; Michael A Galella; Atsu Apedo; David S Nirschl; Katy VanKirk; Arthur 
V Miller; Christine S Huang; Ming Chang; Xue-qing Chen; R. Michael Lawrence. Bristol-
Myers Squibb Company, Princeton NJ 08543, United States  
Elevation of plasma high density lipoprotein cholesterol (HDL-C) is a promising 
approach for the potential treatment of atherosclerosis. Advanced clinical compounds 
that inhibit CETP increase HDL-C levels in humans. In this presentation, we disclose 
the discovery of a new ester series of CETP inhibitors, 1, and the further optimization of 
the ester to provide the DiPhenylPyridylEthanamine series, 2 (DPPE). Additional 
optimization of the quaternary aryl/heteroaryl groups and series SAR will be presented 
leading to key compounds with in vitro and in vivo potency.  
  
MEDI 148 
Phenethylaminoheterocycles as Kv1.5 ion channel inhibitors 
James A Johnson1, james.a.johnson@bms.com; Ningning Xu1; Yoon Jeon1; Heather J 
Finlay1; Alexander Kover1; Mary L Conder2; Huabin Sun2; Danshi Li2; Paul Levesque2; 
Ling Li1; Mei-Mann Hsueh3; Timothy W Harper3; Ruth R Wexler1; John Lloyd1. (1) 
Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 
United States (2) Department of Biology, Bristol-Myers Squibb Research and 
Development, United States (3) Department of Preclinical Candidate Optimization, 
Bristol-Myers Squibb Research and Development, United States  
Atrial fibrillation is a pervasive heart rhythm disorder distinguished by a shortened 
repolarization phase of the action potential of atrial myocytes and an abbreviated atrial 
effective refractory period (ERP). Kv1.5 ion channels conduct the ultrarapid delayed 
rectifier current (IKur) that contributes to this repolarization. Because Kv1.5 channels are 
functionally expressed in the atrium but not the ventricle, selective inhibition of IKur 
potentially leads to prolongation of the atrial ERP without ventricular effects. 
Phenethylaminoheterocycles have been prepared and assayed for inhibition of human 
recombinant Kv1.5 potassium ion channels as a potential approach to the treatment of 
atrial fibrillation. The synthesis and activity of the compounds, as a well as 
pharmacokinetic and pharmacodynamic properties, will be described. 
MEDI 149 
Alkaloid purification strategies for flash chromatography 
Jack E. Silver, jsilver@teledyne.com; Paul Bellinghausen, 
pbellinghausen@teledyne.com; Nancy Fowler, nfowler@teledyne.com. Applications, 
Teledyne Isco, Lincoln NE 68504, United States  
Alkaloids are common compounds derived from natural products. Many alkaloids are 
also synthesized for their medicinal properties. Alkaloids are challenging to purify on 
silica due to their polarity and basicity. The use of appropriate solvents and columns 
allow facile purification of this class of compounds. Examples are provided for silica, 
C18, ion exchange and alternative media such as diol and amine. 
MEDI 150 
Strategies for the flash purification of highly polar compounds 
Jack E. Silver, jsilver@teledyne.com; Paul Bellinghausen, 
pbellinghausen@teledyne.com; Nancy Fowler, nfowler@teledyne.com. Applications, 
Teledyne Isco, Lincoln NE 68504, United States  
Highly polar compounds, such as basic molecules and water soluble dyes, pose unique 
challenges for purification. They can bind to the media, or in the case of C18, elute 
without media interaction thereby preventing purification of the compound in both cases. 
Highly aqueous purifications on a new flash C18 media is demonstrated using dyes. 
HILIC is also explored to purify polar compounds on silica, diol, and amine columns. 
MEDI 151 
Novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 
receptor 
Peter Bach, Peter.Bach@astrazeneca.com. Department of Medicinal Chemistry, 
AstraZeneca R&D, Molndal 43183, Sweden  
A novel series of P2Y12 antagonists for development of drugs within the antiplatelet area 
is presented. The synthesis of the piperazinyl-pyridine urea derivatives and their 
structure-activity relationships (SAR) are described. Several compounds showed P2Y12 
antagonistic activities in the sub-micromolar range. 
MEDI 152 
Green chemistry at AstraZeneca R&D Montreal: Focus on solvent selection 
Mehrnaz Pourashraf1, mehrnaz.pourashraf@astrazeneca.com; François Samson-
Thibault1; Andrew Wells2; Michael Laplante1; Louis-David Cantin1; Christopher 
Walpole1; Mirosɫaw J. Tomaszewski1; Pascal Turcotte3. (1) AstraZeneca R&D, Montreal 
Quebec H4S 1Z9, Canada (2) AstraZeneca Process R&D, Charnwood LE11 5RH, 
United Kingdom (3) Boehringer Ingelheim, Laval Quebec H7S 2G5, Canada  
During the process of drug development, Volatile Organic Compounds (VOCs) are 
released to the atmosphere through the use of solvents in manufacturing processes and 
research and development activities. VOCs result mainly from the use of chlorinated 
and non-halogenated solvents in drug synthesis and contribute to the creation of smog, 
which is harmful to both human health and the environment. A few years ago, 
AstraZeneca undertook measures to eliminate or reduce the impact of toxic chemicals 
that are released during drug synthesis. To achieve this goal, our engineers and 
chemists began collaborations with scientists of other pharmaceuticals companies in 
order to find new and greener ways to work in chemistry. The application of these 
alternatives is not limited to drug manufacturing but is also encouraged in our research 
units. The measures taken at our site, AstraZeneca R&D Montreal, aim to reduce the 
consumption of harmful solvents, particularly halogenated solvents, by replacing them 
with ones which are more environmentally friendly. In addition to this, some new green 
solvents have been introduced into the regular work of our chemists. Although the 
consumption of solvents and chemicals in discovery is typically lower than process and 
manufacturing sites, it is still important that green chemistry is used where possible in 
the early stage of research since it will be then applied to scale-up and development 
activities. 
MEDI 153 
Novel hydrogen sulfide releasing agents 
Yu Zhao, dtzhaoyu@wsu.edu; Hua Wang; Ming Xian. Department of Chemistry, 
Washington State University, Pullman WA 99164, United States  
Hydrogen sulfide (H2S), an emerging signaling molecule, plays important roles in 
biological systems. However, the research on H2S has been hindered by the lack of 
controllable H2S releasing agents, i.e. H2S donors, which could mimic the slow and 
continuous H2S generation process in vivo. Since S-N bonds are unstable and easy to 
break under certain conditions, we envision that N-mercapto compounds are potential 
H2S donors and structural modification could regulate rate/capability of H2S release 
from these donors. We have synthesized and evaluated several types of N-mercapto 
based H2S donors. In this presentation, our progress in this field will be discussed. 
MEDI 154 
QSAR approach in exploring diverse biological activities of Aconitum and 
Delphinium sp. alkaloids 
Malakhat Turabekova1, 2, malohathon@yahoo.com; Bakhtiyor Rasulev1; Farkhad 
Dzhakhangirov3; Danuta Leszczynska2; Jerzy Leszczynski1. (1) Interdisciplinary Center 
for Nanotoxicity, Department of Chemistry and Biochemistry, Jackson State University, 
Jackson MS 39217, United States (2) Department of Civil and Environmental 
Engineering, Jackson State University, Jackson MS 39217, United States (3) 
Department of Pharmacology and Toxicology, Institute of Chemistry of Plant 
Substances AS RUz, Tashkent 100170, Uzbekistan  
Uzbekistan based research unit (ICPS) has been engaged for many decades in 
isolation, purification, modification and pharmacological profile studies of diterpenoid 
alkaloids found in Aconitum and Delphinium plant sp. locally growing in Central Asia. 
These alkaloids have been the targets of considerable interest of medicinal chemists for 
a broad range of demonstrated pharmacological activities including arrhythmogenic 
(neurocardiotoxic), local anaesthetic, antiarrhythmic, curariform, analgesic, hypotensive, 
anti-inflammatory, spasmolytic, neurotropic and psychotropic. For the last few years our 
experimental research is actively accompanied by the computer aided drug design 
methods. Here we report results of our molecular modelling studies and extensive 
QSAR analysis for toxicity, arrhythmogenic, antiarrhythmic, curare-like and local 
anaesthetic activities established earlier for diterpenoid alkaloids from our in-house 
collection. We showed that our results may serve as a good template for revealing 
some rules for enhancing potency and selectivity of studied alkaloids and more new 
promising medicinal candidates 
MEDI 155 
Synthesis of bicyclic peptidomimetics scaffolds 
Stéphane De Cesco, stephane.decesco@mail.mcgill.ca; Mitchell Huot; Nicolas 
Moitessier. Department of Chemistry, McGill university, Montréal Québec H3A2K6, 
Canada  
Peptides are often natural ligands for enzymes and/or receptors. Despite their great 
therapeutic potential the lack of metabolitic stability has limited their use. Therefore 
designing new scaffolds that replace natural peptides had become of great interest. We 
present here our efforts toward the design and development of bicyclic scaffolds 
mimicking a large variety of dipeptides. Synthesis started from three commercially or 
readily available building blocks and final products are obtained in only two steps and 
one purification. The convergent and expedient aspect of the synthesis allowed us to 
quickly introduce diversity with no further synthetic efforts. Work toward the asymmetric 
version of the scaffold will also be presented. 
MEDI 156 
Facile synthesis of highly substituted enamides via oxidative Heck reaction 
Yu Liu, liuy0055@ntu.edu.sg; Dan Li; Cheol-Min Park. Division of Chemistry and 
Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang 
Technological University, Singapore Singapore 637371, Singapore  
Enantiomerically pure beta-amino acids and their derivatives are important building 
blocks for the synthesis of beta-peptides, beta-lactam antibiotics, and many important 
drugs. Among these synthetic methods, straightforward asymmetric hydrogenation of 
beta-aminoacrylic acid derivatives represents one of the simplest routes. And 
functionalization of beta-amidoacrylates under Heck conditions has been limited to 
those with an unsubstituted vinyl group. We report herein oxidative Heck cross-coupling 
conditions that allow for the synthesis of highly substituted enamides. The study reveals 
that the use of pinacol boronates combined with 2-(dicyclohexylphosphino)biphenyl and 
KHF2 greatly improves coupling yields.   
  
MEDI 157 
Allosteric modulation of human sweet receptor as a novel approach to enhance 
sweet taste 
Xiao-Qing Tang, xiao-qing.tang@senomyx.com; Catherine Tachdjian; Donald S 
Karanewsky; Xiaodong Li; Guy Servant; Feng Zhang; Qing Chen; Hong Zhang; Melissa 
S Wong; Vincent Darmohusodo; Goran Petrovic; Sara Adamski-Werner; Jeffrey 
Yamamoto; Joseph R Fotsing. Senomyx, Inc., San Diego CA 92121, United States  
The steady increase of the daily consumption of dietary sugar over the last decades 
may have contributed to the obesity crisis and the early onset of type 2 diabetes 
observed in many developed countries. As a result, various noncaloric sweeteners have 
been developed to reduce dietary sugar intake; however, many are characterized by off-
taste, delayed onset, or lingering of sweetness, and fail to mimic the real sugar taste. 
We present here a unique approach to develop positive allosteric modulators (PAMs) of 
the human sweet receptor to enhance the sweet taste of sugars without producing off-
tastes. Sweet taste is mediated by an obligatory heterodimeric receptor composed of 
two subunits called T1R2 and T1R3. These two subunits correspond to class C GPCRs 
characterized by a Venus Fly Trap (VFT) domain at the N-terminus linked to the C-
terminal heptahelical transmembrane domain (TMD) via a cysteine rich domain (CRD). 
We used a cell based assay for the human sweet taste receptor, high throughput 
screening, assay-guided lead optimization and taste testing with trained panelists to 
identify positive allosteric modulators (PAMs) that could allow a reduction of the amount 
of sweeteners used in consumer products. In taste tests these PAMs do not have 
intrinsic sweetness, but significantly increase the sweetness of a low amount of 
sucralose or sucrose. 
  
MEDI 158 
Empowered antibodies for cancer therapy 
Peter D. Senter, psenter@seagen.com. Seattle Genetics, Inc., Bothell WA 98121, 
United States  
A great deal of interest surrounds the use of monoclonal antibodies (mAbs) for cancer 
therapy. While significant activities have been found for such mAbs as trastuzumab, 
cetuximab, bevacizumab, and rituximab, there are many examples of mAbs that 
recognize tumor associated antigens but are devoid of significant activities in preclinical 
and clinical studies. One of the most powerful strategies for enhancing mAb activity 
involves the generation of antibody drug conjugates (ADCs) for selective delivery of 
anticancer drugs to tumor cells. This is an area that has advanced significantly, based 
on recent clinical studies with SGN-35 (brentuximab vedotin), an anti-CD30-auristatin 
antibody conjugate in patients with Hodgkin lymphoma and anaplastic large cell 
lymphoma. Brentuximab vedotin incorporates advancements and insights in drug and 
linker design, conjugation technology, and target antigen selection for mAb-mediated 
drug delivery. The presentation will overview the science and data behind this promising 
new agent. 
MEDI 159 
Protein medicinal chemistry with an expanded genetic code 
Ho S. Cho, ho.cho@ambrx.com. Department of Technology, Ambrx, Inc., La Jolla CA 
92122, United States  
Traditional small molecule medicinal chemistry is empowered by a sizable repertoire of 
structural diversity that has been embellished by more than a century of advances in 
synthetic methodology. In analogy, protein chemistry is in its infancy where structural 
diversity has been largely limited to the optimization that can be performed with the set 
of chemical groups present in the natural 20 amino acids. The ability to incorporate 
novel amino acids using an expanded genetic code provides a unique and highly 
powerful tool for protein chemists. We have pioneered the application of this novel 
technology for medicinal chemistry purposes and advanced multiple drug candidates to 
human testing. The technological foundation of the work has expanded from the initial 
demonstration in E. coli and 4-helix bundle based proteins to numerous other proteins 
and expression systems. It is the intention of this lecture to provide a state-of-the art 
demonstration of the technology through presentation of a few select projects. 
MEDI 160 
Targeted delivery of imaging and drug cargo using synthetically modified viral 
capsids 
Matthew B. Francis, mbfrancis@gmail.com. Department of Chemistry, University of 
California, Berkeley, Berkeley California, United States and Materials Sciences Division, 
Lawrence Berkeley National Laboratory, Berkeley California, United States  
Nanoscale materials offer promising new platforms for the tissue-specific delivery of 
therapeutic cargo. Through appropriate surface modification, multiple copies of a 
desired targeting group can be displayed to direct these carriers to cell surface markers 
of interest. The use of hollow structures allows drug molecules and radiolabels to be 
sequestered within the assemblies, protecting them from premature degradation and 
masking their influence on biodistribution. To realize this potential, we have developed a 
series of site-selective chemical reactions to convert the protein shell of a virus into a 
coordinated set of targeted delivery agents. Peptides, antibody fragments, and 
aptamers have been installed on the external surfaces, and the inside of each capsid 
has been modified to house high-relaxivity MRI contrast agents and F-18 labels for PET 
imaging. The new protein modification strategies that have enabled the construction of 
these carriers will serve as the focus of this presentation. 
MEDI 161 
Spying on protein conformation, function and assembly using fluorogenic small 
molecules 
Alanna Schepartz, alanna.schepartz@yale.edu. Department of Chemistry, Yale 
University, New Haven CT 06520, United States  
Exploration across the fields of biology, chemical biology, and medicine has led to an 
increasingly complex, albeit incomplete view of the interactions that drive life's 
processes. The ability to monitor and track the movement, activity, and interactions of 
biomolecules, especially in living cells, is an essential part of this investigation. As 
chemists, we seek to understand these macromolecular events at a level of resolution 
that reveals their energetic and structural underpinnings. This objective demands the 
development of increasingly sophisticated methods to image not just the location of a 
biomolecule of interest, but also to reveal its structure and function. Our approach to this 
goal exploits a family of fluorogenic small molecules whose fluorescence is dependent 
on an interaction with a discrete protein sequence, conformation or assembly. This 
lecture will describe recent progress in this area, with an emphasis on the fundamental 
concepts that underlie the use of these molecules for experiments in living cells. 
MEDI 162 
Realizing the potential of antibody-drug conjugates in cancer: Selection of the 
right cytotoxic agent and linker 
Ravi V. J. Chari, ravi.chari@immunogen.com. ImmunoGen, Inc., Waltham MA 02451, 
United States  
We have exploited the tumor specificity of monoclonal antibodies for the targeted 
delivery of highly cytotoxic drugs that are otherwise too toxic to be used on their own. 
Our highly potent tubulin interacting maytansinoid compounds DM1 and DM4, have 
been incorporated in Antibody-Maytansinoid Conjugates (AMCs). The design of each 
maytansinoid conjugate has been tailored to achieve optimal activity for the specific 
cancer target. Linkers have been designed such that the AMCs are stable in circulation, 
and are virtually non-toxic until they bind to the tumor cell through the antibody 
component. They are then activated specifically by the tumor into potent cytotoxic 
agents. Multiple AMCs are currently in clinical evaluation. The design and development 
from the bench to the clinic of these conjugates will be discussed. Mechanistic studies 
on the activation of AMCs, and recent advances in linker design and new cytotoxic 
agents for use in antibody-drug conjugates will be highlighted. 
MEDI 163 
Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer 
Mark X. Sliwkowski, marks@gene.com. Research Oncology, Genentech, Inc., South 
San Francisco CA 94070, United States  
Trastuzumab-DM1 (T-DM1; trastuzumab emtansine) is composed of the humanized 
antibody trastuzumab and DM1, a maytansinoid derivative, linked with a nonreducible 
thioether linker, N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
(SMCC, designated MCC after conjugation). Maytansinoids are natural products that 
are potent antimitotic agents, which like the vinca alkaloids prevent microtubule 
assembly. Due in part to their impressive potency,maytansinoids were investigated as 
drugs for conjugation to monoclonal antibodies. Derivatives of maytansinoids were 
synthesized to allow chemical conjugation to proteins using disulfide linkers. The 
realization that the endocytic pathway is not reducing and our empirical experimental 
observations led us to conclude that the more stable thioether linkage was better suited 
for maytansinoid coupling to trastuzumab. Early promising clinical data were recently 
generated in patients whose tumors have progressed on HER2-directed therapies. 
MEDI 164 
WITHDRAWN 
MEDI 165 
New and innovative business models that foster external collaborations while 
balancing risk and reward 
Richard D Connell, richard.connell@pfizer.com. External Research Solutions COE, 
Pfizer Inc, Groton CT 06340, United States  
Big Pharma has a need and desire to externalize some aspects of research in order to 
gain access to key thought leaders or to new technologies or capabilities that do not 
exist in house. To promote these collaborations, many companies have Business 
Development groups who scan the R&D environment looking for partnerships in the 
biotech or academic communities. Other reasons to build external networks of partners 
include a desire to variabilize costs associated with services or assets that exist in the 
marketplace. Such external relationships provide flexible capacity to Pharma and 
enable a more staffing model that can rise or fall as the business needs dictate. These 
well defined, transactional, or service-derived relationships tend to fall into the domain 
of Contract Research Organizations (CROs) and tend to be managed by outsourcing 
and procurement professionals.   As the push for increased productivity continues, and 
Research budgets continue to feel the strain of finite resources, there is increased 
pressure to look at the new partnership models that help Pharma deliver its portfolio of 
promising medicines in a cost effective way. In this talk, examples of new partnership 
models that externalize Research assets and/or tap into the “wisdom of the crowds” will 
be discussed. These examples described in this talk share the common theme of 
increasing the efficiency of the Research engine. 
MEDI 166 
Translational therapeutics development at NIH 
Christopher Austin, austinc@mail.nih.gov. NIH Center for Translational Therapeutics, 
National Institutes of Health, Bethesda Maryland 20892, United States  
The explosion in mechanistic understanding of human physiology in health and disease, 
exemplified by the Human Genome Project and its successors, has provided a deluge 
of potential new targets for therapeutic development. At the same time, evolution of 
technologies and operational systems for drug discovery has allowed investigators and 
institutions in the public sector to contribute directly to new therapeutics discovery in a 
more vigorous way, particularly for rare and neglected diseases. Over the last decade, 
the NIH has built a variety of programs which complement drug discovery efforts in the 
biopharmaceutical sector, principally in two areas: (a) science, technology, tool, and 
paradigm development to improve scientific understanding and efficiency of the 
therapeutics discovery process, and (b) early stage drug development programs to de-
risk projects particularly for rare and neglected diseases, making them more amenable 
to biopharmaceutical adoption despite their low expected ROI. The mission and 
accomplishments of these programs will be discussed. 
MEDI 167 
Evolving computational tools to cope with ever increasing data volume - focused 
innovation 
Chris Culberson, chris_culberson@merck.com. Merck & Company, Inc., United States  
Scientific enhancements and innovations have allowed us to effectively synthesize 
molecules and measure their physical and biological properties with ever increasing 
speed. However, with the increase, a weakness in our ability to keep pace with the 
analysis of those data has been highlighted. Computational chemists are responsible for 
the initial phases of the data analysis, as well as distilling the analysis into lessons 
learned to lessen the impact of the increased data volume. We can take advantage of 
innovations in general data analysis techniques and remove the current bottleneck only 
to expose the next set of tools not up to the task. In this talk, we will discuss the current 
tools, perceived bottlenecks and future directions for focused innovation in the 
computational chemistry toolbox. 
MEDI 168 
Future role of Medicinal Chemistry and its maturation to Chemical Biology 
Torsten Hoffmann, torsten.hoffmann@roche.com. Department of Discovery Chemistry, 
F. Hoffmann-La Roche Ltd, Basel BS 4070, Switzerland  
Medicinal Chemistry is often referred to as a “mature science” evoking images of the 
grandfather of drug discovery – geriatric, slow and even grumpy. This talk will outline a 
chain of thoughts which conclude that chemistry has a wider role to play in innovative 
drug discovery than it is currently permitted by industry to have. In that respect, three 
Chemical Biology approaches will be briefly discussed: i) small molecules that enable 
intracellular delivery of macromolecules into cytosol, ii) RNA as drug target for the 
regulation of gene expression, and iii) regenerative medicine through small molecules 
that differentiate pluripotent stem cells.  If successful, the application of Chemical 
Biology within industry holds the promise of delivering innovation in healthcare that 
reaches far beyond the current limitations of traditional Medicinal Chemistry. 
MEDI 169 
Academic labs and the discovery of innovative new medicines: From disease 
biology to experimental compounds with drug-like properties 
B Michael Silber, msilber@ind.ucsf.edu. Department of Neurology and Bioengineering 
and Therapeutic Sciences, University of California San Francisco Institute for 
Neurodegenerative Diseases, San Francisco California 94143, United States  
Academic labs have been responsible for virtually all of the basic science discoveries 
that have translated into innovative new medicines, typically discovered and developed 
by pharmaceutical or biotechnology companies. There is widespread acceptance that 
large pharmaceutical and biotechnology companies are no longer able to generate 
enough innovative experimental compounds to support Phase I – III development 
pipelines from internal research. What is needed are new clinically validated targets, 
new compounds with good drug-like properties, along with suitable biomarkers in target 
patient populations, especially in areas with high unmet medical need. Academic labs 
have the potential to contribute, from disease biology and therapeutic hypothesis, to the 
discovery and early development of experimental compounds with good drug-like 
properties, directly and through collaborations with pharmaceutical and biotechnology 
companies. Collaboration is in the best interests of patients and society if it accelerates 
the translation of basic science to new medicines that address unmet medical needs. 
MEDI 170 
How to beat back the commoditzation of the pharmaceutical industry? 
Bernard Munos, bhmunos@gmail.com. InnoThink Center for Research in Biomedical 
Innovation, Indianapolis IN 46228, United States  
The long-predicted pharmaceutical innovation crisis has arrived. New drug approvals for 
big pharma can no longer replace sales lost to generics; $130 billion of US sales face 
patent expiration; R&D spending is under the knife; and the patent cliffs ahead could 
make things worse. Yet, as the industry faces commoditization, the ingredients of 
success are at hand: we have talent, capital, and an accumulating number of cutting-
edge discoveries waiting to be translated into useful therapies.  How to combine these 
ingredients into a winning recipe?  This session will explore the key questions that 
define a successful drug R&D organization: what is the focus? how to manage it? how 
to fund it? how to mitigate risk effectively? It will draw upon what research has shown to 
produce innovation, and will offer actionable ideas to rebut the dire predictions about the 
industry. 
MEDI 171 
Chemical basis of pharmacology 
Brian K. Shoichet, shoichet@cgl.ucsf.edu. Dept. of Pharmaceutical Chemistry, UCSF, 
San Francisco CA 94158-2550, United States  
So dominant has molecular pharmacology become that it is difficult to remember that 25 
years ago it was only an aspiration. Today we understand drug activity through the 
specific receptor molecules with which they interact. To discover new leads we screen 
libraries against such targets, and these targets are related by sequence identity.  A 
generation ago this view was inverted: investigators began with small molecules and 
sought targets, and receptors were related by the ligands that bound them. Here we 
return to this classic idea, seeking unexpected similarities. We compare sets of ligands 
for over 3000 targets to one another. The relationships that emerge predict previously 
unknown off-targets for drugs and reagents, 30 of which have been tested, largely with 
Bryan Roth (UNC-CH), with potencies ranging from 1.2 nM to 14 μM. Applications to 
adverse drug reactions, mechanism of action, new target opportunities, and phenotypic 
screens will be considered. 
MEDI 172 
Multiplex proteomic measurements in drug and diagnostic research and 
development 
Nick Saccomano, nsaccomano@somalogic.com. SomaLogic Inc., United States  
Plasma proteins and secreted proteins, released from cells and surrounding tissues, 
contain important biological information with the potential to inform early diagnostic, 
prognostic, and therapeutic decisions in research and medicine. SomaLogic has 
developed a proteomic biomarker discovery and diagnostic application technology that 
measures 1033 human proteins in low sample volumes (~8 uL of serum/plasma, tissue 
homogenate) with a high-performance, high-throughput, and cost effective assay. The 
assay achieves low limits of detection (1 pM average), ~7 logs of overall dynamic range, 
and ~5% average coefficient of variation. This technology is enabled by a new class of 
DNA aptamers – “SOMAmers” – that contain novel chemically-modified nucleotides, 
which greatly expand the physicochemical diversity of the large combinatorial SELEX 
libraries from which they are selected. Proteins are measured with a process that 
transforms a signature of protein concentrations into a representative DNA 
concentration signature, which is quantified with a DNA microarray, bead-based 
hybridization, or qPCR. We have demonstrated the utility of this technology in a large 
clinical biomarker discovery studies as well as therapeutic R & D applications. 
MEDI 173 
Discovery of CNS drug candidates for treatment of Parkinson's disease and 
Alzheimer's disease 
William Greenlee, william.greenlee@merck.com; Andrew Stamford; Bernard Neustadt; 
Jared Cumming; Daniel Wyss; Allen Yu-Sen Wang; Corey Strickland; Johannes Voigt; 
Johnny Zhaoning Zhu; Jean Lachowicz; Matthew Kennedy; Eric Parker; John Hunter. 
Department of Chemistry, Merck Research Laboratories, Rahway NJ 07065, United 
States  
Parkinson's disease (PD) is a chronic, progressive neurodegenerative disease 
characterized by loss of dopamine-producing cells in the substantia nigra, which results 
in a syndrome of movement disorders. Adenosine A2A antagonists have potential as a 
non-dopaminergic treatment to control the motor symptoms of PD. The discovery of the 
potent adenosine A2A antagonist Preladenant, which has shown efficacy in several 
preclinical models, and improved symptoms of PD when dosed in combination with L-
DOPA, will be described. Alzheimer's disease (AD) is a progressive, ultimately fatal 
neurodegenerative disease with an average life expectancy of 7-10 years after 
diagnosis. A pathological hallmark observed in the brains of AD patients is extracellular 
amyloid plaques, mainly composed of an amyloid β peptide 42 amino acids in length 
(Aβ42). Beta amyloid is produced from the amyloid precursor protein (APP) by the 
action of the enzymes BACE-1 and gamma secretase. Blocking the action of BACE-1 
with small molecule inhibitors is a promising disease modifying therapy that could halt or 
even reverse the progression of AD. Using a fragment screening approach, coupled 
with X-ray crystallography, we have discovered potent BACE inhibitors with promising in 
vivo efficacy. These inhibitors, and their activity in preclinical AD models will be 
described. 
MEDI 174 
Substrate activity screening: A fragment-based method for inhibitor discovery 
Jonathan A Ellman, jonathan.ellman@yale.edu. Departments of Chemistry and 
Pharmacology, Yale University, New Haven CT 06520-8107, United States  
Substrate activity screening (SAS) is a fragment-based method for the rapid 
development of novel, drug-like enzyme inhibitors. The method consists of three steps: 
(1) a diverse library of low molecular weight substrates is screened against an enzyme 
target to identify lead fragments, (2) the identified fragments are rapidly optimized by 
subsequent rounds of analogue synthesis and evaluation, and (3) the optimized 
substrates are converted to inhibitors by direct incorporation of mechanism-based 
inhibitor pharmacophores. Because the assay requires productive substrate binding and 
turnover, false positives often seen in traditional high-throughput inhibitor screens are 
eliminated. Additionally, catalytic substrate turnover results in signal amplification 
enabling the identification of very weakly active lead fragments. The successful 
application of the SAS approach to the rapid identification of novel, potent and selective 
small molecule inhibitors to therapeutically relevant proteases and phosphatases will be 
presented. 
MEDI 175 
Award Address (E.B. Hershberg Award for Important Discoveries in Medicinally 
Active Substances sponsored by Schering-Plough Research Institute). CPP-115: 
A GABA aminotransferase inactivator and new treatment for epilepsy and drug 
addiction 
Richard B Silverman, r-silverman@northwestern.edu. Department of Chemistry, 
Northwestern University, Evanston IL 60208-3113, United States  
An imbalance in the levels of the inhibitory neurotransmitter g-aminobutyric acid (GABA) 
and the excitatory neurotransmitter glutamate can lead to convulsions. Inhibition of g-
aminobutyric acid aminotransferase (GABA-AT), the enzyme responsible for the 
degradation of GABA, increases the GABA levels, which has been shown to produce an 
anticonvulsant effect; it also has been found to lead to a new treatment for drug 
addiction. We have synthesized a variety of mechanism-based inactivators of this 
enzyme and studied their mechanism of action. In this lecture I will discuss the design 
and mechanism of our GABA-AT inactivators and how these compounds led to the 
discovery of CPP-115, a molecule that is currently in preclinical development for the 
treatment of epilepsy and drug addiction. In vitro mechanistic studies and in vitro and in 
vivo efficacy, ADME, and toxicology studies of CPP-115 will be presented. 
MEDI 176 
Thermodynamics-based drug design: Achieving high selectivity 
Ernesto Freire, ef@jhu.edu. Biophysics, Johns Hopkins University, Baltimore Maryland 
21218, United States  
High affinity and selectivity are two essential properties of drug molecules. Selectivity 
has been difficult to achieve, especially for targets that belong to large families of 
structurally and functionally related proteins. There are essentially two ways of 
improving selectivity during lead optimization: 1) a chemical modification of the lead 
compound improves the affinity towards the target to a higher extent than to off target 
molecules; and, 2) a chemical modification of the lead compound actually lowers its 
affinity towards off target molecules. Maximal selectivity is achieved when both 
situations apply simultaneously. Analysis of several protease inhibitors that vary by a 
single functionality indicates that non-polar functionalities can follow either mechanism 
while polar functionalities follow the second one. The actual mechanism reflects the 
balance of desolvation and target interactions and is revealed in the changes in 
thermodynamic signature associated with the compound modification, which can be 
determined by Isothermal Titration Calorimetry (ITC). ITC can be used as an important 
tool for selectivity optimization. 
MEDI 177 
Fragment-based drug discovery: A medicinal chemists perspective 
Andrew Woodhead, a.woodhead@astex-therapeutics.com. Department of Medicinal 
Chemistry, Astex Therapeutics, Cambridge Cambridgeshire CB1 0QA, United Kingdom  
Five years ago most scientists did not consider low molecular weight fragments (MW = 
120-250) with only mM to uM binding affinities to be attractive starting points for drug 
discovery programs. However, today there is widespread acceptance that these 
fragments can be progressed into nM lead series and on into clinical trials. Reported 
examples include clinical candidates that target different protein families such as 
kinases (CDK, Aurora, Akt, raf), protein-protein interactions (Bcl-XL), ATPases (HSP-90) 
and proteases (MMP 2&9).  This presentation has two parts. Firstly, a general overview 
of the techniques associated with fragment based drug discovery. The second part of 
the talk will cover specific examples of fragment optimisation from Astex, highlighting 
the integration of structural information into medicinal chemistry and the influence this 
has on compound design.  Murray CW, Rees DC: The rise of fragment-based drug 
discovery. Nat. Chem. 2009, 1:187-192. 
MEDI 178 
Nature of the hydrogen bond and its role in medicinal chemistry 
Daniel Cheney, daniell.cheney@bms.com. Bristol-Myers Squibb, United States  
Hydrogen bonding plays an essential role in biomolecular assembly and recognition, 
and is a key determinant in drug potency, selectivity and pharmacokinetic and related 
properties. An overview will be given of hydrogen bonding in the context of medicinal 
chemistry. Topics will include physical and structural aspects of the hydrogen bond, the 
estimation and comparison of hydrogen bonding strengths of common drug like 
moieties, the role of hydrogen bonding in protein – drug complexation, and 
considerations of hydrogen bonding in the adjustment of physical properties which 
impact on pharmacokinetics. 
MEDI 179 
From fine tuning to major overhaul: Applications of deuterium medicinal 
chemistry 
Scott L Harbeson, sharbeson@concertpharma.com. Concert Pharmaceuticals, Inc., 
Lexington MA 02421, United States  
Computational and synthetic tools have enabled a more rational approach to lead 
optimization when addressing ADMET challenges in a molecule or scaffold. However, 
the structural changes that are brought to bear on a molecule (solubilizing groups, 
eliminating or blocking metabolic sites, isosteric replacements, prodrugs, etc.) can alter 
the activity and specificity profiles of the compound, thereby necessitating assessment 
of both the ADMET and pharmacology during optimization. In certain cases, balancing 
these often competing molecular requirements results in agents with non-optimal 
metabolic properties. Deuterium medicinal chemistry provides an optimization tool that 
can effect both subtle and marked changes in ADMET properties with minimal 
perturbation of the intrinsic pharmacology of a compound. This presentation will focus 
on specific examples where deuterium has enabled improvements in therapeutic 
entities through decreased clearance (longer half-life), increased bioavailability, or 
metabolic switching away from undesired metabolites. In select cases, deuterium 
medicinal chemistry can yield improvements in safety, efficacy, and/or tolerability 
without significantly altering the biochemical potency and selectivity of a compound. 
MEDI 180 
Polar C-F bond and its potential for influencing molecular design in bioorganic 
and medicinal chemistry 
David O'Hagan, do1@st-andrews.ac.uk. University of St. Andrews, United Kingdom  
The C-F bond is the most polar in organic chemistry and this imparts extreme properties 
which can be used to influence the conformation of organic molecules though 
consequent stereoelectronic and electrostatic effects. We are interested in preparing 
molecules that explore the stereoelectronic influence of fluorine such that predictions 
relating to molecular conformation can be made. These aspects will be outlined in a 
number of case studies. The conformations of alkane stereoisomers carrying upto six 
fluorine atoms arranged along a hydrocarbon chain will be described. Also the influence 
of the C-F bond in heterocyclic and alicyclic ring conformations will be explored and 
stereoselective fluorination of receptor agonists including eg. 3F-GABA and 3F-NMDA 
will be highlighted. 
MEDI 181 
Next generation oral anticoagulant: The discovery of Apixaban, a potent, 
selective, and orally bioavailable factor Xa inhibitor 
Patrick Y. S. Lam, patrick.ys.lam@gmail.com. Bristol-Myers Squibb, Princeton NJ 
08543, United States  
Thrombosis is the leading cause of death in developed countries and there is significant 
need for novel antithrombotics with an improved safety profile. Factor Xa is at the 
junction of the intrinsic and extrinsic pathways of the coagulation cascade. Preclinical 
data has demonstrated that blocking FXa is an effective approach for anticoagulation 
with improved safety profile. Utilizing structure-based drug design tools, we at Bristol-
Myers Squibb have discovered a novel class of potent, selective and orally bioavailable 
Factor Xa inhibitors culminating in Apixaban. Apixaban is being evaluated in a series of 
ongoing or completed Phase III clinical trials.  
  
MEDI 182 
Dose selection for a direct and selective factor IXa inhibitor and its 
complementary control agent: Translating pharmacokinetic and 
pharmacodynamic properties of the REG1 System to clinical trial design 
Christopher P Rusconi1, crusconi@regadobio.com; Thomas J Povsic2; Mark Y Chan2; 
William A Wargin3; Robert A Harrington2; John H Alexander2; Richard C Becker2; 
Steven L Zelenkofske4; Mauricio G Cohen5. (1) Regado Biosciences, Inc, Durham NC 
27701, United States (2) Division of Cardiology, Duke Clinical Research Institute, 
Durham NC, United States (3) ClinPharm Consulting, RTP NC, United States (4) 
Regado Biosciences, Inc, Basking Ridge NJ, United States (5) Cardiovascular Division, 
University of Miami Miller School of Medicine, Miami FL, United States  
The REG1 Anticoagulant System consists of pegnivacogin (aka RB006), a direct 
coagulation FIXa inhibitor and anivamersen (aka RB007), its active control agent. 
Pegnivacogin is a single-stranded nucleic acid aptamer conjugated to a large molecular 
weight polyethylene glycol carrier. Anivamersen is a short oligonucleotide 
complementary to a portion of pegnivacogin. Binding of aniveramersen to pegnivacogin 
irreversibly alters its structure, rendering pegnivacogin unable to interact with FIXa and 
thereby neutralizing its anticoagulant activity. Pegnivacogin is the first FIXa inhibitor to 
be evaluated in an arterial thrombotic indication, with RADAR, a phase 2b study of 
REG1 in ACS-PCI, being recently completed. The focus of this presentation will be the 
selection of doses of pegnivacogin for phase 2 studies, and the effectiveness of 
pegnivacogin in providing protection from ischemic events in ACS-PCI patients. The 
strategy used for selection of dose ranges of anivamersen for phase 2 studies will also 
be discussed as will the impact of REG1 on major bleeding in ACS-PCI. 
MEDI 183 
Discovery and development of the selective PAR-1 antagonist Atopaxar 
Richard Clark1, r-clark@hhc.eisai.co.jp; Tetsuya Kawahara1; Motoji Kogushi1; Shinki 
Kawaguchi1; Makoto Kotake1; Fumiyoshi Matsuura1; Takashi Musha2; Toshiyuki 
Matsuoka2; Nobuaki Sato1; Syuichi Suzuki1; Masahiro Takada1; Taro Terauchi1. (1) 
Tsukuba Research Labs., Eisai Co. Ltd, Tsukuba Ibaraki 300-2635, Japan (2) 
Department of Drug Fostering and Evolution, Eisai Co. Ltd, Tokyo 112-8088, Japan  
Thrombin stimulates human platelets, which are known to play a major role in arterial 
thrombotic diseases, through the activation of protease-activated receptor-1 (PAR-1) 
and protease-activated receptor-4 (PAR-4) It is thought that inhibiting the action of 
thrombin on PAR-1, its principal effector on human platelets, may provide a new 
therapeutic option for atherothrombotic disease with lower risk of bleeding 
complications. We obtained a non-peptide, small molecule PAR-1 antagonist (ER-
97719-15) from high throughput screening using a receptor binding assay system. 
Subsequent modification of this compound led to Atopaxar (E5555) which is currently 
under clinical investigation. This presentation will describe how the original lead was 
developed into the clinical candidate, detail the pharmacological effects of E5555, and 
also present some clinical results with Atopaxar in patients with Acute Coronary 
Syndrome or high risk Coronary Artery Disease. 
MEDI 184 
Prasugrel, a third generation thienopyridine: Lab to patient 
Brian A. Baker, bbaker@dsi.com. Daiichi Sankyo, Inc., Parsippany NJ 07054, United 
States  
The thienopyridine oral antiplatelet agents, ticlopidine and clopidogrel, are prodrugs that 
require metabolism in vivo to active metabolites that irreversibly inhibit the platelet 
P2Y12 ADP receptor. Clopidogrel's platelet inhibitory effects exhibit a relatively slow 
onset and are highly variable. In contrast, prasugrel, a more recent addition to the 
thienopyridine class, has a relatively faster onset of action and is associated with less 
antiplatelet variability. Because the active metabolites of these two agents are 
comparably potent, the faster and greater antiplatelet effects of prasugrel are explained 
by the more efficient conversion to its active metabolite. Results from the TRITON-TIMI 
38 trial which compared prasugrel to clopidogrel in high risk ACS patients scheduled for 
PCI will be discussed. 
MEDI 185 
Development of dabigatran etexilate: A direct, reversible, oral thrombin inhibitor 
Susan Wood1, susan.wood@boehringer-ingelheim.com; Joanne van Ryn2. (1) 
Department of Medical Affairs, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield 
CT 06877, United States (2) Department of CardioMetabolic Disease Research, 
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield CT 06877, United States  
Dabigatran is a selective, reversible and potent inhibitor of thrombin and is orally 
available as the double prodrug, dabigatran etexilate. Antithrombotic efficacy of the 
compound has been demonstrated in a number of animal models of venous and arterial 
thrombosis. In addition, dabigatran inhibits thrombin-induced platelet aggregation. It has 
also been demonstrated in animal models of atherosclerosis and fibrosis to have 
protective effects on proliferation and promote plaque stability. Peak plasma 
concentrations of dabigatran in humans are achieved 1-2 hours after ingestion and the 
half-life in elderly volunteers is 12-14 hours. Dabigatran has a low potential for drug-
drug interactions, does not interact with food and is predominantly renally excreted. For 
the first time it has been demonstrated clinically in patients with atrial fibrillation, that 
there may be an effective and safe alternative to warfarin for stroke prevention. 
MEDI 186 
Discovery of vorapaxar: A thrombin receptor antagonist with promising 
antiplatelet effects 
Samuel Chackalamannil, samuel.chackalamannil@merck.com; Yuguang Wang; 
William J. Greenlee; Mariappan Chelliah; Martin Clasby; Keith Eagen; Zhiyong Hu; Yan 
Xia; George Boykow; Madhu Chintala. MRL, Merck, Kenilworth NJ 07830, United States  
Vorapaxar is a thrombin receptor (also know as protease activated receptor-1 or PAR-1) 
antagonist that is being developed for the treatment of acute coronary syndrome (ACS) 
which comprises a spectrum of clinical conditions ranging from unstable angina to acute 
myocardial infarction. The initial PAR-1 lead was a synthetic analog of the natural 
product himbacine. Extensive lead optimization efforts led to the discovery of vorapaxar 
which is a competitive antagonist of PAR-1with a Ki of 8.1 nM. In a preclinical 
cynomolgus monkey ex vivo platelet aggregation model vorapaxar inhibited agonist 
induced platelet aggregation for > 24 h after oral administration at 0.1 mg/kg. In P-II 
clinical studies vorapaxar met the primary end point of lack of increased bleeding 
compared to placebo and also showed a numerical reduction in periprocedural 
myocardial infarction and major adverse cardiac events. Results from two major P-III 
clinical studies for ACS and secondary prevention of ischemic events are anticipated in 
the future. 
MEDI 187 
Discovery of the novel HCV NS3 protease inhibitor, GS-9451 
Hyungjung Pyun, ppyun@gilead.com; Christopher Sheng; Todd Appleby; Ona 
Barauskas; Thomas Butler; Ruby Cai; Xiaowu Chen; Aesop Cho; Michael Clarke; Amy 
Corsa; Edward Doerffler; Magdeleine Hung; Mingzhe Ji; John Link; Xiaohong Liu; 
Rowchanak Pakdaman; Margaret Robinson; Brian Schultz; Chin Tay; Qiaoyin Wu; Jie 
Xu; Chris Yang; Huiling Yang; William Delaney; Choung Kim. Gilead Sciences, Foster 
City CA 94404, United States  
GS-9451 has been identified as a specific HCV NS3 protease inhibitor and is currently 
in phase 2 clinical development for the treatment of chronic genotype 1 (GT1) HCV 
infection. It has an in vitro EC50 ranging from 7-10 nM in both HCV 1a and 1b replicon 
assays and is highly selective (> 20000-fold) over all tested mammalian proteases. It 
exhibited <ins datetime="2011-03-21T17:23" 
cite="mailto:Gilead%20Sciences,%20Inc.">.good aqueous solubility and excellent 
pharmacokinetic properties in animal model studies. We will discuss the SAR and 
pharmacokinetic optimizations that lead to the discovery of GS-9451. 
MEDI 188 
Discovery of BMS-911543, a highly selective JAK2 inhibitor as clinical candidate 
for the treatment of myeloproliferative disease 
Ashok V Purandare, ashok.purandare@bms.com; Honghe Wan; Gretchen Schroeder; 
Amy Hart; James Grebinski; Jennifer Inghrim; John Tokarski; John Sack; Javed Khan; 
Matthew Lorenzi; Dan You; Becky Penhallow; Theresa McDevitt; Ragini Vuppugalla; 
Yueping Zhang; Stefan Ruepp; Bogdan Sleczka; Kevin Stefanski; Jonathan Lippy; 
Kathy Baldwin; Xiaomei Gu; Celia D'Arienzo; Ramaswamy Iyer; Jennifer Hosbach; 
Jennifer Brown; Elizabeth Fitzpatrick; Louis Lombardo; George Trainor; Marco 
Gottardis; Zheng Yang. Research & Development, Bristol-Myers Squibb, Princeton New 
Jersey 08543, United States  
Myeloproliferative diseases (MPD) are clonal malignancies that arise from 
hematopoietic progenitors and characterized by overproduction of mature and functional 
blood cells. MPDs are classified into classic variants including polycythemia vera (PV), 
essential thrombocythemia (ET) and primary myelofibrosis (PMF). Significant medical 
need exists, as the current standard of care is only palliative and does not change the 
course of these diseases. Recent discovery of activating mutations in the tyrosine 
kinase gene, JAK2, and constitutive activation of the JAK2-STAT pathway, in large 
number of the MPD patients has ignited considerable interest in these diseases and has 
highlighted JAK2 as a therapeutic intervention point for drug discovery efforts. However, 
high sequence homology with other JAK family members has posed a major challenge 
to the design of a selective JAK2 inhibitor. Given that other JAK family members are 
involved in regulation of immune function, it is important to maintain selectivity for JAK2 
over family members in order to mitigate the risks associated with undesired 
immunosuppression. Several JAK2 inhibitors with varying selectivity profiles are 
currently being evaluated in preclinical setting as well as in the clinical trials.   This 
presentation will focus on the discovery of a selective JAK2 inhibitor, BMS-911543, for 
the treatment of MPD. The talk will outline structure based drug design efforts towards 
achieving the desirable selectivity. The presentation will also discuss complete 
biological characterization of the lead candidates that eventually led to the selection of 
the clinical candidate, BMS-911543. 
MEDI 189 
Brain penetrant PI3 kinase inhibitors 
Timothy P Heffron, theffron@gene.com. Department of Discovery Chemistry, 
Genentech, South San Francisco CA 94080, United States  
The well documented deregulation of the PI3K/AKT/mTOR pathway in numerous tumor 
types has established a significant desire for PI3K inhibitors. Aberrant signaling through 
this pathway is observed in a significant majority of glioblastoma. Using in silico 
evaluations to prioritize compounds for synthesis, our program successfully identified 
several potent inhibitors of PI3 kinase capable of crossing the blood-brain barrier. This 
presentation will discuss the use of in silico tools to minimize efflux and brain tissue 
binding while simultaneously improving metabolic stability. In vivo tumor growth 
inhibition in relevant glioblastoma models will also be presented. 
MEDI 190 
Optimization of 5-aryl-3-benzyloxy-pyridin-2-ylamine series to minimize CYP3A4 
inhibition potential: Discovery of Crizotinib (PF-02341066) for oncology 
applications 
J. Jean Cui, jean.cui@pfizer.com; Mitchell Nambu; Pei-Pei Kung; Michelle Tran-Dube; 
Hong Shen; Mason Pairish; Jia Lei; Jerry Meng; Funk Lee; Michele McTigue; Shinji 
Yamazaki; Gordon Alton; Helen Zou; James Christensen; Barbara Mroczkowski. La 
Jolla Laboratory, Pfizer PharmaTherapeutics Worldwide Research, San Diego CA 
92121, United States  
3-Benzyloxy-5-phenyl-pyridin-2-ylamine was created as a class of potent and highly 
selective c-Met inhibitors based on the co-crystal structure of PHA-665752 with c-Met 
kinase domain. However, 3-benzyloxy-5-phenyl-pyridin-2-ylamines showed strong 
inhibition of CYP3A4. Lead optimization of 5-aryl group for solving CYP inhibition issue 
and improving overall pharmaceutical properties was carried out. 3-Benzyloxy-5-
pyrazol-4-yl-pyridin-2-ylamines demonstrated higher ligand efficiency (LE) and 
liphophilic ligand efficiency (LipE) with improved pharmaceutical properties, especially 
reduced CYP inhibition potential. Further optimization of N-substituents on 5-pyrazol-4-
yl group generated clinic candidate PF-02341066 (Crizotinib), which demonstrated 
potent in vitro and in vivo c-Met/ALK inhibition, effective tumor growth inhibition in c-Met 
and ALK driven tumor models, and good pharmaceutical properties. Crizotinib is 
currently in Phase III clinical study, and demonstrates remarkable efficacies for Lung 
cancer patients with EML4-ALK fusion gene. 
MEDI 191 
Discovery and preclinical characterization of BMN 673, a highly potent and orally 
active PARP inhibitor as an anticancer agent 
Bing Wang, BWang@bmrn.com; Daniel Chu; Yuqiao (Jerry) Shen; Ying Feng; Peter 
Myers; Leonard Post. BioMarin Pharmaceutical Inc., United States  
The nuclear enzyme poly (ADP-ribose) polymerase has emerged as an important novel 
target in cancer therapy. It is activated by DNA damage and plays a critical role in single 
strand DNA breaks repair via base excision repair (BER) pathway. PARP inhibitors 
were initially developed as possible chemo-sensitization agents by preventing cancer 
cells from repairing DNA damage caused by cytotoxic drugs. The recent preclinical and 
early clinical results have shown that potent PARP inhibitors can also act as single 
agents to selectively kill cancer cells harboring defects in other DNA repairing proteins, 
such as the breast and ovarian cancer cells with BRCA-1 or BRCA-2 mutations. It is 
hypothesized that in the cancer cells with the mutations of BRCA-1 or BRCA-2, the 
double-strand DNA breaks caused by the accumulation of single-strand DNA breaks 
due to PARP inhibition could not be repaired and consequently would lead to cell death. 
In this presentation, we will disclose the discovery and characterization of BMN 673 
(formerly LT-00673), the most potent PARP inhibitor reported to-date. In cultured 
human cancer cells, BMN 673 significantly enhances the cytotoxic efficacy of both 
temozolomide and SN-38 (active metabolite of Irinotecan). BMN 673 also demonstrates 
single-agent cytotoxicity in BRCA-1 and BRCA-2 mutant tumor cells. In animal PK 
studies, BMN 673 displays good oral bioavailability and pharmacokinetic properties that 
enable single daily dosing. Specifically, the presentation will focus on the identification 
of hit, SAR, and hit-to-lead-to-candidate optimization processes. The PK/PD 
characterization, which aided the selection of the candidate into the clinical 
development, will also be discussed. Currently, the Phase 1 clinical study of BMN 673 is 
underway. 
MEDI 192 
Reviving the dead: Re-evaluation and optimization of a former terminated lead 
series allows for the identification of a candidate CCR2 antagonist 
Clark A Sehon1, clark.a.sehon@gsk.com; Gren Wang1; Andrew Viet1; Terry Hughes2; 
Krista Goodman3; Brian Budzik4; Jing Zhang4; Pamela Haile1; Tom Daniel4; Nathan 
Miller1; Tamara Miskowski4; Dimitri Gotchev4; Minghua Gu5; Ryan Fox3; Hilary Eidam3; 
Ronggang Liu4; Michael Bury1; Feng Ren4; Zhimin Du4; Deyou Sha4; Sarah Dowdell3; 
Xuan Hong2; Subhas Chakravorty2; Christine Webb6; Carla Cornejo6; Alan Olzinski7; 
Roberta Bernard7; Chris Evans2; Amanda Emmons2; Peter Gough8. (1) Department of 
Medicinal Chemistry, Immuno-Inflammation, GlaxoSmithKline, Collegeville PA 19426, 
United States (2) Platform Technology and Science, GlaxoSmithKline, United States (3) 
Department of Medicinal Chemistry, Metabolic Pathways, GlaxoSmithKline, United 
States (4) Department of Medicinal Chemistry, GlaxoSmithKline, United States (5) 
Department of Medicinal Chemistry, Infectious Diseases, GlaxoSmithKline, United 
States (6) Department of Biology, GlaxoSmithKline, United States (7) Department of 
Biology, Metabolic Pathways, GlaxoSmithKline, United States (8) Department of 
Biology, Immuno-Inflammation, GlaxoSmithKline, United States  
The recruitment of monocytes/macrophages is a key process in the growth of 
atherosclerotic lesions and in the subsequent rupture of these plaques. CCR2 plays a 
key role in this recruitment and inhibiting this receptor should decrease the likelihood of 
atherosclerosis.   Our initial sulfonamide lead series was highly selective and potent in 
the primary assay but was significantly less active in plasma, which significantly 
diminished in vivo efficacy. In parallel, after reviewing the historical data from previous 
efforts, the team decided to reevaluate a dipiperidine series. These dipiperdines were 
initially terminated due to poor 7-TM selectivity and the belief that an activity plateau 
had been reached. However, in comparison to the sulfonamide series, the dipiperdines 
did show promising activity in the presence of plasma and were significantly more 
potent in vivo. Therefore, the team elected to diversify and pursue the dipiperdines and 
through a combination of both rational design and array synthesis in which 
breakthroughs were made that improved both selectivity and potency.  Recently, a 
compound was identified from the dipiperidine series with dramatically improved activity 
in the primary and human whole blood shape change assays and excellent 7-TM 
selectivity. This compound has excellent rat PK and p450 profiles and was recently 
selected as the first CCR2 candidate. The strategy employed in the identification of this 
compound and pertinent SAR will be discussed. 
MEDI 193 
Discovery of MK-6096: A novel dual orexin receptor antagonist for the treatment 
of insomnia 
Paul J. Coleman1, paul_coleman@merck.com; John D. Schreier1; Christopher D. Cox1; 
Michael J. Breslin1; David B. Whitman1; Georgia B. McGaughey2; Rodney A. Bednar3; 
Wei Lemaire3; Scott M. Doran4; Steve V. Fox4; Susan L. Garson4; Anthony L. Gotter4; C. 
Meacham Harrell4; Duane R. Reiss4; Tamara D. Cabalu5; Donghui Cui5; Thomayant 
Prueksaritanont5; Joanne Stevens4; Pamela L. Tannenbaum4; Richard G. Ball6; Joyce 
Stellabott7; George D. Hartman1; Christopher J. Winrow4; John J. Renger4. (1) 
Department of Medicinal Chemistry, Merck Research Laboratories, West Point PA 
19486, United States (2) Department of Chemistry Modeling and Informatics, Merck 
Research Laboratories, West Point PA 19486, United States (3) Department of In Vitro 
Sciences, Merck Research Laboratories, West Point PA 19486, United States (4) 
Neuroscience Research, Merck Research Laboratories, West Point PA 19486, United 
States (5) Department of Drug Metabolism and Pharmacokinetics, Merck Research 
Laboratories, West Point PA 19486, United States (6) Department of Pharmaceutical 
Research and Development, Merck Research Laboratories, Rahway NJ 07065, United 
States (7) Department of Pharmaceutical Research and Development, Merck Research 
Laboratories, West Point PA 19486, United States  
Orexin receptors are G-protein coupled receptors expressed within regions of the brain 
that govern the sleep-wake cycle through control of downstream pathways that involve 
histaminergic, dopaminergic, and cholinergic activity. Orexin receptors bind orexin A 
and B neuropeptides which are secreted by neurons projecting from the lateral 
hypothalamus. Genetic and pharmacological studies suggest orexin receptor 
antagonists could provide a novel therapy for treating insomnia and other disorders in 
which sleep/wake cycles are disrupted. The identification of potent orexin receptor 
antagonists is an active area of investigation and small molecule antagonists have 
entered late stage clinical development. We have recently disclosed the discovery of 
Suvorexant, a dual orexin receptor antagonist currently in Phase III studies.  We have 
identified MK-6096, currently in Phase II clinical studies, as a potent dual orexin 
receptor antagonist (DORA) with significant in vivo sleep promoting efficacy in animals 
and humans. The structure of MK-6096 was optimized with respect to potency, 
pharmacokinetic profile, and physicochemical properties. Further, the team utilized 
computational modeling as well as small molecule X-ray diffraction studies to rationalize 
and confirm the preferred conformation for DORA's including MK-6096. The 
development and optimization of lead compounds along with the profile of clinical 
candidate MK-6096 will be presented. 
MEDI 194 
Rationale, design, and evaluation of isoform selective Hsp90 inhibitors: Progress 
towards Grp94 selective inhibition 
Laura B. Peterson1, lbp@ku.edu; Adam S. Duerfeldt1; Jason C. Maynard2; David S. 
Moore3; Christopher V. Nicchitta2; Brian S. J. Blagg1. (1) Department of Medicinal 
Chemistry, The University of Kansas, Lawrence Kansas 66045, United States (2) 
Department of Cell Biology, Duke University Medical Center, Durham North Carolina 
27710, United States (3) Microscopy and Analytical Imaging Laboratory, The University 
of Kansas, Lawrence Kansas 66045, United States  
The 90 kDa heat shock proteins (Hsp90) are molecular chaperones that have rapidly 
evolved into promising therapeutic targets for the treatment of cancer. Recently, a new 
paradigm has emerged for Hsp90 inhibitors; the development of isoform selective 
inhibitors of Hsp90 that may avoid deleterious effects observed with current pan-Hsp90 
inhibitors in clinical trials. However, studies directed toward the inhibition of individual 
isoforms have not been reported. The development of Hsp90 inhibitors that target one 
Hsp90 isoform offers a practical approach towards enhancing selectivity while improving 
toxicity profiles. In addition, isoform selective compounds will aid in elucidation of client 
proteins that each isoform is responsible for chaperoning. The development of isoform 
selective inhibitors has been hindered by the lack of concrete biochemical assays to 
characterize Hsp90 inhibitors selectivity profiles. The design, approach, and initial 
investigation of assays to identify Hsp90 isoform selective inhibitors are described. 
MEDI 195 
Schweinfurthins: Development of their antiproliferative activity 
Joeseph J Topczewski1, joseph-topczewski@uiowa.edu; John A Beutler2; David F 
Wiemer1. (1) Department of Chemistry, University of Iowa, Iowa City Iowa 52242-1294, 
United States (2) Molecular Targets Development Program, National Cancer Institute - 
Frederick, Frederick Maryland 21702-1201, United States  
New chemotherapeutic agents are of greatest value when they attack a novel target 
because such activity can complement currently approved agents. The schweinfurthins 
are a family of potent natural products that appear to display a new mechanism of anti-
proliferative activity. Because the natural source has provided only limited quantities of 
the schweinfurthins, we have undertaken a chemical synthesis of these natural products 
and employed a divergent strategy to prepare assorted congeners. Presented herein is 
the first total synthesis of schweinfurthin A (1), the synthesis of several analogues, and 
their profiles of activity as anti-proliferative agents.   
  
MEDI 196 
Exploration of novel rearrangements of N-allyl ynamides 
Kyle DeKorver1, dekorvek@gmail.com; Richard P. Hsung2. (1) (2) University of 
Wisconsin - Madison, United States  
    
N-allyl ynamides have been found to undergo a novel Pd-catalyzed N-to-C allyl transfer 
through a Pd-π-allyl-ketenimine complex to form ketenimines in situ. Alternatively, a 
thermal 3-aza-Claisen rearrangement can furnish the same ketenimine intermediates, 
which followed by trapping with N and O-nucleophiles results in the de novo synthesis 
of a-allyl amidines, vinylogous amidines, and imidates. Without an external nucleophile 
present, an unexpected 1,3-sulfonyl shift can intercept the ketenimine intermediate, 
allowing access to quaternary nitriles. Similarly, a tandem aza-Claisen–[3,3]-
sigmatrophic rearrangement can be used to generate a,b-unsaturated mixed anhydrides 
with excellent control of the olefin geometry. 
MEDI 197 
Extrinsic recruitment of transcriptional coregulators by bifunctional nuclear 
receptor ligands 
Jonas W. Hojfeldt1, jonaswh@umich.edu; Aaron R. Van Dyke2; Osvaldo Cruz3; 
Yasuhiro Imaeda2; Jorge A. Iniguez-Lhuhi3; Anna K. Mapp4, 2. (1) (2) Department of 
Chemistry, University of Michigan, United States (3) Department of Pharmacology, 
University of Michigan Medical School, United States (4) Chemical Biology Doctoral 
Program, University of Michigan, United States  
Nuclear receptors (NR) are ligand-regulated transcription factors. They offer a means to 
directly affect the transcription of their target genes with small molecules, without 
simultaneous involvement of signaling cascades. This property underlies their success 
as drug targets. Transcriptional control is achieved through recruitment of transcriptional 
coregulators. The conformation of the receptor, which is modulated by ligand binding, 
determines which cofactors are recruited, and the effect is gene context dependent. 
Synthetic ligands are sought that can modulate receptors to yield desired expression 
patterns. Current strategies for ligand discovery are dependent on the intrinsically 
available receptor conformations, and we have thus developed a new strategy. We 
have shown that bifunctional molecules, made as conjugates of NR ligands to ligands of 
non-native transcription components, are able to recruit these targets to the NR and 
modulate transcription. This strategy holds promise to greatly expand the repertoire of 
the important class of NR targeting drugs 
MEDI 198 
Synthetic studies toward pladienolide B: A DNA splicing modulating antitumor 
agent 
David D. Anderson1, ddanders@purdue.edu; Khriesto Shurrush2; Arun Ghosh2. (1) (2) 
Purdue University, United States  
Recently, pladienolide B was isolated from an Okinawan strain of Streptomyces 
platensis and shown to possess an impressive antitumor activity against a range of drug 
resistant cancer cell lines. Subsequent biological studies have concluded its antitumor 
properties result from its unique ability to modulate DNA splicing activity resulting in the 
inhibition of cell growth. This presentation will showcase our recent efforts in developing 
a concise and efficient total synthesis of pladienolide B. Our convergent pathway utilizes 
a combination of readily available chiral synthons and asymmetric methodologies to 
synthesize pladienolide B with a high degree of stereoselectivity. In addition, our recent 
efforts to explore the molecule's key pharmacophoric features through the use of 
structural analogs will be briefly discussed. 
MEDI 199 
Synthesis of simplified discodermolide analogs 
Daniel M. Brody1, DMB93@pitt.edu; Amy L. Grote2; Wanli Pu2; Billy W. Day2, 3. (1) (2) 
Department of Chemistry, University of Pittsburgh, United States (3) Department of 
Pharmaceutical Sciences, University of Pittsburgh, United States  
Discodermolide (1) is a potent microtubule stabilizer, with actions more potent than 
paclitaxel. Pneumotoxicites hindered its development in the clinical setting, and it is also 
of low abundance in nature, and must be synthesized from basic starting materials. 
Many analogs of discodermolide have been prepared. Simplifications to both the 
carbamate/diene and delta-lactone end regions of the molecule have been presented, 
but very few modifications to the linker region have been reported. Here we describe a 
new set of analogs in which the middle portion of discodermolide has been replaced 
with a cis-C=C bond, using olefin metathesis as the major coupling step. The analogs 
incorporate a variety of lactone and diene fragments, further expanding the structure 
activity relationship for discodermolide, and easing the total synthesis for this class of 
agents.   
  
MEDI 200 
Identification of a novel negative allosteric site on human α4β2 and α3β4 nicotinic 
acetylcholine receptors 
Ryan Pavlovicz1, pavlovicz.7@osu.edu; Brandon Henderson2; Andrew Bonnell3; R. 
Thomas Boyd3; Dennis McKay2; Chenglong Li1. (1) Division of Medicinal Chemistry, 
College of Pharmacy, Ohio State University, United States (2) Division of 
Pharmacology, College of Pharmacy, Ohio State University, United States (3) 
Department of Neuroscience, Ohio State University, United States  
We determined the binding site of a class of nAChR negative allosteric modulators 
using computational methods, namely molecular dynamics and blind docking. 
Computationally-determined binding modes were validated by functional studies on 
mutant nAChRs. Based on the models, we hypothesized that T58K and F118V 
mutations on the β subunits would decrease the apparent affinity for the negative 
allosteric modulators compared to wild-type. Functional assays run on these mutant 
receptors yielded 7 and 10 fold decreases in efficacy for the T58K and F118V 
respectively, while leaving agonist activity unchanged. Calculated binding free energies 
to mutant homology models were found to be comparable to the functional data. The 
obstruction of a key loop's dynamics, similar to the mode of action of cobra toxin, is a 
hypothetical mode of antagonism and is supported by structural analysis and dynamics 
studies of models bound to these compounds. 
MEDI 201 
Chemistry at the chemistry-biology interface 
Dale L. Boger, boger@scripps.edu. Department of Chemistry & the Skaggs Institute for 
Chemical Biology, The Scripps Research Institute, United States  
Recent studies conducted at the chemistry-biology interface enlisting natural product 
leads (vancomycin, vinblastine), recently discovered endogenous signaling molecules 
(fatty acid amides) and structure-based drug design (FAAH inhibitors), and 
combinatorial chemistry targeting protein-protein and protein-DNA interactions will be 
detailed.  
MEDI 202 
Imaging tools to assess tissue selectivity 
Thomas Krucker, thomas.krucker@novartis.com. Global Imaging Group, Novartis 
Institutes for BioMedical Research, Cambridge Massachusetts 02139, United States  
Standard methods to determine tissue distribution combine radiolabeled compounds 
with whole body autoradiography or liquid scintillation counting of tissue homogenates. 
Because of the terminal nature of these methods they require large numbers of 
individual samples if multiple time points are required and are limited to preclinical use. 
To overcome such limitations, and observe dynamic whole body biodistribution in 
animals and in patients, a series of in vivo imaging modalities, labeling technologies, 
and reporter systems may offer attractive alternatives. This presentation will provide a 
practical overview of the different imaging technologies and strategies that can be used 
to assess tissue targeting. Examples will be used to illustrate how in vivo and in situ 
imaging can be combined to investigate whole body, organ, and cellular biodistribution. 
MEDI 203 
Intestinal selective CCK-1 receptor agonists for the treatment of obesity 
Kimberly O Cameron, kimberly.o.cameron@pfizer.com; Elena E Beretta; Yue Chen; 
Margaret Chu Moyer; Dilinie Fernando; Hua Gao; Jeffrey Kohrt; Sophie Lavergne; 
Angel Guzman-Perez; Christopher Hoth; Paul Da Silva Jardine; David A Perry; John R 
Hadcock; Denise Gautreau; Michael Makowski; Jana Polivkova; Lucy Rogers; Dennis O 
Scott; Andrew G Swick; Lucinda Thiede; Catherine E Trebino; Richard V Trilles; Julie 
Wilmowski; Yingxin Zhang; Janice E Chin; Richard Elliott; Amit Kalgutkar. Pfizer Global 
Research and Development, Groton CT 06340, United States  
A number of drug targets are expressed within the small intestine. The ability to design 
compounds for these targets that selectively partition into the intestinal wall relative to 
the systemic circulation should enable both efficacy and safety. The cholecystokinin-1 
receptor (CCK1R) is a potential target for the treatment of obesity and/or diabetes and 
is located primarily within the gastrointestinal tract. Studies suggest that activation of the 
CCK1R promotes a satiety effect via the vagal afferent neurons to the central nervous 
system. We recently disclosed the identification of a triazolobenzodiazepinone CCK1 
receptor agonist, CE-326597, that demonstrated robust food intake effects in rodents 
with low systemic exposure. Our data suggest that the efficacy observed is primarily 
driven by intestinal exposure. We will present our approach for identification of a backup 
compound to CE-326597 which offered improved gut to plasma ratios and lower 
systemic exposure relative to CE-326597. 
MEDI 204 
Tissue selective antibody-drug conjugates 
Gail D Lewis Phillips, gdl@gene.com. Department of Research Oncology, Genentech, 
Inc., South San Francisco CA 94080, United States  
Antibody-drug conjugates (ADCs) exploit the antigen-selectivity of antibodies to deliver 
cytotoxic agents specifically to antigen-expressing tumor cells. Although the concept of 
utilizing antibodies for targeting cytotoxic drugs to tumors has existed for several 
decades, successes in clinical development have occurred only in the last several years 
due, in part, to advancements in linker technology and design of highly potent cytotoxic 
agents.  For most solid tumor antigens, differential expression between tumor and 
normal tissue is a key component for achieving both efficacy and safety. In contrast, 
antigen expression in hematologic tumors is often no different than expression in normal 
hematopoietic cells. However, efficacy can be achieved, with an acceptable safety 
profile, due to turnover and renewal of the normal hematoipetic cell population.  
Tolerability studies in rodents and cynomolgus monkeys provide insights into antigen-
independent and –dependent toxicities. Efficacy and safety results for ADCs targeted to 
solid and hematologic tumors will be discussed. 
MEDI 205 
Designing for liver selective drug distribution: Hepatoselective glucokinase 
activators as a case study 
Angel Guzman-Perez, angel.guzman-perez@pfizer.com; Jeffrey A Pfefferkorn; John 
Litchfield; Robert Aiello; Judith L Treadway; Martha L Minich; Kevin J Filipski; 
Christopher S Jones; Meihua Tu; Gary E Aspnes; Hud Risley; Stephen W Wright; Jian-
Cheng Li; Jianwei Bian; John Benbow; Robert L Dow; Mary T Didiuk; Christian 
Perreault; Francis Bourbonais; David R Derksen; Margit MacDougall; Over Cabrera; 
James Landro; Karen Atkinson; Lili Yao; Rachel E Kosa; Nahor Haddish-Berhane; Bo 
Feng; David B Diugnan; Shenping Liu; Mark J Ammirati; John D Knafels. Pfizer Global 
Research and Development, Groton CT 06340, United States  
The ability to target compounds to specific tissues offers the possibility of obtaining 
drugs with lower doses and improved safety. Targeting compounds to the liver is of 
particular interest in the metabolic disease area due to the key role played by this organ 
in glucose and lipid metabolism. For example, activation of glucokinase, the enzyme 
responsible for the conversion of glucose to glucose 6-phosphate, in the liver offers the 
potential for treating diabetes through increased hepatic glucose uptake and 
normalization of the elevated hepatic glucose output in these patients. Activation of 
glucokinase in the pancreas results in insulin secretion, which if excessive, increases 
the risk of hypoglycemia. We have identified a promising oral liver selective glucokinase 
activator. Herein we describe the medicinal chemistry strategy and specific design 
considerations used to target organic anion transporting polypeptides to achieve good 
liver selectivity with overall favorable ADME and PK properties. 
MEDI 206 
Selective androgen receptor modulators (SARMs): The discovery and 
development of tissue selective anabolic therapy 
James T Dalton, jdalton@gtxinc.com; Duane D Miller; Ramesh Narayanan; Casey E 
Bohl; Domingo Rodriguez; K Gary Barnette; Mitchell S Steiner. GTx, Inc., Memphis TN 
38163, United States  
The therapeutic achievements of the selective estrogen receptor modulators have 
provoked an ever-expanding search for agents that modulate the actions of other 
nuclear hormone receptors. The goal of these selective nuclear receptor modulators is 
to maximize the beneficial therapeutic effects and minimize the unwanted clinical side 
effects of the natural hormone. Androgens are essential for muscle mass, bone mass, 
body composition,sebum production, hair growth, and lipid profiles in males and 
females, and prostate size in males. SARMs provide a promising alternative to existing 
anabolic therapies with advantages including receptor specificity, oral bioavailability, 
tissue selectivity, and toxicity profile. We used a battery of in vitro and in vivo systems to 
identify and develop a novel class of aryl propionamide SARMs that demonstrate 
potent, tissue selective pharmacologic activity. In vitro studies showed that SARMs bind 
with high affinity and specificity to AR, occupy a unique binding pocket, and elicit AR 
conformations that modulate distinct genomic and non-genomic signalling networks. 
Animal studies, a pivotal component of our screening paradigm, showed that they 
enhance muscle and bone mass and strength, while decreasing prostate size and 
exhibiting a wide safety margin. A Phase II clinical trial randomized 159 subjects 
diagnosed with either NSCLC, colorectal cancer, non-Hodgkin's lymphoma, chronic 
lymphocytic leukemia or breast cancer to receive GTx-024 or placebo daily for 16 
weeks. GTx-024 exhibited tissue selectivity with beneficial effects on lean body mass 
(muscle) and physical function with no changes in measurements for serum PSA 
(prostate), sebum production (skin and hair), or serum LH (pituitary) compared to 
placebo, supporting its advancement to Phase III clinical trials. Combined, the 
preclinical and clinical data for the aryl propionamide SARMs provide compelling 
evidence of their tissue selectivity and therapeutic promise for the prevention and 
treatment of muscle wasting. 
MEDI 207 
Diverse modes of efficacy and stimulus bias of allosteric modulators of GPCRs 
P. Jeffrey Conn, jeff.conn@vanderbilt.edu. Department of Pharmacology, Vanderbilt 
Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville TN, United 
States  
Allosteric modulators of GPCRs provide a novel approach to modulation of specific 
GPCR subtypes. Negative allosteric modulators (NAMs) inhibit whereas positive 
allosteric modulators (PAMs) potentiate responses to endogenous agonists. Allosteric 
modulators offer high selectivity for targeted receptors and provide an exciting new 
approach to development of novel therapeutic agents. Allosteric modulators of the 
metabotropic glutamate receptor mGluR5 provide an excellent example of the multiple 
modes of efficacy and diverse actions that can be achieved with allosteric modulators of 
GPCRs. Both PAMs and NAMs for mGluR5 have been advanced as drug candidates 
and have robust effects in animal models that predict efficacy in treatment of CNS 
disorders. The diversity of allosteric modulators now available is allowing us to develop 
fundamental new insights into the multiple mechanisms by which these compounds 
regulate GPCR function and are providing new insights into the functional impact of 
different modes of efficacy of allosteric modulators. 
MEDI 208 
Exploiting intracellular domains to create peptide GPCR modulators 
Thomas J McMurry, tmcmurry@anchortx.com. Research and Development, Anchor 
Therapeutics, Cambridge Massachusetts 02142, United States  
Pepducins comprise a short peptide derived from the sequence of a G-protein coupled 
receptor (GPCR) intracellular loop linked to a hydrophobic membrane anchor. This 
breakthrough technology can be readily applied to orphan receptors as well as validated 
targets and results in compounds that modulate GPCR activity via a unique allosteric 
mechanism. The talk will focus on the discovery of CXCR4-targeted pepducin agonists, 
their structure activity relationships and DMPK characteristics. 
MEDI 209 
Lead optimization of a selective M1 muscarinic receptor positive allosteric 
modulator 
Scott D Kuduk1, scott_d_kuduk@merck.com; Ronald K Chang1; Christina N Di Marco1; 
William J Ray2; Lei Ma2; Marion Wittmann2; Matthew A Seager2; Kenneth A Koeplinger3; 
Charles D Thompson3; George D Hartman1; Mark T Bilodeau1. (1) Department of 
Medicinal Chemistry, Merck & Co., West Point PA 19438, United States (2) Department 
of Alzheimer's Research, Merck & Co., West Point PA 19438, United States (3) 
Department of Drug Metabolism, Merck & Co., West Point PA 19438, United States  
Identification of new mechanisms to treat the neurodegenerative effects of Alzheimer's 
disease (AD) represents a major unmet medical need. One approach to ameliorate the 
cognitive decline in AD has been to target the neurons of the basal forebrain cholinergic 
system via activation of the M1 muscarinic receptor. Non-selective M1 muscarinic 
agonists have previously shown positive cognitive effects on in AD patients, but were 
limited due to cholinergic adverse events thought to be mediated by activation of the M2 
to M5 sub-types. One strategy to confer selectivity for M1 is to identify a positive 
allosteric modulator, which would target an allosteric site on the M1 receptor rather than 
the highly conserved orthosteric acetylcholine binding site. HTS lead quinolone 
carboxylic acid BQCA evolved into a highly selective Quinolizidinone carboxylic acid M1 
positive allosteric modulator with good pharmacokinetic and in vivo properties. This 
presentation will focus on the lessons experienced during allosteric modulator lead 
optimization toward identification leading to a compound with enhanced CNS exposure 
and improved efficacy in a rodent in vivo model of cognition for further pre-clinical 
evaluation. 
MEDI 210 
Allosteric modulators of the A3 adenosine receptor 
Kenneth A Jacobson1, kajacobs@helix.nih.gov; Adriaan P IJzerman2; John A 
Auchampach3; Zhan-Guo Gao1. (1) Laboratory of Bioorganic Chemistry, NIDDK, 
National Institutes of Health, Bethesda MD 20892-0810, United States (2) 
Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden 2300RA, The 
Netherlands (3) Department of Pharmacology, Medical College of Wisconsin, 
Milwaukee WI 53226, United States  
A3 adenosine receptor (AR) agonists are of interest for treatment of ischemia, 
inflammation, and cancer. Screening of known antagonists identified positive allosteric 
modulators (PAMs) that enhance agonism of endogenous adenosine and inosine. A 3-
(2-pyridinyl)isoquinoline (VUF5455) has distinct SAR in allosteric and orthosteric 
(presumed from the competitive displacement of orthosteric radioligands) binding to 
A3AR. Docking model of VUF5455 in agonist-occupied A3AR proposed its binding near 
the extracellular loops. Allosteric, but not orthosteric binding of imidazoquinolinamines 
required N274 in TM7. N-(3,4- Dichlorophenyl)-2-cyclohexyl-1H-imidazo[4,5-c]quinolin-
4-amine (LUF6000) increased agonist efficacy (cAMP inhibition and agonist-induced 
GTPγS binding) without affecting agonist potency. LUF6000 converted a potent 
nucleoside-derived A3 neutral antagonist MRS542, but not diverse heterocyclic A3 
antagonists, into full agonist. Scission of the imidazole ring led to 2,4-disubstituted 
quinoline PAMs. Species dependence of LUF6000 indicated robust A3 PAM action in 
human and dog but not rat, mouse, and rabbit, and cardioprotective action is being 
explored. 
MEDI 211 
Lu AF21934: A brain-penetrant mGlu4 positive allosteric modulator tool 
compound 
Dario Doller, dado@lundbeck.com. Chemical & Pharmacokinetic Sciences, Lundbeck 
Research USA, Paramus NJ 07652, United States  
Basal ganglia (BG) circuitry understanding and the unmet medical need in the treatment 
of motor disorders in Parkinson's disease (PD) has led many groups to the investigation 
of glutamate receptor modulation. A decade of research has provided strong support for 
the potential impact of mGlu4 receptor potentiation in restoring a balance to BG circuitry 
in PD.   We have implemented a strong coalition with academic and private 
collaborators, and explored the pharmacology associated with potentiation of the mGlu4 
receptor via a novel biochemical mechanism (positive allosteric modulation), utilizing a 
brain-penetrant tool compound, Lu AF21934.  This presentation will highlight aspects of 
the medicinal chemistry, mechanistic and behavioral pharmacology of our efforts, as 
well as exemplify the potential of open collaboration between the pharmaceutical 
industry and academic and private centers of expertise. 
MEDI 212 
Positive allosteric modulation of the mGluR5 receptor: SAR, SPR and in vivo 
activity of ADX47273 derivatives 
Jean-Philippe Rocher1, jean-philippe.rocher@addexpharma.com; Giovanni Palombi2; 
Stefania Gagliardi2; Béatrice Bonnet1; Emmanuel Le Poul1; Anne-Sophie Bessis1; Sonia 
Poli1; Mark Epping-Jordan1; Bernard Lüdwig1; Robert Lütjens1; Vincent Mutel1. (1) 
Addex Pharmaceuticals S.A., Plan-les-Ouates Geneva 1228, Switzerland (2) Nikem 
Research S.r.l., Baranzate Milano 20021, Italy  
Allosteric modulators of mGluR1-8 have been shown to offer a valid strategy to develop 
non amino-acid like therapeutics that can be administered orally and that readily cross 
the blood-brain barrier. In addition, positive allosteric modulators (PAMs) are unlikely to 
induce a rapid desensitization such as the currently available agonists.  mGluR5 
receptors are located mainly on post-synaptic elements in the brain (cortex, thalamus, 
hippocampus and cerebellum), from where they regulate the activity of NMDA & AMPA, 
as well as the excitability of the post-synaptic neurons. mGluR5 PAMs have emerged as 
a novel class of compounds for the treatment of neuropsychiatric disorders.  The aryl-
oxadiazole ADX47273 has been the topic of intense interest for the pharmacological 
evaluation of the mGluR5 PAM approach; this compound demonstrated promising 
antipsychotic activity in preclinical rodent models for positive symptoms of 
schizophrenia and it was also active in cognition models. ADX47273 has opened an 
avenue to a novel class of drug-like molecules in this field. We will present the 
multiparametric lead optimization program which led to the identification of several 
chemical series of highly selective mGluR5 receptor PAMs. Compared to ADX47273 
which suffered of a poor bioavailability; the new molecules are systematically active in 
rodent behavioral models. 
MEDI 213 
Evolving ecosystem of pharmaceutical research and development 
Ralph E Christoffersen, RChris@Morgenthaler.com. Partner and Head, Life Sciences 
Team, Morgenthaler Ventures, Boulder CO 80303, United States  
Over several decades, the ecosystem that feeds R&D leading to new biotechnology and 
pharmaceutical advances has changed tremendously. During this time, the cost of 
developing new biomedical products has grown nearly ten-fold while productivity 
dropped by a factor of two. Fortunately, some government incentives enlivened 
academic and nonprofit discovery efforts, and venture capital and philanthropy began to 
play major roles in early stage and then later stage product development. Today, a 
powerful matrix of innovation involving venture capital, governmental labs, private 
philanthropy, pharmaceutical and medical device companies is evident throughout this 
ecosystem, and efforts are underway to develop translational interfaces to help address 
many challenges – financial, regulatory, otherwise – in moving ideas through the 
hurdles to ultimately reach the market. This talk will examine the current status of these 
efforts from the perspective of someone who has experience in each of the sectors 
(academia, large pharma, biotech and venture capital investing). 
MEDI 214 
Shortening the pipeline between academia and the private sector 
Regis B. Kelly, Regis.Kelly@qb3.org; Douglas Crawford. California Institute for 
Quantitative Biosciences (QB3), United States  
Although academia is funded by NIH “to enhance the Nation's economic well being” 
(NIH Mission Statement) the enhancement step is usually not ideal. Recently 
universities have created institutions that interface between their scientists and 
technology transfer offices with the goal of speeding up the commercialization of 
academic research. These interface institutions provide mentorship, pre-commercial 
funding or incubator space, all of which can de-risk research while still in an academic 
setting, making it more attractive for licensing or spin-offs. Key challenges for such 
institutions are to know what industry needs, which innovations could be disruptive and 
what is attractive to angel or venture investors. Surprisingly, big pharma seems to be as 
interested in academic spin-outs as in research within academia, thus leading to the 
idea of a bioinnovation ecosystem. QB3 has partnered with Deloitte to evaluate the 
advantages and challenges of such an ecosystem – results of their analysis will be 
presented. 
MEDI 215 
Drug discovery successes in nonprofits and biotech/pharma collaborations 
P. Jeffrey Conn, jeff.conn@Vanderbilt.edu. Department of Pharmacology, Vanderbilt 
Center for Neuroscience Drug Discovery, United States  
Scientists in academic settings have made tremendous advances in understanding 
human disease but often fail to make critical links that allow this information to be useful 
in industry settings. Likewise, fiscal pressures make it increasingly difficult for 
companies to invest in basic research needed to translate these discoveries into 
marketable products. The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) 
invests in early stage drug discovery with a goal of de-risking investment in innovative 
approaches to treatment of serious brain disorders in industry settings. Approximately 
100 VCNDD scientists work in a focused team fashion to advance novel target 
validation, lead discovery, and lead optimization for generation of quality clinical 
candidates. These efforts are now generating a steady pipeline of drug candidates and 
represent multiple approaches to partnering with large pharmaceutical companies, small 
companies, foundations, and NIH in an effort to help develop new sustainable models 
for early stage drug discovery. 
MEDI 216 
Academic approaches to address drug discovery challenges: The Moulder Center 
for Drug Discovery Research at Temple University 
Magid Abou-Gharbia, magid.abougharbia@temple.edu. The Moulder Center for Drug 
Discovery Research at Temple University, United States  
The pharmaceutical industry is currently facing enormous challenges, such as reduced 
efficiencies, declining innovation and the industry's perceived tarnished image. There is 
a clear need for change in the paradigms designed to address these challenges. While 
Pharma have embarked on a range of initiatives, other sectors have also responded. 
The NIH recently announced a new, internally-funded drug discovery initiative. Several 
academic drug discovery centers have also recently been established to facilitate the 
transition of innovative academic ideas and breakthroughs into attractive drug discovery 
opportunities.  The Moulder Center, a multidisciplinary research hub and integrated drug 
discovery unit, was recently founded at Temple University with this very mission in 
mind. The presentation will highlight current challenges facing the pharmaceutical 
industry and the Moulder Center's capabilities and approaches to providing academic 
and biotech researchers with a drug discovery perspective to their biomedical research. 
Results from a Stimulus Challenge Grant-funded project will be highlighted. 
MEDI 217 
Drug discovery and development at Southern Research Institute 
John A. Secrist III, secrist@southernresearch.org. Southern Research Institute, United 
States  
Southern Research Institute has been involved in the discovery of new drugs, mainly for 
cancer, for over 50 years. As a not-for-profit organization with no endowment, we have 
relied on external sources of support for our existence, a fact that has made our drug 
discovery efforts a significant challenge. Financial support for our core businesses has 
been obtained competitively from the federal government, as well as from commercial 
organizations. Additionally, our internal drug discovery efforts have been advanced 
through reinvestment of our own funds (from IP revenues on recently approved drugs). 
Clearly, challenges have included maintaining state of the art equipment and facilities, 
as well as recruiting scientists with the talents needed to carry out effective discovery 
research. This presentation will provide information about our history, operational 
challenges and how we met them, and drug discovery accomplishments over the years 
as well as present our current activities. 
MEDI 218 
Cancer stem cells: Concepts, definitions and clinical relevance 
William Matsui, matsuwi@jhmi.edu. Division of Hematologic Malignancies, The Sidney 
Kimmel Comprehensive Canc. Ctr at John Hopkins, Baltimore MD 21287, United States  
Cancer stem cells (CSCs) have been identified in an ever-increasing number of human 
malignancies. Although initial studies primarily focused on the enhanced tumorigenicity 
and self-renewal potential of CSCs, emerging data have demonstrated that they are 
also relatively drug resistant and highly invasive and migratory. Thus, CSCs may play a 
broad role in clinical oncology that encompasses disease initiation, relapse, and 
progression. Despite these findings, major challenges remain including demonstrating 
that CSCs are clinically relevant, developing potential targeting strategies, and 
identifying the optimal clinical settings to evaluate efficacy. These translational barriers 
will be discussed in greater depth 
MEDI 219 
Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1a signaling 
network: An initial study in GSC11 glioblastoma stem cells 
Carol L. Nilsson, Carol.Nilsson@pfizer.com. Dept. of Structural and Computational 
Biology, Pfizer Global Research and Development, San Diego CA 92121, United States  
GSC11 glioma stem cell responses to perturbations in the IL-6/STAT3/HIF1α loop were 
explored by treatment with a JAK2/STAT3 phosphorylation inhibitor, IL-6 and hypoxia. 
Over 3,000 proteins were identified in the study, which employed phosphoprotein and 
phosphopeptide enrichment, chemical tagging, and tandem mass spectrometry. Multiple 
comparisons between the sample conditions yielded expected changes and novel 
insights into the contribution of each factor to the cancer stem cell response. Taken 
together with a glycolipidomic/transcriptomic study of GSC11, we report the most 
complete systems biology study of cancer stem cell differentiation to date. Enhanced 
understanding may help to discover novel therapeutic approaches that target cancer 
stem cells 
MEDI 220 
Glioma-associated cancer-initiating cells induce immunosuppression 
Amy B. Heimberger1, aheimber@mdanderson.org; Ling-Yuan Kong1; Tiffany 
Doucette1; Jun Wei1; Yongtao Wang1; Ganesh Rao1; Greg Fuller1; Adam Wu2; 
Waldemar Priebe1. (1) Departments of Neurosurgery, Neuropathology and 
Experimental Therapeutics, Univ. of Texas M. D. Anderson Cancer Center, Houston TX 
77030, United States (2) Division of Neurosurgery, Royal University Hospital, United 
States  
Glioblastoma multiforme (GBM) has a dismal survival and cancer-initiating cells have 
been shown to recapitulate the characteristic features of GBM including mediating 
chemotherapy and radiation resistance. We isolated cancer-initiating cells from GBM 
patients and found that they inhibited T cell proliferation and activation, induced 
regulatory T cells, triggered T cell apoptosis and recruit and polarize the MΦs/microglia 
to become immunosuppressive (M2).The immunosuppressive properties were reversed 
when STAT3 is blocked. In mice that co-express PDGF-B + Bcl-2 or STAT3 under the 
control of the glioneuronal-specific Nestin promoter, the high-grade gliomas that 
develop had a marked intratumoral influx of macrophages influenced by tumor STAT3 
expression and were a negative prognosticator. In mice with gliomas treated with the 
STAT3 blockade agent, WP1066, there was a marked increase in survival time. 
Blockade of the STAT3 pathway with agents such as WP1066 would be a compelling 
approach for treating malignant gliomas 
MEDI 221 
Wnt signaling in stem cells and cancer stem cells: A tale of two coactivators 
Michael Kahn, kahnm@usc.edu. Dept. of Biochemistry, University of Southern 
California, Los Angeles CA 90033, United States  
Wnt signaling pathways play divergent roles during development, normal homeostasis 
and disease. Until recently, a rationale for the dichotomous behavior of Wnt/beta-
catenin signaling in controlling both proliferation and differentiation has been unclear. 
We have developed a model to explain the divergent activities of Wnt/beta-catenin 
signaling. Our model highlights the distinct and non-redundant roles of the coactivators 
CBP and p300 in the Wnt/beta-catenin signaling cascade. The critical feature of the 
model is that CBP/catenin-mediated transcription is critical for proliferation and stem 
cell/progenitor cell maintenance; whereas p300/catenin mediated transcription leads to 
the initiation of a differentiation program. Both basic research on differential coactivator 
usage in stem cell (both normal and cancer) populations and the 'bench to bedside” 
translation of this work into the development of PRI-724, the first in man CBP/catenin 
antagonist will be discussed. 
MEDI 222 
Rationale for Smo inhibition as therapeutic intervention in minimal residual 
disease 
Margaret Read, margaret.read@infi.com. Product Development, Infinity 
Pharmaceuticals, Cambridge MA 02139, United States  
Although many cancers respond to initial therapy at rates well above 50%, relapse rates 
are very high, resulting in poor long term survival. One theory for the high rate of 
relapse is the persistence of malignant cells at minimally detectable levels, known as 
minimal residual disease (MRD). IPI-926 is a small molecule that antagonizes the Hh 
pathway by inhibiting Smoothened (Smo) and is currently being evaluated in clinical 
trials. In preclinical models of MRD, administration of IPI-926 significantly delayed time 
to tumor relapse. Overall, these findings suggest that Hh pathway-dependent 
“progenitor cells” may contribute to the high relapse rates seen in patients following 
standard therapies. The rationale for evaluation of Smo inhibitors in the setting of MRD 
following administration of chemo or targeted therapies will be provided 
MEDI 223 
Catalyzing opportunities in translational research 
Francis Collins, collinsf@mail.nih.gov. National Institutes of Health, United States  
NIH has a strong tradition of fueling the development of new approaches for treating 
disease. According to a recent New England Journal of Medicine study, more than 20% 
of innovative drugs approved by the FDA from 1990-2007 were discovered by NIH-
supported researchers. Yet, many conditions, especially rare and neglected diseases, 
still lack effective therapeutics. One problem is that the development pipeline currently 
contains many bottlenecks that reduce efficiency and increase costs. To advance the 
discipline of translational science, NIH has announced plans to create a new center to 
study the various steps of drug development, identify constriction points that may be 
amenable to re-engineering, and experiment with innovative methods to streamline the 
process. In this lecture, the NIH Director will discuss the rationale for establishing the 
National Center for Advancing Translational Sciences, and describe how its activities 
will benefit a wide range of stakeholders. 
MEDI 224 
Acyclonucleosides to Ziagen: A journey 
Robert Vince, vince001@umn.edu. Center for Drug Design, Academic Health Center 
and Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, 
United States  
In 1971, the first acyclonucleoside, acycloadenosine, was reported from our lab in which 
the sugar of a nucleoside was replaced with a 2-hydroxyethoxymethyl moiety. Our 
acycloadenosine was subsequently submitted for testing at Burroughs Wellcome 
Company by my Ph.D. advisor, Howard J. Schaeffer, and was found to have significant 
anti-herpes activity. The adenine was then exchanged with guanine and the subsequent 
acycloguanosine was developed into the anti-herpes drug, Acyclovir.   
   
In 1987, our first carbocyclic 2',3'-dideoxy-2',3'-didehydro 2-amino-6-substituted purine 
nucleoside analogs, called “carbovirs”, were submitted to NIH and were the most active 
cpds found in their new HIV assay after AZT. After a long process. abacavir emerged as 
the candidate for development. Abacavir was approved by the FDA on December 18, 
1998 under the trade name ZiagenR, and as a triple combination with zidovudine and 
lamivudine (TrizivirR), and as a double combination with lamivudine (KivexaR/EpzicomR) 
by GSK.  
   
MEDI 225 
SAHA: The past, present, and future of its special mode of action 
Ronald Breslow, rb33@columbia.edu. Department of Chemistry, Columbia University, 
United States  
Some years ago Dr. Paul Marks and the Breslow lab entered into a collaboration that 
ultimately led to the invention of SAHA, an approved anticancer drug that is now 
marketed by Merck under the name Zolinza. It had a completely new mode of action, 
and was the first drug approved in this class, although now many companies and 
medical scientists are pursuing related compounds with the new target. In this lecture I 
will briefly review the history of its invention, and recent progress in derivatives of SAHA 
with important selectivities, including work now underway in the current Breslow/Marks 
collaboration. 
MEDI 226 
Discovery of the antitumor drug ALIMTATM 
Edward C. Taylor, etaylor@princeton.edu. Department of Chemistry, Princeton 
University, United States  
Cofactors derived from folic acid play key roles in a host of diverse metabolic reactions 
essential for the formation of DNA, RNA, and some amino acids and proteins. Our initial 
search for inhibitors of folate-dependent enzymes first led to the discovery that (6R)-
5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) blocked de novo purine 
biosynthesis and exhibited excellent therapeutic activity against a variety of solid 
tumors. Subsequent investigations, pursued through a remarkable collaboration 
between Princeton University and Eli Lilly & Co., culminated in the discovery of a new 
oncolytic agent, Alimta™ (pemetrexed disodium). This lecture will describe how Alimta 
was discovered, its current clinical status, and our understanding of its unique mode of 
action. 
This image cannot currently be displayed.
MEDI 227 
Bridging the gap between basic science and the clinic: An emerging role for drug 
discovery in an academic medical center campus 
Milton Brown, mb544@georgetown.edu. Georgetown University Medical Center, 
United States  
The gap between academic basic science and clinical translation continues to stall and 
challenge U.S. medical centers. However, without strong synthetic medicinal chemistry 
support, academic medical centers remain inept at advancing drug discovery 
opportunities. We will address the impact, obstacles and challenges of implanting 
medicinal chemistry support and building a successful academic drug discovery and 
development program on an academic medical center campus. We will identify creative 
ways of engaging academic medical centers towards developing productive 
partnerships and unlocking leveraged resources. The model includes the opportunity for 
early vetting of risky projects, strategies to cultivate and harnessing innovative and 
disruptive science, early development of an industrial champion with implantation of an 
industrial scientist in academic residence and opportunities for developing innovative 
proof of concept studies. Discussion will be provided on the impact of embedding drug 
discovery into an academic medical center to support translational research and to 
activate productive academic pharmaceutical partnerships towards developing new and 
impactful medicines. 
MEDI 228 
Metabolomic and network-flux approaches to evaluate and identify high-impact 
targets in cancer 
Edward M. Driggers, edward.driggers@agios.com; Kevin M. Marks; Abhishek Jha; 
Shalini Sethumadhavan; Marie C. Keenan; Collin Hill; Hin-Koon Woo; Andrew N. Tyler. 
Agio Pharmaceuticals Inc., United States  
Metabolic function is an output of not only metabolite levels, but also (and perhaps 
principally) pathway flux. Consequently, methods to evaluate and compare network-
level flux patterns have inherent value in interrogating the metabolic state of cells. We 
have developed a metabolomic analysis platform that a) enables the generation of 
multiple metabolic networks for modeling, b) enables characterization of flux in those 
networks through kinetic flux analysis of time-course data from isotopically labeled 
metabolite pools via LCMS, and c) enables sensitivity analysis of the flux models to 
network topology. We will present the capabilities of this approach in the context of 
examining cell lines that carry metabolic alterations that result in the production of 
modified metabolomics signatures and/or flux patterns. These alterations include 
somatic mutations in enzymes, or amplifications of enzyme encoding genomic regions 
that alter expression levels, both of which can be tightly associated with specific tumor 
types (eg. IDH-2 mutations linked strongly to acute myelogenous leukemeia (AML)). 
MEDI 229 
Cancer metabolism, HIF-1, and novel anticancer therapies 
Gregg L. Semenza, gsemenza@jhmi.edu. The Johns Hopkins University School of 
Medicine, Institute for Cell Engineering, United States  
Increased glucose uptake and metabolism is a universal characteristic of advanced 
solid cancers. There are two well-established mechanisms underlying the 
reprogramming of tumor metabolism. First, intratumoral hypoxia induces the activity of 
the transcriptional activator hypoxia-inducible factor 1 (HIF-1) by inhibiting the O2-
dependent prolyl and asparaginyl hydroxylases that inhibit HIF-1á stability and 
transactivation, respectively. Second, genetic alterations increase the activity of HIF-1, 
MYC, and other transcription factors that increase the expression of glucose 
transporters (GLUT1, GLUT3), glycolytic enzymes (ALDOA, ENO1, HK2, LDHA, 
PKM2), pH regulators (CAR9, NHE1, MCT4), and proteins that inhibit mitochondrial 
metabolism (BNIP3, PDK1). Metabolites, such as the glycolytic end-product lactate, 
also induce HIF-1 activity, thereby providing a signal to further increase glycolytic 
metabolism. We have identified a novel feed-forward mechanism by which glycolytic 
enzyme expression leads to increased HIF-1 transcriptional activity. This pathway may 
be designed to increase HIF-1 activity under non-hypoxic conditions and may be of 
importance in cancers where genetic alterations increase HIF-1á expression in an O2-
independent manner. We have also demonstrated that daily administration of digoxin 
(and other cardiac glycosides), acriflavine, or low-dose doxorubicin (and other 
anthracyclines) blocks tumor growth and inhibits HIF-1 activity by blocking HIF-1á 
synthesis, HIF-1á:HIF-1b dimerization, and HIF-1 DNA binding, respectively. 
MEDI 230 
Identification of lactate dehydrogenase A inhibitors using fragment-based lead 
generation 
Richard A. Ward, richard.a.ward@astrazeneca.com; Jon Winter; Chris De Savi; Ryan 
Greenwood; Stuart Pearson; Alice Hooper; Kin Tam; Alison Hunter; Clare Lane; Julie 
Tucker; Clare Brassington; Alessandro Caputo; Martin Vogtherr; Martin Watson; Geoff 
Holdgate; Gareth Davies; Jonathan Tart; Jonathan Wingfield; Louise Goodwin; Nicky 
Whalley; Susan Critchlow; Kevin Hudson. AstraZeneca, United Kingdom  
Lactate Dehydrogenase A (LDHA) catalyses the conversion of pyrvuate to lactate, 
utilising NADH as a co-factor. It has been identified as an important target in the area of 
cancer metabolism. We shall present our progress using Fragment-Based Lead 
Generation, assisted by x-ray crystallography to develop small molecule LDHA 
inhibitors. Fragment hits were identified by NMR screening and optimised into lead 
compounds with nano-molar binding affinities measured by Biacore, with binding modes 
elucidated by x-ray structure. Finally, we shall summarise their modification into cellular 
active compounds for target validation work. 
MEDI 231 
Mapping dysregulated metabolic pathways in cancer using activity-based 
proteomics 
Daniel K Nomura, DNomura@scripps.edu; Benjamin F Cravatt. Department of 
Chemical Physiology, The Scripps Research Institute, La Jolla CA 92037, United States  
Tumor cells display progressive changes in metabolism that correlate with malignancy, 
including development of a lipogenic phenotype. How stored fats are liberated and 
remodeled to support cancer pathogenesis, however, remains unknown. Here, we show 
that the enzyme monoacylglycerol lipase (MAGL) is highly expressed in aggressive 
human cancer cells and primary tumors, where it regulates a fatty acid network enriched 
in oncogenic signaling lipids that promotes migration, invasion, survival, and in vivo 
tumor growth. Overexpression of MAGL in non-aggressive cancer cells recapitulates 
this fatty acid network and increases their pathogenicity -- phenotypes that are reversed 
by an MAGL inhibitor. Interestingly, impairments in MAGL-dependent tumor growth are 
rescued by a high-fat diet, indicating that exogenous sources of fatty acids can 
contribute to malignancy in cancers lacking MAGL activity. Together, these findings 
reveal how cancer cells can co-opt a lipolytic enzyme to translate their lipogenic state 
into an array of pro-tumorigenic signals. We also show that MAGL expression and the 
expression of several other metabolic enzymes correlate with EMT and cancer stem cell 
markers across a broad panel of human cancer cell lines. These data point to a set of 
metabolic enzymes and pathways, such as the MAGL-endocannabinoid/fatty acid 
network, that may create key biochemical changes in cancer cells that support their 
progression to a high-malignancy state. Disrupting these pathways with small-molecule 
inhibitors, as we show with MAGL and its cognate inhibitor JZL184 in this study, could 
impair tumor cell pathogenicity and offer novel ways to treat the most aggressive forms 
of cancer. 
MEDI 232 
Modulation of pyruvate kinase activity and its role in cell metabolism 
Matthew G. Vander Heiden, mvh@mit.edu. Koch Institute for Integrative Cancer 
Research at MIT and the Dana Farber Cancer Institute, United States  
Genetic driver events in cancer activate signaling pathways that alter cell metabolism, 
and clinical evidence has linked metabolism with cancer outcomes. Together, this has 
raised interest in targeting metabolic enzymes for cancer therapy. The best strategy to 
target cancer metabolism, however, remains unclear. Cancer cells exhibit altered 
metabolism to efficiently incorporate nutrients into biomass to support proliferation. The 
M2 isoform of pyruvate kinase (PK-M2) promotes anabolic metabolism and is selected 
for optimal tumor growth in vivo. Paradoxically, the ability of PK-M2 to promote anabolic 
metabolism is associated with decreased pyruvate kinase enzyme activity, and 
genetically engineered mouse cancer models support the notion that loss of pyruvate 
kinase activity favors tumor growth. Nevertheless, the ability to reactivate pyruvate 
kinase may also be important for some tumor cells. These findings suggest that 
pyruvate kinase activity modulation may be a strategy to target cancer. Results from 
studies using small molecule activators of PK-M2 to restore the high pyruvate kinase 
activity found in most normal tissues will be presented. How these and associated 
studies inform efforts to target glucose metabolism for cancer therapy will also be 
discussed. 
MEDI 233 
Discovery, development, and utility of activators of the human M2 isoform of 
pyruvate kinase 
Craig J. Thomas1, craigt@mail.nih.gov; Matthew B. Boxer1; Jian-kang Jiang1; Matthew 
G. Vander Heiden2, 3, 4; Martin J. Walsh1; Kyle Brimacombe1; Min Shen1; Amanda P. 
Skoumbourdis1; Hee Won Park5, 6; Lewis C. Cantley3, 7; Douglas S. Auld1. (1) NIH 
Chemical Genomics Center, National Human Genome Research Institute, United States 
(2) Dana Farber Cancer Institute, United States (3) Department of Systems Biology, 
Harvard Medical School, United States (4) David H. Koch Institute for Integrative 
Cancer Research at MIT, United States (5) Structural Genomics Consortium, University 
of Toronto, Canada (6) Department of Pharmacology, University of Toronto, Canada (7) 
Division of Signal Transduction, Beth Israel Deaconess Medical Center, United States  
Pyruvate kinase (PK) is a critical metabolic enzyme operating at the ultimate step in 
glycolysis. In humans there are two pyruvate kinase genes and each produces two 
distinct gene products by alternative splicing. Following embryonic development, adult 
tissues switch to either PK-M1 or the tissue specific L or R isozymes. However, in 
cancerous cell lines revert entirely to the M2 isoform. Rapidly proliferating cells 
(including embryonic and cancer cells) require elevated levels of molecular building 
blocks, many of which are the products of glycolysis. Mechanistically the M2 isoform 
requires activation by fructose-1,6-bis phosphate (FBP) and it has been demonstrate 
that oncogenic phosphotyrosine peptides can bind the M2 isoform in a manner that 
displaces FBP and effectively down-regulates PK-M2 activity. Down-regulation of PKM2 
is suggested to allow diversion of glycoyltic intermediates towards nucleotide and lipid 
biosynthesis. Taken together these studies imply a therapeutic strategy where activation 
of PKM2 can potentially restore normal cellular metabolism. We describe here the 
identification and optimization and utility of several small molecule activators of human 
PKM2. 
MEDI 234 
Synthesis and preclinical evaluation of BAY 94-9392: A novel PET tracer for 
tumor specific imaging 
Heribert Schmitt-Willich, heribert.schmitt-willich@bayer.com; Mathias Berndt; 
Matthias Friebe; Norman Koglin; Andre Mueller; Volker Gekeler; Ludger M. Dinkelborg. 
Bayer Healthcare Pharmaceuticals, Germany  
Positron Emission Tomography (PET) tracers targeting adaptations of the inter-mediary 
tumor metabolism possess the potential to be highly specific tumor imaging agents. 4-
[F-18]Fluoro-L-glutamate (BAY 85-8050) was shown to accumulate in tumors.1 
However, in vivo defluorination in cancer patients limits its use as a viable alternative to 
FDG ([F-18]-Fluorodeoxyglucose).2  In this study, several novel F-19 and [F-18] L-
glutamate derivatives were synthesized and investigated in cell competition assays to 
characterize the responsible transporter and to analyze the tolerated conformational 
space. (4S)-(3-[F-18]fluoropropyl)-L-glutamate (BAY 94-9392) was selected as the most 
promising candidate. Stereospecific precursor synthesis and radiolabeling have been 
optimized and the resulting F-18 labeled tracer was characterized in several in vitro and 
in vivo tumor models comprising transporter-selective knock-down cells. Tracer uptake 
competition studies demonstrated specific transport of BAY 94-9392 via the 
cystine/glutamate exchanger (xCT, SLC7A11). No metabolites were observed. PET 
imaging with excellent tumor visualization and high tumor to background ratios was 
achieved in preclinical tumor models. In addition, in contrast to FDG, BAY 94-9392 did 
not accumulate in inflammatory lesions.  Both preclinical and clinical studies are in 
progress for further characterization.    
   
MEDI 235 
Putting cancer on a diet: Targeting fatty acid biosynthesis 
R. Wooster, richard.f.wooster@gsk.com; M.A. Hardwicke; R. Plant; K. Oleykowski; J. 
Kruger; J. Ariazi; C. Sherk; K. Bachman; C. Parrish; J. Luengo; H. Lin. GlaxoSmithKline, 
United States  
In the 1920s, Otto Warburg observed that cancer cells have a voracious appetite for 
glucose and produce lactic acid even in the presence of ample oxygen. This is due to 
an increase in glycolysis and a decrease in oxidative phosphorylation. More recently it 
has become clear that additional metabolic pathways are deregulated in cancer, notably 
the activation of anabolic pathways including amino acid and pentose phosphate 
production, and increased fatty acid biosynthesis. For cancer drug discovery the 
challenge is to identify the exact metabolic pathways and nodes on which cancer cells 
rely, intersecting this with targets whose inhibition can be tolerated by normal cells. 
Fatty acid synthase (FAS) meets these criteria and is a novel lipid metabolism target for 
oncology.    FAS is the only human enzyme that synthesises the 16 carbon fatty acid 
palmitate from acetyl-CoA and malonyl-CoA. The gene encoding this enzyme is 
amplified in cancer cells, the protein over-expressed and dramatic increases in fatty 
acid production have been observed in human tumours. In contrast to normal cells, 
cancer cells rely on de novo synthesis of palmitate rather than sourcing this fatty acid 
from the diet. Inhibition of FAS in cancer cells by potent and selective small molecule 
inhibitors decreases phospholipid synthesis and increases the levels of malonyl-CoA. In 
vitro the inhibition of FAS increases PARP cleavage and causes a G2 arrest of cancer 
cells. In vivo the inhibition of FAS is effective in the treatment of subcutaneous tumour 
xenografts. 
MEDI 236 
Huntington's disease: Biology, therapeutic strategies, and translational 
challenges 
Ignacio Munoz-Sanjuan, ignacio.munoz@chdifoundation.org. Department of Biology, 
CHDI Foundation Inc., Los Angeles CA 90046, United States  
Huntington Disease (HD) is a dominantly inherited neurodegenerative disorder that 
results from expansion of the poly-glutamine repeat in the Huntingtin (HTT) gene. There 
are currently no effective treatments for this devastating disease. Given its monogenic 
nature, disease modification therapies for HD should be theoretically feasible. Currently, 
pharmacological therapies aimed at disease modification by altering levels of HTT 
protein are in late-stage preclinical development. In addition, based on our current 
understanding of HTT function and the main pathological mechanisms identified as 
central to HD progression, we have advanced the identification and development of 
novel small molecule drugs with potential utility in HD. At the CHDI Foundation we are 
evaluating novel small molecule therapeutics based on their ability to affect the following 
mechanisms: basal ganglia synaptic dysfunction, autophagy and bioenergetics. During 
this presentation, I will also review existing genetic models of HD, current biomarker and 
translational efforts both for measuring disease progression as it is relevant to disease 
modification trials, as well as to the modulation of disease-relevant mechanisms. 
MEDI 237 
Assessing HD biology: Biomarkers 
Michael Orth, michael.orth@chdifoundation.org. Department of Biology, CHDI 
Foundation Inc., Los Angeles CA 90046, United States  
Huntington disease is a neurodegenerative disorder caused by a CAG repeat 
expansions mutation in the huntington gene. There is currently no causal treatment, 
while symptomatic treatment can improve quality of life HD is invariably incapacitating, 
and eventually fatal, with motor, cognitive and behavioral problems.   The development 
of novel therapeutics is a major quest in HD. Once available they need to be evaluated 
carefully. This requires reliable assessment tools. In addition, future therapeutics, and 
thus clinical trials with them, may focus on particular sub-groups of patients or specific 
pathways. Thus, biomarkers are needed that serve at least these purposes in that they 
are   1) An indicator of the biological state of HD  2) They can be objectively measured 
and evaluated reflecting a change of normal biological processes, or HD specific 
pathogenic processes,   3) They measure pharmacologic responses to a therapeutic 
intervention.  In HD, the candidates for biomarkers include the clinical measurement of 
the phenotype, e.g. motor signs, using rating scales, imaging the brain including 
magnetic resonance imaging and other parameters that can be measured in easily 
accessible body fluids or tissues. There may not be a single biomarker, or set of 
markers, for all stages of HD, and there may be yet other markers for the purpose of 
inclusion of patients into trials and the assessment of the effects of therapeutics 
targeting specific pathways. To date, imaging the brain seems most promising; 
however, the cost of scanning and the great care required for data quality when 
comparing results obtained in different scanners call for complementary and simpler 
markers for instance in blood or cerebro-spinal fluid. There is hope that the large scale 
efforts under way will go some way to meet this challenge. 
MEDI 238 
Discovery of brain penetrant JNK3 inhibitors as potential therapeutics for the 
treatment of Huntington's disease 
John Wityak1, john.wityak@chdifoundation.org; Kevin F McGee2; Bryan C Duffy2; Ren 
Hua Song2; Michael P Conlon2; Douglas Kitchen2; Marieke Lamers3; Philip Leonard3; 
Macarena Irigoyen4; Michele Luche4; Janet Adolphson4; Mei Bai4; Ryan Newell4; Eric 
Pastor4; Shawn Khademi4; Monica Hultman4; Haifa Ghandour4; Peter Michels2; Leticia 
Toledo-Sherman1; Alexander S Kiselyov1; Maria Beconi1; Ignacio Munoz-Sanjuan1; 
Jonathan Bard1; Celia Dominguez1. (1) CHDI Foundation, Inc., Los Angeles CA 92009, 
United States (2) AMRI, Albany NY 12212, United States (3) BioFocus DPI Limited, 
Saffron Waldon Essex CB10 1XL, United Kingdom (4) AMRI, Bothell WA 98021, United 
States  
c-Jun NH2-terminal kinases (JNKs) are members of the MAP kinase family that are 
primarily activated by cytokines and exposure to environmental stress. JNK3 is the 
isoform primarily expressed in brain, where it phosphorylates the N-terminal 
transactivation domain of c-Jun, resulting in enhancement of c-Jun dependent 
transcriptional events. JNK3 has been implicated as a therapeutic target in various 
neurodegenerative disorders, including Huntington's disease, where it is believed to 
play a regulatory role in the signaling pathways during neuronal apoptosis. It has been 
shown that inhibition of JNK3 leads to beneficial effects in various models of 
neurodegeneration. Our goal is to identify brain penetrant proof of concept tools for in 
vivo validation of JNK3 as a therapeutic target for the treatment of Huntington's disease. 
CHDI's strategy is to benchmark literature JNK3 inhibitors as potential tools, while 
working to develop promising hits from virtual screening into potent, brain penetrant 
JNK3 inhibitors. CHDI has begun collaborations with AMRI to establish the necessary 
biochemical and cellular assays to support a medicinal chemistry program, and with 
BioFocus to enable structural biology support of CADD. This presentation will provide 
an update on the status of our program, including the challenges met and the path 
forward in our goal towards proof of concept and a potential therapeutic for Huntington's 
disease. 
MEDI 239 
Advances in the development of selective brain penetrant KMO inhibitors as 
potential treatment for Huntington's disease 
Leticia M Toledo-Sherman1, leticia.toledo-sherman@chdifoundation.org; Michael 
Prime2; Dirk Winkler3; Maria Beconi1; Fred Brookfield2; Chris Brown2; Stephen 
Courtney2; Andreas Ebneth3; Rachel Grigg2; Estelle Hamelin-Flegg2; Peter Johnson2; 
Volker Mack3; Richard Marston2; William Mitchel2; Paula Pena2; Laura Reed2; 
Selvaratnam Suganthan2; Ignacio Munoz-Sanjuan4; Eric Schaeffer4; Derek Weddell2; 
Naomi Went2; Christin Winkler3; John Wityak1; Christopher Yarnold2; Celia Dominguez1. 
(1) Medicinal Chemistry, CHDI Foundation Inc, Los Angeles CA 90045, United States 
(2) Chemistry, Evotec (UK) Ltd, Abingdon OX14 4SA, United Kingdom (3) Biology, 
Evotec AG, Hamburg, Germany (4) Translational Biology, CHDI Foundation Inc, Los 
Angeles CA 90045, United States  
Dysregulation of the kynurenine pathway has been implicated in a variety of central 
nervous systems disorders, including Huntington's Disease. Several metabolites of 
kynurenine catabolism are bioactive and can modulate both synaptic and inflammatory 
processes in adult tissues. In particular, kynurenic acid (KYNA) can act as a 
neuroprotective agent through its weak antagonistic activity at the NMDA receptor; in 
addition, KYNA has been shown to modulate synaptic glutamate release and 
cholinergic signaling, activities which might be of relevance to HD pathophysiology. 
Other kynurenine metabolites, 3-hydroxy-kynurenine (3HK), and quinolinic acid (QA), 
have been shown to be neurotoxic in vitro and in vivo. In early stage HD patients as well 
as in the R6.2 model of HD, 3HK levels are elevated in a region-specific manner. The 
enzyme which catalyzes the coversion of kynurenine to 3HK is Kynurenine mono-
oxygenase (KMO). CHDI, in collaboration with Evotec, has identified and optimized a 
series of selective inhibitors of KMO. The presentation will cover the status of the 
program, and describe the challenges associated with the development of brain 
penetrant molecules that display adequate pharmacokinetic properties for in vivo 
efficacy testing in HD animal models. 
MEDI 240 
Selective HDAC class IIa inhibitors as potential therapeutics for Huntington's 
disease 
Roland Burli1, roland.burli@glpg.com; Celia Dominguez2. (1) Department of Medicinal 
Chemistry, BioFocus, Saffron Walden Essex CB10 1XL, United Kingdom (2) 
Department of Medicinal Chemistry, CHDI Foundation, Los Angeles California 90045, 
United States  
Huntington's disease (HD) is a genetic, neurodegenerative disorder that causes 
abnormal muscle coordination and leads to cognitive decline, dementia and premature 
death. HDAC4 is one of eleven metal-dependent histone deacetylase isoforms (HDACs) 
and has been recognized as a potential target for HD. The target validation is based on 
the finding that heterozygous knock down of the HDAC4 gene in R6/2 mice (disease 
model) resulted in a partially restored phenotype (personal communication, Professor 
Gill Bates, King's College London). As HDAC4 adopts multiple biological functions, the 
critical question remains whether blockage of its catalytic site will be sufficient to 
replicate the knockdown data.   To determine this, we developed HDAC4 inhibitors with 
excellent cell-based activity and isoform selectivity. Progress toward an in vivo proof-of-
concept study will be reported, which includes PK/PD readouts in brain and muscle 
tissue as well as optimization of the inhibitors for in vitro ADME and in vivo 
pharmacokinetic properties. 
MEDI 241 
Design of selective phosphodiesterase inhibitors and their potential utility for the 
treatment of Huntington's disease 
Patrick R Verhoest, patrick.r.verhoest@pfizer.com. Neuroscience Medicinal Chemistry, 
Pfizer, Groton CT 06371, United States  
Phosphodiesterase inhibitors have shown proven utility as therapeutics in multiple 
diseases by inhibiting the hydrolysis of specific pools of cyclic nucleotides. Pfizer has 
invested heavily in identifying and advancing selective inhibitors for multiple PDEs into 
clinical trials. The neuroscience group through structure based drug design and parallel 
chemistry enablement have identified a PDE10 (PF-2545920) and a PDE9 (PF-
4447943) inhibitor that have advanced into phase 2 clinical testing. These compounds 
have appropriate pharmacokinetics in humans and exhibit clear central target 
engagement. As part of an effort to identify alternative indications, a collaboration was 
developed with CHDI. Through internal work and at CHDI, PDE10 and PDE9 inhibitors 
have shown potential utility for the treatment of Huntington's Disease (HD). PDE10 
inhibitors have been shown to improvement behavioral measurements and prolong 
survival in the R6/2 transgenic mice. Multiple PDE inhibitors have shown positive 
outcomes in electrophysiology measurements including improving LTP in R6/2 brain 
slices. In this presentation, the phase 1 human data, preclinical HD efficacy data and 
medicinal chemistry strategy will be disclosed. 
MEDI 242 
Discovery of TAK-441, a pyrrolo[3, 2-c]pyridine derivative: A highly potent and 
orally active investigational hedgehog signaling inhibitor 
Satoshi Sasaki1, Sasaki_Satoshi@takeda.co.jp; Tomohiro Ohashi1; Yuya Oguro1; 
Toshio Tanaka1; Zenyu Shiokawa1; Nobuhiro Fujii2; Sachio Shibata1; Yoshihiko Sato1; 
Yoji Sagiya1; Hiroko Yamakawa1; Harumi Hattori1; Maki Miyamoto2; Shigeru Kondo2; 
Yoshimasa Ishimura2; Hideaki Tojo2; Atsuo Baba1. (1) Pharmaceutical Research 
Division, Takeda Pharmaceutical Co., Ltd., Tsukuba Ibaraki 3004293, Japan (2) 
Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd., Osaka Osaka 
5328686, Japan  
The Hedgehog (Hh) signaling pathway plays an important role in cell growth and 
differentiation during embryonic development and is activated in several types of 
cancer. It therefore represents an attractive anti-cancer therapeutic target and several 
Hh signal inhibitors are currently being assessed in clinical trials. High throughput 
screening of our compound library identified several inhibitors of Hh signaling. 
Subsequent efforts to improve the pharmacokinetic profile of these compounds led to 
discovery of the investigational agent TAK-441, a novel pyrrolo[3,2-c]pyridine-4-one 
derivative. TAK-441 potently inhibited Hh signaling in vitro in a Gli reporter assay (IC50 = 
4.4 nM) and also demonstrated an excellent pharmacokinetic profile (mouse cassette 
dose, 10 mg/kg; AUC0-8h 28.35 μgh/mL). Oral administration of TAK-441 (25 mg/kg 
once daily) completely inhibited tumor growth in a mouse medulloblastoma allograft 
model without significant toxicity. In this presentation, we will describe the design and 
biological evaluation of TAK-441 and related compounds. 
MEDI 243 
Novel pyrido[2,3-b]pyrazines as orally active ERK inhibitors 
Matthias Paul Harald Gerlach, mgerlach@aezsinc.com; Irene Seipelt; Gilbert Mueller; 
Tilmann Schuster; Lars Blumenstein; Babette Aicher; Eckhard Guenther; Michael Teifel. 
Aeterna Zentaris GmbH, Germany  
A common feature of many deregulated molecular lesions in cancer is the activation of 
the RAS - Raf - MEK - ERK signal transduction pathway (hereafter referred to as the 
ERK pathway).  This pathway controls a number of fundamental cellular process 
including cell survival, proliferation, motility and differentiation. It is constitutively 
activated in cancers of the lung, colon, pancreas, kidney, and ovary. ERK is pivotal in 
the pathway downstream of RAS, Raf and MEK, acting as central point where multiple 
signaling pathways coalesce to drive transcription.     Here we present the structure 
class of pyrido[2,3-b]pyrazines, which has been identified as novel, potent, orally active 
inhibitors for ERK.     The poster describes our efforts during a medicinal chemistry 
program supported by X-ray crystallography and molecular modeling towards the 
optimization of pyrido[2,3-b]pyrazines as novel series of ERK inhibitors. So far, 
compounds with activity values in the low nanomolar range have been identified. The 
synthesis, structure-activity relationships, physicochemical data and ADME parameter, 
as well as encouraging in vivo data of this structure class are presented.    In summary, 
we designed a series of novel, potent inhibitors of ERK kinase by starting with a 
submicromolar lead compound 1 (D-89220), followed by several optimization cycles 
within a structure-guided medicinal chemistry program. This optimization led amongst 
others to the identification of the compound AEZS-131, which is currently under in vivo 
evaluation. 
MEDI 244 
Synthesis and SAR studies of colchicine binding site tubulin inhibitors as potent 
and orally bioavailable anticancer agents 
Yan Lu1, lu_yane@hotmail.com; Chien-Ming Li2; Zhao Wang1; Jianjun Chen1; Wei Li1; 
James T Dalton2; Duane D Miller1; Wang Jin1. (1) University of Tennessee, Health 
Science Center, United States (2) GTX Inc., United States  
A series of phenyl amino thiazoles (PAT) was designed and synthesized in an effort to 
develop promising anti-cancer agents. We obtained PAT derivatives from modifications 
of 4-substituted methoxybenzoyl-aryl-thiazoles (SMART) by introducing an NH linkage 
between the A and B rings. The antiproliferative activity of PAT agents against 
melanoma and prostate cancer cell lines was evaluated and structure-activity 
relationships were developed. The PAT template maintained nano molar (nM) range 
potency against cancer cell lines via inhibiting tubulin polymerization, was not 
susceptible to P-glycoprotein mediated multidrug resistance in vitro, and markedly 
improved solubility and bioavailablity compared with the SMART template. This data 
suggested that these new synthesized amino linked compounds have appropriate 
potency and PK profiles to be developed as a new class of orally bioavailable antitubulin 
agents. Synthesis, SAR and biological evaluation of the SMART agents will be 
presented. 
MEDI 245 
Photoimmunotherapeutic nanoparticles: Combination therapy for metastatic 
breast cancer 
Anna M. Williams, wila@uga.edu; Jitendra Gangwal, jiten@uga.edu; Shanta Dhar. 
Department of Chemistry, University of Georgia, Athens Georgia 30602, United States  
Photoimmunotherapy (PIT) is a promising field for cancer treatment that combines the 
phototoxic and immune-stimulating ability of photodynamic therapy (PDT) with the 
widespread effectiveness of the immune system. We speculate that co-delivery of an 
immunostimulant with a photosensitizer using a nanoparticle delivery platform will be a 
useful means to attack metastatic cancer. To investigate this, we have initiated the 
construction of new PIT agents using a hybrid nanoparticulate delivery platform for the 
treatment of late-stage breast cancer. Briefly, we encapsulated a photosensitizer within 
a polymeric nanoparticle core made up of poly(D,L-lactic-co-glycolic acid)-b-
poly(ethylene glycol) (PLGA-b-PEG). After coating the outside of the polymeric core 
with gold nanoparticles, we further modified the gold surface with CpG-ODN, a single-
stranded DNA that is a known immunostimulant. Synthesis, PDT activity, and immune 
stimulatory effects of these constructs will be presented. 
MEDI 246 
7-Azaindenoisoquinolines: Topoisomerase I inhibitors with improved water 
solubility 
Evgeny Kiselev1, ekiselev@purdue.edu; Sean DeGuire1; Andrew Morrell1; Keli 
Agama2; Thomas Dexheimer2; Yves Pommier2; Mark Cushman1. (1) Department of 
Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, and The 
Purdue Center for Cancer Research, Purdue University, West Lafayette IN 47907, 
United States (2) Laboratory of Molecular Pharmacology, Center for Cancer Research, 
National Cancer Institute, Bethesda MD 20892, United States  
A series of 7-azaindenoisoquinoline topoisomerase I (Top1) inhibitors have been 
prepared to investigate the effect of increased electron deficiency of the aromatic 
system on the ability to stabilize Top1-DNA cleavage complex. Ab initio calculations 
suggest that introduction of the nitrogen into the aromatic system of indenoisoquinolines 
would facilitate charge transfer complex formation with DNA, thus improving the π-π 
stacking interactions. The present study shows that 7-azaindenoisoquinolines 
demonstrate substantially improved water solubility without decrease in the Top1 
inhibitory activity or cytotoxicity. Analysis of the results of biological evaluation revealed 
that some lactam ring substituents enable intercalation into free DNA whereas others 
only allow binding to the Top1-DNA cleavage complex. 
MEDI 247 
Synthesis and evaluation of novel androgen receptor inhibitors: Potential 
candidates for castrate-resistant prostate cancer treatment 
Sanjay V. Malhotra1, malhotrasa@mail.nih.gov; Vineet Kumar1; Yeong Sang Kim2; 
Sunmin Lee2; Jane Trepel2. (1) Laboratory of Synthetic Chemistry, SAIC-Frederick, Inc., 
National Cancer Institute at Frederick, Frederick Maryland 21702, United States (2) 
Medical Oncology Branch, CCR,, National Cancer Institute, Bethesda Maryland 20892, 
United States  
Growing new cases of porstate cancer in United States and worldwide, have warranted 
an urgent need for more effective therapy against prostate cancer. Castrate-resistant 
prostate cancer (CRPC) represents progression from androgen-dependent to androgen-
independent disease, which makes Androgen receptor (AR) an important target in 
CRPC. We have synthesized a series of benzylideneacetophenone based compounds 
and shown their activity in the inhibition of androgen receptors. An extensive structure-
activity relationship (SAR) was performed on a systematically designed library of this 
scaffold for impact on PSA gene expression. The hit compounds were treated with 
LNCaP cells and the inhibition of AR target genes PSA, TMPRSS2 (androgen and AR 
dependent genes) and UBE2C (androgen independent, AR dependent genes) was 
determined. Also, these studies have identified small molecules that inhibit AR target 
gene expression significantly in 22Rv1 a prostate cancer cell line, in which PSA 
expression is insensitive to FDA-approved drug bicalutamide.  Acknowledgement: This 
Project has been funded with federal funds from the National Cancer Institute, NIH 
under contract No. HSN261200800001E 
MEDI 248 
Ortho-amido diphenylamines as MEK5 inhibitors 
Suravi Chakrabarty1, chakrabartys@duq.edu; Patrick T. Flaherty1; Darlene Monlish2; 
Jane Cavanaugh2; Sankar G. Manepalli3; Jeffry D. Madura3. (1) Mylan School of 
Pharmacy, Department of Medicinal Chemistry, Duquesne University, Pittsburgh PA 
15282, United States (2) Mylan School of Pharmacy, Department of Pharmacology, 
Duquesne University, Pittsburgh PA 15282, United States (3) Bayer School of Natural 
and Environmental Sciences, Duquesne University, Pittsburgh PA 15282, United States  
The mitogen activated protein kinase (MAPK) pathway mediates intracellular responses 
to extracellular events. It mediates significant cellular events including embryogenesis, 
cell differentiation, cell proliferation, and cell death. Phosphorylation of unique isoforms 
of ERK (Extracellular signal-Regulated Kinases) by its complementary kinase (MEK) is 
the most selective event in the MAPK signaling cascade. ERK5 is the only known 
substrate of MEK5. MEK5 mediated generation of pERK5 is initiated by binding of an 
extracellular mitogen or ligand, activation of MEKK2 or MEKK3, and then subsequent 
formation of catalytically active pMEK5. MEK5 and pERK5 are significantly up regulated 
in specific tumor types including breast and prostate cancers. A series of 
diphenylamines were designed based on a homology model of MEK5 based on the X-
ray crystal structure of MEK1 (PDB ID: 3EQC) and the MEK5 selective inhibitor shown 
below. The design, modeling, synthesis, and testing of amide and aryl variations will be 
presented.  
  
MEDI 249 
Syntheses and antitumor activity of N-hydroxyethyl-4-aza-
didehyropodophyllotoxin derivatives 
Ajay Kumar1, drajaybhati@gmail.com; Vineet Kumar2; Antonio E. Alegria1; Sanjay V. 
Malhotra2. (1) Department of Chemistry, University of Puerto Rico at Humacao, 
Humacao Puerto Rico 00791, United States (2) Laboratory of Synthetic Chemistry, 
SAIC-Frederick, Inc.,, National Cancer Institute at Frederick, Frederick Maryland 21702, 
United States  
Podophyllotoxin (PPT) has been known to possess anti-tumor activity. Derivatives of 
podophyllotoxin, namely etoposide, etopophos and teniposide have been developed for 
the treatment of a variety of malignancies. However, due to the drug resistance 
developed by cancer cells as well as side effects associated with the use of these 
agents in clinic, the search for new effective anticancer analogues of podophyllotoxin 
remains an intense area of research. The structural complexity of podophyllotoxin, 
arising from the presence of four stereogenic carbons in ring C has restricted most of 
the structural activity relationship (SAR) studied by derivatization of the parent natural 
product rather than by de novo multi-step chemical synthesis. Our endeavor in this field 
lead to synthesis of a library of N-hydroxy aza-podophyllotoxin derivatives, which were 
screened for their antitumor activity using the National Cancer Institute's 60 human 
tumor cell line screen. This was followed by a screen of in vivo activity using a panel of 
tumor hollow-grafts implanted in mice consisting of breast (MDA-MB-231), non-small 
lung (NCI-H23 and NCI-H522), colon (SW-620 and COLO 205), melanoma (UACC-62, 
MDA-MB-435 and LOXIMVI), ovarian (OVCAR-5 and OVCAR-3) and CNS (U251 and 
SF-295) cell lines. This is the first report of aza-podophyllotoxins anticancer activity 
evaluation on such a broad panel of cancer cell lines. The toxicity of all the active 
compounds was low, while their antiproliferative activity was high, providing a wide 
therapeutic window for their potential application as anticancer drugs. 
Acknowledgement: This Project has been funded with federal funds from the National 
Cancer Institute, NIH under contract No. HSN261200800001E 
MEDI 250 
Structure-based design of urea and methylurea inhibitors of B-RafV600E: The 
development of highly potent and efficacious inhibitors 
Zhaoyang M Wen1, zwen@gene.com; Simon Mathieu1; Ignacio Aliagas1; Bruno 
Alicke1; Edna F Choo1; Stefan Gradl1; Stephen Gould1; Janet Gunzner1; Wendy B 
Young1; Guiling Zhao1; Steve Wenglowsky2; Jonas Grina2; Joachim Rudolph1. (1) 
Department of Discovery Chemistry, Genentech, Inc., South San Francisco CA 94080, 
United States (2) Department of Medicinal Chemistry, Array Biopharma, Boulder CO 
80301, United States  
The V-600 mutation of B-Raf kinase results in constitutive activation of the MAPK signal 
pathaway and is present in nearly 8% of all solid tumors and particularly prevalent in 
melanoma. Using structure-based design, we herein report a novel series of urea and 
methylurea inhibitors of B-RafV600E demonstrating high enzyme and cell potency. This 
presentation will also detail in vitro and in vivo efficacy and pharmacokinetic profiles of 
this new class of B-Raf inhibitors. 
MEDI 251 
Discovery of potent, selective inhibitors of mutant B-Raf 
Cynthia L Palmer, cindy.palmer@pfizer.com; Jingrong Cui; Judith Deal; Danlin Gu; 
Chuangxing Guo; Susan Kephart; Maria A Linton; Indrawan McAlpine; Mason Pairish; 
Shubha Bagrodia; Yixue Cao; Shinji Yamazaki; Dorothy DeLisle; Annette John-Baptiste. 
Pfizer Worldwide Research and Development, San Diego California 92121, United 
States  
Discovery of potent, selective inhibitors of mutant B-Raf   Cynthia L. Palmer, Jingrong 
Cui, Judith Deal, Danlin Gu, Chuangxing Guo, Susan Kephart, Maria A. Linton, 
Indrawan McAlpine, Mason Pairish, Shubha Bagrodia, Yixue Cao, Shinji Yamazaki, 
Dorothy DeLisle, Annette John-Baptiste   B-Raf is mutated in a number of human 
cancers including melanoma, thyroid and colorectal. Raf is a key kinase in the 
Ras/Raf/Mek pathway, thus making mutant B-Raf an attractive oncology target. 
Discussed herein is the medicinal chemistry effort done at Pfizer directed at developing 
a potent mutant B-Raf inhibitor starting from a potent phenol-pyrazole lead, (2-(3-(3-
hydroxy-5-methylphenyl)-4-(2-((S)-2-hydroxypropylamino)pyrimidin-4-yl)-1H-pyrazol-1-
yl)acetonitrile (compound 1). As common to phenolic compounds, secondary 
metabolism, especially glucuronidation, resulted in poor PK properties. Investigation of 
phenol replacements led to the identification of hit azaindole, (2S)-1-(4-(1-isopropyl-3-
(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl)pyrimidin-2-ylamino)propan-2-ol 
(compound 2). Also presented is the optimization of the hit azaindole to give compound 
3 which not only demonstrated improved ADME properties, but also excellent kinase 
selectivity and efficacy in animal TGI studies.  
  
MEDI 252 
Discovery of potent selective B-RafV600E kinase inhibitors 
Judith Deal, judy.deal@pfizer.com; Cynthia Palmer; Jingrong Cui; Danlin Gu; 
Chuangxing Guo; Susan Kephart; Maria Linton; Tami Marrone; Indrawan McAlpine; 
Michele McTigue; Mason Pairish; Scott Sutton; Dorothy DeLisle; Kristina Rafidi; Evan 
Smith; Shinji Yamazaki; Xiao-Hong Yu; Shubha Bagrodia. Pfizer Worldwide Research 
and Development, San Diego CA 92121, United States  
The discovery of selective potent B-RafV600E kinase inhibitors is described. Kinase 
counter-screening of file compounds led to a phenol, 3-bromo-5-(4-pyridin-4-yl-1H-
pyrazol-3-yl)phenol, which showed moderate B-RafV600E potency and attractive ligand 
efficiency. The phenol series was optimized to improve potency but had consistently 
poor PK properties. Several heterocycles were successfully identified to replace the 
phenol head group. Further optimization led to potent, selective B-RafV600E kinase 
inhibitors with good pharmaceutical properties and in vivo efficacy. 
MEDI 253 
Evaluation of glycosidated ginsenoside mimics as anticancer agents 
Sanjay V. Malhotra, malhotrasa@mail.nih.gov; Ian Jamie Talisman. Laboratory of 
Synthetic Chemistry, SAIC-Frederick, Inc., National Cancer Institute, Frederick 
Maryland 21702, United States  
Ginsenosides are active components of the ginseng plant, which has been frequently 
used as a traditional herbal medicine for weakness and fatigue. More recently, it has 
been evaluated for various disease states including diabetes, Parkinson's disease, and 
cancer. Over thirty different ginsenosides, comprised of a steroid core of 17 carbon 
atoms arranged in a 6,6,6,5 ring system, have been isolated from ginseng. 
Ginsenosides exhibit a range of anticancer activities depending on the carbohydrate 
substitution pattern of the core. However, the complexity of the core makes medicinal 
chemistry efforts to systematically vary the carbohydrate portion of these molecules 
difficult. We have designed a series of glycosylated ginsenoside mimics to reduce the 
size of the core and facilitate structure activity relationship evaluation. Herein, we report 
the synthesis of a small library of ginseng saponin mimics. On evaluation, several of 
these compounds were shown to inhibit growth and/or target pathways implicated in the 
progression of certain cancers. Results of these studies will be presented. 
Acknowledgement: This Project has been funded with federal funds from the National 
Cancer Institute, NIH under contract No. HSN261200800001E 
MEDI 254 
Improved cisplatin efficacy using sterol modified liposomes 
Heidi M Kieler-Ferguson1, kieler@berkeley.edu; Jean M Fréchet1; Francis C Szoka 
Jr.2. (1) Department of Chemistry, University of California-Berkeley, Berkeley CA 94720-
1460, United States (2) Department of Bioengineering and Therapeutic Science, 
University of California-San Francisco, San Francisco CA 94143, United States  
Cisplatin, a widely used chemotherapeutic, suffers from severe toxicity. Attempts to 
circumvent this toxicity through liposomal encapsulation have yielded liposomes 
incapable of cisplatin release or with complicated formulations, not amenable for clinical 
use. Utilizing a new class of sterol modified lipids (SML), we investigated lipid 
anisotropy and acyl chain length effect on cisplatin leakage. SML-liposomes with shorter 
acyl chain lengths provided better cisplatin release, higher in vitro toxicities, and easier 
formulation conditions, with several promising candidates for in vivo studies.  
  
NIH GM061851 & EB003008 
MEDI 255 
Synthesis and cytotoxicity of cisplatin analogs against oncogenic cells 
Van Vo, vanv@unlv.nevada.edu; Ontida Tanthmanatham; Haesook Han; Pradip K. 
Bhowmik; Bryan L. Spangelo. Department of Chemistry, University of Nevada, Las 
Vegas, Las Vegas Nevada 89154, United States  
Cisplatin belongs to a family of platinum-containing compounds used in the treatment of 
various cancers. While quite effective, its application is limited. In hope of discovering 
more suitable compounds, a series of cisplatin analogues of the formula (4,4′-bis[R]-
2,2′-bipyridine)PtCl2 [where, R = varying alkoxy groups] were synthesized. The 
antitumor activities of these compounds were examined in a lung cancer cell line (A549) 
using the MTS cell proliferation assay. Three compounds, where R = -O(CH2)2CH3 
(EC50 = 36±4 µM), -O(CH2)3CH3 (EC50 = 24±2 µM), -O(CH2) 4CH3 (EC50 = 43±1 µM), 
were found to be more effective than cisplatin (had no effect, even up to 1 mM 
concentration) after a one hour treatment. Similar results were obtained when 
compound R = -O(CH2)3CH3 was tested on several other cancer cell lines . These 
results demonstrate the potential utilization of these compounds as chemotherapeutic 
drugs and warrant further investigation to determine its mechanism of action. 
MEDI 256 
Semisynthetic parthenolide analogs: Chemical probes of biological function and 
new anticancer agents 
Daniel A Harki, daharki@umn.edu; Dan Wang; Joseph K Hexum; F A Meece. 
Department of Medicinal Chemistry, University of Minnesota, Minneapolis MN 55414, 
United States  
Parthenolide (PTL) is a plant-derived natural product from feverfew (Tanacetum 
parthenium) and a well-established active component of many natural medicines. The 
anti-inflammatory properties of PTL have been reported in scores of scientific 
publications, resulting in its evaluation as a therapeutic for leukemia, breast cancer, 
prostate cancer, and pancreatic cancer. Additionally, PTL has been shown to selectively 
kill acute myelogenous leukemia stem cells without destroying normal hematopoietic 
stem cells, and this finding has generated excitement in the drug discovery community. 
Notably, cancer stem cells are highly resistant to chemotherapeutic drugs and treatment 
regimens that allow cancer stem cells to survive may ultimately result in disease 
relapse. Our laboratory has synthesized a number of PTL analogues to (I) elucidate the 
mechanism of action of this compound and (II) to optimize the potency and 
pharmacokinetic parameters of PTL. Our progress in both areas will be presented. 
MEDI 257 
Application of ProTide technology to gemcitabine: A successful approach to 
overcome key cancer resistance mechanism 
Magdalena Slusarczyk, slusarczykm1@cf.ac.uk; Christopher McGuigan. Welsh School 
of Pharmacy, Cardiff University, Cardiff Wales CF10 3NB, United Kingdom  
A family of gemcitabine prodrugs carrying a phosphoramidate moiety was synthesized 
and biologically evaluated for anti-cancer activity on different tumor cell lines. These 
compounds were obtained by applying the ProTide technology to gemcitabine using 
phosphorochloridate chemistry. Among all synthesized molecules bearing various aryl, 
amino acids and ester moieties, the L-Alanine series exhibited good anti-cancer activity 
in the in vitro experiments. In particular one compound (NUC-1031) was recognized to 
be more potent in pancreatic cell lines (Mia-Pa-Ca-2, Bx-PC-3) than gemcitabine. On 
the basis of its favourable in vitro data, the effect of our lead compound on tumor growth 
in the nude mouse xenograft models was examined. NUC-1031 showed statistically 
significant reduction in pancreatic tumor volume versus the parent molecule and control. 
Hence, a Phase I/II study utilising NUC-1031 is planned. Data suggest that NUC-1031 
may bypass and overcome the key limitations associated with parent gemcitabine's 
clinical effectiveness. 
MEDI 258 
64Cu-TE2A-NCS-trastuzumab as a potential PET radiotracer for tumors expressing 
Her2/neu receptor: Synthesis, radiolabeling, and in vivo studies  
Ajit V. Dale1, ajitvdale@gmail.com; Darpan N. Pandya1; Jung Y. Kim2; Yeong S. Ha1; 
Gwang I. An2; Jeongsoo Yoo1. (1) Department of Molecular/Nuclear Medicine, 
Kyungpook National University, Daegu 700-422, Republic of Korea (2) Molecular 
Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul 
139-706, Republic of Korea  
New bifunctional chelate, which holds Cu(II) ions firmly and also makes facile 
conjugation with antibodies, is an essential component for the successful development 
of 64Cu-immunoconjugates. Here we report new synthesis of TE2A-NCS and 
demonstrate its usefulness as a potential bifunctional chelate. TE2A-NCS was 
synthesized from cyclam in seven steps with 58% overall yield. Then, it was easily 
conjugated to the trastuzumab antibody via its NCS functional group. The conjugate 
TE2A-NCS-trastuzumab was labeled in 94% radiolabeling yield within 10 min at 30°C. 
After purification, the radiochemical purity was greater than 99%. When 64Cu-TE2A-
NCS-trastuzumab was injected into nude mice bearing NIH3T6.7 tumor xenografts, 
tumor was clearly visualized with high signal to background ratio at 1 and 2 days. 
Biodistribution data was also well matched with microPET data. All our data 
demonstrate high potential of TE2A-NCS as a promising bifunctional chelator. 
MEDI 259 
Synthesis of a folate targeted camptothecin prodrug using a monodisperse PEG 
spacer 
Walter A. Henne, whenne@govst.edu; Audrea Rhymes; John Hakenjos. Chemistry, 
Governors State University, University Park IL 60484, United States  
The folate receptor (FR) has emerged as an attractive target for selective delivery of 
folate coupled therapeutic agents. We describe the construction and assessment of a 
folate conjugate synthesized using a monodisperse, FMOC protected PEG building 
block. The PEG spacer serves to ensure water solubility and optimal ligand-receptor 
interaction. Assembly was achieved using FMOC solid phase synthesis to build a folate 
PEG cysteinyl construct, which was further reacted with pyridyldithioethyl carbonate 
camptothecin. The conjugate demonstrated an IC50 value of approximately 6 nM in an 
FR+ KB cancer cell line, and its activity was blocked when assessed in the presence of 
a 1000 fold excess of free folic acid. Moreover, the conjugate yielded a relative binding 
affinity and serum binding comparable to previously synthesized constructs with peptide 
spacers. Together, these studies demonstrate the utility of newly available, 
monodisperse, FMOC PEG building blocks for the synthesis of targeted therapeutic 
agents. 
MEDI 260 
Development of substituted benzothiazoles as ERK5 inhibitors 
Ruth H Bawn1, R.H.Taylor@ncl.ac.uk; Bernard T Golding1; Roger J Griffin1; Tim 
Hammonds2; Hing Leung3; David Newell1; Laurent Rigoreau2; Ai Ching Wong2; Celine 
Cano1; Ian R Hardcastle1. (1) Department of Chemistry, Newcastle Cancer Centre at 
the Northern Institute for Cancer Research, Newcastle upon Tyne Tyne and Wear NE1 
7RU, United Kingdom (2) Discovery Laboratories, Cancer Research Technology, 
London WC1E 6BT, United Kingdom (3) Department of Cancer Sciences and Molecular 
Pathology, The Beatson Institute for Cancer Research, Glasgow University, Glasgow 
G61 1BD, United Kingdom  
Deregulated ERK5 signalling is linked to cancer, including prostate cancer.1 Small 
molecule ERK5 inhibitors may be effective cancer therapies.2 Benzothiazoles were 
identified as hits in an ERK5 high-throughput screen (IC50s = 60-900 nM). Examples 1-3 
were resynthesised but were inactive. The 5-sulfonamido isomers 4 showed modest 
activity. Thiocyanatobenzene 5 showed activity. SARs of additional substituted 
benzothiazoles will be discussed.   
     
MEDI 261 
Computational assessment of the potential role of chalcogenated flavonoids as 
antioxidants, enzyme inhibitors and cell signalling modulators via computational 
analysis 
Alexandra M M Antunes, alexandra.antunes@ist.utl.pt; Gonçalo C Justino; Inês L 
Martins; Catarina R Charneira; M Matilde Marques. Centro de Química Estrutural, 
Instituto Superior Técnico, Lisbon - 1049-001, Portugal  
Flavonoids have been studied for decades due to their putative health-promoting 
effects, initially attributed to their antioxidant capacity as H-atom donors and, more 
recently, to their ability to modulate cell signalling pathways. We have synthesized sulfur 
and selenium-containing derivatives of chrysin and quercetin, and evaluated their 
potential antioxidant activity both experimentally, by assessing their capacity to reduce 
the DPPH radical, and by using computational methods to probe the energetics of the 
various mechanisms contributing to their antioxidant activity.  Their role as signal 
modulators has been surveyed by computational docking of the various derivatives to 
key proteins, including CYPs and various kinases involved in signalling. The role of 
these compunds as potential modulators of signalling-dependent carcinogenic pathways 
is discussed in terms of their interactions with protein residues and inhibition constants. 
MEDI 262 
Metallocene derivatives as selective estrogen receptor modulators a 
computational docking to estrogen receptors α and β 
M Matilde Marques, matilde.marques@ist.utl.pt; Gonçalo C Justino; Shrika G Harjivan. 
Centro de Química Estrutural, Instituto Superior Técnico, Lisbon - 1049-001, Portugal  
Organometallic moieties have been frequently incorporated in known drugs aiming to 
improve their therapeutic properties. Raloxifene, a benzo[b]thiophene derivative, is a 
selective estrogen receptor (ER) modulator (SERM) with ER agonist effects on bone 
and lipid metabolism and antagonistic effects on endometrium and breast tissue [1].  
Building on our previous work [2], focused on ferrocenyl-benzo[b]tiophene derivatives 
as ER agonists, we have setup a library of metallocene-containing raloxifene analogues 
which were docked against ER α and β. The best ligands of the library are at least as 
potent as raloxifene in binding to the receptor, albeit with a different pattern of 
interaction with the amino acid side chains. Results will also be discussed in terms of 
the contribution of each structural moiety of the group to the overall protein-ligand 
interaction.  [1] Cohen, F.J., et al., Obstet. Gynecol. 95, 104 (2000).  [2] Ferreira, A.P., 
et al., Organometallics, 28, 5412 (2009). 
MEDI 263 
2-Acetylamino-3-[4-(2-acetylamino-2-carboxyethylsulfanyl-
thiocarbonylamino)phenylthiocarbamoylsulfanyl]propionic acid – a novel 
glutaredoxin inhibitor 
Satya S Sadhu1, satyasaisadhu@rediff.com; Eduardo Callegari2; Xiangming Guan1; 
Teresa M Seefeldt1. (1) Department of Pharmaceutical Sciences, South Dakota State 
University, Brookings South Dakota 57005-0099, United States (2) BRIN-USDSM 
Proteomics Facility, University of South Dakota, Vermillion South Dakota 57069, United 
States  
Protein S-glutathionylation is a process cells employ, when under oxidative stress, to 
protect the sulfhydryl group of proteins from irreversible oxidation through formation of a 
mixed disulfide bond. Glutaredoxin is the enzyme responsible for de-glutathionylation of 
proteins after resolution of the oxidative stress. Inhibition of glutaredoxin could be useful 
as a tool to study protein S-glutathionylation as well as other applications. For various 
reasons, no effective glutaredoxin inhibitor is currently available. 2-Acetylamino-3-[4-(2-
acetylamino-2-carboxyethylsulfanylthio-
carbonylamino)phenylthiocarbamoylsulfanyl]propionic acid (2-AAPA) was previously 
found to be a glutathione reductase inhibitor. Here we would like to report that the 
compound is also an effective irreversible glutaredoxin inhibitor. Mass spectrometric 
results along with substrate protection experiments confirmed the covalent modification 
at the active site. The Ki and kinact of 2-AAPA against glutaredoxin were determined to 
be 91.3 µM and 0.13 min-1, respectively. The ability of 2-AAPA to inhibit intracellular 
glutaredoxin was confirmed with a human ovarian cancer cell line. 
MEDI 264 
Novel 3H-spiro[naphtho[1,2-b][1,4]oxathiine-2,4'-piperidine]-5,6-diones as 
anticancer agents 
David Vensel, dvensel@arqule.com; Manish Tandon; Syed M. Ali; Eugene Kelleher; 
Jason Hill; Hui Wu; Yanbin Liu; Patrick Hutchins; Rui-Yang Yang; Magdi Moussa; Jean-
Marc Lapierre; Mark A. Ashwell; Woj Wrona. ArQule, Inc, 19 Presidential Way Woburn 
MA, United States  
ß-Lapachone (3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b] pyran-5,6-dione ), a natural 
product found in Pau d'arco trees (Tabebuia impetiginosa), has broad anti-cancer 
activities. ARQ 501, a fully synthetic version of ß-lapachone, elevates E2F-1 levels 
leading to the activation of the cell cycle checkpoint which results in the selective 
apoptotic cell death of cancer cells and is effective against human ovarian cancer and 
prostate cancer xenografts in mice. Promising anticancer activity has been observed in 
multiple Phase II studies.   In this poster we describe the chemistry and structure-
activity-relationships of series of 3H-spiro[naphtho[1,2-b][1,4]oxathiine-2,4'-piperidine]-
5,6-diones from which a second-generation E2F-1 elevator was identified for clinical 
development.  We present the strategy employed to develop the SAR within this series 
as well as the synthetic challenges encountered in the optimization. 
MEDI 265 
Small molecule Mer inhibitor for novel treatment of acute lymphoblastic leukemia 
Chao Yang1, chaoyang@email.unc.edu; Jing Liu1; Weihe Zhang1; Chatura Jayakody1; 
Catherine Simpson1; Victoria Korboukh1; Jacqueline Norris-Drouin1; Deborah 
DeRyckere2; William Janzen1; Doug Doug Graham2; Xiaodong Wang1; Stephen Frye1. 
(1) Department of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill NC 
27599, United States (2) Department of Pediatrics,, The University of Colorado, Denver, 
Aurora CO 80045, United States  
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. 
Current standards of treatment are significantly compromised by therapy-induced 
toxicity, development of resistance, and relapse. Ectopic expression of receptor tyrosine 
kinases Mer plays a critical role in the pathogenesis of ALL through initiation of anti-
apoptotic signaling. Inhibition of Mer expression attenuates survival signaling and 
increases the efficacy of cytotoxic agents in xenograft mice model of leukemia. A series 
of novel pyrazolopyrimidine analogs shows good inhibition of Mer. Hit compound was 
identified and structure-activity relationship (SAR) has been established. Hit to lead 
optimization generates a series of lead compounds with sub-nanomolar in vitro potency 
versus Mer kinase and sub-micromolar cellular potency. Lead compounds were further 
evaluated for ADME, toxicity and selectivity against other kinase families with promising 
results. Among them, CY00076-78A1 was selected as a promising candidate. Further 
optimization toward a clinical candidate is underway. 
MEDI 266 
Development of clickable small molecule inhibitors of histone acetyltransferases 
Dongwook Kang, kangdongwook@mail.nih.gov; Hans Luecke. Lab of Bioorganic 
Chemistry, NIDDK / National Institutes of Health, Bethesda MD 20892, United States  
Histone acetylation and deacetylation play essential roles in the regulation of gene 
transcription in eukaryotes. Histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) regulate these histone modifications. It is critical to develop 
small molecule modulators of these enzymes in order to study their functions and 
potential therapeutic applications. Genetic and other biological studies indicate that 
dysfunction of HATs correlate with several human diseases including: cancer, 
neurodegeneration, asthma, diabetes, AIDS, cardiac hypertrophy, etc. Therefore, 
inhibitors of HATs might have therapeutic potential for treating these diseases.   Despite 
the large number of potent and selective HDAC inhibitors, very few molecules are 
known to possess HAT inhibitory activity. Isothiazolones are a class of synthetic small 
molecule HAT inhibitors. We are developing a variety of synthetic isothiazolones 
including azide and alkyne functionalized derivatives for use as “clickable” probes of 
HAT activity in mammalian cell lines.  We will present new synthetic routes to efficiently 
prepare benzo- and pyridoisothiazolones in a single reaction step from 2,2'-dithiobis-
benzoic acid and 2,2'-dithiobis-3-pyridinecarboxylic acid. We will also present our 
studies on the HAT inhibitory potential of these small molecules and their utility as 
probes of HAT activity in vivo. 
MEDI 267 
Proteomimetics of coactivators of the androgen receptor 
Patrick T Weiser, weiserp@gmail.com; Robert N Hanson. Department of Chemistry 
and Chemical Biology, Northeastern University, Boston MA 02115, United States  
Androgen receptor (AR) coactivator proteins play a significant role in the regulation of 
cell proliferation in prostate cancer by binding to AR and recruiting other coactivators 
that lead to gene transcription. We have designed a scaffold consisting of a bipolar 4, 4' 
-biphenyl core that mimics the alpha helical FXXLF motif of the coactivators, where L is 
leucine, F is phenylalanine, and X is any amino acid, and can successfully inhibit 
coactivator binding. A combinatorial approach was used in the synthesis of these 
molecules by constructing the amino and carboxy termini separately from 2-substituted 
phenols and coupling them together using Suzuki conditions. First and second 
generation libraries, as well as selected intermediates, have undergone time resolved 
fluorescence energy transfer, reporter gene and competitive binding studies on both the 
AR and the estrogen receptor alpha (ERα) and lead compounds have show low 
micromolar affinity. 
MEDI 268 
Synthesis and biological evaluation of a novel drug conjugate bearing DHA-
propofol and a second-generation taxoid 
Joshua D Seitz1, jdseitz@ic.sunysb.edu; Edison S Zuniga1; Iwao Ojima1, 2. (1) 
Chemistry, Stony Brook University, Stony Brook NY 11794-3400, United States (2) 
ICB&DD, Stony Brook NY 11794-3400, United States  
Recently it has been shown that conjugation of docosahexaenoic acid (DHA) to the 
general anesthetic propofol results in a novel compound which selectively induces 
apoptosis in breast cancer cells. DHA also has been show to target cytotoxic agents to 
tumors resulting in tumor-specific accumulation in vivo, as exemplified by the DHA-
paclitaxel conjugate, Taxoprexin. To exploit these favorable properties, a novel 
conjugate linking a second generation taxoid, SB-T-1214, to DHA-propofol in the para 
position of the aromatic ring has been synthesized. The synthesis and biological 
evaluation of this compound will be presented.  
  
MEDI 269 
Synthesis and biological evaluation of the R- and S-enantiomers of the antitubulin 
6-methyl cyclopenta[d]pyrimidines as cytotoxic agents that parallel predicted 
antitubulin activities 
Sudhir Raghavan1, gangjee@duq.edu; Aleem Gangjee1; Ying Zhao1; Susan L. 
Mooberry2; Ernest Hamel3. (1) Graduate School of Pharmaceutical Sciences, Duquesne 
University, Pittsburgh PA 15282, United States (2) Department of Pharmacology, 
University of Texas Health Science Center at San Antonio, San Antonio TX 78229, 
United States (3) National Cancer Institute at Frederick, National Institutes of Health, 
Frederick MD 21702, United States  
Molecules that target microtubules in cancer cells are amongst the most utilized 
chemotherapeutic agents. However, problems such as multidrug resistance, poor water 
solubility, and/or toxicity are severe limitations for such agents. We recently reported a 
racemic mixture of a 6-CH3 cyclopenta[d]pyrimidine that binds to the colchicine site on 
tubulin, exhibited potent antiproliferative activity and circumvented Pgp and βIII tubulin 
mediated resistance. Molecular modeling studies predicted only a slight difference in the 
tubulin binding activities of the R- and S-enantiomers of N-(4-methoxyphenyl)-N,2,6-
trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride. The synthesis and 
evaluation of the individual enantiomers demonstrate a parallel between the predicted, 
docked activities and the observed activities of these enantiomers on tubulin and will be 
discussed. 
MEDI 270 
Synthesis and in silico and in vitro anticancer biological evaluation of N-aromatic 
sulfohydrazone derivatives 
Christian Tadeo Moreno-Reyes, qfb_christian@live.com; Argelia Camargo-Ordoñez; 
Virgilio Bocanegra-Garcia; Sheila Martínez; Gildardo Rivera. Medicinal Chemistry, 
Universidad Autonoma de Tamaulipas, Reynosa Tamaulipas 88740, Mexico  
Cancer is one of the most prevalent diseases in the world. Cancer cell resistance to 
chemotherapy is important to investigate new classes of agents for cancer treatment. In 
this work, initially we propose the synthesis of sulfo-lactams derivatives using classical 
Staudinger reaction as anti-cancer agents, but, results shows 3 series (propionic, 
phenoxy and phenyl acid) of N-aromatic sulfohidrazone derivatives with yields ranging 
from 2 to 44.6%. Additionally, the anti-tumor activity of obtained compounds was 
evaluated in silico and in vitro by the National Cancer Institute of United States. In vitro 
results showed that none of these compounds inhibit human tumor cell growth with 
values > 68%. Interestingly, antituberculosis and antiparasitic activities were showed in 
the in silico tests using the program PASS. 
MEDI 271 
Inhibition of anti-apoptotic Bcl-2 proteins by α-helix mimetics: A novel approach 
for cancer therapy 
Kajal A Bhimani1, kab075000@utdallas.edu; Dang Tran2; Myoung H Kim2; Rey-Chen 
Pong3; Jer-Tsong Hsieh3; Jung-Mo Ahn1. (1) Department of Chemistry, The University 
of Texas at Dallas, Richardson Texas 75080, United States (2) Department of Molecular 
Biology and Immunology, The University of North Texas Health Science Center, Forth 
Worth Texas 76107, United States (3) Department of Urology, The University of Texas 
Southwestern Medical Center, Dallas Texas 75390, United States  
One of the cardinal features of cancer is an evasion from programmed cell death (i.e., 
apoptosis) and it is manifested mainly by activation of anti-apoptotic members of Bcl-2 
family proteins (e.g., Bcl-2, Bcl-xL and Mcl-1) and/or dysfunction of pro-apoptotic 
members (e.g., Bax, Bak, Bad, Bim, Bik and Puma). Hence, the Bcl-2 family has been 
considered as an attractive target to induce apoptotic cell death. Their structures consist 
of up to four conserved Bcl-2 homology (BH) domains that are found to be α-helical 
segments. In particular, an amphipathic α-helical BH3 segment of pro-apoptotic proteins 
(also known as minimal death domain) binds to a hydrophobic groove formed by BH1-3 
domains of anti-apoptotic members and regulates the process of apoptosis by inducing 
oligomerization of Bax and Bak that in turn releases cytochrome c. Thus, we have 
developed helix-mimicking small molecules to emulate the BH3 domains of pro-
apoptotic proteins as inhibitors of anti-apoptotic ones. A series of the BH3 mimetics 
were designed based on a rigid tris-benzamide scaffold that projects three side chain 
functionalities found at the i, i+4 and i+7 positions of the helical BH3 domains. The 
synthesized BH3 mimetics were evaluated on their inhibitory activities by various cell-
based assays. A number of them showed strong inhibition of cell proliferation and 
induction of apoptosis as evidenced by caspase activation, DNA fragmentation, and 
PARP cleavage on various prostate cancer cell lines. All of these illustrate a high 
potential of the BH3 mimetics in disrupting Bcl-2 protein complexes. 
MEDI 272 
Spiruchostatin C, an HDAC inhibitory compound isolated from Burkholderia 
thailandensis 
Paul Klausmeyer1, klausmeyerp@mail.nih.gov; Suzanne Shipley1; Thomas G 
McCloud1; Karina Zuck1; David J Newman2. (1) Natural Products Support Group, SAIC-
Frederick, Inc., Frederick MD 21702, United States (2) DTP, DCTD, NCI-Frederick, 
Frederick MD 21702, United States  
Histone deacetylases (HDACs) are a family of enzymes involved in the regulation of 
eukaryotic and prokaryotic RNA synthesis, and have been validated as a target in the 
treatment of cancer. Continuing research in this area is aimed at finding inhibitors 
(HDACi's) having unique selectivity toward the 18 known HDACs, which could 
potentially be used to treat other types of cancer or as experimental tools in assessing 
the function of HDAC isoforms. In our lab, bioactivity guided fractionation of a 
Burkholderia thailandensis organic solvent extract has resulted in the isolation and 
identification of a new HDACi, a depsipeptide named spiruchostatin C. Structural 
elucidation was accomplished by LC/MS, advanced Marfey's analysis, and 1- and 2-D 
NMR techniques. In the NCI 60 human tumor cell screen, spiruchostatin C showed 
differential selectivity among cell lines compared to FK228, an HDACi approved for 
treatment of human cutaneous T-cell lymphomas. 
MEDI 273 
Anticancer activity of small molecule inhibitors of CREB-mediated gene 
transcription 
Xiangshu Xiao, xiaoxi@ohsu.edu; Bingbing Li. Oregon Health & Sciences University, 
United States  
The cyclic-AMP response-element binding protein (CREB) is a stimulus-activated 
transcription factor. Its transcription activity entails its binding with CREB-binding protein 
(CBP) after CREB is phosphorylated at Ser133. A multitude of protein serine/threonine 
kinases including PKA, PKB and MAPK CREB can phosphorylate CREB. Since these 
pathways are often deregulated, CREB is found to be overactivated in variety of solid 
and liquid cancer tissues. These results suggest that chemical inhibitors of CREB-
mediated gene transcription are promisingly novel cancer therapeutics. We previously 
identified naphthol AS-E as a small molecule inhibitor of CREB-CBP interaction with low 
micromolar potency. In this presentation, we will present data to show that this small 
molecule inhibitor exhibits antiproliferative activities in a variety of solid cancer cell lines 
through activation of apoptosis with low micromolar potency. Consistent with its 
mechanism of action, naphthol AS-E downregulates the expression of CREB target 
genes in cancer cells and its antiproliferative activity is dependent on CREB-CBP 
interaction in cells. Collectively, these studies represent the first small molecule inhibitor 
of CREB-CBP interaction with promising anticancer activities. 
MEDI 274 
Synthesis and biological evaluation of a novel DARPin-SB-T-1214 bioconjugate 
targeting CD-326 (EpCAM) overexpression on the cancer cell surface 
William T Berger1, chembill631@yahoo.com; Manuel Simon2; Andreas Plückthun2; 
Iwao Ojima1, 3. (1) Department of Chemistry, Stony Brook University, Stony Brook NY 
11794-300, United States (2) Department of Biochemistry, University of Zürich, Zürich 
8006, Switzerland (3) Institute of Chemical Biology & Drug Discovery, Stony Brook NY 
11794-300, United States  
Traditional chemotherapy relies solely on the concept that rapidly dividing cancer cells 
will more readily uptake cyctotoxic agents as compared with normal tissues. In actuality, 
many other types of rapidly dividing healthy tissues (e.g., bone marrow, hair follicles) 
can also be affected, leading to systemic toxicity. To address this issue, we have 
synthesized and evaluated several tumor-targeting drug conjugates bearing self-
immolative disulfide linkers as well as vitamins and mAb's as tumor-targeting modules 
with substantial success. Building upon these successes, novel SB-T-1214 
bioconjugate covalently linked, via a self-immolative disulfide linker, to a Designed 
Ankyrin Repeat Protein (DARPin, Ec4) was designed, synthesized, and evaluated in-
vitro for both cytotoxicity and specificity. The synthesis of the novel tumor-targeting drug 
conjugate and results of their biological evaluation will be discussed. 
MEDI 275 
Design, development, and crystal structure of a cell permeable peptidomimetic 
inhibitor of mixed lineage leukemia 1 (MLL1)-WD repeat domain 5 (WDR5) 
interaction as a new approach in cancer therapy 
Hacer Karatas1, 2, 3, hkaratas@umich.edu; Elizabeth C. Townsend4; Yong Chen5, 6; 
Denzil Bernard2, 3; Yali Dou4; Ming Lei5, 6; Shaomeng Wang1, 2, 3, 7. (1) Department of 
Medicinal Chemistry, University of Michigan, United States (2) Department of Internal 
Medicine, University of Michigan, United States (3) Department of Comprehensive 
Cancer Care, University of Michigan, United States (4) Department of Pathology, 
University of Michigan, United States (5) Howard Hughes Medical Institute, University of 
Michigan, United States (6) Department of Biological Chemistry, University of Michigan, 
United States (7) Department of Pharmacology, University of Michigan, United States  
MLL1 is a Histone-3 Lysine-4 (H3K4) methyl transferase, which is misregulated in 
leukemia. Upregulation of the target genes HoxA9 and Meis-1 links MLL1 with its 
tumorigenic properties. Therefore targeting the catalytic activity of MLL1 to repress 
expression of these genes could be a novel approach in cancer therapy. H3K4-
methylation by MLL1 requires formation of a core complex consisting of MLL1, WDR5, 
RbBP5 and Ash2L, where the interaction of MLL1 with WDR5 is essential for catalytic 
activity. We developed a cell permeable peptidomimetic inhibitor of MLL1-WDR5 
interaction, Compound-A (Mw=633Da), which binds to WDR5 with Ki<1nM, and can 
efficiently inhibit catalytic activity of the reconstituted MLL1 core complex, in vitro. 
Furthermore Compound-A can block H3K4-trimethylation at HoxA9 promoter and 
reduce HoxA9 expression in MLL1-AF9 transformed BM cells. Crystal structure of 
Compound-A bound to WDR5 confirms our design strategy. These results suggest that 
inhibitors targeting MLL1-WDR5 interaction might have a therapeutic potential for 
cancer. 
MEDI 276 
Potential anticancer agents: Identification of small molecules as procaspase-3 
activators 
Anil K Sharma1, anil_sharma@envigenpharma.com; A. Clay Clark2; Josh Schipper2; 
Sarah MacKenzie2. (1) Department of Chemistry, ENVIGEN Pharmaceuticals, Inc., 
Research Triangle Park NC 27709, United States (2) Department of Molecular and 
Structural Biochemistry, North Carolina State University, Raleigh NC 27695, United 
States  
Recent efforts for the treatment of cancer have focused on reestablishing the extrinsic 
or intrinsic apoptotic pathways, or both, by inhibiting antiapoptotic molecules, such as 
IAPs or c-FLIP, or by elevating levels of proapoptotic factors, such as Bcl-2 antagonists. 
Our primary goal for the treatment of cancer is the restoration of apoptosis in tumor cells 
via activation of procaspase-3. Procaspase-3 zymogen is the precursor of caspase-3, 
can be an important target of chemotherapy-induced tumor cell death. The 
concentration of procaspase-3 is elevated in a number of cancer cell lines, but there are 
no deleterious effects on the cancer cells unless it undergoes autocatalytic activation or 
proteolysis by caspase-9, that results in caspase-3 activation. Our preliminary data have 
shown that even the change in confirmation of procaspase-3 results in its activation. 
Small molecules that selectively bind the dimer interface of procaspase-3 effectively kill 
cellular proteins without converting the proenzyme into caspase-3. 
MEDI 277 
Mitochondria targeted photodynamic therapy 
Sean Marrache, sm186@uga.edu; Shanta Dhar. Department of Chemistry, University 
of Georgia, Athens GA 30602, United States  
Photodynamic therapy(PDT) with a photosensitizer(PS) that targets mitochondria 
causes a prompt release of cytochrome c into the cytoplasm and activation of caspases 
that are responsible for cell degradation. Mitochondria have repeatedly been implicated 
as targets of porphyrin mediated PDT. A systematic study to direct the PDT drugs 
towards their cellular target, mitochondria of the cancer cell, is not fully explored. PDT 
causes mitochondrial damage and induces apoptosis. We hypothesize that construction 
of engineered targeted drug delivery systems to direct PDT drugs to the mitochondria 
would allow for effective phototherapeutics. This would result in a higher concentration 
of singlet oxygen in the mitochondria of cancer cells. We have initiated the synthesis of 
a series of mitochondria targeting polymers to study nanoparticle(NP) assisted delivery 
and anticancer properties of metallophthalocyanines. One construct, which includes a 
mitochondria targeting moiety on NPs with encapsulated zinc-phthalocyanine(ZnPc) is 
represented in  
   . 
MEDI 278 
Design of negative allosteric modulators of the dopamine D2 receptor 
Satyendra Mishra1, smishra@umn.edu; Swapna Bhagwanth1; Ritesh P. Daya2; Jordan 
K. Mah2; Ram K. Mishra2; Rodney L. Johnson1. (1) Department of Medicinal Chemistry, 
University of Minnesota, Minneapolis MN 55455, United States (2) Department of 
Psychiatry & Behavioral Neuroscience, McMaster University, Hamilton Ontario L8N 
3Z5, Canada  
Prolyl-leucyl-glycinamide (PLG) is a unique endogenous peptide, which modulates 
dopamine receptor subtypes of the D2 receptor family within the CNS in an allosteric 
manner. Previously, we demonstrated that diastereomeric pairs of 5.6.5-spirobicyclic 
lactam mimics of PLG differing in the stereochemistry at the C-8a' position (1a/1b; 
2a/2b) exhibited opposing modulatory activities at the D2 dopamine receptor with 1a and 
2a being positive modulators and 1b and 2b being negative modulators (Raghavan, B.; 
et al. J. Med. Chem. 2009, 52, 2043). We hypothesized that the opposite bridgehead 
chirality resulted in a different pucker of the scaffold's thiazolidine ring, which in turn 
caused the C-2' methylene group to jut into a different area of topological space, 
thereby producing the negative modulatory effect. To test this hypothesis we designed 
the gem-dimethyl derivatives 3a, 3b, 4a, and 4b with the idea that such a substitution 
places steric bulk in the topological space that the C-2' methylene group occupies in the 
negative modulators. We postulated that with such a substitution we would be able to 
convert a positive modulator into a negative one. Pharmacological results on the 
designed molecules support our hypothesis.   
  
MEDI 279 
Structure-activity relationships of the systemically active peptide  kappa opioid 
receptor antagonist zyklophin 
Anand A Joshi1, jsh_nnd@yahoo.com; Thomas F Murray2; Jane V Aldrich1. (1) 
Department of Medicinal Chemistry, University of Kansas, Lawrence KS 66045, United 
States (2) Department of Pharmacology, School Of Medicine, Creighton University, 
Omaha NE 68178, United States  
Kappa opioid receptor (KOR) antagonists have potential applications in the treatment of 
drug abuse and depression. We have prepared the peptide KOR selective antagonist 
zyklophin (Patkar, et al., J. Med. Chem. 2005, 48, 4500) that is systemically active and 
appears to cross the blood-brain barrier (Aldrich, et al., PNAS 2009, 106, 18396). Our 
objectives in the present study are to identify structural features of zyklophin that are 
responsible for its high KOR selectivity and antagonist activity, and to enhance its 
potency. We synthesized several zyklophin analogs with different N-terminal alkyl 
substituents, amino acid substitutions, and varying the residues involved in the cyclic 
constraint. The peptides were prepared by Fmoc (fluorenylmethyloxycarbonyl) solid 
phase synthesis with selective deprotection of the residues involved in the cyclization. 
Preliminary pharmacological data suggest that the fifth residue and the N-benzyl 
modification contribute to the peptide's KOR affinity and antagonist activity. Supported 
by NIDA grant R01 DA018832.   
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Probes for narcotic receptor mediated phenomena: Effect of C4a alkyl and ar-
alkyl chain length on the opioid receptor affinity of N-methyl cis-4a-substituted 
1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols 
Malliga R Iyer1, iyerma@mail.nih.gov; Christina M Dersch2; Richard B Rothman2; 
Arthur E Jacobson1; Kenner C Rice1. (1) Drug Design and Synthesis Section, Chemical 
Biology Research Branch, National Institute on Drug Abuse, Rockville Maryland 20852, 
United States (2) Clinical Psychopharmacology Section, Chemical Biology Research 
Branch, National Institute on Drug Abuse, Addiction Research Center, Baltimore 
Maryland 21224, United States  
Benzofuro[2,3-c]pyridinols are partial structures of oxide-bridged phenylmorphans. 
Racemic cis-benzofuro[2,3-c]pyridin-6-ol with a phenethyl substituent on nitrogen and a 
C4a ethyl substituent 1 have been shown by Hutchison, et al. to have a high affinity for 
opioid receptors. As part of our continuing interest in benzofuro[2,3-c]pyridin-ol series of 
compounds, we have devised a simpler route for the synthesis of these compounds. 
This route enabled the studies on heretofore, unexplored analogs in the racemic cis-
benzofuro[2,3-c]pyridin-6-ol series of compounds. A study involving the effect of chain 
length and substitution at the C4a position of cis-hexahydrobenzofuro[2,3-c]pyridin-6-ols 
was undertaken. The N-methyl-C4a-alkyl 2 and ar-alkyl 3 derivatives were synthesized 
and their affinity on opioid receptors was determined. Binding studies and functional 
assays revealed interesting trends. Data from this study will be discussed. Additional 
manipulations were made to modify the N-substitution. Synthesis and binding studies of 
the C4a phenethyl N-substituted derivatives 4 will also be presented.  
  
MEDI 282 
Design and synthesis of aminothiazole meriolin hybrid compounds as CDK5 
inhibitors 
Dhruv Shah1, shahd@duq.edu; Prashi Jain1; Patrick T. Flaherty1; Sankar G. 
Manepalli2; Jeffry D. Madura2. (1) Mylan School of Pharmacy, Duquesne University, 
Pittsburgh PA 15282, United States (2) Bayer School of Natural and Environmental 
Sciences, Duquesne University, Pittsburgh PA 15282, United States  
Cyclin dependent kinase 5 (CDK5) is a proline-directed serine/threonine kinase, which 
plays a prominent role in the pathology of Alzheimer's disease. CDK5 has been 
implicated in tau hyperphosphorylation that ultimately precipitates as neurofibrillary 
tangles (NFTs), a classic hallmark of Alzheimer's disease. The high homology between 
CDK5 with CDK2 (60% overall) has presented a challenge in developing selective 
inhibitors. Known compound 1 has been shown to have nanomolar inhibitory activity 
against CDK5. Novel hybrid analogs incorporating features of both 1 and Meriolin 5 (2) 
have been explored. The design, synthesis and enzymatic analysis of these new hybrid 
compounds will be presented. 
MEDI 283 
Discovery and structure-activity relationship studies of 1,3-cyclohexyl-diamides 
as novel mGlu5 receptor negative allosteric modulators 
Hao Zhou1, hazh@lundbeck.com; Michel Grenon1; Guiying Li1; Hermogenes N 
Jimenez1; Christina L Bonvicino2; Xiaosui Pu2; Sidney W Topiol1; Robbin M Brodbeck2; 
Gamini Chandrasena1; Darío Doller1. (1) Chemical & Pharmacokinetic Sciences, 
Lundbeck Research USA, Paramus NJ 07652, United States (2) Synaptic Transmission 
Disease Biology Unit, Lundbeck Research USA, Paramus NJ 07652, United States  
Metabotropic glutamate receptors (mGlus) are a class of G-protein coupled receptors 
(GPCRs) that respond to the excitatory neurotransmitter glutamate. Eight mGluRs 
(mGluR1-8) have been identified and classified into three groups (group I, II, and III) 
based on their sequence homology, second messenger coupling, and pharmacology. 
Potential therapeutic applications for negative allosteric modulators of mGlu5 (mGlu5 
NAM) include pain, acute migraine, anxiety, depression, fragile X syndrome, drug 
dependency, GERD, and Parkinson's disease. Herein we report a novel series of 1,3-
cyclohexyl-diamides as mGlu5 NAMs. The structure-activity relationship and ADME 
properties of selective compounds of this chemotype will be presented. 
MEDI 284 
N-aryl pyrrolidinyl oxadiazoles as potent mGlu5 positive allosteric modulators 
Mathivanan Packiarajan1, matp@lundbeck.com; Christine G. Mazza Ferreira1; Sang-
Phyo Hong1; Andrew D. White1; Gamini Chandrasena1; Albert J. Robichaud1; Robbin M. 
Brodbeck2. (1) Chemical & Pharmacokinetic Sciences, Lundbeck Research USA, 
Paramus New Jersey 07652, United States (2) Synaptic Transmission, Disease Biology 
Unit, Lundbeck Research USA, Paramus New Jersey 0762, United States  
Glutamate is the major excitatory neurotransmitter in the central nervous system acting 
on both ionotropic and metabotropic glutamate receptors. Eight subtypes of 
metabotropic glutamate receptors (mGluRs) have been identified and classified into 
group I (mGlu1 and mGlu5), group II (mGlu2 and mGlu3) and group III (mGlu4, mGlu6, 
mGlu7 and mGlu8) receptors. mGlu5 receptor modulation has been shown in various 
preclinical models to be potentially beneficial in a number of disease states. Activation 
of mGlu5 receptors has been postulated to ameliorate positive symptoms and cognitive 
deficits in schizophrenia. Through screening of our internal compound collection, we 
identified N-Aryl pyrrolidinyl oxadiazoles as leads which exhibit moderate EC50 at the 
mGlu5 receptor. Optimization led to identification of highly potent compounds with 
acceptable in vitro metabolic clearance, CYP inhibition, hERG and PK properties. Here 
we report our efforts towards identification of N-Aryl pyrrolidinyl oxadiazoles as potent 
mGlu5 positive allosteric modulators. 
MEDI 285 
Disposition characteristics and functional activity of LSP1-2111, an orthosteric 
Group III metabotropic glutamate receptor agonist 
Dario Doller1, dado@lundbeck.com; Sang-Phyo Hong1; Kevin G. Liu1; Maria D 
Bacolod1; Michelle A Uberti2; Manuel Cajina1; Francine Acher3; Paolo Gubellini4. (1) 
Chemical & Pharmacokinetic Sciences, Lundbeck Research USA, Paramus NJ 07652, 
United States (2) Synaptic Transmission Disease Biology Unit, Lundbeck Research 
USA, Paramus NJ 07652, United States (3) Laboratoire de Chimie et Biochimie 
Pharmacologiques et Toxicologique, UMR 8601, CNRS, Université Paris Descartes, 
Paris Cedex, France (4) Institut de Biologie du Développement de Marseille - Luminy 
(IBDML), UMR 6216, CNRS/Aix-Marseille Université, Marseille, France  
LSP1-2111 [(2S)-2-amino-4-(hydroxy(hydroxy(4-hydroxy-3-methoxy-5-
nitrophenyl)methyl)phosphoryl)butanoic acid; 1] is a novel orthosteric, preferential 
agonist of the mGlu4 receptor, a member of the group III mGlu receptor family.  We 
report herein our studies on the in vitro pharmacology and CNS disposition of this 
compound. In addition, the in vitro brain electrophysiology studies showing the 
functional potentiation of the inhibitory actions of LSP1-2111 on EPSC by the mGlu4 
positive allosteric modulator Lu AF21934 ((1S,2R)-N1-(3,4-dichlorophenyl)-cyclohexane-
1,2-dicarboxamide, 2) will be discussed.   
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Discovery and development of central nervous system (CNS) penetrant casein 
kinase 1 (CK1δ/ε) inhibitors 
Jianke Li, jianke.li@pfizer.com; Jenifer A. Bradley; Michael A. Burge; Todd W. Butler; 
Ramalakshmi Y. Chandrasekaran; Angela C. Doran; Katherine E. Fisher; Paul Galatsis; 
David F. Gebhard; Ashley N. Hanks; Michele P. Kelly; John D. Knafels; Scot R. Mente; 
James D. Offord; Jeffrey F. Ohren; Vanessa Paradis; Blossom Sneed; Chakrapani 
Subramanyam; Todd A. Wisialowski; Laura E. Zawadzke; Travis T. Wager. Worldwide 
Research and Development, Pfizer, Groton CT 06340, United States  
CK1 delta (CK1δ) and CK1 epsilon (CK1ε) are closely related members of a family of 
seven mammalian serine/threonine protein kinases previously known as casein kinases 
that have been identified as key regulatory factors in the control of circadian rhythms. 
Therefore, inhibitors of CK1δ/ε may be of therapeutic value in circadian rhythm 
disrupted disorders such as: jet lag, shift work and psychiatric disorders (i.e. treatment 
resistant depression and bipolar). In this work, we'll disclose the structure activity 
relationships (SAR) and kinase selectivity for a set of novel CK1 inhibitors. Further, the 
application of structure based drug design that transformed a p38 single point hinge 
binder into a selective CNS penetrant two point binding CK1 inhibitor will be described. 
MEDI 288 
Synthesis and evaluation of thiazolo[4,5-d]-pyrimidines as corticotropin releasing 
factor receptor antagonists 
Bhimanna K Kuppast1, bhimanna.kuppast@sdstate.edu; Pawel Szymanski1; 
Christophina Lynch1; Yueshan Hu2; Gareth E Davies1, 2, 3; Hesham Fahmy1. (1) 
Department of Pharmaceutical Sciences, South Dakota State University, Brookings 
South Dakota 57006, United States (2) Avera Institute for Human Behavioral Genetics, 
Avera Behavioral Health Center, Sioux Falls South Dakota 57108, United States (3) 
Department of Psychiatry, University of South Dakota, Brookings South Dakota 57006, 
United States  
Corticotropin releasing factor(CRF) is a 41 amino acid endogenous neuropeptide 
synthesized by specific hypothalamic nuclei in the brain and involved in the regulation of 
the Hypothalamus-Pituitary-Adrenal (HPA) axis. It is the principle modulator of 
mammalian physiological and behavioral responses to stress. Physiological responses 
of CRF are mediated through two receptors namely CRF1 and CRF2. CRF1 mediates 
normal responses to stress and CRF2 appears to play an important role in fine-tuning 
stress responses. Thus CRF represents new opportunity for the treatment of major 
depression and anxiety.  Various peptide and non-peptide molecules are shown to 
inhibit CRF and thiazolo [4,5-d]-pyrimidines are one of them. We have prepared various 
derivatives of the fused thiazolo-pyrimidines as non-peptide CRF receptor antagonists. 
Few of the derivatives were analyzed for their effect on cell viability, effect on CRF1, 
Serotonin, CREB1, Dopamine transporter, MAO-A, NPY and Dopamine β-hydroxylase 
gene expression in αT3-1 pituitary mouse cell lines and Cyclic AMP levels. The gene 
expression studies were compared with known antagonist Antalarmin. A Few of the 
derivatives were shown to have comparable effects with Antalarmin in up- regulating 
gene expression and reducing Cyclic AMP levels. The binding affinities for these 
compounds using the CRF receptors will be measured to select lead compounds that 
can be further evaluated for their potential antianxiety and antidepressant properties. 
MEDI 289 
Tetra-alkyl bis-phosphates as bivalent inhibitors of butyrylcholinesterase: 
Compounds with potential for the treatment of Alzheimer's disease 
Kim Ngan Tu, Kim.Tu@student.csulb.edu; Carmen Castillo; Omar Gallegos; Reyna 
Raya; Elise Van Fossen; Roger A. Acey; Kensaku Nakayama. Department of Chemistry 
and Biochemistry, California State University, Long Beach, Long Beach California 
90840, United States  
Butyrylcholinesterase (BChE) is a non-specific cholinesterase found in blood plasma 
with unknown physiological function. It is thought to play a role in growth and 
development and to act as a scavenger of cholinergic toxins as well as having an 
auxiliary role in synaptic transmission. BChE, like AChE, can hydrolyze acetylcholine. 
Since BChE activity in the brain of Alzheimer's patients is elevated 40-90% above 
normal, BChE inhibitors can increase acetylcholine concentration in the brain. 
Therefore, these inhibitors may hold promise in the treatment of cognitive loss due to 
Alzheimer's disease. Different structural variations of the bivalent inhibitors, tetra-alkyl 
bis-phosphates, were prepared and evaluated in vitro for their inhibitory activity against 
BChE to determine the optimal linker chain length between two phosphates and the 
alkyl groups in order to maximize inhibition. These bivalent inhibitors are thought to 
interact at two sites of the enzyme and, therefore, their inhibitory properties may be 
magnified. 
MEDI 290 
What it takes to make amphetamine act different than dopamine at the human 
dopamine transporter 
Renata Kolanos1, rkolanos@vcu.edu; Rachel L Deitz2; Louis J De Felice2; Richard A 
Glennon1. (1) Department of Medicinal Chemistry, Virginia Commonwealth University, 
Richmond VA 23219, United States (2) Department of Physiology and Biophysics, 
Virginia Commonwealth University, Richmond VA 23298, United States  
The predominant action of the human dopamine (DA) transporter (hDAT) is re-uptake of 
extracellular DA into presynaptic neurons; however exposure of hDAT to 
psychostimulants can result in a reverse effect. Amphetamine (AMPH) and AMPH-like 
compounds are hDAT substrates that increase extracellular DA by diminishing DA re-
uptake and releasing DA stored in synaptic vesicles. Although DA and AMPH produce 
inward currents through hDAT, only S(+)AMPH induces a persistent inward current. 
This persistent depolarization of dopaminergic neurons may play a role in the behavioral 
effects of psychostimulants. To understand which structural features are important in 
recognition of DA-like vs AMPH-like substrates we synthesized AMPH/DA hybrids and 
recorded currents through hDAT expressed in Xenopus laevis oocytes. All compounds 
possessing hydroxyl group(s) on the benzene ring behaved like DA and did not produce 
a persistent depolarization. Based on these results lack of ring hydroxylation could be 
the key structural feature accounting for AMPH-like action at hDAT. [NIH 
RC1DA028112] 
MEDI 291 
Preparation of potential serotonin transporter (SERT) inhibitors for diagnosing 
depression 
Danniebelle N. Haase1, dnhaase@mail.med.upenn.edu; Brian P. Lieberman1; Karl 
Plöessl1; Hank F. Kung1, 2. (1) Department of Radiology, University of Pennsylvania, 
Philadelphia PA 19104, United States (2) Department of Pharmacology, University of 
Pennsylvania, Philadelphia PA 19104, United States  
The relationship between serotonin and depression is well documented. Currently 
serotonin reuptake inhibitors (SSRIs) that target the serotonin transporter (SERT) are 
prescribed to treat millions of people with depression. Positron emission tomography 
(PET) imaging agents are useful for studying the binding sites of psychoactive drugs 
and monitoring the efficacy of such drugs. Several biphenylthiol imaging agents have 
been developed to study binding to SERT. On the contrary, ligands possessing a 
biphenyloxide core are relatively unexplored. Additionally, the routine use of several 
standard SERT tracers in medical centers is limited as many are labeled with carbon-
11. Thus in this study, novel fluorine-containing biphenyloxides were prepared as 
potential probes to examine SERT binding in the brain. 
MEDI 292 
Synthesis of Pawhuskin analogs 
Alyssa M Mick, alyssa-mick@uiowa.edu; Jeffrey D Neighbors; David F Wiemer. 
Department of Chemistry, University of Iowa, Iowa City Iowa 52242-1294, United States  
The isolation of the pawhuskins from the purple prairie clover Dalea purpea was 
reported in 2004. These compounds are prenylated stilbenes that bind to opioid 
receptors, an activity that is surprising given that they are non-nitrogenous. Pawhuskin 
A was shown to be a kappa selective antagonist with moderate binding affinity, and 
kappa antagonists are of special interest as potential treatments for stimulant abuse as 
well as other disorders. To help elucidate the novel pharmacophore of the pawhuskins, 
we have synthesized a number of new analogues. Our previous research on 
schweinfurthin synthesis employed a late-stage Horner–Wadsworth–Emmons 
condensation reaction to prepare the central stilbene olefin, and a similar chemical 
approach has been used to prepare pawhuskins. The chemical syntheses of these new 
pawhuskin analogues will be presented, along with hypotheses of opioid receptor 
interaction tested by further compound design.   
  
MEDI 293 
Conformationally rigid histone deacetylase inhibitors correct ΔF508-CFTR protein 
function 
Chris J. Vickers1, vickers@scripps.edu; Christian A. Olsen2; Darren M. Hutt3; Ana 
Montero1; Luke J. Leman1; Bruce E. Maryanoff1; William E. Balch3; M. Reza Ghadiri1. 
(1) Department of Chemistry, The Scripps Research Institute, La Jolla California 92037, 
United States (2) Department of Chemistry, Technical University of Denmark, Denmark 
(3) Department of Cell Biology, The Scripps Research Institute, La Jolla California 
92037, United States  
Histone deacetylase (HDAC) inhibitors have shown partial efficacy toward correcting 
cystic fibrosis transmembrane conductance regulator (CFTR) protein function in ΔF508-
CFTR models. While current treatment options for CF generally concentrate on disease 
symptoms such as management of inflammation and bacterial infection, therapy using 
HDAC inhibitors has the potential to treat and correct the underlying etiology associated 
with the disorder. Subsequently, we have synthesized conformationally well-defined 
cyclic tetrapeptide derivatives based on the natural product HDAC inhibitor Apicidin, in 
order to formulate a pharmacophore model to describe and enhance the bioactivity of 
these molecules. Through this study we have developed HDAC inhibitors which improve 
CFTR trafficking from the endoplasmic reticulum (ER) while ultimately increasing ion 
conductance across the plasma membrane of a lung epithelial cell line expressing 
ΔF508-CFTR. 
MEDI 294 
Design and synthesis of pyridazinone-phenethylamine based histamine H3 
receptor antagonists 
Reddeppa reddy Dandu, rdandu@cephalon.com; Jacquelyn Lyons; Rita Raddatz; 
John A Gruner; Joanne R Mathiasen; Lisa D Aimone; Zeqi Huang; Greg Hosteller; 
Caitlyn Benfield; Robert L Hudkins. Medicinal Chemistry, Cephalon, Inc., West Chester 
Pennsylvania 19380, United States  
The histamine H3 receptor (H3R) is a G-protein coupled receptor (GPCR) located 
primarily in the brain that functions as an autoreceptor to modulate histamine release 
and as an inhibitory heteroreceptor, regulating the release of key neurotransmitters 
including acetylcholine (ACh), dopamine (DA), norepinephrine (NE), and serotonin (5-
HT) that are involved in attention, vigilance, and cognition. Thus, H3R antagonists may 
have utility in addressing a variety of CNS disorders associated with deficits in 
wakefulness, attention, and cognition, including attention-deficit hyperactivity disorder 
(ADHD), Alzheimer's disease (AD), mild cognitive impairment, and schizophrenia. We 
have identified potent and orally bioavailable pyridazinone-phenethylamine analogs as 
histamine H3 receptor antagonists. The synthesis, SAR, selectivity and 
pharmacokinetics of the pyridazinone-phenethylamine series will be presented. 
MEDI 295 
Facile preparation of optical/nuclear dual imaging probes using radionuclides 
Yeong Su Ha1, gksksrkd@naver.com; Gwang Il An2; Se-Il Park1; Jungmin Oh3; 
Jeongsoo Yoo1. (1) Department of Molecular Medicine, Kyungpook National Univerity 
School of Medicine, Daegu 700-422, Republic of Korea (2) Department of Molecular 
Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul 
139-706, Republic of Korea (3) Korea Basic Science Institute Chuncheon Center, 
Gangwon-do 200-701, Republic of Korea  
Molecular imaging has become an indispensable research tool in many areas of 
biomedical science. Recently, even though it is still a challenge to integrate different 
imaging modalities into single imaging probes, multi-modality imaging has become 
possible due to the synthesis of hybrid dual- or triple-modality imaging probes. Here we 
report new facile methods for the preparation of optical/nuclear dual imaging probes 
using Cerenkov radiation. The characteristics of this technology as a new optical 
imaging modality were examined with respect to sensitivity, spatial resolution and tissue 
penetration. By simply radiolabeling antibodies with appropriate positron-emitting 
radionuclides, optical imaging-based dual modality imaging probes were easily 
prepared in high yields.  
  
MEDI 296 
Discovery of MK-3168: A clinical PET tracer as a target engagement biomarker for 
FAAH 
Ping Liu1, ping_liu2@merck.com; Terence Hamill2; Marc Chioda1; Harry Chobanian1; 
Selena Fung1; Yan Guo1; Linus S. Lin1; Catherine Abbadie3; Jessica Alexander3; Hong 
Jin3; Suzanne Mandala3; Lin-Lin Shiao3; Wenping Li2; Sandra Sanabria2; David 
Williams2; Zhizhen Zeng2; Richard Hajdu4; Nina Jochnowitz4; Mark Rosenbach4; Bindhu 
Karanam5; Maria Madeira5; Gino Salituro5; Joyce Powell5; Ling Xu5; Patricia Miller2; 
Jacquelynn Cook2; Marie Holahan2; Aniket Joshi2; Stacey O’Malley2; Mona Purcell2; 
Diane Posavec2; Tsing-bau Chen2; Kerry Riffel2; Mangay Williams2; Rebecca 
Blanchard6; Inge De Lepeleire7; Ruben Declercq7; Guy Bormans8; Koen Van Laere8; 
Tjibbe De Groot8; Nele Evens8; Kim Serdons8; Richard Hargreaves2; Kathleen A 
Sullivan3; Ravi P Nargund1; Robert J DeVita1. (1) Department of Medicinal Chemistry, 
Merck Research Laboratories, Rahway NJ 07065, United States (2) Imaging Research, 
Merck Research Laboratories, West Point PA 19438, United States (3) Department of 
Immunology, Merck Research Laboratories, Rahway NJ 07065, United States (4) 
Department of Pharmacology, Merck Research Laboratories, Rahway NJ 07065, United 
States (5) Department of Preclinical DMPK, Merck Research Laboratories, Rahway NJ 
07065, United States (6) Clinical Pharmacology, Merck Research Laboratories, Upper 
Gwynedd PA 19454, United States (7) Clinical Pharmacology Europe, Merck Research 
Laboratories, Brussels B-12000, Belgium (8) Leuven PET Center, Merck Research 
Laboratories, Leuven B-3000, Belgium  
Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme responsible for the 
breakdown of several fatty acid ethanolamide (FAE) signaling molecules, including the 
endocannabinoid arachidonoyl ethanolamide (anandamide, AEA), and the related lipids 
N-palmitoyl ethanolamide (PEA) and N-oleoyl ethanolamide (OEA). Inhibition of FAAH 
leads to elevated levels of these endogenous FAEs which act on cannabinoid, vanilloid, 
and other receptors to suppress pain transmission. Thus, a small molecule FAAH 
inhibitor is expected to provide therapeutic benefit in the management of inflammatory 
and neuropathic pain. Genetic and pharmacological data in rodents support a 
hypothesis that a high level of FAAH inhibition in the CNS is necessary for maximal 
analgesic efficacy. In order to provide data to guide dose selection for clinical studies 
and establish the relationship between enzyme inhibition and PD response, a clinical 
PET tracer suitable for measuring central occupancy of the FAAH enzyme is highly 
desirable. This presentation will discuss the FAAH program's target engagement 
strategies and focus on the efforts that led to the discovery of a novel FAAH PET tracer 
(MK-3168). Preclinical results in rhesus monkey and initial clinical results with this PET 
tracer will also be disclosed. 
MEDI 297 
Nuclear/MR dual-modality imaging agent based on liposome 
Jong Hee Kim1, nik21c@nate.com; Jeongsoo Yoo1; Hui Jin Song2; Youn Ji Kim1; 
Darpan N. Pandya1; Yeong Su Ha1; Gwang Il An3; Yongmin Chang4. (1) Department of 
Molecular Medicine, Kyungpook National University School of Medicine, Daegu 700-
422, Republic of Korea (2) Department of Medical and Biological Engineering, 
Kyungpook National University School of Medicine, Daegu 700-422, Republic of Korea 
(3) Molecular Imaging Research Center, Korea Institute of Radiological and Medical 
Sciences, Seoul 139-706, Republic of Korea (4) Department of Diagnostic Radiology, 
Kyungpook National University School of Medicine, Daegu 700-721, Republic of Korea  
Liposome has been heavily utilized in drug delivery during last several decades, and 
now is seeking new application in imaging. Currently no single imaging modality 
provides all information for the characterization of complex body system. Instead, 
multimodality imaging, which combines two different imaging modality, gives various 
promising results. Especially the combination of nuclear imaging and magnetic 
resonance (MR) imaging will benefit due to their highly complimentary nature. Here we 
report new nuclear/MR dual-modality imaging probes based on liposome. Nuclear/MR 
dual imaging probe is prepared by incorporation of radio-iodine labeled lipophilic small 
molecule on liposome membrane and encapsulation of Gd complex inside of liposome. 
Gamma camera and MR imaging was successfully obtained in tumor-baring mice using 
single dual imaging probes. 
  
MEDI 298 
WITHDRAWN 
MEDI 299 
New cephalosporin-derived inhibitor of ß-lactamase: Synthesis, mechanism, and 
structure 
David C McLeod1, dmcleod@smu.edu; Elizabeth Rodkey2; Yashar Niknafs2; 
Christopher R Bethel3; Robert A Bonomo3; Paul R Carey2; Focco van den Akker2; John 
D Buynak1. (1) Chemistry, Southern Methodist University, Dallas Texas 75275, United 
States (2) Biochemistry, Case Western Reserve University School of Medicine, 
Cleveland Ohio 44106, United States (3) Louis Stokes Cleveland Department of 
Veterans Affairs Medical Center, Cleveland Ohio 44106, United States  
A new cephalosporin-derived inhibitor of class A ß-lactamases was prepared and 
evaluated kinetically, spectroscopically, and crystallographically. This molecule inhibits 
via a novel mechanism that was confirmed crstallographically through a complex with 
the SHV-1 ß-lactamase. The individual steps of the proposed mechanism were verified 
using Raman Spectroscopy. 
MEDI 300 
N-Chlorooxazolidin-2-ones as antimicrobial agents at neutral pH 
Eric D Turtle, eturtle@novabaypharma.com; Charles Francavilla; Timothy P Shiau; 
Donogh J.R. O'Mahony; Eddy Low; Bum Kim; Lisa C Friedman; Meghan E Zuck; Louisa 
D'Lima; Ping Xu; Francis Ruado; Nicholas P. Wayham; Mark B Anderson; Ramin Najafi; 
Rakesh K Jain. NovaBay Pharmaceuticals, Inc., Emeryville CA 94608, United States  
Previously synthesized N-chloramines have excellent activity at low pH; however, they 
can display reduced activity at physiological pH. Our recent structure activity/stability 
relationship efforts allowed us to identify new N-chlorooxazolidinones as agents with 
improved antimicrobial activity under a broad range of pH evaluations. Syntheses and in 
vitro antimicrobial activity of new 5-membered heterocycles are discussed, 
demonstrating potent antimicrobial compounds with bactericidal activity (1 hr MBC) 
against Staphylococcus aureus and Escherichia coli at 0.5 µg/mL and fungicidal activity 
(1 hr MFC) against Candida albicans as low as 8 µg/mL at pH 7.  
  
MEDI 301 
Methoxy β-Lactam derivatives as antimicrobial compounds 
Jeanette T Minah1, jeanetteminah@gmail.com; Kriti Arora2; Helena Boshoff I.M. 
Boshoff2; Jeffrey Deschamps Deschamps3; Monika I. Konaklieva1. (1) Department of 
Chemistry, American University Washington, DC 20016 20016, United States (2) 
Department of Tuberculosis Research Section, LCID, NIAID, NIH MD 20892, United 
States (3) Department of Code 6030, Naval Research Laboratory Washington, DC 
20375, United States  
Adequate treatment of infectious diseases is under siege due to microorganisms that 
are resistant to currently available antibiotics. However, while drug-resistance exists in a 
wide range of clinically important microorganisms, new drug development has 
significantly lagged behind the need. To address that need, new approaches to drug 
development are necessary. Examples of such compounds prepared in our laboratories 
comprise of monocyclic beta-lactams with distinct substituent groups attached to an 
aromatic thiol, at the C4 of the β-lactam ring. These compounds, especially methoxy- 
thiophenols demonstrate activity specifically against Mycobacterium tuberculosis (Mtb). 
Structure-activity relationship (SAR) of these lactams against Mtb will be presented. 
MEDI 302 
Quaternary ammonium stabilized dichloroamines as antimicrobial agents 
Eddy Low Low1, elow@novabaypharma.com; Eric D Turtle1; Donogh J. R. O'Mahony1; 
Charles Francavilla1; Bum Kim1; Timothy P. Shiau1; Lisa C. Friedman2; Louisa M. 
D'Lima2; Nicole J. Alvarez2; Ping Xu2; Nicholas P. Wayham2; Mark B. Anderson2; Ramin 
(Ron) Najafi2; Rakesh K. Jain1. (1) Drug Discovery, Novabay Pharmaceuticals, 
Emeryville CA 94608, United States (2) Novabay Pharmaceuticals, Emeryville CA 
94608, United States  
N,N-Dichlorotaurine and N-chlorotaurine are potent, broad-spectrum antimicrobial 
agents produced by neutrophils during phagocytosis. Their use as a therapeutic agent 
is only limited due to their short shelf-life in solution at room temperature. Our structure 
activity/stability relationship study identified compound 1 as a water stable 
dichloroamine that retains excellent in vitro activity and good solution stability. A 
medicinal chemistry approach to improve the antimicrobial activity while maintaining 
aqueous stability of this class of agents will be examined. These analogs depict a profile 
of bactericidal activity (1 hr MBC) against Staphylococcus aureus and Escherichia coli 
in the range of 2-2048 µg/mL at both pH 4 and pH 7 with several analogs exhibiting 
potent activity. Furthermore, some analogs had fungicidal activity (1 hr MFC) against 
Candida albicans in the range of 4-2048 µg/mL at pH 7.   
  
MEDI 303 
Penicillin sulfones: An investigation of the effect of the 2'-substituent 
Micheal Nottingham1, mnottingha@smu.edu; Sundar R. R. Pagadala1; Christopher R 
Bethel2; Paul R Carey3; Focco van den Akker3; Robert A Bonomo2; John D Buynak1. (1) 
Department of Chemistry, Southern Methodist University, Dallas Texas 75275, United 
States (2) Department of Infectious Diseases, Louis Stokes Cleveland Department of 
Veterans Affairs Medical Center, Cleveland Ohio 44106, United States (3) Department 
of Biochemistry, Case Western Reserve University School of Medicine, Cleveland Ohio 
44106, United States  
2'-Substituted penicillin sulfones (e.g. tazobactam) represent a clinically proven class of 
ß-lactamase inhibitor. Still, little is known regarding the SAR of these compounds, 
particularly against the ß-lactamases that have arisen in the past decade. We will report 
the synthesis and evaluation of a systematic series of 2'-substituted penicillin sulfones 
against a wide panel of serine ß-lactamases, including class A and D carbapenemases. 
MEDI 304 
Synthesis and biological evaluation of new pyrimidin-2-one and 1,2,6-thiadiazines 
derivatives as anti-Trypanosoma cruzi agents 
Sheila Martínez1, sheila_qfb_2@hotmail.com; Guzmán Álvarez2; Diego Benitez2; Javier 
Varela2; Gildardo Rivera1; Rossana Di Maio2; Hugo Cerecetto2; Mercedes González2. 
(1) Medicinal Chemistry, Universidad Autonoma de Tamaulipas, Reynosa Tamaulipas 
88740, Mexico (2) Organic Chemistry, Universidad de la Republica, Montevideo 
Montevideo 11400, Uruguay  
Chagas' disease is caused by Trypanosoma cruzi, and is one the most important 
parasitic diseases in Latin America. Currently the only drugs available are Benznidazol 
and Nifurtimox, but they show toxicity and limited efficacy in the chronic phase. In order 
to address these deficiencies, our group synthesized two series of compounds 
derivatives of pyrimidin-2-one and 1,2,6-thiadiazines and then were tested in vitro on 
epimastigotes of T. cruzi. The most active compounds showed IC50 values between 1.4 
to 16 µM, and all of them had a nitro group in its structure. Finally, we test the inhibition 
capacity of those compounds on enzyme triosephosphate isomerase from T. cruzi, 
which is an enzyme involved in the glycolytic pathway of the parasite. Some of the test 
compounds showed IC50 values of inhibition below 15 µM. Therefore, the results of this 
work have positive implications in the development of new agents anti-T. cruzi. 
MEDI 305 
Synthesis and biological evaluation of 2,7-di-ester quinoxaline 1,4 di-N-oxide as 
antituberculosis agents 
Irma Torres, mima.018@hotmail.com; Mario Sanchez-Sanchez; Lilia Gomez-Caro; 
Virgilio Bocanegra-Garcia; Gildardo Rivera. Medicinal Chemistry, Universidad 
Autonoma de Tamaulipas, Reynosa Tamaulipas 88740, Mexico  
Tuberculosis is a high mortality disease worldwide and there are few terapeutic 
alternatives and an incresing drug resistance. Quinoxaline derivatives, which have show 
diverse biological activities, interesting also have been reported with antituberculosis 
activity.  In this study, we describe the synthesis a new series of compounds derivatives 
from 2,7-di-ester quinoxaline 1,4-di-N-oxide, which were obtained using the classical 
Beirut reaction with a yield of 5-30%. All the compounds have been characterized by 
means of Infrared and Nuclear Magnetic Resonance and tested in vitro on 
Mycobacterium tuberculosis H37Rv.  According to an analysis of structure-activity 
relationship we did determined that ethyl quinoxaline-7-carboxylate 1,4-di-N-oxide 
derivatives show a better inhibition activity on Mycobacterium tuberculosis H37Rv than 
analogues of methyl quinoxaline-7-carboxylate, with a minimum inhibitory concentration 
values less than 6.25 µg/mL. These results show that ethyl quinoxaline-7-carboxilate 
1,4-di-N-oxide could be considered as promising antituberculosis lead series. 
MEDI 306 
Sulfonyl-polyol N,N-dichloroamines with fast-acting, broad-spectrum 
antimicrobial activity 
Timothy P. Shiau, tshiau@novabaypharma.com; Eddy Low; Bum Kim; Eric D. Turtle; 
Charles Francavilla; Donogh J. R. O'Mahony; Lisa C. Friedman; Loiusa M. D'Lima; 
Andreas Jekle; Meghan Zuck; Nichole J. Alvarez; Mark Anderson; Ron (Ramin) Najafi; 
Rakesh K. Jain. Novabay Pharmaceuticals, Emeryville CA 94608, United States  
Our ongoing efforts are discovering novel N,N-dichloroamines as potent antimicrobial 
and virucidal agents. These agents contain polyol side chains that impart unique 
physiochemical properties suitable for the treatment of infectious diseases of the skin 
and body surfaces. These agents show good activity against a broad range of bacterial 
and viral pathogens and a series of sulfonyl-polyols which show both bactericidal and 
virucidal activity will be discussed. For example, these compounds show 1-hour MBC of 
16-512 ug/ml against E. coli and 4-512 ug/ml against S. aureus. The lead compounds 
were tested in a tissue culture irritancy model and showed only minimal irritation at the 
highest concentrations tested. 
   
MEDI 307 
Modifications on the side chain and the A-ring of diaryl ethers: Activity, kinetics, 
and drug-like properties 
Pan Pan1, pan.pan@stonybrook.edu; Nina Liu1; Cheng-Tsung Lai1; Sonam Shah1; 
Gopal R Bommineni1; Susan Knudson2; Richard A Slayden2; Peter J Tonge1. (1) 
Department of Chemistry, State University of New York at Stony Brook, Stony Brook NY 
11794-3400, United States (2) Department of Microbiology, Immunology, and 
Pathology, Colorado State University, Fort Collins CO 80523-1682, United States  
The treatment of tuberculosis (TB) has become increasingly problematic due to the 
emergence of multi drug resistance. Diaryl ethers demonstrate potent antibacterial 
activity against drug resistant TB, by targeting the enoyl-acyl carrier protein reductase 
InhA. Previously, we reported modifications on the B-ring to improve the hydrophilicity 
and activity. We also identified slow-onset inhibitors of InhA, which is significant given 
previous correlation between slow-onset kinetics and the in vivo efficacy. Here, we 
present the optimization on drug-like properties of the diaryl ethers. Among 12 A-ring 
analogs and 11 side chain analogs, five compounds showed similar or improved 
inhibitory activity compared to parent compounds. With selective modulation on the 
shape of side chains, we disrupted the slow-onset kinetics with wtInhA and rebuilt it with 
InhA mutants. The results confirmed the key residues for slow-onset kinetics predicted 
by molecular dynamics simulation, which will inspire the further design of slow-onset 
InhA inhibitors. 
MEDI 308 
Effect of the aryl ring heteroatom attached at C4 on the antimicrobial activity of N-
carbamylated β-Lactams 
Juliana Fritz1, jf9075a@gmail.com; Kriti Arora2; Helena I.M. Boshoff2; Balbina J. 
Plotkin3; Jacalyn Green3; Monika Konaklieva1. (1) Department of Chemistry, American 
University, Washington DC 20016, United States (2) Department of Tuberculosis 
Research, National Institutes of Health, LCID, NIAID, Bethesda MD 20892, United 
States (3) Department of Microbiology and Immunology, Midwestern University, 
Chicago IL 60515, United States  
New approaches to drug development are especially needed to target the organisms 
that are nearly universally resistant to antibiotics via production of enzymes that 
inactivate the drugs, e.g. β-lactamases. The design of antimicrobial compounds with 
new mode of action has reached a state of urgency. β-Lactams having arylthio-groups 
at C4, have been previously prepared in our laboratories and tested for intrinsic 
antimicrobial activity. From these azetidinone thioethers, the most active compounds 
are against two phylogenetically very distant bacterial species – Moraxella catharralis 
(M. cat.) and Mycobacterium tuberculosis (Mtb). The synthesis and structural-activity 
relationship of arylethers and arylselenylethers at C4 as compared to their arylthio 
counterparts is discussed. 
MEDI 309 
Enhancing in-vitro antimicrobial activity of some antibiotics with cyclopeptide 
Maria Ngu-Schwemlein, schwemleinmn@wssu.edu; Lisa Rudd, ruddl@wssu.edu; 
Adrian B Rudd; Tarshona Stevens. Chemistry, Winston-Salem State University, 
Winston-Salem NC 27110, United States  
A strategic approach to preventing antibiotic resistance is to treat bacterial infections 
with more than one drug at a time. Synergies of interaction can both increase the 
efficacy of the combination and reduce the probability of the bacterium's survival by 
developing a fortuitous mutation conveying resistance. Cationic cyclopeptides, in their 
capacity to compromise the integrity of bacterial membranes, could present itself as a 
valuable synergist for antimicrobial chemotherapy. In this study, we investigated the 
synergistic activities of some amphiphatic cationic cyclopeptides and five types of 
common antibiotics. Cyclopeptides containing a glutamyl residue were prepared by 
microwave-assisted solid phase peptide synthesis. Their invitro intrinsic antimicrobial 
activities were tested against Gram-positive and -negative bacteria by the microdilution 
antimicrobial susceptibility test. Synergistic activities were evaluated by conducting 
checkerboard titration assays. The correlation between antimicrobial and synergistic 
activities of the peptides with various types of antibiotics will be discussed. 
MEDI 310 
Development of PET radiotracers based on small molecule antitubercular drugs 
Gwendolyn A Marriner1, marrinerga@mail.nih.gov; Dale O Kiesewetter2; Tathagatha 
Mukherjee1; Danielle M Weiner1; Daniel M Schimel1; Emmanuel K Dayao1; Laura E 
Via1; Clifton E Barry1. (1) National Institute of Allergy and Infectious Diseases, National 
Institutes of Health, Rockville MD 20892, United States (2) National Institute of 
Biomedical Imaging and Bioengineering, National Institutes of Health, Rockville MD 
20892, United States  
The ability of drugs to penetrate tuberculosis (TB) lesions in the lung may be a predictor 
of efficacy of new TB treatments. Using 18F to radiolabel small molecule antitubercular 
drugs would allow Positron Emission Tomography (PET) imaging to analyze 
biodistribution of both novel and existing drugs in real-time to assess which compounds 
have the highest probability of becoming effective TB treatments. Additionally, PET 
imaging offers a non-invasive way to monitor disease state in patients or study animals. 
Response to chemotherapy can currently be monitored using [18F]-fluorodeoxyglucose 
(FDG); however, imaging agents that respond to bacterial load rather than secondary 
markers of infection such as inflammation would provide powerful tools to evaluate 
whether chemotherapy is effective. We have synthesized and evaluated both a [18F]-
linezolid analog and a [18F]-PA-824 analog in vivo using rabbits infected with 
Mycobacterium tuberculosis. We are currently developing routes to other [18F]-labeled 
antitubercular drugs including fluoroquinolones. 
MEDI 311 
Towards the development of shelf-stable N-chloro amines as topical anti-
microbial agents 
Donogh J. R. O'Mahony, djromahony@yahoo.com. NovaBay Pharmaceuticals, 
Emeryville CA 94608, United States  
N-chloramine derivatives have long been known to be potent fast-acting antimicrobial 
agents. However, with the exception of chloramine-T, employed for prevention of 
gangrene in wounds during WW2, few N-chloramines have been commercialized as 
topical anti-microbial agents. NVC-422, a 2,2-dimethyl derivative of the unstable 
endogenous antimicrobial N,N-dichlorotaurine, exhibits good long-term aqueous 
solution stability, and was selected for evaluation in clinical trials for treatment of 
impetigo and viral conjunctivitis. Recent investigations on analogues of NVC-422 
revealed that subtleties in the substitution pattern have significant influences on the 
stability of the parent N-chloro bond in aqueous solution, and ultimately on the shelf-life 
of the final therapeutic agent. We will explore the importance of the stereoelectronic 
environment around the nitrogen atom and the overall lipophilicity of the molecule as we 
sought to identify windows of stability during our continuing efforts to identify 
antimicrobial and virucidal agents with improved potency and spectrum. 
MEDI 312 
Development of an exploratory chemical probe for profiling histidine kinases 
Samson Francis1, carlsone@indiana.edu; Kaelyn E Wilke1; Erin E Carlson1, 2. (1) 
Department of Chemistry, Indiana University, Bloomington IN 47405, United States (2) 
Department of Molecular and Cellular Biochemistry, Indiana University, Bloomington IN 
47405, United States  
Two-component signal transduction systems (TCS) are commonly used by bacteria to 
couple environmental stimuli to adaptive responses through the use of gene regulatory 
systems. The high degree of homology around the ATP-binding sites of these systems 
suggests that appropriately designed compounds could serve as probes for the global 
profiling of histidine kinase activities. Using a focused-library virtual screen coupled with 
a receptor-based design strategy, we have identified a scaffold with potential utility for 
the exploration of the ATP-binding sites in TCS. The devised chemical probes will be 
utilized in the study of histidine kinase signaling in a diversity of organisms, with focus 
on Streptococcus pneumoniae. 
MEDI 313 
Towards the synthesis of novel boronates as potential HIV-1 protease inhibitors 
Andrea L Faulkner, faulknan@cwu.edu; Leah L Holmberg, holmberl@cwu.edu; Julia 
J Jennings, jenningsj@cwu.edu; Michael D Frank, frankmic@cwu.edu; John D 
Schreiber; Jesse L Nye; Donald R Clayton; Levente Fabry-Asztalos. Chemistry, Central 
Washington University, Ellensburg Washington 98926-7539, United States  
Drug discovery for HIV/AIDS has resulted in many life-saving therapies, making a 
profound impact on modern medicine. Current drug therapies exist, but are highly 
susceptible to resistance development, have poor bioavailability, and cause several side 
effects. For this reason, there is an urgent need to develop new types of inhibitors that 
address those difficulties. We are synthesizing novel boronates that were designed as 
dual-mode, competitive and associative, inhibitors of HIV-1 protease. Recent studies 
showed that boron-modified inhibitors have a higher affinity for the protease than their 
corresponding non-boronated analogs. Furthermore, the boron-modified structures were 
inhibitory to an HIV-1 protease variant that is resistant to several HIV-1 protease 
inhibitors. A library of both straight chain and cyclic boronates are being synthesized. 
The cyclic boronates, due to their structural rigidity, are expected to be better inhibitors 
than the straight chain compounds. 
MEDI 314 
Discovery and synthesis of cyclohexenyl derivatives as modulators of CC 
Chemokine Receptor 2 activity 
Gregory D. Brown1, gregory.brown@bms.com; Douglas G. Batt1; George V. Delucca1; 
Qing Shi1; Andrew J. Tebben2; Qihong Zhao3; Dauh-Rurng Wu4; Joel C. Barrish1; Percy 
H. Carter1. (1) Department of Discovery Chemistry, Bristol-Myers Squibb Company, 
Princeton NJ 08543, United States (2) Department of Computer-Assisted Drug Design, 
Bristol-Myers Squibb Company, Princeton NJ 08543, United States (3) Department of 
Discovery Biology, Bristol-Myers Squibb Company, Princeton NJ 08543, United States 
(4) Department of Discovery Chemical Synthesis, Bristol-Myers Squibb Company, 
Princeton NJ 08543, United States  
CC Chemokine Receptor 2 (CCR2) is the primary chemokine receptor on monocytes 
recruited to sites of inflammation. On the basis of extensive pre-clinical studies, CCR2 
inhibition is a mechanism of interest for the potential treatment of a number of diseases, 
including both atherosclerosis and diabetes. A novel cyclohexenyl series of CCR2 
antagonists has been discovered. The cyclohexenyl exemplars are a series of small, 
rigid compounds exhibiting submicromolar binding affinity for CCR2. Modification of the 
substituents on the cyclohexene ring led to the identification of a group of potent CCR2 
antagonists. The design, synthesis, and structure activity relationships of these 
cyclohexenyl derivatives will be reported. 
MEDI 315 
Identification and synthesis of potent and selective pyridyl-isoxazole based 
agonists of sphingosine-1-phosphate 1 (S1P1) 
Junqing Guo, junqing.guo@bms.com; Scott H. Watterson; James Kempson; Steve H. 
Spergel; Charles L. Langevine; Robert V. Moquin; Ding Ren Shen; Melissa Yarde; Mary 
Ellen Cvijic; Dana Banas; Richard Liu; Suzanne J. Suchard; Kathleen Gillooly; Tracy 
Taylor; Sandra RexRabe; Dave J. Shuster; Kim W. McIntyre; Georgia Cornelius; Celia 
Darienzo; Anthony Marino; Praveen Balimane; Luisa Saltercid; Murray McKinnon; Joel 
C. Barrish; Percy H. Carter; William J. Pitts; Jenny Xie; Alaric J. Dyckman. Bristol-Myers 
Squibb Research and Development, United States  
Sphingosine-1-phosphate (S1P) is the endogenous ligand for the sphingosine-1-
phosphate receptors (S1P1-5). The interaction of S1P with the S1P receptors plays a 
fundamental physiological role in a number of processes including vascular stabilization, 
heart development, lymphocyte homing, and cancer angiogenesis. Agonism of S1P1, in 
particular, has been shown to block lymphocyte trafficking from the thymus and 
secondary lymph nodes, resulting in immunosuppression. This presentation will outline 
the identification and synthesis of a potent and selective series of pyridyl-isoxazole 
based agonists of S1P1. A compound in this series demonstrated efficacy when 
administered orally in a rodent model of arthritis. 
MEDI 316 
Purine derivatives as potent BTK inhibitors for autoimmune diseases 
Qing Shi, qing.shi@bms.com; Chunjian Liu; James Lin; Alaric J. Dyckman; Hedy Li; 
Lauren E. Vandevier; Cullen Cavallaro; Steven Spergel; James R. Burke; Andrew 
Tebben; Joann Strnad; Neha Surti; Jodi K. Muckelbauer; Kim Mcintyre; Katerina 
Leftheris; Percy H. Carter; Joseph Tino; George V. Delucca. Bristol-Myers Squibb, 
United States  
Purine derivatives were investigated as potent and selective BTK inhibitors as 
exemplified by Compound 3. Structure activity relationship studies of the 2, 6, and 9 
position substituents of the purine core and their importance to potency and selectivity 
will be highlighted. Further characterization of compound 3, including its X-ray structure 
determination in BTK, kinase selectivity profile, ADME properties, cellular functional 
potency, and its activity in animal models will also be discussed.   
  
MEDI 317 
Nicotinamide derivatives as potent BTK inhibitors for autoimmune diseases 
George V De Lucca1, george.delucca@bms.com; Qing Shi1; Chunjian Liu1; Andrew 
Tebben1; Joann Strnad1; Neha Surti1; Jodi K Muckelbauer1; Kim Mcintyre1; James R 
Burke1; Katerina Leftheris1; Percy H Carter1; Joseph Tino1; Chiehying Chang2. (1) 
Research and Development, Bristol-Myers Squibb Company, Princeton New Jersey 
08540, United States (2)  
Starting from an internal screening hit (1) we were able to optimize this nicontinamide 
series to obtain potent and selective BTK inhibitors as exemplified by Compound 2. 
Structure activity relationship studies of the 2, 5, and 6 position substituents of the 
nicontinamide core and their importance to potency and selectivity will be highlighted. 
Further characterization of nicotinamides, including X-ray structure determination in 
BTK, kinase selectivity profile, ADME properties, cellular functional potency, and its 
activity in animal models will also be discussed.   
   
MEDI 318 
Synthesis and SAR of quinoxaline MK-2 inhibitors 
Yonghan Hu1, fred.hu@pfizer.com; Steve Kirincich1; J. Christian Baber2; Satenig 
Guler3; Nikolaos Papaioannou1; Kevin Parris1; Steve Tam1; Weiheng Wang1; Julie Liu1; 
Marina Shen1; Lin-Ling Lin1; Jean-Baptiste Telliez1; Frank Lovering1. (1) Pfizer Global 
Research and Development, Cambridge MA 02140, United States (2) Cubist, Lexington 
MA 02421, United States (3) Astra Zeneca, United States  
MK2 is a Serine/Threonine kinase regulated by phosphorylation by p38 MAP kinase. 
MK2 knockout mice have been shown to be deficient in LPS-induced TNF production, a 
cytokine that plays a significant role in a number of inflammatory disease states 
including rheumatoid arthritis. MK2 knockout mice are also resistant to collagen induced 
arthritis. Compounds that inhibit MK2, therefore, could potentially be useful in the 
treatment of many TNF mediated diseases such as rheumatoid arthritis.   In order to 
circumvent the metabolic liabilities of the lead benzothiadiazole 1, we identified the 
isostere quinazoline 2 which proved to not form reactive metabolites. Structure based 
drug design reslulted in compound 16 which has shown promising PK results and has 
fared well in the rat LPS-TNF model. Further improvements in drug-like properties and 
in the human whole blood potency will be necessary to further improve this series of 
MK-2 inhibitors. 
MEDI 319 
Strategic design and synthesis of analogs aimed at de-risking  hERG and µAmes 
liabilities of a potent and selective IKK-2 inhibitor 
John R. Springer1, john.r.springer@pfizer.com; Shaun R. Selness1; Danny Garland1; 
Richard F. Heier1; Balekudru Devadas1; Michele Promo1; Serge G. Wolfson1; 
Dominique Bonafoux1; Yiding Hu2; Shentian Yang3; Sheri L. Bonar4; Sumathy 
Mathialagan4. (1) Department of Medicinal Chemistry, Pfizer Inc., Cambridge 
Massachusetts 02140, United States (2) Department of Pharmacokinetics and Drug 
Metabolism, Pfizer Inc., Chesterfield Missouri 63017, United States (3) Department of 
Structural Chemistry, Pfizer Inc., Chesterfield Missouri 63017, United States (4) 
Department of Inflammation Biology, Pfizer Inc., Chesterfield Missouri 63017, United 
States  
A previously described series of Aminopyridinecarboxamide-based inhibitors of IKK-2 
were synthesized and tested against human recombinant IKK-2 and IL-1β stimulated 
synovial fibroblasts and PHA-408 (Fig. 2) was identified as a potent, selective, and 
efficacious ATP-competitive inhibitor of IKK-2 yet this class of inhibitor produced signals 
in both hERG and µAmes toxicity assays. Our efforts focused on developing a strategic 
design approach to de-risk hERG and µAmes liabilities of this chemical class providing 
a path forward for treatment of inflammatory diseases.   
  
MEDI 320 
Discovery of indazoles as inhibitors of Tpl2 kinase 
Yonghan Hu1, fred.hu@pfizer.com; Derek Cole2; Rajiah Denny1; David Anderson1; 
Manus Ipek1; Yike Ni1; Suvit Thaisrivongs1; Xiaolun Wang1; J. Perry Hall1; Julie Liu1; 
Michael Luong1; Lih-Ling Lin1; Jean-Baptiste Telliez1; Ariamala Gopalsamy1. (1) Pfizer 
Global Research and Development, Cambridge MA 02140, United States (2) Takeda, 
San Diego CA 92121, United States  
Tpl2 kinase is a serine/threonine kinase in the MAP3K family. Tpl2 activates the 
MEK/ERK signaling pathway and stimulates TNF production. Tpl2 is important for both 
TNF production and signaling. Therefore, Tpl2 has become a highly desirable target for 
treating Rheumatoid Arthritis.  The synthesis and structure-activity studies of a novel 
series of indazoles as inhibitors of Tpl2 kinase are described. 
MEDI 321 
Structure – activity relationships of pyrrole based S-nitrosoglutathione reductase 
inhibitors 
Xicheng Sun1, xicheng.sun@n30pharma.com; Jian Qiu1; Sarah A Strong1; Louis S 
Green1; Jan W. F Wasley2; Dorothy B. Colagiovanni1; Sarah C. Mutka1; Joan P. 
Blonder1; Adam M. Stout1; Jane P. Richards1; Lawrence Chun3; Gary J. Rosenthal1. (1) 
N30 Pharmaceuticals LLC, Boulder Colorado 80301, United States (2) Simpharma LLC, 
Guilford Connecticut 06437, United States (3) Emerald BioStructures, Bainbridge Island 
Washington 98110, United States  
The enzyme S-nitrosoglutathione reductase (GSNOR) is a member of the alcohol 
dehydrogenase family (ADH) that regulates the levels of S-nitrosothiols (SNOs) through 
catabolism of S-nitrosoglutathione (GSNO). GSNO and SNOs are implicated in the 
pathogenesis of many diseases including those in respiratory, cardiovascular, and 
gastrointestinal systems. The pyrrole based N6022 was recently identified as a potent, 
selective, reversible and efficacious GSNOR inhibitor which is currently in clinical 
development for acute asthma. We describe here the synthesis and structure activity 
relationships (SAR) of novel pyrrole based analogues of N6022 focusing on imidazole 
replacement, scaffold modification and propionic acid modifications. We have identified 
a number of potent and novel GSNOR inhibitors that demonstrate efficacy in an OVA-
induced asthma model in mice. 
MEDI 322 
Discovery of dehydro-oxopiperazine acetamides as novel Bradykinin B1 receptor 
antagonists for treatment of pain and inflammation 
Wenyuan Qian Qian, wqian@amgen.com; Jian Jeffrey Chen; Jason Human; Toshi 
Aya; Jiawang Joe Zhu; Tanya Peterkin; Kaustav Biswas; Leyla Arik; Eileen Johnson; 
Gondi Kumar; Smriti Joseph; Janan Jona. Department of Chemistry Research & 
Discovery, Amgen, Thousand Oaks CA 91320, United States  
Kinins are released at sites of tissue injury and produce pain and inflammation via 
activation of constitutively expressed Bradykinin B2 and inducible Bradykinin B1 
receptors. In the last decade there has been intense interest in identifying orally active 
Bradykinin B1 receptor antagonists for the treatment of inflammation and pain. We 
recently discovered oxopiperazine acetamide 1 as a potent B1 antagonist. In this 
presentation, we will report a new dehydro-oxopiperazine acetamide series 2 that 
results in higher binding potency. This improvement in potency, compared to its 
saturated counterpart, enabled further modifications leading to compounds 3 which can 
maintain potency while significantly lowering the overall molecular weight compared to 
2. As a result of the reduced molecular weight, some of these truncated analogs exhibit 
improved PK properties. The synthesis of the chiral dedydro-oxopiperazine acetamide 
core structure and the SAR will be disclosed.  
  
MEDI 323 
Inhibition of COX-2 and ASIC-3 by structural analogs of diclofenac 
Tyler Rose1, trose@usn.edu; Daniel Williams1, dwilliams@student.usn.edu; Kyle 
Hansen1; Ronald Bodi McEwen1; Emmanuel Deval2; Eric Lingueglia2. (1) Roseman 
University of Health Sciences, South Jordan Utah 84095, United States (2) Institut de 
Pharmacologie Moleculaire et Cellulaire, Valbonne, France  
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) whose actions are thought 
to be at least partially mediated by its inhibition of cyclooxygenase (COX) isozymes 
(COX-2 IC50 = 50 nM). Unlike most other NSAIDs, diclofenac also modestly inhibits 
(IC50 = 92 μM) acid-sensing ion channel 3 (ASIC-3), a sodium-conducting ion channel 
activated by low pH that is likely to be involved in pain signaling. In light of 
disadvantages associated with NSAIDs (gastrointestinal and cardiovascular side effects 
and an analgesic ceiling) and opioid drugs (addiction, physical dependency), 
compounds that target ASIC-3 may provide an attractive new approach to pain 
pharmacotherapy. Our goal is to modify the structure of diclofenac in an attempt to 
minimize COX inhibition and maximize ASIC-3 inhibtion. To this end, we will describe 
the synthesis of a series of diclofenac analogues and the results of their use in inhibition 
assays against COX-2 and ASIC-3. 
MEDI 324 
Design and synthesis of novel pyrrolo[1,2-b]pyridazine derivatives of 
phosphodiesterase 4 (PDE4) inhibitors 
Mitsuaki Okumura1, mitsuaki.okumura@jp.astellas.com; Yoshito Abe1; Tsuyoshi 
Mizutani1; Kouzo Sawada2; Kazuhiko Ohne1; Noriaki Maeda3; Takashi Manabe2; 
Makoto Inoue1. (1) Drug Discovery Research, Astellas Pharma Inc., Tsukuba Ibaraki 
305-8585, Japan (2) QA, RA and Pharmacovigilance, Astellas Pharma Inc., Itabashi-ku 
Tokyo 174-8612, Japan (3) Drug Discovery Research, Astellas Pharma Inc., Chuo-ku 
Tokyo 103-8411, Japan  
PDE4 is an enzyme responsible for the hydrolysis of cyclic 3',5'-adenosine 
monophosphate (cAMP). PDE4 inhibitors are believed to be beneficial for the treatment 
of various inflammatory disease, because elevation of cAMP is known to suppress 
activation of inflammatory cells. Pyrrolo[1,2-b]pyridazine series of PDE4 inhibitors were 
discovered and optimization of the series led to the identification of ASP9831, a potent 
inhibitor with excellent oral bioavailability. ASP9831 significantly reduced the elevation 
of alanine aminotransferase (ALT) at 1.0 mg/kg in a rat model of D-galactosamine-
induced acute hepatitis without delaying gastric emptying. 
MEDI 325 
NS-78, novel vitamin D3 antedrug as new agent for psoriasis 
Hironori Otsu, h.ootsu@po.nippon-shinyaku.co.jp; M. Shirai; H. Fujieda; S. Yasufuku; 
S. Nisio; K. Honjo; T. Sasagawa; H. Tanaka; T. Ego; K. Kosugi; I. Kashimori; F. Katoh; 
T. Kyo-i. Nippon Shinyaku Co., Ltd., Japan  
Plaque psoriasis, a common form of psoriasis, is a chronic, hyperproliferative, 
inflammatory disease of skin, characterized by red, scaly, raised plaques. Topical 
products of vitamin D3 analogs have become first-line therapy for plaque psoriasis. The 
mode of action is thought to be an inhibition of epidermal cell proliferation, an induction 
of epidermal cell differentiation, an inhibition of IL-1/6/8 production in epidermal cell, an 
inhibition of T cell activation, and so on owing to vitamin D3 receptor activation.  Vitamin 
D3 analogs currently used for psoriasis include calcipotriol, tacalcitol, maxacalcitol (only 
available in Japan) and calcitriol. Although topical products of vitamin D3 are currently 
first-line therapy for plaque psoriasis, drug compliance of the products is rather low 
since those vitamin D3 analogs have to be administered twice-daily. Furthermore, a 
dosing of the products is limited because of high risk of hypercalcemia due to their 
intrinsic hypercalcemic action and/or severe local irritation in skin.  Antedrug is defined 
as an active synthetic derivative that is designed to undergo biotransformation to an 
inactive form upon entry in systemic circulation. Based on the concept of antedrug, we 
have been developing NS-78, a novel vitamin D3 analog, in order to overcome problems 
of existing topical products of vitamin D3 analogs. The features of NS-78 are; (1) Higher 
pharmacological activity than currently available topical vitamin D3 products, (2) Fast 
metabolization in systemic circulation, (3) Local activity in skin maintained for 24 hours 
(It is expected to be effective by once-daily administration), and (4) Lower risk of 
hypercalcemia and milder local irritation in skin than calcipotriol.  Based on the above 
characteristics, NS-78 is expected to be an effective treatment for psoriasis, which 
overcomes the problems of existing topical vitamin D3 products. 
MEDI 326 
Development of activity-based fluorescent probes targeting the 
immunoproteasome 
Lalit Kumar Sharma1, lku223@uky.edu; Na-Ra Lee2; Kimberly Cornish Carmony2; 
James Marks2; Kyung Bo Kim2. (1) Department of Chemistry, University of Kentucky, 
Lexington KY 40506, United States (2) Department of Pharmaceutical Sciences, 
College of Pharmacy, University of Kentucky, Lexington KY 40536, United States  
The proteasome plays an important role in regulating intercellular protein homeostasis 
by initiating degradation of intercellular proteins conjugated with polyubiquitin chains. 
The immunoproteasome, an alternative proteasome form, is constitutively expressed in 
cells of hematopoietic origin and can also be induced in normal cells by exposure to 
cytokines. Exposure to these stimuli induces the synthesis and incorporation of 
immunoproteasome catalytic subunits LMP2, MECL1 and LMP7, replacing their 
constitutive proteasome counterparts Y, Z and X respectively. The major function of the 
immunoproteasome is thought to promote adaptive immune responses. Recent studies 
have associated elevated levels of the immunoproteasome catalytic subunits with some 
pathological disorders such as cancer and autoimmune disorders. However, the 
detailed understanding of immunoproteasome function is still lacking, due in large part 
to the lack of appropriate molecular probes selectively targeting immunoproteasome. 
This talk will focus on the synthesis and characterization of active site-directed 
molecular probes that selectively inhibit LMP7, a major catalytic subunit of the 
immunoproteasome. Also, the development of fluorescent imaging probes targeting 
LMP7, which allow rapid detection and localization of catalytically active 
immunoproteasome, will be discussed. These imaging probes provide a valuable tool to 
analyze the functions and dynamics of the immunoproteasome in living cells.   
  
MEDI 327 
CCR2b-specific antagonists part 4: New design, synthesis, and SAR of (4-
heteroarylthiophen-2-yl)methyl-(R)-3-aminopyrrolidine derivatives 
Tomohide Ida, t.ida@teijin.co.jp. Teijin Pharma Limited, Japan  
The Chemokine Receptor CCR2b is a member of G protein coupled receptor family and 
has been known to play an important role in chronic inflammatory diseases including 
multiple sclerosis, rheumatoid arthritis and atherosclerosis. In our exploring studies for 
the CCR2b receptor antagonists we constructed a QSAR model of the ligand binding 
site with several compounds by using Sybyl/CoMFA and the other method, and we have 
made use of the model in the optimization of 1-substituted-(R)-3-aminopyrrolidines. 
After the synthetic work of various derivatives, we have identified (4-heteroarylthiophen-
2-yl)-methyl-(R)-3-aminopyrrolidine derivatives with potent inhibitory activity. We will 
present the structure-activity-relationship of the (R)-3-aminopyrrolidine series with early 
ADME properties and so on. 
MEDI 328 
Discovery and SAR of novel heteroarylphenyl aniline derivatives as Rho kinase 
inhibitors 
Junko Watanabe1, junko.watanabe@jp.astellas.com; Takeshi Terasawa2; Kouzo 
Sawada3; Yoshimasa Imamura1; Hiroki Fukudome1; Jun Maeda1; Nobuaki Takeshita1; 
Makoto Takeuchi1; Mitsuaki Ohta1. (1) Drug Discovery Research, Astellas Pharma Inc., 
Japan (2) Astellas Research Technologies Co. Ltd., Japan (3) QA, RA and 
Pharmacovigilance, Astellas Pharma Inc., Japan  
Rho kinase (ROCK), a 160-kDa serine/threonine kinase, is the effector of Rho, a small 
GTP-bound protein. Two isoforms, ROCK1 and ROCK2, have been identified, and 
these enzymes are involved in a variety of physiological functions including cytoskeletal 
control, cell growth, cell migration, apoptosis and many aspects of inflammatory 
responses. Therefore ROCK inhibitor has the potential to be a medicine for 
inflammatory diseases; rheumatoid arthritis and osteoarthritis etc. We selected Wf-536, 
a known ROCK inhibitor, as a lead compound. Modification of this compound produced 
novel heteroarylphenyl aniline derivatives as potent and selective ROCK inhibitors. We 
also discovered that several compounds induced an analgesic effect on a 
monoiodoacetate-induced arthritis model in rats with ED50 values of less than 1 mg/kg 
after oral administration.  We will report the synthesis, the SAR and the pharmacological 
properties of the heteroarylphenyl aniline derivatives. 
MEDI 329 
Oxazolecarboxamide derivatives as novel IRAK-4 inhibitors 
Hiroshi Inami1, hiroshi.inami@jp.astellas.com; Tsuyoshi Mizutani1; Junko Watanabe1; 
Hiroyuki Usuda1; Shinya Nagashima1; Tomonori Ito1; Naohiro Aoyama1; Toru Kontani1; 
Hisashi Hayashida2; Takeshi Terasawa2; Ayako Moritomo1; Takeshi Ishikawa1; Kazumi 
Hayashi1; Makoto Takeuchi1; Mitsuaki Ohta1. (1) Drug Discovery Research, Astellas 
Pharma Inc, Japan (2) Astellas Research Technologies Co. Ltd, Japan  
Interleukin-1 receptor associated kinase-4 (IRAK-4) is an essential molecule in Toll-like 
receptors (TLR)- and IL-1 receptor-mediated signaling pathways and thought to be an 
attractive therapeutic target for various autoimmune and inflammatory diseases 
including rheumatoid arthritis, systemic lupus erythematosus (SLE), diabetic 
nephropathy, gout and sepsis. In our search for novel IRAK-4 inhibitors, high-throughput 
screening of our compound library and subsequent structural modifications resulted in 
the discovery of a novel series of oxazolecarboxamide derivatives showing potent 
inhibitory activity with nanomolar IC50 values. Moreover, selected compounds exhibited 
significant effects in rodent arthritis models as well as kidney disease models after oral 
administrations. Synthesis, structure–activity relationships and pharmacological 
properties of the oxazolecarboxamide derivatives will be presented. 
MEDI 330 
KMO inhibitors as potential therapeutic agents for the treatment of HD: Towards 
proof-of-concept studies 
Christopher Yarnold1, chris.yarnold@evotec.com; Michael Prime1; Dirk Winkler2; 
Maria Beconi3; Fred Brookfield1; Chris Brown1; Stephen Courtney1; Andreas Ebneth2; 
Rachel Grigg1; Estelle Hamelin-Flegg1; Peter Johnson1; Volker Mack2; Richard 
Marston1; William Mitchell1; Paula Pena1; Laura Reed1; Selvaratnam Suganthan1; 
Ignacio Munoz-Sanjuan3; Eric Schaeffer3; Leticia Toledo-Sherman3; Derek Weddell1; 
Naomi Went1; Christin Winkler2; John Wityak3; Celia Dominguez3. (1) Evotec (UK) Ltd, 
Abingdon Oxon OX14 4SA, United Kingdom (2) Evotec AG, Hamburg, Germany (3) 
CHDI Foundation, Los Angeles California CA 90045, United States  
Kynurenine mono-oxygenase (KMO) is an enzyme in the Kynurenine Pathway (KP) that 
catalyses the conversion of kynurenine (KYN) into 3-hydroxykynurenine (3-HK), a 
precursor of quinolinic acid (QA), a neurotoxin. It has been shown that in early stage 
Huntington's Disease (HD) brains, 3-HK is increased in both striatum and cortex. 
Furthermore, QA and 3-HK levels were found to be elevated in the striatum, cortex and 
cerebellum of R6/2 HD transgenic mice. Through extensive medicinal chemistry it has 
become apparent that the KMO inhibitory activity of our lead molecule is highly 
dependent on the presence of an acidic moiety in the molecule. Compounds with acidic 
moieties do not penetrate the brain well and this poster describes our efforts to 
investigate the Structure Activity Relationship of these inhibitors and our strategy for 
modifying this moiety to achieve brain penetration. We present progress towards the 
identification of compounds for proof-of-concept studies in HD. 
MEDI 331 
Development of potent and selective transglutaminase-2 inhibitors for the 
treatment of Huntington's disease 
Michael E Prime1, michael.prime@evotec.com; John Wityak2; Stephen Courtney1; 
Christopher Yarnold1; Fred Brookfield1; Richard Marston1; Peter Johnson1; Osamu 
Ichihara1; Sabine Schaertl3; Andreas Ebneth3; Andreas Scheel3; Ignacio Munoz-
Sanjuan2; Celia Dominguez2; Douglas Macdonald2; Leticia Toledo-Sherman2; Maria 
Beconi2. (1) Discovery Chemistry, Evotec, Abingdon Oxfordshire OX14 5NB, United 
Kingdom (2) CHDI, Los Angeles California 90045, United States (3) Corporate 
Headquarters, Evotec Hamburg, Hamburg, Germany  
Tissue transglutaminase 2 (TG2; TGM2; human Gene ID# 7052) is a multi-functional 
protein primarily known for its calcium-dependent enzymatic activity of crosslinking 
proteins via an isopeptide bond formation between glutamine and lysine residues. TG2 
over-expression and activity has been found to be associated with Huntington's disease 
(HD) by several investigators. Interestingly, genetic deletion of TG2 in two different 
transgenic HD mouse models, results in improved phenotypes including a reduction in 
neuronal death and prolonged survival. Here we report a novel class of TG 2 inhibitors 
which have been developed from a small non-selective molecule to analogues that 
display nanomolar potencies with desired selectivity profiles over the other TGase 
isoforms. We also report the identification of a significant plasma stability issue following 
in vitro DMPK profiling and the subsequent development of a second-generation 
inhibitor with improved stability and potential for proof-of-concept in vivo studies. 
MEDI 332 
Tetrahydrofuro[3,4-b]pyridiones as prolyl hydroxylase inhibitors 
Vincent J Colandrea1, vince_colandrea@merck.com; Joshua G McCoy1; 
Kothandaraman Shankaran1; Deodial Guiadeen1; Kenneth Alves2; Julie DeMartino3; 
Richard Hajdu2; Carol Ann Keohane2; Russell Lingham3; Fredric Masse2; Scott Salowe3; 
Sharon Tong4; Junying Wang4; Matthew Wyvratt1; Jeffrey J Hale1. (1) Rahway 
Discovery Chemistry, Merck Research Laboratories, Rahway NJ 07065, United States 
(2) Rahway Central Pharmacology, Merck Research Laboratories, Rahway NJ 07065, 
United States (3) Department of Immunology, Merck Research Laboratries, Rahway NJ 
07065, United States (4) Rahway Preclinical DMPK, Merck Research Laboratories, 
Rahway NJ 07065, United States  
Hypoxia-inducible factor (HIF) is a α/β heterodimeric gene transcription factor for a 
multitude of genes including glycolytic enzymes, erythropoietin and VEGF. Levels of 
HIF are regulated metabolically via hydroxylation of proline residues on the a-subunit by 
a family of hydroxylases known as prolyl hydroxylases (PHD's). Inhibitors of the three 
isoforms of PHD's (PHD1-3) stabilize HIF and consequently stimulate the production of 
red blood cells (RBC's) through the modulation of erythropoietin (EPO), the EPO 
receptor, and proteins responsible for iron handling and transport. As a result, much 
interest has arisen in small molecule PHD inhibitors for the treatment of anemia. Herein, 
we will discuss our lead optimization efforts on the tetrahydrofuro[3,4-b]pyridone 
scaffold. 
MEDI 333 
Isolating bioactive compounds from medicinal plants of Puerto Rico 
XueQiang Zha, zhaxueqiang@yahoo.com.cn; Vibha Bansal, vibha.bansal@upr.edu; 
Aixa Castro; Ricardo Diaz; Yadhira Lugo Jose. Department of Chemistry, University of 
Puerto Rico at Cayey, Cayey Puerto Rico 00736, Puerto Rico  
Urokinase type Plasminogen Activator (uPA) has been implicated as a key mediator of 
cellular invasion and metastasis of tumor cells, angiogenesis and chronic wounds. 
Inhibitors of uPA are thus good candidates for use as drugs in treatment of cancer and 
other disease situations where uPA-driven degradation of extra cellular matrix or uPA-
dependent cell migration is thought to be important. Plants of 15 different species were 
collected from Puerto Rico. The collected samples were dried to a constant weight in an 
oven at 40-50°C and then ground to fine powder. The dried powders were extracted 
with methanol and partitioned with petroleum ether (PE), chloroform (CHL), ethyl 
acetate (EA) and n-butanol (BUT) in a serial manner. The extracts were dried and re-
dissolved in methanol and tested for the presence of inhibitors of uPA using Fibrin Plate 
Assay. Among the 15 plants, the inhibition of uPA was observed in 8 species. 
MEDI 334 
SiliaBond HOBt: A versatile and reusable silica-supported reagent used in API 
Raif Kadri, raifkadri@silicycle.com; David Dubé; Olivier Marion; Geneviève Gingras; 
François Béland. SiliCycle Inc., Quebec City Quebec G1P 4S6, Canada  
It has been reported in the literature that 25% of all synthetic pharmaceutical drugs 
contain an amide function1. 1-hydroxybenzotriazole (HOBt) is commonly used as an 
amide coupling precursor in peptides synthesis which is a great interest for API 
preparation. Moreover, utilization of HOBt can increase yield and decrease racemization 
occurring during the amide synthesis.  By bonding HOBt on silica, the possibility of 
explosion caused by the exothermic decomposition of dry HOBt is eliminated. The 
newest addition to the SiliaBond Reagent product line, SiliaBond HOBt, can be easily 
activated in the same condition as in homogeneous solution by using preferably a base 
such as N,N-diisoprpylethylamine. Furthermore, this supported reagent can be recycled 
many times without limitation in the performance.  This poster presents the usefulness 
of the SiliaBond HOBt for the amine protection using benzylcarbamate and the 
synthesis of N-hydrosuccinimide ester using anhydrides or activated carboxylic acids. 
MEDI 335 
Hit to lead approaches: Working in enabled chemical space to achieve rapid 
project progression 
Bruce A Lefker1, bruce.a.lefker@pfizer.com; Matt Wessel2; Toby Underwood1; Edward 
Conn1; Ann Wright1; Peter Dorff1; George Chang1; Ravi Garigipati1; Michael Brodney1; 
Subas Sakya1; Coffman Karen1; Steve Coffey1; Kimberly Cameron1; David Perry1; 
Bruce Hay1; Wenhua Jiao1; Kevin Liu1; Sandra Gilbert1; Shari Deninno1; Michael 
Deninno1; Tommy Chen1. (1) Department of Medicinal Chemistry, Pfizer Inc, Groton CT 
06340, United States (2) Department of Computational Chemistry, Schrodinger LLC, 
Portland OR 97204, United States  
The pharmaceutical industry is coming under increasing pressure to identify quality 
chemical matter with reduced costs and shorter time frames. In our Hit to Lead 
chemistry group, we have been able to efficiently convert early lead structures into high 
quality lead matter that has enabled rapid project progression and testing of biological 
mechanisms. In a number of projects we used iterative library design and synthesis to 
achieve these objectives. This presentation will highlight strategies and approaches our 
team has used to quickly move projects through key decision points. 
MEDI 336 
GALAS modeling methodology applications in the prediction of the drug 
metabolism related properties 
Pranas Japertas1, pranas.japertas@acdlabs.com; Remigijus Didziapetris1; Justas 
Dapkunas1, 2; Andrius Sazonovas1. (1) ACD/Labs, Inc., Vilnius LT-08117, Lithuania (2) 
Department of Biochemistry and Biophysics, Vilnius University, Vilnius LT-08117, 
Lithuania  
This work investigates the possibilities of effective third-party model utilization in 
predicting drug metabolism related properties. A major problem is that training sets 
rarely cover chemical space and experimental protocols of 'in-house' projects. A method 
is needed that allows any company to tailor a third-party predictive algorithm to its 
needs using proprietary data. We present GALAS modeling methodology that provides 
a possibility to expand the Applicability Domain of the models with the help of a custom 
database of experimental values. Use of the method is illustrated with examples of its 
application in predicting cytochrome P450 substrate and inhibitor specificity as well as 
regioselectivity. Relatively small amount (3 to 5) of similar compounds has to be added 
to substantially improve predictions for compounds not represented in the original 
training set. Similarly the models are shown to be able to utilize experimental data 
obtained using different protocol compared to training set data. 
MEDI 337 
Analysis of screening results from a proprietary inactive kinase-focused 
screening library 
Audra M Dalton, adalton@arqule.com; Nivedita D Namdev; Mark A Ashwell. 
Department of Chemistry, ArQule, Inc., Woburn MA 01801, United States  
Recently we described how an understanding of the role of hydrophobic residues within 
the ATP-binding cleft of inactive protein kinases can be utilized for the identification of 
selective, small molecule kinase inhibitors. Utilizing this knowledge we employed an in 
silico approach for the creation of a proprietary, focused library having a bias toward the 
inactive conformation of protein kinases with excellent Rule of 5 compliance.   A key 
feature of the construction of this library has been the use of parallel chemistry to 
provide rapid compound selection. This library has been screened against a wide 
variety of kinases and herein we provide an analysis of the screening results using three 
Ligand Efficiency Indices: PEI, BEI, SEI. These indices provide an effective framework 
for the interpretation of screening data.  Applications of this methodology in the 
selection and optimization of lead compounds from hit generation programs for multiple 
kinases will be presented. 
MEDI 338 
Improving kinase inhibitor selectivity through exploring adjacent non-conserved 
pockets 
Kristoffer R Brandvold, kristofb@umich.edu; Matthew B Soellner. Department of 
Medicinal Chemistry, University of Michigan, Ann Arbor MI, United States  
The study of protein kinase activity has implications in the understanding of both healthy 
and disease-state biological systems. Selective regulation of kinase activity using small 
molecules is challenging due to the inherent promiscuity of conventional ATP-
competitive inhibitors. The authors will present a strategy designed to improve upon the 
selectivity of ATP-competitive inhibitors by incorporating elements that interact with 
variable regions outside of the canonical ATP-pocket. The approach employs an ATP-
competitive inhibitor adorned with an alkyne, which allows for facile conjugation with a 
variety functionalized azides through click chemistry. Biochemical and cellular 
applications will be discussed. 
MEDI 339 
Deuterium in drugs for cardiovascular disease: Design and synthesis of 
deuterated cilostazol and ranolazine analogs with enhanced metabolic stability 
Julie F Liu, jliu@concertpharma.com; Vinita Uttamsingh; Sophia Nguyen; Gary W 
Bridson; Adam J Morgan; Craig E Masse; Roger Tung; Scott Harbeson; Richard 
Gallegos. CoNCERT Pharmaceuticals, Inc., Lexington MA 02421, United States  
Cilostazol (Pletal®) and ranolazine (Ranexa®) are approved in the US and abroad as 
cardiovascular agents. Cilostazol, indicated for the reduction of symptoms of intermittent 
claudication, is a PDE3 inhibitor which affects platelet aggregation and vasodilation. 
Ranolazine, a treatment for chronic angina, provides anti-ischemic and anti-anginal 
effects through an undetermined mechanism. Both drugs are dosed orally BID and are 
extensively metabolized, primarily by CYP3A. We have prepared novel deuterium-
modified analogs of cilostazol and ranolazine in which certain hydrogen atoms have 
been selectively replaced with deuterium. Deuterium effects on metabolism are 
unpredictable, even when deuterium is inserted at a known site of metabolic oxidation. 
Our research has identified multiple novel deuterated analogs of cilostazol and 
ranolazine with enhanced metabolic stability. Syntheses of these compounds via routes 
which allow for precise deuterium incorporation will be described. Data comparing our 
precision-deuterated analogs to cilostazol and ranolazine with respect to metabolic 
clearance will be presented. 
MEDI 340 
Design and synthesis of deuterated iloprost analogs with potential for enhanced 
pharmacokinetic properties 
Bhaumik A Pandya, bpandya@concertpharma.com; George Borg; Craig E Masse; 
Scott Harbeson; Roger Tung. Medicinal Chemistry, Concert Pharmaceuticals Inc., 
Lexington MA 02421, United States  
     
As part of our ongoing effort to apply the Deuterated Chemical Entity Platform (DCE 
Platform TM) to clinically validated drugs, the synthesis of deuterated analogs of the PGI2 
mimetic iloprost (Ventavis®) was carried out. The DCE Platform™ has been shown to 
positively impact certain drugs' absorption, distribution, metabolism and/or excretion 
(ADME) properties creating the potential for improved drug efficacy, safety, and 
tolerability. Deuterated isotopologs of iloprost, an approved agent for pulmonary arterial 
hypertension (PAH), have the potential to provide an improved pharmacokinetic profile 
relative to iloprost, which has a human half-life of 25-30 minutes. The design and 
synthesis of deuterated analogs employing routes amenable to precise deuterium 
incorporation will be presented. 
MEDI 341 
Design and synthesis of deuterated darunavir analogs with enhanced 
pharmacokinetic properties 
Adam J Morgan, amorgan@concertpharma.com; Craig E Masse; Sophia Nguyen; 
Changfu Cheng; Gary Bridson; Vinita Uttamsingh; Roger Tung; Scott Harbeson. 
Department of Medicinal Chemistry, Concert Pharmaceuticals, Inc., Lexington MA 
02421, United States  
    
As part of an ongoing effort to apply the Deuterated Chemical Entity Platform (DCE 
Platform™) to clinically validated drugs, the synthesis of deuterated analogs of the HIV 
protease inhibitor darunavir (Prezista®) was carried out. The devised synthetic routes 
allowed for site selective deuterium incorporation with high levels of isotopic purity. 
Several deuterated analogs displaying marked levels of in vitro metabolic stabilization 
were identified with compound 1a exhibiting a 39% increase in in vitro half life. Details of 
the convergent synthetic routes to the isotopologs along with results from human liver 
microsomal assays will be presented. 
MEDI 342 
Strategies in lead optimization: Shedding light on the relationship between 
lipophilicity and clearance 
Dario Doller, dado@lundbeck.com. Chemical & Pharmacokinetic Sciences, Lundbeck 
Research USA, Paramus NJ 07652, United States  
Projecting human pharmacokinetics is a key step in de-risking drug candidates prior to 
entering the clinic. Low clearance compounds present advantages, and significant 
efforts are devoted to engineer this property into biologically active chemotypes. There 
is some perception that lowering cLogP is a sound medicinal chemistry strategy to 
produce drug candidates with low in vivo clearance.  Experimentally, hepatic 
metabolism liabilities are estimated using in vitro intrinsic clearance (CLint) 
determinations with pooled human microsomes, and applying the well-stirred model to 
produce a projected hepatic clearance, CLH. While ignored early on, the free fraction in 
the microsomal incubation (fumic) is now recognized as a key parameter in the well 
stirred equation. Extensive research has led to a number of simple mathematical 
relationships linking fumic and cLogP.  We present simulations of intrinsic unbound 
clearance (CLint,u) suggesting that the apparent linear relationship with cLogP is driven 
mainly by the dependence of fumic on cLogP. 
MEDI 343 
Synthesis of a biotin conjugate of the tylophorine analog DCB-3503 bearing a 
novel PEG-based tether 
Samson Francis, dcbaker@utk.edu; David C. Baker. Department of Chemistry, 
University of Tennessee, Knoxville TN 37996-1600, United States  
In our continued efforts towards probing the physiologically relevant protein binding 
partners of the phenanthrolizidine alkaloids, we wish to report the design and synthesis 
of a biotinylated derivative of the tylophorine analog DCB-3503 bearing a novel tether. 
The interaction between a molecular probe and its target is typically governed by 
variables such as linker length and composition; as such, we chose to incorporate a 
PEG-based linker of exceptional length, between the active head unit and the biotin 
moiety. Attachment of a heterobifunctional PEG derivative to the phenanthrene skeleton 
of DCB-3503 followed by “click” conjugation with PEG-functionalized biotin facilitated 
access to the target probe. Modeling studies indicated that a significant portion (21.365 
Å) of the DCB-3503-biotin conjugate remained sufficiently exposed even after simulated 
streptavidin capture, making it suitable for targeting any potentially elusive binding 
partners. Furthermore, owing to its exceptional length and enhanced hydrophilicity, this 
novel tether may find uses in other applications such as drug delivery.  
  
MEDI 344 
Synthesis and structure-activity relationship of liposomal substrates for 
phospholipase A2 
Hélène Viart, hmvi@kemi.dtu.dk; Mads H. Clausen. Department of Chemistry, 
Technical University of Denmark, Kgs. Lyngby 2800, Denmark  
A recent innovation in the use of liposomes as drug delivery systems consists of 
covalently attaching an anticancer drug at the sn-2 position of phospholipids. However, 
some of those lipids could not be hydrolyzed by sPLA2.   
    
Steric bulk in the vicinity of the sn-2 position appears to prevent hydrolysis of the 
substrate. Structurally different lipids have been synthesized and formulated as 
liposomes, subjected to sPLA2 and the hydrolysis rates have been compared to 
Molecular Dynamics simulations of the enzyme/substrate complexes. 
MEDI 345 
Discovery of atrop fixed alkoxy-aminobenzhydrol derivatives: Novel, highly 
potent and orally efficacious squalene synthase inhibitors 
Masanori Ichikawa1, ichikawa.masanori.uf@daiichisankyo.co.jp; Aki Yokomizo2; 
Masao Itoh2; Noriyasu Haginoya2; Kazuyuki Sugita3; Hiroyuki Usui2; Koji Terayama4; 
Akira Kanda5. (1) Lead Discovery and Optimization Research Laboratories I, Daiichi 
Sankyo Co., LTD., 1-2-58, Hiromachi, Shinagawa-ku Tokyo 140-8710, Japan (2) Lead 
Discovery and Optimization Research Laboratories II, Daiichi Sankyo Co., Ltd. Tokyo, 
Japan (3) Institute of Molecular and Cellular Biosciences Tokyo, Japan (4) 
Cardiovascular-Metabolics Research Laboratories, Daiichi Sankyo Co., Ltd. Tokyo, 
Japan (5) Biological Research Laboratories, Daiichi Sankyo Co., Ltd. Tokyo, Japan  
To obtain efficient small molecule squalene synthase inhibitors, we designed and 
prepared a flexible 2-aminobenzhydrol template. The X-ray co-crystallographic study 
revealed our compound's unique 11-membered ring conformation binding mode with an 
intramolecular hydrogen bond. However, the template was composed of a pair of easy 
rotatable atropisomers. In an effort to fix the isomerization, we found a highly potent 
alkoxy-aminobenzhydrol scaffold. Moreover, two of the series of compounds exhibited 
specific plasma lipid-lowering effects in in vivo animal models.  
  
MEDI 346 
Discovery of novel tricyclic compounds as squalene synthase inhibitors 
Masanori Ichikawa1, ichikawa.masanori.uf@daiichisankyo.co.jp; Masami Ohtsuka2; 
Hitoshi Ohki2; Noriyasu Haginoya2; Masao Itoh2; Hiroyuki Usui2; Koji Terayama3; Akira 
Kanda4. (1) Lead Discovery and Optimization Research Laboratories I, Daiichi Sankyo 
Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku Tokyo 140-8710, Japan (2) Lead Discovery 
and Optimization Research Laboratories II, Daiichi Sankyo Co., Ltd. Tokyo, Japan (3) 
Cardiovascular-Metabolics Research Laboratories, Daiichi Sankyo Co., Ltd. Tokyo, 
Japan (4) Biological Research Laboratories, Daiichi Sankyo Co., Ltd. Tokyo, Japan  
In the present article, we have reported the design, synthesis, and identification of 
highly potent benzhydrol derivatives as squalene synthase inhibitors (compound 1). 
However, there was concern regarding the possibility of the isomerization of benzhydrol 
part via carbo cation in acidic condition. In order to obtain a more stable and efficient 
inhibitor in the body environment, we focused on Takeda's benzoxazepin ring and 
designed a new tricyclic scaffold by the incorporation of heterocycles. Prepared 
pyrrolobenzoxazepine derivatives showed in vitro and in vivo effective activities.  
  
MEDI 347 
Structure-based design and optimization of 1,3-oxazin-2-one inhibitors of 11β-
hydroxysteroid dehydrogenase type 1 
Colin M Tice, ctice@vitaerx.com; Zhenrong Xu; Wei Zhao; Salvacion Cacatian; Yuan-
Jie Ye; Suresh B Singh; Peter Lindblom; Brian M McKeever; Paula M Krosky; Barbara A 
Kruk; Jennifer Berbaum; Richard K Harrison; Judith A Johnson; Yuri Bukhtiyarov; 
Reshma Panemangalore; Boyd B Scott; Yi Zhao; Joseph G Bruno; Jennifer Togias; 
Joan Guo; Rong Guo; Gerard M McGeehan; Linghang Zhuang; Wei He; David A 
Claremon. Vitae Pharmaceuticals, Fort Washington PA 19034, United States  
11β-HSD1 is an attractive target for the treatment of diabetes. Application of a 
proprietary structure-based drug design methodology led to the rapid identification of 
oxazinone 1 with an IC50 value of 42 nM. Optimization around this scaffold afforded a 
lead compound with an IC50 value of 0.75 nM. This compound was orally bioavailable 
and, in cynomolgus monkeys, reduced plasma cortisol levels following a cortisone 
challenge. 
   
MEDI 348 
Indolyl/dihydroindolyl N-glycinamides as potent NPY5 antagonists 
Lingyun Wu1, lwu@lundbeck.com; Kai Lu1; Mathivanan Packiarajan1; Vrej Jubian1; 
Gamini Chandrasena1; Toni Wolinsky2; Mary W Walker2. (1) Chemical & 
Pharmacokinetic Sciences, Lundbeck Research USA, Paramus NJ 07652, United 
States (2) Neuroinflammation Disease Biology Unit, Lundbeck Research USA, Paramus 
NJ 07652, United States  
Neuropeptide Y (NPY) is a 36 amino acid neuropeptide widely expressed in the central 
and peripheral nervous systems possessing a diverse array of biological functions 
including influencing blood pressure, food intake, circadian rhythms, and stress 
sensitivity. NPY exerts its effects through interaction with specific receptors of the 
GPCR super family. Five NPY receptors have been identified to date (Y1, Y2, Y4, Y5, 
and Y6). Subtype specific ligands are needed to evaluate the therapeutic potential of 
modulating the brain's neuropeptide Y system. Through our efforts to investigate the 
utility of modulating the NPY system, a benzothiazepine glycinamide was identified as 
an NPY5 antagonist lead. Optimization efforts targeting improvements in potency, 
microsomal stability, and PK properties culminating in the discovery of a new class of 
structurally novel indolyl/dihydroindolyl glycinamides as NPY5 antagonists will be 
presented. 
MEDI 349 
Synthesis and biological evaluation of dual PPAR/cannabinoid ligands 
Ruth Pérez-Fernández1, rperezf@iqm.csic.es; Nieves Fresno1; Manuel Macías2; José 
Elguero1; Juan Decara2; Fernando Rodríguez de Fonseca2; Pilar Goya1. (1) Instituto de 
Química Médica, CSIC, Madrid 28006, Spain (2) Fundación Hospital Carlos Haya, 
Spain  
Peroxisome proliferator-activated receptors (PPARs) belong to the superfamily of 
nuclear receptors and consist of three isoforms. They are involved in the regulation of 
glucose and lipid metabolism, as well as in adipogenesis, feeding and other processes 
such as inflammation and neuroprotection. Therefore, they are interesting targets in 
medicinal chemistry. It has been reported that combining cannabinoids with other 
compounds (other cannabinoids or PPAR agonists) increases their therapeutic 
potential. We report the synthesis and evaluation of dual ligands targeting the 
cannabinoid receptor and PPARs. They are the first examples of dual compounds with 
nanomolar affinity for both receptors. Therefore, it can be considered an interesting lead 
in the search of a new class of dual ligands capable of modulating metabolism with 
potential neuroprotective activities. 
MEDI 350 
Design, synthesis and SAR of triazolopyridazine based cannabinoid-1 receptor 
antagonists 
Yanting Huang1, yanting.huang@bms.com; Chongqing Sun1; Amarendra Mikkilineni1; 
Guixue Yu1; Ximao Wu1; Zhengxiang Gu1; Natesan Murugesan1; Bruce A. Ellsworth1; 
Annapurna Pendri1; Philip Sher1; Gang Wu1; Yeheng Zhu1; Doree Sitkoff2; Liya Kang3; 
Yifan Yang3; Ning Lee3; Mary Jane Cullen3; William Keim3; Mary Ann Pelleymounter3; 
Paul Stetsko4; Gerry Everlof4; Olafur Gudmunsson4; Susan Johnghar4; Steven Wu4; 
Asoka Ranasinhe4; Wenying Li4; Kamelia Behnia4; Kenneth E. Carlson3; William R. 
Ewing1. (1) Department of Metabolic Disease Chemistry, Bristol-Myers Squibb 
Research and Development, Princeton NJ 08543-5400, United States (2) Department of 
Computer Assisted Drug Design, Bristol-Myers Squibb Research and Development, 
Princeton NJ 08543-5400, United States (3) Department of Metabolic Disease Biology, 
Bristol-Myers Squibb Research and Development, Princeton NJ 08543-5400, United 
States (4) Department of Preclinical Candidate Optimization, Bristol-Myers Squibb 
Research and Development, Princeton NJ 08543-5400, United States  
Pharmacologic blockade with CB1 (cannabinoid-1 receptor) antagonists results in 
hypophagia and decreased body weight in animal models. These observations have 
stimulated the search for potent and selective CB1 antagonists as a treatment for 
obesity. Several CB1 antagonists have demonstrated sustained weight loss in obese 
patients. Unfortunately, the long term safety profiles, e.g. the risk of psychiatric side 
effects, have halted the development of many centrally acting CB1 antagonists. 
However, there is continuing interest in exploring the CB1 blockage mechanism for 
therapeutic applications through other approaches, including the peripheral system.  As 
part of a program to identify novel antagonists with improved CB1 in vitro and in vivo 
potency, as well as high selectivity for CB1 vs CB2 receptor, we designed and 
generated a series of novel 5,6-fused bicyclic (triazolopyridazine) templates by 
conformationally constraining the pyrazine carboxamide. The synthesis, SAR and 
pharmacology of the triazolopyridazine template based CB1 antagonists will be 
presented. 
MEDI 351 
Discovery of a new class of small molecule ROMK blockers for the treatment of 
hypertension 
Haifeng Tang, haifeng_tang@merck.com; Yan Yan; Reynalda deJesus; Nardos 
Teumelsan; Yuping Zhu; Shawn Walsh; Aurash Shahripour; Ha Sookhee; Karen 
Owens; Brande Thomas-Fowlkes; John Felix; Jessica Liu; Martin Kohler; Birgit Priest; 
Timothy Bailey; Richard Brochu; Maria Garcia; Gregory Kaczorowski; Magdalena 
Alonso-Galicia; Sophie Roy; Lihu Yang; Sandy G Mills; Kathleen Sullivan; Alexander 
Pasternak. Merck Research Labs, Rahway New Jersey 07065, United States  
Hypertension, also known as high blood pressure, is a serious chronic health problem. 
Persistent hypertension is one of the risk factors for stroke, myocardial infarction, heart 
failure, arterial aneurysm, and is also a leading cause of chronic kidney failure. Although 
a large number of treatments are available, many patients fail to achieve adequate 
blood pressure control and physicians commonly prescribe combination therapies. 
Among the existing antihypertensive agents, thiazide diuretics remain the second most 
widely prescribed class despite liabilities such as hypokalemia.  The Renal Outer 
Medullary Potassium channel (ROMK, Kir1.1) is involved in salt reabsorption in the 
kidney. Human genetics suggested that ROMK blockers could be used as novel 
diuretic/natriuretic agents with reduced liabilities over the currently used diuretics. 
Genetic ablation of ROMK in rodents also supports these expectations. Thus, selective 
ROMK blockers are expected to be superior diuretics for the treatment of hypertension.  
This presentation will disclose a new class of selective small molecule ROMK blockers 
discovered from a High Throughput Screening (HTS) campaign. Basic SAR of this lead 
class will be discussed. Medicinal chemistry efforts leading to improvement of off-target 
selectivity and PK properties in preclinical species will be detailed. 
MEDI 352 
Discovery and optimization of potent and selective tissue factor/factor VIIa 
inhibitors 
Shinsuke Hirota1, s-hirota@hhc.eisai.co.jp; Richard Clark1; Fumiyoshi Matsuura1; 
Kazunobu Kira1; Hiroshi Azuma1; Tadashi Nagakura1; Tatsuo Horizoe1; Kimiyo Tabata1; 
Kazutomi Kusano1; Takao Omae1; Atsushi Inoue1; David Critchley2. (1) Tsukuba 
Research Laboratories, Eisai Co., Ltd., Tsukuba-shi Ibaraki 300-2635, Japan (2) 
Department of Scientific Operations & Clinical Support, Eisai Product Creation Systems, 
Hatfield, United Kingdom  
The blood clotting mechanism has been classified into two pathways, the "intrinsic 
clotting pathway" which begins with activation of factor XII (FXII) upon contact with 
negative charged substances, and the "extrinsic clotting pathway" which is activated by 
tissue factor (TF) and factor VII (FVII). Since the pathology of thrombosis onset is 
associated with specific expression of TF, it has been suggested that extrinsic clotting is 
of major importance. Compounds that inhibit clotting factor VIIa, which is furthest 
upstream in the extrinsic clotting pathway of the clotting cascade, are thought to have 
potential use as therapeutic and/or prophylactic agents for diseases associated with 
thrombus formation, such as thrombosis, in which the extrinsic clotting mechanism 
plays a part. Here, we will describe the discovery of potent and selective triazolone 
derivatives as TF/FVIIa inhibitors. We will illustrate the synthesis and structure-activity 
relationships of the series and present the results of a human micro dosing study. 
MEDI 353 
Nano-sensors for apoptosis detection in atherosclerotic plaques 
Ellen Broering, ebroerin@uga.edu; Shanta Dhar. Department of Chemistry, University 
of Georgia, Athens Georgia 30602, United States  
Nano-sensors for Apoptosis Detection in Atherosclerotic Plaques  Ellen Broering and 
Shanta Dhar*  Department of Chemistry, The University of Georgia, Athens, GA 30602  
Email: ebroerin@uga.edu  Atherothrombotic vascular disease is responsible for more 
deaths than any other disease in the industrialized world. Although molecular-genetic 
approaches have identified arterial-wall targets, most approaches cannot be tailored to 
oral medications or to consistent therapy. Apoptosis of macrophages and smooth 
muscle cells along the arterial wall serves as a target for detection of plaque vulnerable 
to embolism. The anionic phosphatidylserine (PS) on the external membrane is one of 
the earliest signs of apoptosis and can be detected prior to a thrombic event. To detect 
atherosclerotic evidence noninvasively, we began constructing a long-circulating 
nanoparticle platform, which can selectively target macrophages and sense apoptosis. 
We encapsulated MRI active iron oxide nanocrystals in a core of poly(D,L-lactic-co-
glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG). The nanoparticle surface was 
modified by macrophage targeting mannose, PS-targeting peptides, and Zn2+ binding 
domains, which can bind the PS. The utility of these nano-constructs in the diagnosis of 
atherosclerosis will be discussed. 
MEDI 354 
Cholesterol-derived novel anti-apoptotic agents on the structural basis of 
ginsenoside Rk1 
Hongchan An1, godofks0@snu.ac.kr; Sujin Lee1; Sony Maharjan2; Kyeojin Kim1; Nam-
Jung Kim1; Hyun-Jung Choi2; Young Taek Han1; Young-Guen Kwon2; Young-Ger Suh1. 
(1) College of pharmacy, Seoul National University, Seoul, Republic of Korea (2) 
Department of Biochemistry, Yonsei University, Seoul, Republic of Korea  
It has been known that vascular endothelial cell (VEC) apoptosis can induce an 
alteration in the integrity of vessels and the function of endothelium. Therefore, 
apoptosis inhibition has been considered as a new approach for treatment of vascular 
disorder.   Our efforts for development of the potent anti-apoptotic agents have driven 
discovery of ginsenoside Rg3 and Rk1, which exhibit potent anti-apoptotic activity in 
human umbilical vein endothelial cell (HUVEC) lines. However, instability of Rk1 and the 
extract process-dependent composition of ginsenosides limited studies on biological 
functions and underlying mechanisms of their biological activities.  Based on our 
preliminary studies, we attempted to develop novel and structurally simplified VEC 
apoptosis inhibitors by introducing the carbohydrate equivalents. In addition, we 
selected cholesterol scaffold to substitute for the protopanaxadiol backbone of Rk1 in 
terms of structural similarity and ready accessibility. Taking together these, we have 
conducted design and synthesis of a series of cholesterol analogues. 
MEDI 355 
Discovery of novel polyamidoamine (PAMAM) dendrimer conjugated A3 
adenosine receptor agonist ligand as a cardioprotective agent 
Dilip K Tosh1, toshd@mail.nih.gov; Ahuva Isak2; Bella Chanyshev2; Yelena Chepurko3; 
Khai Phan1; Edith Hochhauser3; Asher Shainberg2; Kenneth A Jacobson1. (1) 
Laboratory of Bioorganic Chemistry, NIDDK, National Institute of Health, Bethesda MD 
20892, United States (2) Bar-Ilan University, The Mina and Everard Goodman Faculty 
of Life Sciences, Ramat Gan, Israel (3) The Cardiac Research Laboratory, Felsenstein 
Medical Research Center, Tel Aviv University, Petah Tikva, Israel  
Adenosine released during myocardial ischemia mediates cardioprotective 
preconditioning. The chemical and biological properties of multivalent drugs bound to 
nanocarriers may differ greatly from those of the corresponding monomeric agents. 
Multivalent nucleoside conjugates have been synthesized from poly(amidoamine) 
(PAMAM) dendrimeric polymers, and their effects in rat primary cardiac cell cultures and 
in an isolated heart model were investigated. Three conjugates of A3 adenosine 
receptor (AR) agonists, chain-functionalized at the C2 or N6 position, were 
cardioprotective, with greater potency than the monomeric agonist Cl-IB-MECA, and 
protection was blocked by an A3AR antagonist. Multivalent amide-linked MRS5216 
(selective for A1 and A3ARs) and triazole-linked A3AR-selective MRS5246 and 
MRS5539 (optionally with fluorescent label) protected ischemic rat cardiomyocyte 
cultures and isolated hearts with improved infarct size, rate of pressure product, and 
rate of contraction and relaxation (p<0.05 vs. controls). Thus, strategically derivatized 
nucleosides tethered to biocompatible polymeric carriers display enhanced 
cardioprotective potency via activation of the A3AR on surface of cardiomyocytes. 
MEDI 356 
Phenyl isoxazole voltage-gated sodium channel blockers: Structure and activity 
relationship 
Istvan Macsari, istvan.macsari@astrazeneca.com; Lars Sandberg; Yevgeni Besidski; 
Yiva Gravenfors; Tobias Ginman; Johan Bylund; Tjerk Bueters; Per I. Arvidsson. CNSP 
iMed Science, AstraZeneca Research and Development, Sweden  
Blocking of certain sodium channels is considered to be an attractive mechanism to 
treat chronic pain conditions. Phenyl isoxazole carbamates were identified as potent 
and selective NaV1.7 blockers. Structural analogues, both carbamates, ureas and 
amides, were proven to be useful in establishing the structure activity relationship and 
improving ADME related properties. Amide 1 showed a good overall in-vitro profile, that 
translated well to rat in-vivo PK.   
  
MEDI 357 
Discovery of a clinically useful alkyl amine renin inhibitor 
Colin M. Tice1, ctice@vitaerx.com; Lanqi Jia1; Robert D. Simpson1; Jing Yuan1; 
Zhenrong Xu1; Wei Zhao1; Salvacion Cacatian1; Joan Guo1; Alexey Ishchenko1; Suresh 
B. Singh1; Zhongren Wu1; Brian M. McKeever1; Yuri Bukhtiyarov1; Judith A. Johnson1; 
Christopher P. Doe2; Richard K. Harrison1; Gerard M. McGeehan1; Lawrence W. 
Dillard1; John J. Baldwin1; David A. Claremon1. (1) Vitae Pharmaceuticals, United 
States (2) GlaxoSmithKline, United States  
Structure guided optimization of a series of non-peptidic alkylamine renin inhibitors 
allowed the rational incorporation of additional polar functionality into the previous lead 
inhibitor series. Replacement of the cyclohexylmethyl group occupying the S1 pocket 
with a (R)-3-(tetrahydropyranyl)methyl group and utilization of a different attachment 
point improved the selectivity of the compounds, leading to the identification of clinical 
candidate VTP-27999. This compound demonstrated excellent selectivity over related 
and unrelated targets, >15% oral bioavailability in three species, oral efficacy in a dTGR 
model of hypertension and bioavailability in human. 
MEDI 358 
Synthesis and antioxidant activity of carbonate co-drugs 
Martha A. Hass, martha.hass@acphs.edu; Alaa M. Hammad. Arts & Sciences, Albany 
College of Pharmacy and Health Sciences, Albany New York 12208, United States  
The aim of this project was to synthesize new antioxidant compounds for use as topical 
agents to protect the skin against oxidative damage caused by ultraviolet radiation. Co-
drugs derived from tocopherol (TOC) and lipoic acid (LA), were prepared by coupling 
lipol (derived from reduction of lipoic acid) to chloroformates of TOC. Co-drugs were 
subjected to metabolic and chemical hydrolysis and hydrolysis products were quantified 
by HPLC. Antioxidant activity of the co-drugs was determined by measuring inhibitory 
potency of the co-drugs on lipid peroxidation. Compounds were prepared in good yield 
(42-66%). Carbonate co-drugs hydrolyzed in the presence of enzyme as exhibited by a 
decrease in co-drug concentration and a concurrent increase in concentration of lipol 
and TOC, but were stable in the absence of enzyme. Hydrolyzed co-drugs inhibited lipid 
peroxidation to a greater extent than TOC or lipol alone, suggesting the antioxidant 
activity is synergistic. 
MEDI 359 
Binding of hydrophobic side chains in the S2' pocket of Thermolysin: Is it 
entropic or enthalpic driven binding? 
Nader N Nasief1, nnn2@buffalo.edu; Adam Biela2; Gerhard Klebe2; David Hangauer1. 
(1) Department of Chemistry, University at Buffalo, The State University of New York, 
Buffalo NY 14260, United States (2) Department of Pharmaceutical Chemistry, Philipps 
University, Marburg 35032, Germany  
The entropy-driven hydrophobic effect is one of the major driving forces for ligand-
macromolecule binding. The binding thermodynamic parameters, and affinity, of a 
series of thermolysin phosphonamidate inhibitors were evaluated wherein a range of 
hydrophobic side chains were present for interacting with the S2' pocket. The results 
showed that favorable entropy changes dominate binding when the ligand hydrophobic 
groups are large (e.g. isobutyl and benzyl) but favorable enthalpy dominates when the 
hydrophobic side chains are small (e.g. Me and Et). The cause of this enthalpy-driven 
binding is attributed to the formation of stronger H-bonds among the water molecules 
hydrating the unburied portion of the smaller hydrophobic groups in the ligand-enzyme 
complex. The reinforcement of the H-bond networks by the polar and H-bonding groups 
in the ligand-enzyme complex might be the cause of the enhanced H-bonding strength 
among the nearby water molecules. 
MEDI 360 
Preparation and evaluation of novel mechanism-based inhibitors of rhomboid 
proteases 
Jonathan M. Large1, jonathan.large@tech.mrc.ac.uk; Keith Ansell1; Nathalie Bouloc1; 
Yonka Christova2; Matthew Freeman2; Vinothkumar K. Ragunath2; Simon Osborne1; 
Olivier A. Pierrat2; Ela Smiljanic1; Kvido Strisovsky2; Debra Taylor1. (1) Centre for 
Therapeutic Discovery, MRC Technology, United Kingdom (2) MRC Laboratory of 
Molecular Biology, United Kingdom  
Rhomboids are a family of conserved intramembrane serine proteases which are known 
to participate in a number of diverse and important biological processes, ranging from 
possible roles in EGFR signaling to involvement in malarial parasite invasion of red 
blood cells. There is considerable interest in the structural and functional 
characterization of rhomboids and their potential validation as disease targets, and the 
identification of small molecules that can inhibit or activate rhomboid activity would 
contribute significantly to this area of work.     This poster will describe the application of 
a recently developed high-throughput screening approach to uncovering such 
molecules, and the identification of a series of β-lactams as potent and selective 
rhomboid inhibitors. Synthetic approaches to a range of analogues and key structure 
activity relationships will be presented, together with in vivo studies and observations on 
the likely mechanism of action. 
MEDI 361 
Inside the mind of a medicinal chemist 
Peter S Kutchukian1, peter.kutchukian@novartis.com; Jordan Xu2; Mika Lindvall2; Meir 
Glick1; Natasja Brooijmans1. (1) Lead Discovery Informatics, Center for Proteomic 
Chemistry, Novartis Institutes for BioMedical Research, Cambridge MA 02139, United 
States (2) Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 
Emervyville CA 94608, United States  
The prioritization of compounds from large hit lists for further follow-up is an especially 
challenging task for medicinal chemists. During this step of drug discovery, multiple 
parameters such as synthetic accessibility, target specificity, solubility, and potential 
mutagenicity, in addition to assay activity, must be considered simultaneously. We 
sought to elucidate parts of the thought process of chemists during hit assessment by 
asking them to select chemical fragments (MW<300) that they would be willing to work 
with from a putative “hit” list. We subsequently applied data mining techniques to 
understand their choices. In all, twenty-seven chemists were asked to survey ~4,000 
compounds. Bayes models were built using various combinations of properties 
(measuring ring topology, size, polarity, etc.) to try and understand which features were 
most important to individual chemists. We rigorously demonstrate that the majority of 
chemists only used 1-2 parameters during their fragment assessment, suggesting that 
medicinal chemists reduce a complicated problem into a more tractable one by focusing 
on a few parameters rather than on several. Interestingly, follow up questionnaires 
revealed that many chemists were unaware of what parameters dominated their 
decisions. The heretofore illusive “intuition” of medicinal chemists was further revealed 
by visually investigating individual models, and exposing subtle preferences such as 
combinations of functional groups or scaffold topology. We present our findings in the 
context of previous psychology studies that have been performed in the area of complex 
problem solving and decision theory, and discuss the implications on drug discovery. 
MEDI 362 
Computer LeadOpt assistance in medicinal chemistry 
Marcus Gastreich, marcus.gastreich@biosolveit.de. BioSolveIT GmbH, St. Augustin 
53757, Germany  
In times of restructurings, more computation has to be accomplished by MedChems 
themselves. For software development, this prompts to acknowledge strong boundary 
conditions:  - MedChem core expertise is synthesis, so the learning barrier for new 
software must be absent, and results must be delivered in seconds. - MedChems are 
"pattern recognizers" (C. Lipinski), so good visualization is key - especially in 2D. - We 
all need to communicate to colleagues and bosses, so software must generate 
graphics, tables/reports with high aesthetics and seamlessly integrate into Office tools 
etc.  Several years of research have now addressed these issues, and we are now 
ready to present a collection of tools we think are of high interest to the MedChem 
personnel. The software is a monolithic suite that not only supports drag and drop of 
mol2, sdf, pdb files, but also lets users drag result 2D and 3D graphics into PowerPoint, 
Word etc. with a single click.  Novel computational tasks included are: 1. Desolvation-
respecting affinity estimation (“Hyde”) with visualization of energy issues in compounds. 
2. Scaffold replacement engine (“ReCore”) that - within seconds - gives proposals for 
iterative optimization respecting pharmacophores and/or synthesis vectors. 3. 2D 
protein-ligand display (“PoseView“ which was recently also linked to the PDB website). 
4. Protein preparation which resolves crystallographic ambiguities such as H-positions.  
Experience in several big pharmas revealed that the time won can be re-invested in 
core MedChem tasks. We will showcase example workflows highlighting successes 
plus take a glance at the science behind. 
MEDI 363 
Effective use of in-silico tools in lead optimization 
Pranas Japertas1, pranas.japertas@acdlabs.com; Andrius Sazonovas1; Kiril Lanevskij1, 
2. (1) ACD/Labs, Inc., Vilnius LT-08117, Lithuania (2) Department of Biochemistry and 
Biophysics, Vilnius University, Vilnius LT-08117, Lithuania  
Despite constant advances in QSAR field, computational approaches in general still fail 
to meet the expectations. In this work we attempt to re-assess the role of various in-
silico tools in building an effective lead optimization strategy. From the modeling 
perspective the emphasis is put on the mechanistic interpretations utilizing the most 
basic physicochemical characteristics of the compounds, e.g., lipophilicity, size, 
ionization, etc. The phenomenon of local 'anomalies' – the so-called 'activity cliffs' – is 
also covered providing suggestions for the statistical methods (pairwise QSAR) suitable 
to resolve such issues. Automated Hansch and Free-Wilson type analysis (Auto-SAR 
approach) is presented as a viable solution to include target affinity data in the analysis, 
potentially suggesting most promising candidates. Finally the potential of various in-
silico techniques in the evaluation of other lead optimization aspects, such as synthetic 
feasibility or patentability prospects is overviewed. 
MEDI 364 
Deformable nanogels into nanoscale suprastructures and their application in 
nanomedicine 
Xiangliang Yang, yangxl@hust.edu.cn; Huibi Xu; Huabing Chen; Hongda Zhu; Qibing 
Zhou. National Engineering Research Center for Nanomedicine, Huazhong University of 
Science and Technology, Wuhan Hunan 430074, China  
Assembly of nanoparticles as interfacial stabilizers at oil-in-water (O/W) interfaces into 
microscopic suprastructures for stabilizing Pickering emulsions is an intriguing focus in 
the fields of chemical industry and material sciences. However, it is still a major 
challenge to assemble these nanoscale suprastructures for the applications in medicine. 
We show that it is possible to fabricate the nanodroplets by assembling highly 
deformable nanogels into the nanoscale suprastructures. The hydrogen bonding 
interaction between the nanogels at the O/W interface are possibly responsible for the 
stabilization of the nanoscale suprastructures. The nanoscale suprastructures are 
further employed to stabilize the paclitaxel-loaded nanodroplets, which are found to 
provide sustained release of the drug, prolonged in vivo blood circulation, and enhanced 
tumor growth inhibition. This approach provides a novel universal strategy to fabricate 
nanoscale suprastructures for stabilizing nanodroplets with built-in payloads using 
deformable nanoparticles and displays a promising potential in nanomedicine.   
  
MEDI 365 
Fast and efficient purification of lipids and lipid-based compounds using flash 
chromatography 
Melissa J Wilcox, melissa.wilcox@grace.com; Kiran Chodavarapu; Kathy Lawrence; 
Kimberly Wolfson. Department of Technology, Grace Davison Discovery Sciences, 
Deerfield IL 60015, United States  
Lipids play a major role in biological functions due to their presence in all cells. Lipids 
are usually hydrophobic in nature, soluble in organic solvents, and contain nonpolar 
fatty acid groups. Purifying complex mixtures containing non-chromophoric or poorly 
chromophoric compounds like lipids can be difficult. Traditional ultraviolet (UV) detection 
fails to detect lipids and impurities that are present at low levels or lack chromophores, 
requiring a 'collect all' approach that can add significant time to the purification process.   
This work demonstrates purification of lipid-based compounds (fatty acids, sterols, 
stearins, and others) that are weakly chromophoric using a Reveleris® flash 
chromatography system. With RevealX™detection technology in the Reveleris® 
System, chemists can purify lipid-based compounds that are non-chromophoric with 
speed and high purity. A variety of Reveleris cartridge chemistries can be applied to 
maximize separation and purity of complex lipid mixtures. 
MEDI 366 
Efficient purification of small peptides using flash chromatography with 
RevealX™ detection technology 
Melissa J Wilcox, melissa.wilcox@grace.com; Kiran Chodavarapu; Kathy Lawrence; 
Kimberly Wolfson. Grace Davison Discovery Sciences, Deerfield IL 60015, United 
States  
Newly discovered peptide sequences provide tools in understanding the functions of 
biological systems and support for novel drug development. Purification of synthetic 
peptides is an essential step in the drug discovery process. It is traditionally done by 
preparative chromatography, which can be expensive and time consuming. Flash 
chromatography is a fast and cost-efficient approach to purify synthetic peptides and 
other small molecules.   This work demonstrates purification and recovery of small 
peptides using a Reveleris® Flash Chromatography System with RevealX™ 
technology. Using the Reveleris® flash chromatography system combined with high 
capacity Reveleris® cartridges streamlines purification of small peptides. 
MEDI 367 
WITHDRAWN 
MEDI 368 
Potent and selective inhibition of cysteine proteases from Plasmodium 
falciparum and Trypanosoma brucei 
Veronika Ehmke1, veronika.ehmke@org.chem.ethz.ch; Matthias Rottman2; Reto Brun2; 
Tanja Schirmeister3; François Diederich1. (1) Laboratory of Organic Chemistry, ETH 
Zurich, Switzerland (2) Swiss Tropical and Public Health Institute, Switzerland (3) 
Institute of Pharmacy, University of Würzburg, Germany  
Malaria and African sleeping sickness, caused by the parasitic protozoa Plasmodium 
falciparum and Trypanosoma brucei, are among the most severe tropical diseases 
representing health issues in the developing world.[1] The emergence of multidrug-
resistant parasite strains, in addition to limitations of chemotherapies, demand the 
development of new drugs with novel mechanisms of action. P. falciparum and T. brucei 
offer several potential target enzymes, including a number of essential cysteine 
proteases. Falcipain-2, a hemoglobinase of P. falciparum, and rhodesain, a cathepsin L-
like hydrolase of T. brucei, emerged as targets for drug development since they exhibit 
crucial roles in the parasites' life-cycles. Based on X-ray crystal structures, we utilized 
computer-aided modeling to design drug-like molecules featuring a nitrile residue as 
electrophilic head group to covalently interact with the catalytic cysteine.[2] With our 
structure-based design approach, we prepared functionalized triazine nitriles which 
were tested against falcipain-2 and rhodesain. Single-digit nanomolar activities were 
obtained for the designed ligands. Biological assays showed in most cases good 
selectivity against closely related human enzymes. Cell-based assays against the 
parasites revealed moderate in vitro activity. These results gave rise for detailed 
optimization studies which are currently ongoing. 
     
MEDI 369 
Designing isoform selective inhibitors of phosphoinositide 3-kinases 
Michelle Miller, michelle.miller@monash.edu; Philip Thompson; Ian Jennings; Zhaohua 
Zheng; Jo-Anne Pinson. Department of Medicinal Chemistry, Monash University 
Institute of Pharmaceutical Sciences, Parkville Victoria 3082, Australia  
Phosphatidylinositol 3-kinases (PI3K) hold significant therapeutic potential as novel 
targets for multiple diseases. The four closely related Class I isoforms have been 
implicated in cancer (α, β, δ), thrombosis (β) and various inflammatory and autoimmune 
disorders (γ, δ). A highly conserved active site presents researchers with a compelling 
challenge to develop isoform selective inhibitors able to limit off-target effects. Drawing 
on the current understanding of the mechanisms of isoform selectivity, we have sought 
to target regions of non-conserved residues through substitution and derivatisation of 
the non-selective inhibitor, ZSTK4741. To date, we have been able to achieve significant 
changes in isoform selectivity through simple substitutions. The design, synthesis and 
activity of these inhibitors will be presented.  (1) Yaguchi, S.; Fukui, Y.; Koshimizu, I.; 
Yoshimi, H.; Matsuno, T.; Gouda, H.; Hirono, S.; Yamazaki, K.; Yamori, T. Journal of 
the National Cancer Institute 2006, 98, 545. 
MEDI 370 
Structure activity relationship, in vitro and in vivo profile of JN403, a nAChR α7 
selective agonist 
Joachim Nozulak1, joachim.nozulak@novartis.com; Daniel Hoyer2; Frederique 
Chaperon2; Kurt Lingenhoehl2; Annick Vassout2; Dominik Feuerbach2. (1) Global 
Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel 4002, 
Switzerland (2) Neuroscience Research, Novartis Institutes for BioMedical Research, 
Basel 4002, Switzerland  
Several lines of evidence suggest that the nicotinic acetylcholine receptor α7 (nAChR 
α7) is involved in neuropsychiatric disorders like schizophrenia and Alzheimer's 
disease. By optimizing a quinuclidine carbamate scaffold, we have discovered a novel 
selective nicotinic acetylcholine receptor (nAChR) α7 agonist, JN403, (S)-(1-aza-
bicyclo[2.2.2]oct-3-yl)-carbamic acid (S)-1-(2-fluoro-phenyl)-ethyl ester. JN403 was 
evaluated in a number of in vitro systems of different species, at recombinant receptors 
using radioligand binding and signal transduction studies. JN403 has high affinity for 
human recombinant nAChR α7 (pKD = 6.7) and stimulates calcium influx in GH3 cells 
recombinantly expressing the human nAChR α7 with a pEC50 of 7.0 and an Emax of 85 
%. JN403 shows low binding activity at a panel of neurotransmitter receptors. JN403 
rapidly penetrates into the brain after p.o. administration in mice and rats. In mice, 
JN403 facilitates learning/memory performance over a dose range of 1-3 mg/kg, s.c. 
JN403 shows anxiolytic-like properties in rats (10-30 mg/kg, p.o.) and the effects are 
retained after a 6 h pre-treatment period and following subchronic administration. In 
DBA/2 mice, JN403 restores sensory gating, both in anaesthetized and awake animals 
(50 mg/kg, s.c.). Altogether, the present set of data suggests that nAChR α7 agonists, 
and notably JN403, may be beneficial for improving learning/memory performance and 
restoring sensory gating deficits. 
MEDI 371 
Design, synthesis, and pharmacological evaluation of dihydrobenzofuran amide 
derivatives as γ-secretase modulators 
Martin Pettersson, martin.pettersson@pfizer.com; Douglas S Johnson; Chakrapani 
Subramanyam; Kelly Bales; Gregory Kauffman; Christopher J O’Donnell; Christopher 
am Ende; Benjamin Fish; Michael Green; Ricardo Lira; Patrick Mullins; Thayalan 
Navaratnam; Leslie Pustilnik; Cory Stiff; Beth Vetelino; Kathleen Wood; Longfei Xie; 
Liming Zhang. Neuroscience, Pfizer Worldwide Research and Development, Groton CT 
06340, United States  
γ-Secretase modulators (GSMs) have emerged as a potential disease modifying 
treatment for Alzheimer's disease. While γ-secretase inhibitors (GSIs) block the 
cleavage of all γ-secretase substrates including Notch, which is important for cell 
differentiation, GSMs selectively alter the cleavage site of the amyloid precursor protein 
(APP) to reduce the formation of the neurotoxic peptides Aβ42 and Aβ40. As an intra-
membrane cleaving aspartyl protease, γ-secretase presents a significant challenge for 
small molecule drug discovery. This is exemplified by the relatively high cLogP 
observed for compounds reported in the GSM patent literature. The alignment of 
potency, clearance, and brain penetration, while maintaining good physicochemical 
properties to ensure an adequate therapeutic index has proven to be particularly 
challenging. This presentation will describe our efforts toward this goal, which have 
resulted in the discovery of centrally active GSM leads. 
MEDI 372 
Discovery of potent and selective inhibitors of Ataxia telangiectasia mutated and 
Rad3 related (ATR) protein kinase as potential anticancer agents 
Jean-Damien Charrier, jean-damien_charrier@vrtx.com. Chemistry, Vertex 
Pharmaceuticals (Europe) Ltd, United Kingdom  
Exploiting genetic lesions in cancer that drive a reliance on druggable proteins for 
survival provides an opportunity to deliver safer anti-cancer drugs. Two related kinases, 
ATM and ATR, are key regulators of a critical survival pathway that responds to DNA 
damage. In normal cells, these kinases have an overlapping role. However, defects in 
ATM signaling pathway are common in cancer and could drive reliance on ATR for 
survival from DNA damage. Here, we describe the discovery of the first potent, selective 
and drug-like ATR inhibitors. We show that cancer cells with defects in ATM signaling 
pathway are markedly sensitized to the cytotoxic effects of DNA damaging agents by 
ATR inhibition. In stark contrast normal cells, with a functional ATM pathway, can 
tolerate ATR inhibition. These findings establish ATR inhibition as a novel and safe 
approach to dramatically increase the efficacy of many widely used DNA damaging 
drugs and ionising radiation. 
MEDI 373 
Synthesis of functionlized pyrroles as building blocks for novel inhibitors of 
bacterial DNA gyrase 
Pamela J Hill, pam.hill@astrazeneca.com; Gregory S Basarab; Shanta Bist; Oluyinka 
Green; Sheila Hauck; Ken Hull; Brian Sherer. Infection Discovery, AstraZeneca, R&D 
Boston, Waltham MA 02451, United States  
Bacterial DNA gyrase is a type II topoisomerase that is responsible for DNA topology 
during cell replication. Inhibitors of DNA gyrase block DNA synthesis and ultimately lead 
to cell death. Fragment based lead generation using NMR identified low molecular 
weight fragments that bind to the ATP binding site of bacterial DNA gyrase with 
millimolar affinity. Of the fragment hits, the pyrrole was chosen due to the hydrogen 
bonding motif and the opportunities for optimization. Chemistry was designed to achieve 
unique regioselective functionalizations of pyrrole fragments. A structure based drug 
design approach was used to elaborate fragments into lead compounds of novel 
pyrrolamide class with good antibacterial potency. Lead compounds demonstrated low 
nanmolar potency against the target with good physical properties and demonstrated 
efficacy in animal models.  
  
MEDI 374 
Synthesis and SAR analysis of a library of TSHR modulators 
Erika E Englund1, englundee@mail.nih.gov; Susanne Neumann2; Elena Eliseeva2; 
Josh McCoy1; Steve Titus1; Wei Zheng1; Noel Southall1; Juan Marugan1; Craig 
Thomas1; Christopher Austin1; Marvin Gerhsngorn2; Wenwei Huang1. (1) National 
Institutes of Health Chemical Genomics Center, Bethesda MD 20892, United States (2) 
National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda MD 20892, 
United States  
Thyroid stimulating hormone (TSH), an α/β heterodimeric glycoprotein hormone, is 
secreted from the anterior pituitary gland and binds to the TSH receptor (TSHR). TSHR 
is mainly expressed in thyroid follicular cells, but is also found in the bone, brain, kidney, 
testis, endometrium, and immune system. A TSHR modulator could provide a valuable 
pharmacological tool for researchers interested in exploring this receptor and a small 
molecula antagonist has the potential to be used clinically for patients with Graves' 
disease. Recombinant human TSH (rhTSH, ThyrogenR) has been used in the follow-up 
of patients with thyroid cancer. A small molecule TSHR agonist could produce the same 
beneficial effects as rhTSH, but with greater ease of oral administration. Previously, a 
library of 73,180 compounds was screened at NCGC and a selective TSHR agonist was 
identified. SAR studies have led to the identification of a more potent TSHR agonist and 
new TSHR antagonists and inverse agonists. 
MEDI 375 
Progress toward the development of small molecule inhibitors of TLR-4 signaling 
Sherry A Chavez, sherry.chavez@colorado.edu; Alexander J Martinko; Michael N 
Pham; Sara Coulup; Kui Cheng; Douglas E Bevan; Hang Yin. Department of Chemistry 
and Biochemistry, University of Colorado at Boulder, Boulder Co 80309, United States  
It has been demonstrated that the heterodimerizaiton of TLR4 (Toll Like Receptor 4) 
and the accessory protein MD2 is responsible for the up regulation of pro-inflammatory 
cytokines such as TNF-a and IL1-b through the activation of the NF-kB signaling 
pathway. This TLR4 induced pro-inflammatory signaling has been implicated in a 
several autoimmune diseases as well as in sepsis, making TLR4 an interesting 
therapeutic target. Herein, we describe the identification, synthesis and biological 
results for a series of small molecule inhibitors that exhibited effectiveness and 
selectivity for the modulation of the TLR4-mediated inflammation response. [Figure 1] 
MEDI 376 
Small molecule modulation of the Lysophosphatidic acid pathway in the 
treatment of neoplastic growth 
James E East1, je5y@virginia.edu; Kevin R Lynch2; Timothy L Macdonald1. (1) 
Department of Chemistry, University of Virginia, Charlottesville VA 22902, United States 
(2) Department of Pharmacology, University of Virginia, Charlottesville VA 22902, 
United States  
Lysophosphatidic Acid (LPA) is an endogenous phospholipid signaling molecule 
implicated in a myriad of neoplastic disease states including breast and prostate cancer. 
LPA contributes to these diseases due its role in numerous biological processes such 
as angiogenesis, cell proliferation, migration and invasion. LPA is synthesized from 
lysophosphatidylcholine (LPC) by the Nucleotide Phosphatase/Pyrophosphatase 2 
(NPP2) enzyme Autotaxin (ATX). Once synthesized by ATX, LPA goes on to act on one 
of five LPA Receptors (LPA1-5). These receptors are classical G-protein coupled 
receptors (GPCRs) that are responsible for Ca2+mobilization and increasing MAP kinase 
and phosphatidylinositol bisphosphate (PIP2) pathway activities.   Our labs have 
developed two small molecules derived from L-tyrosine: one, VPC8a202, that inhibits 
the synthesis of LPA while the other, VPC51299 blocks the signaling of the LPA1 and 
LPA3 receptors.  These compounds are not only efficacious in in vtiro studies but have 
been shown to reduce tumor size and metastasis in vivo. 
MEDI 377 
HTS and structure-activity based discovery of a novel class of 4-quinoline 
carboxylic acids with excellent anti-influenza activity 
Priyabrata Das1, priyabrata.das@utsouthwestern.edu; Liang Zhang2; Mirco Schmolke3; 
Yaming Wang4; Xiaoyi Deng5; Michael G. Roth1; David E Lavy4; Adolfo Garcia-Sastre3; 
Margaret A Phillips5; Beatriz Fontura2; Jef de Brabander1. (1) Department of 
Biochemistry, University of Texas Southwestern Medical Center at Dallas, Dallas TX 
75390, United States (2) Department of Cell Biology, University of Texas Southwestern 
Medical Center at Dallas, Dallas TX 75390, United States (3) Department of Medicine, 
Mount Sinai School of Medicine, New York NY 10029, United States (4) Department of 
Pathology, New York University School of Medicine, New York NY 10016, United States 
(5) Department of Pharmacology, University of Texas Southwestern Medical Center at 
Dallas, Dallas TX 75390, United States  
     
Influenza virus NS1 protein is a major pathogenic factor. NS1 inhibits host gene 
expression and antiviral response by down regulating host nuclear mRNA processing 
and export as well as signaling pathways involved in interferon response. As a result, 
novel inhibitors of NS1 protein are important for anti-influenza drug discovery. Our 
studies started with the identification of 4-quinoline carboxylic acid 1 (IC50 = 260 nm) 
from a high throughput screen. Here, we describe the synthesis and in vitro evaluation 
of novel 4-quinoline carboxylic acid analogues to determine the structure-activity 
relationship. Replacement of the aromatic propyloxy substituent with a methyl, fluorine, 
2-pyridyloxy, 3-pyridyloxy substituent resulted in significantly lowered antiviral activity, 
whereas replacement with a trifluoromethyloxy, phenoxy substituent increased potency 
in this assay. It was found that replacement of quinoline chlorine with hydrogen, fluorine 
and nitro group resulted in increased activity. These efforts have led the discovery of 14, 
an extremely potent analogue with highest antiviral activity (IC50 = 36 nm). We noticed 
that compound 14 and analogues are structurally related to brequinar, also a 4-
quinoline carboxylic acid. Brequinar is a known inhibitor of human dihydroorotate 
dehydrogenase (DHODH), a key enzyme in the de novo biosynthesis of pyrimidines. 
Based on this information we tested 14 and analogues for their ability to inhibit 
recombinant human DHODH. This assay led to the discovery of the target enzyme for 
the anti-influenza activity as DHODH with compound 14 showing the best DHODH 
inhibitory activity. 
MEDI 378 
Design, synthesis and biological evaluation of tumor-targeting drug conjugates 
bearing dual-warheads 
Edison S Zuniga1, ezuniga@ic.sunysb.edu; Iwao Ojima1, 2. (1) Department of 
Chemistry, State University of New York at Stony Brook, Stony Brook New York 11794-
3400, United States (2) State University of New York at Stony Brook, ICB&DD, Stony 
Brook New York 11794-3400, United States  
Combination therapy with single pharmacokinetics, obviously, has potential advantages 
over conventional protocol. Thus, we designed and synthesized a tumor-targeting drug 
conjugate bearing two different anticancer agents, SB-T-1214 and topotecan, as 
warheads. SB-T-1214 targets microtubules, while topotecan targets topoisomerase I in 
the nucleus. We have observed substantial synergy between these two agents in 
certain cancer cells in vitro. Accordingly, a highly beneficial synergistic effect on efficacy 
is expected when these two agents are delivered to cancer cells simultaneously by a 
dual warhead conjugate via receptor-mediated endocytosis. In order to examine the 
anticipated synergy between two warheads in a fair manner, we also synthesized two 
other conjugates bearing the taxaoid or topotecan as one warhead and phenol as a 
dummy warhead, using exactly the same scaffold as that of the dual warhead 
conjugate. The synthesis and biological evaluation of these novel tumor-targeting drug 
conjugates will be presented.   
  
MEDI 379 
Development and validation of a predictive quantitative structure-activity-
relationship (QSAR) model for the TAB generation of isoprenylcysteine 
carboxylmethyl transferase (Icmt) inhibitors 
Jaimeen D. Majmudar1, 2, jmajmuda@purdue.edu; Gregory Wilson1; Joel A Bergman1, 
2; Kalub Hahne3, 2; Markus Lill1; Christine Hrycyna3, 2; Richard A Gibbs1, 2. (1) 
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 
West Lafayette IN 47907, United States (2) Purdue Center for Cancer Research, 
Purdue University, West Lafayette IN 47907, United States (3) Department of 
Chemistry, Purdue University, West Lafayette IN 47907, United States  
Icmt is the last downstream enzyme to perform post-translational modifications on Ras. 
Mutant Ras is implicated in 30% of all cancers and greater than 90% of all pancreatic 
cancers. Inactivating Icmt causes Ras to mislocalize and inhibits oncogenic signaling. 
Icmt is an enzyme that is embedded in the ER. There is no experimental or calculated 
structure for Icmt. In the absence of structural information, we have adopted a 
substrate-based approach and have synthesized a library of compounds that are 
nanomolar inhibitors of Icmt. To understand the inhibition requirements of this class of 
compounds, we have initiated a QSAR effort. Development of the QSAR model (using 
Raptor) has provided us with a predictive model with a R2 of 0.83 and a predictive R2 of 
0.72 
     
The model has successfully predicted activities of a few analogs. We are in the process 
of further evaluating the predictive power of the QSAR model by synthesizing analogs 
predicted by the model and evaluating them against Icmt. 
MEDI 380 
Thalidomide analogs reduce apoptosis in a PDT-induced apoptosis model 
Cindy Patinote1, 2, cindy.patinote@gmail.com; Bernard Pucci1, 2; Susan Shahzidi3; Jahn 
Nesland3; Qian Peng3; Christiane Contino-Pepin1, 2. (1) Department of Chemistry, 
Laboratoire de Chimie BioOrganique et des Systèmes Amphiphiles, AVIGNON 84000, 
France (2) Department of Chemistry, Institut des Biomolécules Max Mousseron, UMR 
5247, CNRS, AVIGNON 84000, France (3) Department of Pathology, Norwegian 
Radium Hospital, The Oslo University Hospital, Oslo 0310, Norway  
Based on our previous results for neuroinflammation treatment, we investigated the 
potential anti-apoptotic activity of derivatives of APA-Thalidomide in a PDT-induced 
apoptosis model.  
       
Compared to NAC, two analogues efficiently reduced ROS and singlet molecular 
oxygen mediated apoptosis. One of them was about twenty times more active than the 
reference antioxidant. 
MEDI 381 
Physicochemical and DMPK property calculations: How well can measured data 
be predicted? 
Daniel F Ortwine, ortwine.daniel@gene.com. Department of Discovery Chemistry, 
Genentech, South San Francisco California 94080, United States  
Calculation of physicochemical and DMPK properties of candidate molecules ahead of 
synthesis is becoming more widespread with the availability of predictive models. 
Commercial software is available to do predictions, and many companies have 
developed models using internal data. Which properties can be calculated accurately, 
and which ones remain problematic to forecast? Are commercially available models 
adequate, or must one develop their own models? How truly widespread is model 
usage, and what prevents models from being employed more effectively? This talk will 
cover available software and models, and touch on factors governing acceptance and 
usage of computational models by medicinal chemists. Considerations for developing 
internal models versus using commercial software will be described. An example of a 
deployment of a DMPK model to chemists' desktops will be presented, and its 
subsequent impact on drug properties across the organization will be described. 
MEDI 382 
QSAR ADMET models that stand the test of time 
Andrew M Davis, andy.davis@astrazeneca.com. Department of Medicinal Chemistry, 
AstraZeneca Respiratory and Inflammation Innovative Medicines, Mölndal Gothenburg, 
Sweden  
Quantitative structure-activity models have been core computational chemistry tools 
since their popularization by Hansch and Fujita in the early 1960's. For many years they 
were limited in their applicability to congeneric series and small datasets.     Research in 
the 1990's highlighted the potential to “tune-down” or “tune-out” ADME (absorption, 
distribution, metabolism, elimination) –linked development attrition by prudent ADME 
screening in Discovery. The growing ADME datasets, and the fact that many of these 
endpoints were more bulk-property controlled, rather than structure-class specific, 
provided fruitful opportunities for computational chemistry to use QSAR tools to build 
“global” cross project ADME QSAR models. These have been very successful in 
building-in good ADME properties into molecules at the compound design-stage. More 
recently a similar focus on toxicology has provided tox-based QSAR models, allowing 
us to add “T” to the acronym to broaden the study to ADMET models    But QSAR's are 
empirical models that only offer the potential to encode information provided within the 
description of the training set. Predictions can only confidently be made when the 
prediction molecule is within the domain of applicability of the original model. But 
molecular design evolves within a project, as data feedback guides compound design, 
and therefore the project chemical space tends to grow away from the original QSAR 
model. This poses a problem for QSAR models.     We will describe our own exploration 
of the relationship between prediction quality and time, for a number of representative 
ADMET endpoints in Discovery projects. We will describe how we have identified robust 
machine learning techniques, and used these together with informatics automation to 
build, and update “global” cross-project and “local” series-specific ADMET QSAR 
models that can stand the test of time. 
MEDI 383 
Use of azaheterocycles to modulate metabolic rates of drug metabolism 
Jeffrey P. Jones, jpj@wsu.edu. Department of Chemistry, Washington State 
University, Pullman WA 99163, United States  
Many new potential drugs have nitrogen in heterocyclic rings. The incorporation of 
nitrogen may be important for the pharmacophore, or the physical characteristics of the 
molecule. Incorporation of nitrogen can also have profound effects on the 
pharmacokinetics of a molecule. Three separate computational approaches to 
understanding the effects of nitrogen on metabolism will be presented. The first two 
have to do with modeling nitrogen-heme-iron interactions in cytochrome P450 enzymes 
and the third with predicting regioeselectivity and rates of aldehyde oxidase mediated 
reactions. 
MEDI 384 
In silico toxicity assessment, back to the future 
Constantine Kreatsoulas, Constantine_Kreatsoulas@merck.com. Global Structural 
Chemistry - Chemistry Modeling & Informatics, Merck & Co., Inc., West Point PA 19486-
0004, United States  
As the pace of pharmaceutical drug discovery accelerates and greater numbers of 
preclinical candidates are identified by high throughput screening and synthetic 
methods, the demand for safety assessment resources has increased. As most in vitro 
toxicology assays are, at best, medium throughput, it is apparent that rapid in silico 
assessment methods must be developed and validated for use in early discovery. 
Regulatory agencies have long been at the forefront of utilizing computational tools to 
aid in the analysis of small molecules. Methods to effectively utilize all of the public and 
proprietary data available to extract meaningful information must be developed and 
validated. This discussion will present a series of examples to illustrate a) the different 
approaches used to model various preclinical toxicity endpoints, b) the pitfalls 
associated with relying solely on statistics to guide assessment of a molecule, and c) 
tools for capturing the metadata associated with risk analysis. 
MEDI 385 
PK profiles from your desktop: Predicting clinical pharmacokinetics 
Natilie A. Hosea, natilie.hosea@pfizer.com. Department of Pharmacokinetics, 
Dynamics and Metabolism, Pfizer, San Diego CA 92121, United States  
Quantitative human pharmacokinetic (PK) predictions play a critical role in assessing 
the quality of potential oral drug candidates where clearance, volume of distribution, 
bioavailability and the plasma-concentration-time profiles are the desired endpoints. 
While many methods for conducting predictions utilize in vivo data, predictions can be 
conducted successfully from in vitro or in silico data, and modeling and simulation. This 
approach is facilitated using GastroPlus™ which has been reported to accurately 
predict the absorption and PK profile of small drug-like molecules. Herein, case studies 
are described where GastroPlus™ modeling and simulation was employed using in vitro 
and in silico data to predict human PK. The results obtained provided key information 
that led to decisions on either dose selection, chemistry strategy to improve lead matter 
or clinical protocol design, thus demonstrating the value of modeling and simulation in 
both early discovery and exploratory development for predicting absorption and 
pharmacokinetic profiles. 
